

The Toxicology of Glycol Ethers and its Relevance to Man (Fourth Edition) Volume I

Technical Report No. 95

ISSN-0773-8072-95 Brussels, February 2005

ECETOC TECHNICAL REPORT No. 95

© Copyright - ECETOC AISBL

European Centre for Ecotoxicology and Toxicology of Chemicals 4 Avenue E. Van Nieuwenhuyse (Bte 6), B-1160 Brussels, Belgium.

All rights reserved. No part of this publication may be reproduced, copied, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the copyright holder. Applications to reproduce, store, copy or translate should be made to the Secretary General. ECETOC welcomes such applications. Reference to the document, its title and summary may be copied or abstracted in data retrieval systems without subsequent reference.

The content of this document has been prepared and reviewed by experts on behalf of ECETOC with all possible care and from the available scientific information. It is provided for information only. ECETOC cannot accept any responsibility or liability and does not provide a warranty for any use or interpretation of the material contained in the publication.

The Toxicology of Glycol Ethers and its Relevance to Man

CONTENTS - VOLUMES I AND II

EXECUTIVE SUMMARY	1
SUMMARY AND CONCLUSIONS	3
Recommendations for further work	13
1. INTRODUCTION	14
1.1 Conversion factors and physico-chemical properties	14
1.2 Production and use	14
1.2.1 Manufacture of ethylene-series glycol ethers	14
1.2.2 Manufacture of propylene-series glycol ethers	15
1.2.3 Uses	15
2. TOXICOLOGICAL OVERVIEW	17
2.1 Acute toxicity	17
2.2 Irritation and sensitisation	18
2.3 Repeated-dose toxicity	19
2.3.1 Effects on the haematopoietic system and the peripheral blood	19
2.3.2 Testes	21
2.3.3 Kidney	22
2.3.4 Liver	22
2.3.5 Lymphatic tissue and immunotoxicity	23
2.3.6 Neurological effects	24
2.4 Genotoxicity and cell transformation	24
2.4.1 Evaluation	25
2.5 Chronic toxicity and carcinogenicity	25
2.5.1 Evaluation	27
2.6 Reproductive and edevelopmental toxicity	27
2.6.1 Evaluation	28
2.7 Absorption, distribution, metabolism and elimination	28
2.7.1 Absorption and distribution	28
2.7.2 Metabolism and elimination	29
2.7.3 Summary and conclusions	34
2.8 Cardiac sensitisation	35
2.9 Neurotoxicity	35
3. HUMAN EXPOSURE AND HEALTH EFFECTS	37
3.1 Human exposure	37
3.1.1 Human volunteer studies	37
3.1.2 Consumer exposure	41
3.1.3 Occupational exposure	42

3.1.4 Measurement methods 3.2 Health effects	56 59
3.2.1 Haematological effects	60
3.2.2 Behavioural and neurological effects	62
3.2.3 Reproductive effects	63
3.2.4 Other effects, including poisoning	67
3.3 Occupational exposure limit values	72
4. SUBSTANCE PROFILES (VOLUME II/CD)	73
4.1 Substance profile: EGME	
4.2 Substance profile: EGMEA	
4.3 Substance profile: EGDME	
4.4 Substance profile: DEGME	
4.5 Substance profile: DEGDME	
4.6 Substance profile: TEGME	
4.7 Substance profile: TEGDME	
4.8 Substance profile: MAA	
4.9 Substance profile: EGEE 4.10 Substance profile: EGEEA	
4.11 Substance profile: EGDEA 4.11 Substance profile: EGDEE	
4.12 Substance profile: DEGEE	
4.13 Substance profile: DEGEEA	
4.14 Substance profile: DEGDEE	
4.15 Substance profile: TEGEE	
4.16 Substance profile: EGiPE	
4.17 Substance profile: EGiPEA	
4.18 Substance profile: EGnPE	
4.19 Substance profile: EGnPEA	
4.20 Substance profile: EGPhE	
4.21 Substance profile: EGBE	
4.22 Substance profile: EGBEA	
4.23 Substance profile: DEGBE	
4.24 Substance profile: DEGBEA	
4.25 Substance profile: TEGBE	
4.26 Substance profile: EGHE	
4.27 Substance profile: DEGHE	
4.28 Substance profile: 2PG1ME	
4.29 Substance profile: 2PG1MEA	
4.30 Substance profile: 1PG2ME	
4.31 Substance profile: 1PG2MEA	
4.32 Substance profile: DPGME	
4.33 Substance profile: TPGME	
4.34 Substance profile: 2PG1EE	
4.35 Substance profile: 2PG1EEA	
4.36 Substance profile: DPGEE 4.37 Substance profile: PGPE	
4.38 Substance profile: DPGPE	
1.50 buobuile profile. Di Gi L	

4.39 Substance profile: 2PG1PhE	
4.40 Substance profile: 2PG1BE	
4.41 Substance profile: DPGBE	
4.42 Substance profile: TPGBE	
4.43 Substance profile: PGTBE	
4.44 Substance profile: DPGTBE	
5. BIBLIOGRAPHY	74
5.1 Databases consulted	74
5.2 References quoted	74
5.3 References not quoted	159
APPENDIX A: SPECIAL ABBREVIATIONS	170
APPENDIX B: CONVERSION FACTORS FOR VAPOUR CONCENTRATIONS IN AIR	173
APPENDIX C: OCCUPATIONAL EXPOSURE LIMIT VALUES	174
MEMBERS OF THE TASK FORCE	194
MEMBERS OF THE SCIENTIFIC COMMITTEE	196

EXECUTIVE SUMMARY

This report provides an update of an earlier ECETOC review ^a of a number of important ethylene and propylene glycol mono-ethers and di-ethers (glymes). It includes substantial new information concerning the human health consequences of exposure to this class of chemicals. The report presents toxicity data profiles for each individual compound.

Glycol mono-ethers are liquids that combine the solubility characteristics of ethers and alcohols since both functional groups are present. As a result, they are widely used in solvent applications, including formulations such as paints, inks and cleaning fluids. Non-solvent applications include uses as anti-icing agents in jet fuel, hydraulic system fluids and as chemical intermediates.

The hazard assessment of several glycol ethers can be based on short-term exposure studies because long-term exposure have not lead to more severe or different systemic effects. Glycol ethers have the potential to penetrate the skin (as a liquid or vapour) and this, therefore, represents a potentially significant route of exposure.

The majority of glycol ethers are of low acute toxicity; the main effect seen in laboratory animals at high doses is narcosis, typical of many solvents. Some glycol ethers are eye irritants. Overall, numerous studies with glycol ethers show that they do not exhibit genotoxic activity. The results of carcinogenicity studies with glycol ethers are consistent with this lack of genotoxic activity.

The systemic toxicity of the ethylene-based glycol ethers is mediated by their metabolism to the corresponding alkoxyacetic acids. Methyl- and ethyl-substituted ethylene glycol ethers can cause bone marrow depression, testicular atrophy, developmental toxicity, and immunotoxicity in animals. It should be noted that methyl- and ethyl-ethers of ethylene glycol are not used in consumer products in Europe. In contrast, the longer chain ethylene glycol ethers (ethylene glycol butyl ether, -propyl ether, -isopropyl ether and -phenyl ether) do not cause any of these effects. Toxicity commonly associated with the longer chain homologues involves red blood cell haemolysis (anaemia), to which humans are resistant. The alkoxyacetic acid metabolites of glycol ethers are responsible for the haemolysis.

None of the ethylene-bond effects have been observed for the propylene glycol ethers (α -isomers in commercial products); they are secondary alcohols and cannot be metabolised to their corresponding alkoxypropionic acids. Propylene glycol ethers are dealkylated to propylene glycol and then oxidised. The only change observed with propylene glycol ethers is an adaptive liver response and male rat kidney toxicity, which is not considered relevant to humans.

ECETOC TR No. 95

_

^a ECETOC. 1995. The toxicology of glycol ethers and its relevance to man. Technical Report 64. European Centre for Ecotoxicology and Toxicology of Chemicals, Brussels, Belgium [ISSN-0773-8072-64]

Reports of a number of effects in humans have been associated with glycol ether exposure, such as anaemia, granulocytopenia and leukopenia, increased risk of abortion or reduced sperm count in painters. Many such reports relate to methyl- and ethyl-substituted glycol ethers and are confounded by simultaneous exposures to other chemicals as well as limited information on exposure levels, which do not allow firm conclusions to be made concerning the contribution of glycol ethers to the observed effects. The toxicological findings reported to date indicate that, except for haemolytic anaemia and the liver and kidney effects in long-term studies, the effects seen in animals are also relevant to humans.

SUMMARY AND CONCLUSIONS

Glycol mono-ethers are liquids that combine the solubility characteristics of ethers and alcohols since both functional groups are present in the molecule. They are therefore widely used in solvent applications, including formulations such as paints, inks and cleaning fluids. Non-solvent applications include uses as anti-icing agents in jet fuel, hydraulic system fluids and as chemical intermediates.

The majority of glycol ethers are of low acute toxicity. Clinical signs of acute intoxication in animals are consistent with non-specific depression of the central nervous system, which is typical of many solvents. Lethargy and haemoglobinuria have been observed in glycol ethers that produced haemolysis in rodents. Although some glycol ethers are irritant to the eye, most are not, and none are appreciably irritant to the skin on acute exposure. As with other solvents, prolonged or repeated skin exposure may lead to a severe skin irritation. It is recognised that the glycol ether class lacks specific determinants for either genotoxicity or carcinogenicity. Negative results obtained in conventional genotoxicity assays, both *in vivo* and *in vitro*, confirm the lack of genotoxic activity for this class of solvents. Some glycol ethers have been tested in life-time studies in rats and mice, including ethylene glycol ethyl ether, ethylene glycol *n*-butyl ether, diethylene glycol ethyl ether, 2-propylene glycol 1-methyl ether and propylene glycol *tert*-butyl ether. However, the tumour responses seen in these cases were probably caused by mechanisms that are species-specific or reflect a mode of action to which humans are resistant. Overall, glycol ethers do not pose a significant genotoxic or carcinogenic risk to humans.

For the ethylene-based glycol ethers, the major route of metabolism is via alcohol and aldehyde dehydrogenases to the corresponding alkoxyacetic acids. A secondary route involves O-dealkylation to ethylene glycol and its oxidation metabolites. The metabolism of propylene-based glycol ethers varies with the isomer type. The α -isomers, which are used commercially, cannot be oxidised to acids, and O-dealkylation by microsomal cytochrome P450 (CYP) is the predominant route of metabolism. The minor impurity β -isomers are, like the ethylene glycol ethers, substrates for alcohol and aldehyde dehydrogenases, producing the corresponding propoxyacetic acids. They may also undergo O-dealkylation. This explains the main difference in the toxicities of the ethylene-based and propylene-based glycol ethers.

Within the ethylene-based series, the short chain ethers, including methyl- and ethyl-ethers of ethylene glycol and their acetates, show different toxicity effects from the higher propyl and butyl homologues. Methyl- and ethyl-substituted ethylene glycol ethers and derivatives have been shown to cause bone marrow depression, testicular atrophy, developmental toxicity, and immunotoxicity in animals. The toxicological effects observed are due to the alkoxyacetic acid metabolites, methoxyacetic acid and ethoxyacetic acid, which show relatively slow excretion rates especially in larger animals. In contrast, the longer chain ethylene glycol ethers (ethylene

glycol butyl ether, -propyl ether, -isopropyl ether and -phenyl ether) do not cause these effects because methoxyacetic and ethoxyacetic acid are not formed. Methyl and ethyl ethers of ethylene glycol are not used in consumer products in Europe.

The toxicity commonly associated with the longer chain ethylene-series homologues involves red blood cell haemolysis with secondary effects relating to this haemosiderin accumulation in the spleen, liver and kidney, and a compensatory haematopoiesis displayed in bone marrow. Ethylene glycol butyl ether, the most studied in this series, produces haemolytic anaemia in rats, rabbits and mice, showing greater sensitivity than other species, including guinea pigs. Those glycol ethers that cause haemolytic effects are more toxic than the other glycol ethers in respective susceptible species. Humans exhibit a resistance to glycol ether-induced haemolytic anaemia.

The toxicity of the propylene glycol ethers with the alkoxy group at the primary position (α -isomers, main isomers found in commercial products) is quite different from that of the ethylene glycol ethers. These ethers cannot be metabolised to their corresponding alkoxypropionic acids. None of the effects mentioned above have been reported and the only evidence of toxicity is towards liver and kidney. In the case of propylene glycol methyl ether, developmental effects have been reported when the primary position is occupied by a hydroxyl group (β -isomer). The β -isomer is not produced as a commercial product, and is found as a minor component (< 0.5%) of commercial propylene glycol methyl ether.

Target organ toxicity for the lower molecular weight ethylene-series glycol ethers in animals has been related to the extent of formation of methoxyacetic acid or ethoxyacetic acid, which may affect one or more of testes, bone marrow, thymus or developing offspring. For example, administration of ethylene glycol methyl ether in rats produces thymic and testicular atrophy, lymphocytopenia, and neutropenia with a near complete failure of blood cell precursor development in the bone marrow. Methoxypropionic acid has also been shown to produce developmental effects. With the exception of the developmental toxicity, these adverse effects are reversed upon removal of exposure. In sharp contrast, ethylene glycol butyl ether does not produce these effects, but produces haemolytic anaemia in rodents, accompanied by a compensatory bone marrow hyperplasia. Butoxyacetic acid has been shown to induce haemolysis in several animal species. An exception in the ethylene glycol ether series is ethylene glycol phenyl ether (phenoxyethanol), which is a more potent haemolytic agent (in the rabbit) than its metabolite, phenoxyacetic acid.

The liver has frequently shown an increased weight, in the absence of significant pathological change, following high doses of ethylene- and propylene-series glycol ethers. This has been interpreted as an adaptive change. Kidney weight changes and histopathological changes have been identified following dipropylene glycol ethyl ether and 2-propylene glycol methyl ether administration. These changes are associated with the accumulation of $\alpha_{2\mu}$ -globulin in the case of

2-propylene glycol 1-methyl ether only in male rats. Based on information from several other hazard assessments of chemicals, they are considered not to be relevant for humans. This is also most likely the case for dipropylene glycol ethyl ether, but definitive analytical confirmation is not available.

The hazard assessment of several glycol ethers can be based on systemic changes found in short-term exposure studies, such as haematological effects and organ weight changes. These effects do not appear to increase in studies of long-term duration. This observation, together with the overall absence of genotoxic effects, indicates that long-term exposure is unlikely to lead to more severe or different effects. In the specific case of ethylene glycol butyl ether, hepatic oxidative stress due to haemolysis has led to tumours following lifetime exposure. Repeated oral dosing of ethylene glycol butyl ether in mice resulted in irritation of the forestomach. Irritation has also been observed in inhalation studies, probably due to oral ingestion from grooming and mucociliary transfer, which progressed to hyperplasia and forestomach tumours on prolonged exposure in a cancer bioassay.

Glycol ethers have the potential to penetrate the skin and this, therefore, represents a potentially significant route of exposure. In studies conducted in animals, dermal exposures result in toxicities similar to those following oral administration. Some comparative *in vitro* data show that the degree of penetration varies with chemical structure, with the rate decreasing with increasing molecular weight. Recent studies with ethylene glycol butyl ether indicate that dermal absorption from the vapour phase is a minor but not insignificant component of total systemic exposure.

Systemic health effects in humans have been reported to be associated with exposures to ethylene glycol methyl ether, ethyl ether and their acetates and also diethylene glycol dimethyl ether based on evaluation of worker populations and case reports. Ethylene glycol methyl and ethyl ethers exposure has been associated with anaemia, granulocytopenia and leukopenia. All such reports of human related effects are confounded by simultaneous exposures to other chemicals as well as limited information of exposure levels. The number of observations and the limited information on the level of exposure do not allow firm conclusions to be made concerning the contribution of glycol ethers to the observed effects. Although the available literature concerning human exposures to ethylene glycol methyl ether, -ethyl ether and the acetates do not provide conclusive evidence, the data reported to date indicate that, with the exception of haemolytic anaemia and the liver and kidney changes seen in some of the carcinogenicity bioassay studies, effects seen in animals are likely to be relevant to humans.

Several epidemiological studies have investigated the possible association between exposure to glycol ethers and aspects of the male and female reproductive system. Some of these studies have found increased risks in workers exposed to glycol ethers. However overall conclusions are difficult to draw because of the strong inter-correlation between exposure to other agents, the

possibility of recall bias and the variety of endpoints investigated. Further epidemiological studies are needed to confirm or refute these findings.

Overviews of the hazards and available data on glycol ethers are presented in Table 2 and 3. The toxicological information on individual glycol ethers is detailed in their substance profiles (Section 4.1 to 4.44). The following abbreviations are used for the names of glycol ether compounds (Table 1).

Table 1: List of glycol ethers and abbreviations

Abbreviation	Name	
Ethylene-based		
DEGBE	Diethylene glycol butyl ether	
DEGBEA	Diethylene glycol (mono) n-butyl ether acetate	
DEGDEE	Diethylene glycol diethyl ether	
DEGDME	Diethylene glycol dimethyl ether	
DEGEE	Diethylene glycol (mono) ethyl ether	
DEGEEA	Diethylen e glycol ethyl ether acetate	
DEGHE	Diethylene glycol (mono) hexyl ether	
DEGME	Diethylene glycol (mono) methyl ether	
EGBE	Ethylene glycol (mono) <i>n</i> -butyl ether	
EGBEA	Ethylene glycol (mono) <i>n</i> -butyl ether acetate	
EGDEE	Ethylene glycol diethyl ether	
EGDME	Ethylene glycol dimethyl ether	
EGEE	Ethylene glycol ethyl ether	
EGEEA	Ethylene glycol (mono) ethyl ether acetate	
EGHE	Ethylene glycol (mono) <i>n</i> -hexyl ether	
EGiPE	Ethylene glycol (mono) isopropyl ether	
EGiPEA	Ethylene glycol (mono) isopropyl ether acetate	
EGME	Ethylene glycol (mono) methyl ether	
EGMEA	Ethylene glycol (mono) methyl ether acetate	
EGnPE	Ethylene glycol (mono) <i>n</i> -propyl ether	
EGnPEA	Ethylene glycol (mono) <i>n</i> -propyl ether acetate	
EGPhE	Ethylene glycol (mono) phenyl ether	
MAA	Methoxyacetic acid ^a	
TEGBE	Triethylene glycol (mono) <i>n</i> -butyl ether	
TEGDME	Triethylene glycol dimethyl ether	
TEGEE	Triethylene glycol (mono) ethyl ether	
TEGME	Triethylene glycol (mono) methyl ether	
Propylene-based	, , , ,	
1PG2ME	1-Propylene glycol 2-methyl ether	
1PG2MEA	1-Propylene glycol 2-methyl ether acetate	
2PG1BE	2-Propylene glycol 1- <i>n</i> -butyl ether	
2PG1EE	2-Propylene glycol (mono) 1-ethyl ether	
2PG1EEA	2-Propylene glycol 1-ethyl ether acetate	
2PG1ME	2-Propylene glycol 1-methyl ether	
2PG1MEA	2-Propylene glycol 1-methyl ether acetate	
2PG1PhE	2-Propylene glycol 1-phenyl ether	
DPGBE	Dipropylene glycol (mono) <i>n</i> -butyl ether	
DPGEE	Dipropylene glycol (mono) ethyl ether	
DPGME	Dipropylene glycol (mono) methyl ether	
DPGPE	Dipropylene glycol (mono) propyl ether	
DPGTBE	Dipropylene glycol (mono) propyl emer Dipropylene glycol tert-butyl ether	
PGPE	Propylene glycol <i>n</i> -propyl ether	
PGTBE	Propylene glycol <i>tert</i> -butyl ether	
TPGBE	Tripropylene glycol (mono) <i>n</i> -butyl ether	
TPGME	Tripropylene glycol (mono) methyl ether	

^a Not a glycol ether, but has similar toxicity

Table 2: Summary of hazards a posed by glycol ethers

Section	Compound	CAS ^b number	Haemolysis	Haematopoietic toxicity	Testicular toxicity	Reproductive toxicity	Developmental toxicity	Immuno- toxicity	Geno- toxicity	Carcinogenicity	Other effects
	Ethylene-ser										
4.1	EGME	109-86-4	-ve	+ve	+ve	+ve	+ve	+	-ve	No data	CNS °/behavioural effects
4.2	EGMEA	110-49-6	-ve	+ve	+ve	+ve (limited data)	+ve	+	-ve	No data	
4.3	EGDME	110-71-4	No data	No data	+ve	+ve	+ve	No data	-ve	No data	CNS/behavioural effects
4.4	DEGME	111-77-3	-ve	-ve	+ve	No data	+ve (weak)	-ve	-ve	No data	
4.5	DEGDME	111-96-6	-ve	+ve	+ve	+ve	+ve	No data	-ve	No data	
4.6	TEGME	112-35-6	-ve	-ve	-ve	No data	-ve	No data	-ve	No data	
4.7	TEGDME	112-49-2	-ve	-ve	+ve	+ve	+ve	(+ve)	No data	No data	
4.8	MAA ^a	625-45-6	-ve	+ve	+ve	+ve	+ve	+	-ve	No data	
4.9	EGEE	110-80-5	-ve	+ve	+ve	No data	+ve	-ve	-ve	-ve (limited data)	
4.10	EGEEA	111-15-9	-ve	+ve (limited data)	+ve	+ve	+ve	-ve	-ve	No data	
4.11	EGDEE	629-14-1	-ve	No data	No data	No data	+ve	-ve	No data	No data	
4.12	DEGEE	111-90-0	-ve	-ve	+ve	-ve	-ve	-ve	-ve	No data	
4.13	DEGEEA	112-15-2	No data	No data	No data	No data	No data	No data	-ve	No data	
4.14	DEGDEE	112-36-7	No data	No data	No data	No data	-ve	No data	No data	No data	
4.15	TEGEE	112-50-5	-ve	-ve	-ve	No data	-ve	No data	No data	No data	
4.16	EGiPE	109-59-1	+ve	-ve	-ve	No data	-ve	No data	-ve	No data	
4.17	EGiPEA	91598-97-9	No data	No data	No data	No data	No data	No data	No data	No data	
4.18	EGnPE	2807-30-9	+ve	-ve	-ve	No data	-ve	No data	No data	No data	
4.19	EGnPEA	20706-25-6	+ve	-ve	-ve	No data	-ve	No data	No data	No data	
4.20	EGPhE	122-99-6	+ve(rabbits)	-ve	-ve	-ve	-ve	No data	-ve	No data	

Table 2: Summary of hazards a posed by glycol ethers (cont'd)

Section	Compound	CAS b number	Haemolysis	Haematopoietic toxicity	Testicular toxicity	Reproductive toxicity	Developmental toxicity	Immuno- toxicity	Geno- toxicity	Carcinogenicity	Other effects
	Ethylene-sei	ies (cont'd)									
4.21	EGBE	111-76-2	+ve	-ve	-ve	-ve	-ve	-ve	-ve	±	
4.22	EGBEA	112-07-2	+ve	-ve	-ve (limited data)	No data	No data	No data	No data	No data	
4.23	DEGBE	112-34-5	-ve	-ve	-ve	-ve	-ve	No data	-ve	No data	
4.24	DEGBEA	124-17-4	+ve	-ve	No data	No data	No data	No data	No data	No data	
4.25	TEGBE	143-22-6	-ve	-ve	-ve	No data	-ve	No data	No data	No data	
4.26	EGHE	112-25-4	-ve	-ve	-ve	No data	-ve	No data	-ve	No data	
4.27	DEGHE	112-59-4	-ve	-ve	No data	No data	No data	No data	-ve	No data	
	Propylene-se	eries									
4.28	2PG1ME	107-98-2	-ve	-ve	-ve	-ve	-ve	-ve	-ve	-ve	
4.29	2PG1MEA	108-65-6	-ve	-ve	-ve	-ve	-ve	No data	-ve	No data	
4.30	1PG2ME	1589-47-5	-ve	-ve	-ve	No data	$\pm ve$	No data	-ve	No data	
4.31	1PG2MEA	70657-70-4	-ve	-ve	-ve	No data	+ve	No data	No data	No data	
4.32	DPGME	34590-94-8	-ve	-ve	-ve	No data	-ve	No data	-ve	No data	
4.33	TPGME	25498-49-1	-ve	-ve	-ve	No data	-ve	No data	-ve	No data	
4.34	2PG1EE	1569-02-4	-ve	-ve	-ve	No data	-ve	No data	-ve	No data	
4.35	2PG1EEA	54839-24-6	-ve	-ve	-ve	No data	No data	No data	-ve	No data	
4.36	DPGEE	30025-38-8	-ve	-ve	-ve	-ve	No data	No data	-ve	No data	
4.37	PGPE	1569-01-3	-ve	-ve	-ve	No data	-ve	No data	-ve	No data	
4.38	DPGPE	29911-27-1	-ve	-ve	-ve	No data	No data	No data	-ve	No data	
4.39	2PG1PhE	770-35-4	-ve	-ve	-ve	No data	No data	No data	-ve	No data	
4.40	2PG1BE	5131-66-8	-ve	-ve	-ve	No data	-ve	No data	-ve	No data	

^a Not a glycol ether, but has similar toxicity

Table 2: Summary of hazards a posed by glycol ethers (cont'd)

Section	Compound	CAS ^b number	Haemolysis	Haemato-poietic toxicity	Testicular toxicity	Reproductive toxicity	Developmental toxicity	Immuno- toxicity	Geno- toxicity	Carcinogenicity	Other effects
	Propylene-se	eries (cont'd)									
4.41	DPGBE	29911-28-2	-ve	-ve	-ve	No data	-ve	No data	-ve	No data	_
4.42	TPGBE	55934-93-5	-ve	-ve	-ve	No data	No data	No data	-ve	No data	
4.43	PGTBE	57018-52-7	-ve	-ve	-ve	-ve	-ve	No data	-ve	+ve	
4.44	DPGTBE	132739-31-2	-ve	-ve	-ve	No data	No data	No data	-ve	No data	

^a-ve, negative: no effects, +ve, positive: effects on organ or system; ±, equivocal; (-ve) or (+ve), insufficient data

^b Chemicals Abstracts Service

^c Central nervous system

Table 3: Summary of available a data on glycol ethers

Section	Compound	CAS number	Acute toxicity	Irritation	Sensitisation	Reproductive toxicity	Developmental toxicity	Repeated-dose toxicity	Genotoxicity	Carcinogenicity	Other ^b
	Ethylene-seri	ies									
4.1	EGME	109-86-4	+	+	-	+	+	+	+	-	K/M, N, Im, H
4.2	EGMEA	110-49-6	+	+	-	-	+ (lim ited)	+ (limited)	+	-	Im, H
4.3	EGDME	110-71-4	+ (oral)	-	-	-	+	+ (limited)	+ (limited)	-	K/M, N
4.4	DEGME	111-77-3	+	+	-	-	+	+	+	-	Im
4.5	DEGDME	111-96-6	+	+	+	+	+	+	+	-	K/M, H
4.6	TEGME	112-35-6	+	-	-	-	+	+	+	-	K/M, N
4.7	TEGDME	112-49-2	+ (oral)	-	-	+	+	+	-	-	
4.8	MAA °	625-45-6	+	+(skin)	-	+	+	+	+	-	K/M, Im, H
4.9	EGEE	110-80-5	+	+	-	+	+	+	+	+ (limited)	K/M, N, Im, H
4.10	EGEEA	111-15-9	+	+	+	+	+	+	+	-	K/M, Im
4.11	EGDEE	629-14-1	+	+	-	-	+	+ (limited)	-	-	K/M
4.12	DEGEE	111-90-0	+	+		+	+	+	+	+ (limited)	K/M, H
4.13	DEGEEA	112-15-2	+	+	+	-	-	-	+	-	
4.14	DEGDEE	112-36-7	+ (oral)	+ (eye)	-	-	+	+ (limited)	-	-	
4.15	TEGEE	112-50-5	+	+	-	-	+	+	-	-	K/M
4.16	EGiPE	109-59-1	+	+	+	-	+	+	+	-	K/M
4.17	EGiPEA	91598-97-9	-	-	-	-	-	-	-	-	
4.18	EGnPE	2807-30-9	+	+	+	-	+	+	-	-	K/M, N
4.19	EGnPEA	20706-25-6	+	+	+	-	+	+	-	-	K/M
4.20	EGPhE	122-99-6	+	+	+	+	+	+	+	-	K/M
4.21	EGBE	111-76-2	+	+	+	+	+	+	+	+	K/M, N, Im, H
4.22	EGBEA	112-07-2	+	+	-	-	_	+ (limited)	-	-	Н

Freedom_0001156_0017

Table 3: Summary of available a data on glycol ethers (cont'd)

Section	Compound	CAS number	Acute toxicity	Irritation	Sensitisation	Reproductive toxicity	Developmental toxicity	Repeated-dose toxicity	Genotoxicity	Carcinogenicity	Other ^b
4.23	DEGBE	112-34-5	+	+	+	+	+	+	+	-	K/M, N, H
4.24	DEGBEA	124-17-4	+	+	-	-	-	+ (limited)	-	-	K/M
1.25	TEGBE	143-22-6	+	+	-	-	+	+ (limited)	-	-	K/M
1.26	EGHE	112-25-4	+	+	-	-	+	+	+		
4.27	DEGHE	112-59-4	+	+	-	-	-	+ (limited)	+	-	
	Propylene-se	ries									
1.28	2PG1ME	107-98-2	+	+	+	+	+	+	+	+	K/M, N, H
.29	2PG1MEA	108-65-6	+	+	+	-	+	+ (limited)	+	-	K/M
.30	1PG2ME	1589-47-5	+	+	-	-	+	+	+		K/M
.31	1PG2MEA	70657-70-4	+	+	-	-	+	+	-	-	
.32	DPGME	34590-94-8	+	+	+	-	+	+	+	-	K/M
.33	TPGME	25498-49-1	+	+	-	-	+	+	+	-	
.34	2PG1EE	1569-02-4	+	+	-	-	+	+	+	-	
.35	2PG1EEA	54839-24-6	+	+	+	-	-	+	+	-	
.36	DPGEE	30025-38-8	+	+	+	+	-	+	+	-	K/M, N
.37	PGPE	1569-01-3	+	+	-	-	+	+	+	-	
.38	DPGPE	29911-27-1	+	+	-	-	-	+	+	-	
.39	2PG1PhE	770-35-4	+	+	-	-	-	+	+	-	K/M
.40	2PG1BE	5131-66-8	+	+	+	-	+	+	+	-	K/M
.41	DPGBE	29911-28-2	+	+	+	-	+	+	+	-	K/M
.42	TPGBE	55934-93-5	+	+	+	-	-	+	+	-	
.43	PGTBE	57018-52-7	+	+	+	+	+	+	+	+	K/M
.44	DPGTBE	132739-31-2	+	+	+	-	-	+	+	-	K/M, N

^a+, data are available; -, no data are available

^b Abbreviations: K/M, kinetics; N, neurotoxicity; Im, immunotoxicity; H, human data

^c Not a glycol ether, but has similar toxicity

Recommendations for further work

Several glycol ethers are part of the International Council of Chemical Associations (ICCA) programme on High Production Volume chemicals, which requires a base set of data to be available on all chemical substances registered on the ICCA tracking system. Glycol ethers covered in several submissions that have been developed for the ICCA programme are: ethylene glycol phenyl ether, ethylene glycol propyl ether, ethylene glycol *n*-hexyl ether, diethylene glycol ethyl ether, diethylene glycol butyl ether acetate, diethylene glycol butyl ether acetate, triethylene glycol butyl ether, propylene glycol butyl ether and propylene glycol phenyl ether. The reports have been submitted to the US-EPA and OECD for review.

The overall evaluation of these compounds indicates certain knowledge gaps and the need to:

- Develop biological action levels for ethylene glycol methyl ether and/or methoxyacetic acid
 that are based on biomonitoring data and which will help control dermal exposure situations.
 This would be based on the no-observed adverse effect level for methoxyacetic acid, which
 may require more data to derive a definitive value.
- Determine the role of haemolytic anaemia in inducing oxidative stress that could lead to toxicological effects, especially in the liver.
- Further validate biological monitoring methods, focusing on the relationship of biological effects to airborne exposure values.
- Obtain exposure and/or use data from downstream users and consumer groups covering both qualitative (for example frequency, duration and control measures used) and quantitative determinants that address personal air measurements and biological monitoring.

1. INTRODUCTION

This report collects and assesses available toxicity and human health related information on selected ethylene and propylene glycol mono-ethers and di-ethers (glymes) that are of regulatory and/or commercial interest. It provides a critical update of a previous ECETOC (1995) review, published as Technical Report No. 64 a, and identifies gaps in knowledge and proposals for research.

Following an overview of production and use (Section 1.2), the report presents an evaluation of the toxicity database (Section 2) and significant new information on human exposure (Section 3.1) of glycol ethers. The available information on adverse human health effects is discussed in Section 3.2, followed by an overview of current occupational exposure limit (OEL) values (Section 3.3). Individual toxicity data profiles are presented for each of the ethylene glycol ethers in Section 4.1 to 4.27, and for propylene glycol ethers in Section 4.28 to 4.44. Abbreviated names of compounds are given in Table 1 above; special abbreviations are listed at Appendix A.

1.1 Conversion factors and physico-chemical properties

Conversion factors for concentrations in air at standard conditions (20°C and 1,013 hPa) are given for each compound (toxicity profile) in Section 4. The generic formula is given in Appendix B. In this report, converted values are given in parentheses. The relative density (D_4^{20}) of a compound (compared to that of water at 4°C = 1,000 kg/m³) is given as required. Data on the physico-chemical properties of each compound are given at the above standard conditions, unless stated otherwise.

1.2 Production and use

1.2.1 Manufacture of ethylene-series glycol ethers

Ethylene glycol mono-ethers are produced in closed continuous processes by reacting ethylene oxide with an anhydrous alcohol (usually methyl, ethyl or butyl alcohol). Temperature, pressure, reactant molar ratios and catalysts are selected to yield the required product mix. For example, high ratios of alcohol to ethylene oxide are used when ethers of mono-ethylene glycol are manufactured, whereas lower ratios favour the production of diethylene-, triethylene- and higher glycol ethers. Although most diethylene- and triethylene glycol mono-methyl ethers are co-produced *in situ* with the corresponding mono-ethylene glycol ether, they can also be made

^a That in itself updated earlier ECETOC reviews from 1982 and 1985.

through the specific reaction of ethylene oxide with an isolated ethylene glycol mono-ether. Because of the large difference in boiling points, mixtures of glycol ethers are typically separated by distillation.

The ethylene-series glycol ether acetates are produced by the reaction of glycol ether and acetic acid in the presence of a catalyst. The reaction is carried out at elevated temperature followed by separation and purification and is carried out in either a batch or continuous mode.

1.2.2 Manufacture of propylene-series glycol ethers

Production of propylene glycol mono-ethers follows the generalised scheme described above for ethylene-series products. They are produced by the catalysed reaction of propylene oxide and an alcohol. As a result, propylene glycol mono-alkyl ethers are the primary products, with some diand tri-propylene glycol mono-alkyl ethers formed from the further reaction of the mono-alkyl ether with excess propylene oxide. However, while reaction kinetics favour the production of 1-alkoxy-2-propanol (secondary or α -isomer), trace amounts of the corresponding 2-alkoxy-1-propanol (primary or β -isomer) are also formed. By further manipulating the reaction conditions, the proportion of α -isomer can be increased to 99% or more of the final stream. The process can be carried out either in a batch or continuous mode.

The propylene-series glycol ether acetates are produced by the reaction of glycol ether and acetic acid in the presence of a catalyst. The reaction is carried out at elevated temperature followed by separation and purification and is carried out in either a batch or continuous mode.

1.2.3 Uses

Glycol mono-ethers combine the solubility characteristics of ethers and alcohols since both functional groups are present in the molecule. They are therefore widely used in solvent applications, including formulations such as paints, inks and cleaning fluids. Non-solvent applications include uses as anti-icing agents in jet fuel, hydraulic system fluids and as chemical intermediates.

Total use of glycol ethers in western Europe during 1999 was 422 kt. This volume comprised 233 kt for the ethylene-series and 189 kt for the propylene-series (Chinn *et al*, 2000) (Table 4).

Table 4: Western Europe consumption of glycol ethers by end-use in 1999

%		kt
Ethylene-series		233
Brake fluids	27	
Surface coatings (as glycol ethers)	29	
Surface coatings (as glycol ether acetates)	12	
Pesticides, printing inks, jet fuel additives	6	
Industrial cleaners	4	
Other	21	
Propylene-series		189
Surface coatings (as glycol ethers)	32	
Surface coatings (as glycol ether acetates)	24	
Leather, pesticides, electrical, industrial cleaners, resins	23	
Printing inks	12	
Other	9	_
Total:		422

a Chinn et al, 2000

A number of glycol ethers are worthy of specific mention due to their specific usage patterns.

Four commercially available glycol ethers have shown reproductive and developmental effects in laboratory animals. These are ethylene glycol ethyl ether (EGEE) and ethylene glycol methyl ether (EGME) and their acetates (EGEEA and EGMEA). The usage of these materials is restricted to jet fuel de-icing and pharmaceutical production. Sales of products containing these substances to the general public are forbidden in the EU (INSERM, 1999).

Diethylene glycol methyl ether (DEGME) is mainly used as an anti-icing fluid in jet fuel and a chemical intermediate, a processing solvent and as a solvent in paints and floor polishes. Diethylene glycol butyl ether (DEGBE) is used as a solvent in paints, dyes, inks, detergents and cleaners. Both DEGME and DEGBE have undergone risk assessment in the EU under the Existing Substances Regulation and the uses of these materials are subject to appropriate controls (European Chemical Bureau, 2000, 2001).

Glymes (glycol diethers) are specialised materials used in a variety of industrial processes as solvents, in chemical reactions involving metals, inorganic salts and organo-metallics (Ferro, 2002).

Methoxy acetic acid (MAA) is a specialised substance used mainly in the production of pharmaceuticals where it is used to separate racemic mixtures.

2. TOXICOLOGICAL OVERVIEW

2.1 Acute toxicity

Oral

The acute oral toxicity of many glycol ethers and their acetates has been studied extensively; they generally exhibit a low to moderate order of acute oral toxicity in rodents. In the majority of cases, LD₅₀ values are greater than 2,000 mg/kgbw, excluding those compounds that produce haemolysis (Section 2.3.1 below). Much of the data are historical and this makes quantitative comparison of glycol ether toxicity difficult because of inter- and intra-laboratory variations.

An early study by Smyth *et al* (1941) is supported by a more recent and comprehensive comparative research programme on nine glycol ethers in mice and rats (Krasavage and Terhaar, 1981a). The study was performed according to good laboratory practice (GLP) standards and provides the most definitive data on the comparative acute oral toxicity of ethylene and diethylene glycol ethers. The acute toxicity of mono-ethylene glycol mono-ethers was generally higher than that of the corresponding diethylene glycol mono-ethers in both rats and mice, while systemic toxicity was greater in rats than in mice. Generally, within each series of ethylene and diethylene glycol ethers, the toxicity of the compound increased with increasing molecular weight; those materials causing significant haemolysis (EGBE, EGPhE) showed more marked acute toxicity in rodents. LD₅₀ values were generally higher in fed animals than in starved animals. Clinical signs of toxicity included inactivity, laboured breathing, rapid respiration, anorexia, slight to moderate weakness, tremors, prostration and death.

The available data indicate that propylene or dipropylene glycol ethers are less toxic by the oral route in rats than the corresponding ethylene or diethylene glycol ethers. The primary ethers of propylene glycol are considered to be less toxic than the secondary ethers.

Dermal

Glycol ethers and their acetates generally exhibit a low to moderate order of acute dermal toxicity in laboratory animals. In the majority of cases, the acute dermal LD₅₀ values are greater than 2,000 mg/kgbw, although a moderate order of dermal toxicity is exhibited by EGBE, EGBEA and EGiPE. Studies *in vitro* with excised human skin have demonstrated that glycol ethers penetrate the cutaneous barrier at different rates of flux. The rate of penetration within the mono-ethylene glycol series was inversely related to alcohol chain length. Diethylene glycol mono-ethers penetrated less rapidly than their mono-ethylene counterparts.

Inhalation

Acute inhalation toxicity data for a number of gl ycol ethers show a range of toxic responses. Glycol ethers of relatively low volatility (typically di-, triethylene and propylene glycol ethers) have a low order of acute inhalation toxicity and laboratory animals appear able to tolerate acute exposures to saturated vapour with little or no adverse toxicological effects.

Moderate toxicity is seen in animals exposed by inhalation to EGME, EGEE and EGBE. Testicular damage has been observed after acute inhalation exposure to EGME or EGEE. Haemolytic effects were observed in rats exposed to EGBE by inhalation; rats are particularly sensitive to EGBE induced haemolysis, whereas humans are more resistant to this effect. In general, the propylene glycol based mono ethers do not exhibit haemolytic or testicular toxicity on acute inhalation exposure. Depression of the CNS and increased liver weight has been reported in rodents exposed to high vapour concentrations.

2.2 Irritation and sensitisation

Skin irritation

The majority of glycol ethers do not cause significant skin irritation upon acute exposure; however, severe irritation has been associated with prolonged or repeated skin contact.

Eye irritation

Standard laboratory eye irritation tests have yielded a range of responses following single exposure to the undiluted test material. Many of the glycol ethers caused slight to moderate eye irritation, typically conjunctival redness and swelling. A number of compounds, primarily the higher alkyl derivatives (EGPhE, DEGDEE, EGiPE, EGnPE, PGBE, EGBE, DEGBE, TEGBE and EGHE) induced more marked eye irritation. Some studies have reported tissue damage and corneal injury with recovery following removal of the test compound. Severity of the eye irritation was reduced by dilution of the glycol ether in water.

Skin sensitisation

Data available from a limited number of studies indicate that glycol ethers are not skin sensitisers.

2.3 Repeated-dose toxicity

Glycol ethers have been extensively investigated for their specific toxicity profiles and target organs following repeated administration. Studies have been conducted in a variety of laboratory animal species, by different routes of exposure and exposure durations.

Generally, the target organs and toxicity profiles of all glycol ethers are detectable shortly after administration. Many effects are notable after single exposure. There is minimal difference between the effects following subacute (up to 28 days) and subchronic (up to 90 days) exposure, either in qualitative or in quantitative terms. Administration routes are of minor importance for the effects observed.

There are few species differences in response to glycol ethers. The most important differences are the lack of haemolytic effects of EGBE and its metabolite 2-butoxyacetic acid (BAA) in humans, in contrast to rodents, and the greater sensitivity of rats than mice to immunotoxicity of EGME and MAA. Short chain alkoxy acetic acids (MAA, ethoxyacetic acid [EAA]) and methoxypropionic acid (MPA) are excreted more slowly in larger organisms, including humans, than in rodents. The significance of this difference in species sensitivity is not known. The elimination rate of the alkoxy acetic acids in rabbits is slower than in rats; this might be a factor in the more pronounced effects in rabbits compared to rats (EGME, 1PG2ME).

A limited number of glycol ethers can cause adverse effects in the bone marrow and the germinal epithelium of the testes. These are: EGME, EGMEA, EGEE, EGEEA, EGDME and DEGDME. In the case of 1PG2ME, data on the rabbit, a sensitive species, are not available and hence no overall conclusion can be drawn. Biotransformati on to their respective metabolites is responsible for all their specific effects. The same compounds are also selectively toxic to the foetus. All other glycol ethers do not exert such effects. Furthermore EGME, but not EGEE, exerts a specific CNS effect (loss of avoidance-escape response), which has been observed in humans and in animal models, most likely mediated by the metabolite MAA.

Ethylene glycol ethers of medium chain length (EGPE, EGBE and their acetates; to some extent also EGPhE) may cause haemolytic effects in rodents, but not in humans. For EGBE, the metabolite BAA was shown to be responsible for this effect. In the specific case of EGPhE, it is considered to be the parent compound and not a metabolite that causes haemolysis.

2.3.1 Effects on the haematopoietic system and the peripheral blood

Two distinctly different types of haematological effects have been observed with glycol ethers, depending on their chain length.

EGME, EGEE and their acetate esters exert detrimental effects on the haematopoietic system in the bone marrow (blood cell formation) and cause a deficiency of all cell elements (red and white) of haematopoiesis (generalised pancytopenia) in rats, mice and rabbits. Similar effects are also observed with EGDME and DEGDME. The toxicity to the haematopoietic system is observable in all species investigated, including humans. 1PG2ME does not cause adverse effects in rats or mice, but data in rabbits, which are generally considered a more sensitive species, are not available.

The cellular damage is characterised by a reduction in both myeloid and erythroid elements and in mega-karyocytes. Haematology findings in mice, rats and rabbits suggest that EGEE is less potent than EGME and EGMEA. Significant effects on the haematopoietic system have not been reported for the ethers of triethylene glycol.

In contrast, EGnPE, EGiPE, EGBE, EGBEA and EGPhE exert detrimental effects only to mature peripheral RBCs; the erythrocyte membranes show increased osmotic fragility and are subject to intravascular lysis. Secondary changes may occur as a result of intravascular haemolysis. The haemolytic effect does not directly affect the white blood cell (WBC) count and is species-specific (mice, rats and rabbits show haemolysis; guinea pigs are more resistant): it does not occur in humans.

In vitro investigations with EGBE and BAA including human erythrocytes showed both the mediation of the EGBE effects by BAA and the resilience of human erythrocytes towards BAA even at high concentrations. This low sensitivity to haemolysis was also shown for erythrocytes from humans with certain congenital blood defects, such as sickle cell anaemia. Young rats appear to be less sensitive to EGBE- (BAA-) induced haemolysis than adult rats because old rats also tend to have a higher number of old erythrocytes that are more susceptible to haemolysis than younger erythrocytes. When, after the first administration(s), old erythrocytes are replaced by younger erythrocytes, rats become less sensitive and higher doses are needed to induce haemolysis. DEGBE does not show haemolytic activity; furthermore, no haematological effects have been reported in the more limited studies conducted with TEGBE.

EGPhE may cause haemolytic anaemia in rabbits exposed orally or via the skin. Increased erythrocyte fragility and signs of intravascular haemolysis are similar to the effects reported for EGBE, although in this case rats appear to be less susceptible than rabbits (EGPhE). In contrast to EGBE, the metabolism of EGPhE to phenoxyacetic acid (PhAA) produces a less potent haemolytic agent, which may explain, in part, the observed species difference.

Propylene glycol mono-ethers (2-propylene glycol 1-methyl ether [2PG1ME], 2-propylene glycol 1-ethyl ether [2PG1EE], 2-propylene glycol 1-n-butyl ether [2PG1BE] and 2-propylene glycol

1-phenyl ether [2PG1PhE]) neither exhibit adverse effects on haematopoiesis nor produce haemolytic anaemia.

Evaluation

In summary, low molecular weight ethylene glycol ethers, through their metabolites, produce pancytopenia. In contrast, higher molecular weight ethylene-based molecules, through their metabolites, produce a compensatory haemolysis of peripheral red blood cells to which humans are resistant. Propylene-based glycol ethers have no haematological actions.

2.3.2 Testes

EGME, EGEE and their acetates adversely affect spermatogenesis. There is an increasing database suggesting that DEGDME and EGDME, and to a limited extent DEGME, may also produce similar effects. Leydig cells, responsible for testosterone production, are not affected. These testicular effects require the formation of MAA or EAA.

MAA is a potent testicular toxicant in rats (Miller *et al*, 1982b). The testicular atrophy is characterised by decreased testes weight and histological lesions showing apoptosis and degeneration of the germinal epithelium in the seminiferous tubules with a specific impact on pachytenic and subsequently also on other stages of the spermatogenic cycle (Sections 4.1.4.3 and 4.8.4.3). At higher doses or prolonged exposure all stages of spermatogenesis may be adversely affected.

Comparative studies indicate that EGME is the most potent glycol ether inducing testicular toxicity. Lesions were observed in rats, mice and rabbits following all routes of exposure (oral, dermal or inhalation). The most sensitive species is considered to be the rabbit, with a minimum effect level of 30 ppm EGME vapour (95 mg/m³) over 90 days (Miller *et al*, 1982a, 1983a). For DEGDME vapour, exposure to 98 ppm (550 mg/m³) was a minimum effect level in male rats (Du Pont, 1988b).

A range of simple physiological compounds (such as serine, acetate, sarcosine, glycine, and D-glucose) administered concurrently with EGME reduced or prevented the degenerative changes in the testes. It is hypothesised that MAA may interfere with one-carbon unit pathways and that these "antagonists" can donate a carbon unit that may be used in purine nucleotide biosynthesis. Reduced availability of bases might predominantly affect late stage pachytene spermatocytes, which are known to be undergoing rapid RNA synthesis (Mebus and Welsch, 1989). Co-administration of serine enantiomers may provide protection against EGME induced teratogenesis in mice (Clarke *et al*, 1991a).

2.3.3 Kidney

A number of studies with ethylene and propylene glycol ethers have reported adverse effects on the kidneys. In general, effects were confined to the high dose and in the presence of other signs of toxicity such as reduced weight gain. There are two distinct effects: those exacerbated through the metabolite, mono-ethylene glycol (MEG) and, secondly, a male rat-specific nephropathy.

MEG is a potential metabolite of ethylene glycol ethers as shown in the case of EGME. MEG is more nephrotoxic in dogs, rabbits and humans than in mice and rats. This has to be taken into account for glycol ethers exerting low systemic toxicity but which are potentially metabolised to MEG. The metabolic pathways of EGBE have been clearly elucidated, which shows that, in addition to BAA also some metabolic transformation to MEG potentially occurs. Thus, subsequent oxaluria (excess of calcium oxalate in urine) may be regarded as an additional candidate for biomonitoring in humans.

Male rats treated with DPGEE showed some hyaline droplet formation in the proximal tubule cells (BP, 1990b). Elevated deposition of $\alpha_{2\mu}$ -globulin and cell proliferation were also seen in the kidneys of male rats exposed to 2PG1ME (11,200 mg/m³) (Cieszlak *et al*, 1996a; Spencer *et al*, 2002) and PGTBE (Doi *et al*, 2004; NTP, 2004). This male rat-specific kidney response is not relevant to human hazard assessment (US-EPA, 1991).

2.3.4 Liver

Repeated-dose studies have occasionally reported histological changes in the liver, including cloudy swelling and centrilobular enlargement (e.g. EGEE, TEGME). Chronic exposure to EGBE, 2PG1ME and PGTBE produced a centrilobular hypertrophy in mice. These effects are more representative for adaptive phenomena and enzyme induction than cytotoxicity.

Elevated liver weights at high-doses have been also reported following exposure to EGBE or propylene glycol mono-alkyl ethers. The increased weight is considered to be reversible, reflecting an adaptive metabolic response rather than a specific organ toxicity as judged by an expert panel within the US-National Toxicology Program study on EGBE (NTP, 2000). The total incidence of hepatic tumours (adenoma and carcinoma) in mice was not altered following lifetime exposure to EGBE, but there was an indication of a progression from hepato-adenoma to carcinoma in males, which may reflect oxidative stress.

2.3.5 Lymphatic tissue and immunotoxicity

Toxicity to lymphoid organs and tissues, including pronounced thymus weight reduction, has been reported following repeated exposure of laboratory animals to EGME, DEGDME and DEGME, and to the metabolite MAA (rats more than mice). Similarly pronounced effects have not been reported in comparable tests for other ethylene or propylene glycol ethers. A comparative 28-d drinking water study with EGME and EGBE in rats (Exon *et al*, 1991) found that EGME, but not EGBE, caused a dose-related reduction in thymus weight. Microscopic examination confirmed overall atrophy and loss of the clear demarcation between the cortex and medulla within the thymus lobules in high dose animals (approximately 600 mg/kgbw/d). Similar effects have been reported also in rabbits exposed to EGME vapour and in mice following oral administration.

Specific antibody reduction and a dose related increase of natural killer (NK) cell cytotoxic activity has been reported for rats after administration of EGME and its metabolite MAA. Inbred Lewis rats were a particularly sensitive strain. The immunotoxicity of EGME was reduced in the presence of the alcohol dehydrogenase (ADH) inhibitor 4-methylpyrazole, suggesting that MAA is a prerequisite for immunotoxicity of EGME (Smialowicz, 1996).

The decreases in humoral immune responses and increases in cell-mediated responses may have contributed to the observed anti-tumour effects of EGME in tumour inoculation experiments and of EGEE seen in a 2-year study. On the other hand, EGEE, EGEEA, and the metabolite EAA showed no immunotoxicity using the same test protocol as for EGME and MAA (Smialowicz *et al*, 1991a,b, 1992; Riddle *et al*, 1992). DEGME was also devoid of such effects in this protocol but has been reported to cause lymphocyte depletion of the thymus following oral administration of 2,000 mg/kgbw/d for up to 20 days (Kawamoto *et al*, 1990a).

EGBE has been reported to cause decreased thymus weights or thymic atrophy in some studies that have used high doses. However, no consistent effects on white cells have been reported and the recorded responses could also be secondary or stress-induced effects in the sequel of the RBC haemolysis following administration of EGBE. It has also been reported that the large number of immature erythrocytes that appear in the blood following EGBE administration can affect WBC counts (Ghanayem *et al*, 1987a). EGBE had no effect on immunoglobulin class G (IgG) antibody production or primary antibody response, delayed type hypersensitivity, cytokine production or splenocyte numbers (Exon *et al*, 1991; Smialowicz *et al*, 1992). The proliferative activity of guinea pig lymphocytes *in vitro* was not affected by non-cytotoxic doses of EGBE (2 mmol/l) or its metabolite BAA (1 mmol/l) (Unilever, 1990).

1PG2MEA caused some thymic atrophy in rats at inhalation exposure to 2,800 ppm (15,400 mg/m³) for 4 weeks (BASF, 1984d; Ma-Hock *et al*, 2005). However, since the metabolite

2-MPA is excreted slower in rabbits than in rats and rabbit studies on this endpoint are not available, a final assessment is not possible.

On balance, with the exception of those glycol ethers that may produce MAA, the large number of other glycol ethers investigated in subacute/subchronic studies are not considered to be specifically immunotoxic.

2.3.6 Neurological effects

Reversible neurological effects have been reported in humans with EGME, which appear to be typical and most likely mediated by MAA (Section 4.1.5.2). In rats exposed to 400 to 500 ppm EGME (1,270 - 1,580 mg/m³) for 7 days, an inhibition of the avoidance-escape response and impairment of hind limb motor function was observed. This behavioural change is different to the transient CNS depression, which results from inhalation of other organic solvents (Goldberg *et al*, 1962; Savolainen, 1980).

TEGME produced no adverse neurological effects in a 90-day drinking water study in male and female rats that was specifically designed to study neurological effects at nominal doses of 0, 400, 1,200 or 4,000 mg/kgbw/d (Gill and Negley, 1990).

Neurological effects have not been systematically examined for other glycol ethers, although the large number of subacute/subchronic studies do not indicate that these materials in general produce adverse effects on nervous tissue. At high, sublethal doses, a reversible CNS depression was seen, which is a general feature of solvent toxicity.

2.4 Genotoxicity and cell transformation

There are some reports with positive findings in genotoxicity assays with ethylene-based glycol ethers, which are detailed below. However, the majority of studies undertaken with the ethylene-based chemicals is negative, demonstrating an overall lack of genotoxicity. Studies on the propylene-based glycol ethers do not indicate a genotoxic potential.

EGME studies in a wide range of *in vitro* and *in vivo* tests do not indicate significant genotoxic potential for this material. A few studies have produced effects and these are mentioned in Section 4.1.4.4.

Results of numerous *in vitro* and *in vivo* assays have shown that EGBE is non-genotoxic. A few studies have found effects and these are summarised in Section 4.21.4.4. Reviews by Elliot and Ashby (1997) as well as by the US-NTP (2000) have concluded that EGBE is non-mutagenic.

For DEGBE, a dose-related increase in mutation frequency in the mouse lymphoma cell assay in the absence of metabolic activation has been reported; no effect was seen in the presence of metabolic activation (Thompson *et al*, 1984). However, in view of the level of response and the uniformly negative results from a number of other genotoxicity assays (Thompson *et al* 1984; Unilever, 1984c,d; Zeiger *et al*, 1992; Gollapudi *et al*, 1993), this isolated result does not indicate that DEGBE represents a significant genotoxic hazard for mammals.

DEGDME has been associated with a marginal increase in the number of recessive lethal mutations in *Drosophila melanogaster*. However, other genotoxicity tests were negative and the *Drosophila* data are not considered to indicate that DEGDME represents a significant genotoxic hazard for mammalian species (McGregor *et al*, 1983).

Administration of DEGDME has been associated with reduced fertility in rats and abnormal sperm head morphology; there was an equivocal dominant lethal response (McGregor *et al*, 1983). It is probable that the adverse *in vivo* effects of DEGDME administration are due to testicular toxicity rather than genotoxicity.

2.4.1 Evaluation

Most of the glycol ethers that have been assessed were tested in *Salmonella typhimurium* (Ames test); whilst the test protocols were not always to current standards, none of the studies indicated a mutagenic potential. Also the vast majority of other genotoxicity assays with glycol ethers have not reported any mutagenic activity.

The occasional positive genotoxicity results are not considered to indicate a significant genotoxic hazard for these glycol ethers. Reported positive findings were generally either obtained with non-validated methods or were isolated findings that could not be confirmed with validated test systems.

2.5 Chronic toxicity and carcinogenicity

Lifetime studies with EGBE (NTP, 2000), 2PG1ME (Spencer *et al*, 2002) and PGTBE (Doi *et al*, 2004; NTP, 2004) have been conducted in rats and mice. A study with EGEE has also been undertaken although histopathology data were not reported, thus limiting its utility (Melnick, 1984).

Rats were exposed to EGBE by inhalation at 31.2, 62.5 or 125 ppm (153, 307 or 614 mg/m³), while mice were exposed at 62.5, 125 or 250 ppm (307, 614 or 1,230 mg/m³). Significant haematological effects were reported, in both species, consisting of a concentration-dependent

compensatory anaemia resulting from RBC haemolysis and present at 3, 6 and 12 months of exposure. Treatment-related non-neoplastic lesions were reported in the olfactory epithelium (hyaline degeneration in rats at all doses) and spleen at 125 ppm in both species. A dose-related increase in Kupffer-cell pigmentation was present in livers of all exposed animals. Female animals were more affected than males for both species. In female rats exposed to 125 ppm, benign or malignant phaeochromocytomas of the adrenal glands were not statistically increased but exceeded the historic control range (NTP, 2000).

In mice, significant non-neoplastic lesions were present in the bone marrow, olfactory and respiratory epithelia, and the urogenital system. Ulcers and epithelial hyperplasia of the forestomach were present in mice with effects more severe in females. In female mice at 250 ppm, the incidence of combined squamous-cell papilloma of the forestomach was increased, and a single case of forestomach carcinoma occurred. This forestomach finding is associated with prolonged, exposure-induced, irritation leading to hyperplasia and papilloma formation. Liver neoplasms (in particular haemangiosarcoma) were observed in male mice but not female mice (NTP, 2000). Subsequent research indicates that this tumorigenic response is likely to be a consequence of oxidative stress subsequent to RBC haemolysis and haemosiderin deposition in the liver (Boatman *et al*, 2004).

Inhalation studies with 2PG1ME vapour were undertaken in rats and mice, both exposed to 0, 300, 1,000 or 3,000 ppm (0, 1,125, 3,745 or 11,250 mg/m³) for 2 years, to characterise its chronic toxicity/carcinogenicity. Primary treatment-related effects included: initial sedation of animals exposed to 3,000 ppm; elevated mortality in high-exposure male rats and mice; elevated deposition of $\alpha_{2\mu}$ -globulin and associated nephropathy in male rat kidneys and increased occurrence/severity of eosinophilic foci of altered hepatocytes in male rats. No toxicologically relevant, statistically significant increases in ne oplasia occurred in either species. A numerical increase in the incidence of kidney adenomas occurred in intermediate-exposure male rats; however, the association with $\alpha_{2\mu}$ -globulin nephropathy, a male rat specific effect, indicated a lack of relevance for human risk assessment (Spencer *et al*, 2002).

Inhalation studies with PGTBE have been conducted in rats and mice exposed to 0, 75, 300 and 1,200 ppm (0, 410, 1,650, 6,600 mg/m³) for 2 years. Survival, haematology and clinical chemistry were unaffected and decreases in body weight occurred in both species at the top dose. Clinical signs were observed in mice at 1,200 ppm. The main target organs were the liver and kidney. Liver adenomas were increased in male rats: the incidence of hepatocellular adenoma/carcinoma increased in top dose male and female mice. Renal tubular degenerations were seen in male rats in all dose groups, with accompanying increases in $\alpha_{2\mu}$ -globulin. Marginal increases in the incidences of renal tumours were reported at 300 and 1,200 ppm in male rats (Doi *et al*, 2004; NTP, 2004).

EGEE administered by gavage to rats and mice at dose levels of 0, 500, 1,000 or 2,000 mg/kgbw for 103 weeks produced a high mortality at the highest dose, probably associated with stomach ulceration and this top dose group was terminated after 18 weeks. Testicular atrophy was observed in mice dosed with 1,000 and 2,000 mg/kgbw. Enlargement of the adrenals and reductions in spontaneous gross lesions of the spleen, pituitary and testes compared to controls were seen at 500 and 1,000 mg/kgbw. Chronic treatment with EGEE also caused a decrease in the incidences of enlarged spleens and pituitaries and of subcutaneous (s.c.) masses in the mammary gland region in the aging female rats. Histopathology data are not published for this study, although there was no increase in tumour incidence reported for treated groups (Melnick, 1984). Studies with EGEE did not show leukaemogenic potential (Dieter, 1990).

2.5.1 Evaluation

In conclusion, the six recent studies with glycol ethers have shown some evidence of tumour formation in rats and mice. The predominant mode of action of EGBE is to produce haemolysis, which has resulted in oxidative stress in mouse liver that can be related to haemangiosarcoma. The mouse forestomach response is secondary to a local irritative effect. The four studies with the propylene glycol ethers, 2PG1ME and PGTBE produced male rat specific nephropathy with a low level of related renal tumours. PGTBE also caused an increase in liver hypertrophy and tumours, probably secondary to metabolic adaptation. Each of the tumour responses seen in rats or mice has a mechanism that is either species-specific or reflects a mode of action to which humans are resistant. IARC (2004) concluded that EGBE and PGTBE are not classifiable as to their carcinogenicity to humans (Group 3) on the basis of limited evidence in experimental animals and inadequate evidence in humans.

2.6 Reproductive and developmental toxicity

Several glycol ethers have been evaluated for potential effects on fertility and the developing offspring, with a significant structure-activity relationship emerging. The relationship between structure and reproductive or developmental toxicity of the glycol ethers and their acetates follows the broad principles established for other toxicity endpoints. Oxidation to the respective alkoxyacetic acid is a prerequisite for the expression of both developmental toxicity and testicular atrophy, thus secondary propylene glycol ethers are not toxic. Furthermore, the potency of the toxic glycol ethers decreases as the lengths of the alkyl and alkoxy chains increase; EGME and MAA are the most potent.

EGME, EGMEA, EGEE, EGEEA, EGDME, EGDEE, DEGME, DEGDME, TEGDME, 1PG2ME, and 1PG2MEA have all been shown to cause developmental toxicity, with EGME and EGMEA being the most potent. EGMEA, EGEEA, and 1PG2MEA have a similar degree of

developmental toxicity (both qualitatively and, on a molar basis, quantitatively) as the respective glycol ethers, underlining their rapid de-acetylation. Ethylene glycol ethers with alkyl chains of three or more carbon atoms, and propylene glycol ethers other than 1PG2ME and its acetate, do not express developmental toxicity.

The pattern of developmental effects in a number of species is characterised by a range of structural anomalies (affecting the development of the cardiovascular system, CNS and urogenital system, as well as the skeleton), with foetotoxicity and embryo lethality occurring at higher doses. In the case of the ethylene glycol methyl ethers EGME (and EGMEA), EGDME, DEGDME and TEGDME, the developmental effects are mediated by the common metabolite MAA, a conclusion that is supported by the commonality of the effects elicited, and the relationship between potency and conversion to the acid and the developmental toxicity of MAA itself.

Effects upon fertility are largely related to testicular atrophy, characterised by selective degeneration of pachytenic spermatocytes in rodents. As with developmental toxicity, EGME and EGMEA are the most potent of the ethylene glycol ethers, and the effects are all mediated via conversion to MAA. However, the effects of treatment upon the testis generally appear to be reversible on cessation of exposure.

2.6.1 Evaluation

In summary, those glycol ethers that can be metabolised to the low-molecular-weight alkoxy acids can cause developmental effects in animals. Metabolites of the higher molecular weight glycol ethers, such as EGBE, do not produce developmental toxicity. The testicular toxicity of MAA and EAA will alter fertility and, in the absence of these testicular effects, no reproductive toxicity is associated with glycol ethers.

2.7 Absorption, distribution, metabolism and elimination

2.7.1 Absorption and distribution

Glycol ethers and their acetates are readily absorbed following oral administration or inhalation. Dermal absorption is also an important exposure route; penetration rates in human epidermis *in vitro* have shown a rank order for liquid contact: EGME > 2PG1ME > EGEEA > EGEE > EGBE > DEGME > DEGEE > DEGBE (Dugard *et al*, 1984). For EGBE, dermal uptake may account for about 75% of the total systemic exposure in humans during whole-body exposure to EGBE vapour (Johanson and Boman, 1991). Further work provided a lower estimate of 15 to 27% of total systemic exposure through dermal uptake (Corley *et al*, 1997) are necessary to

establish total systemic burden arising from dermal exposure to EGBE vapour and to assess the implications for occupational exposure.

Once absorbed, glycol ethers are readily distributed throughout the body; no substantial accumulation of the parent compound has been observed. However, the alkoxyacetic acid metabolites of EGME (MAA) and EGEE (EAA) have shown evidence of accumulation in animals and humans (Scott *et al*, 1989; Groeseneken *et al*, 1989a,b; Ghanayem *et al*, 1990; Medinsky *et al*, 1990); in contrast, the metabolite of EGBE (BAA; half-life of elimination 5.77 h) shows no evidence of significant accumulation (Johanson *et al*, 1986a).

2.7.2 Metabolism and elimination

Glycol ethers follow two main oxidative pathways of metabolism, either via ADH or the microsomal CYP mixed function oxidase (MFO) (O-demethylation or O-dealkylation). The first pathway gives rise to the formation and excretion of alkoxyacetic acids. The second mainly leads to the production and exhalation of carbon dioxide (CO₂) via ethylene glycol (MEG) or propylene glycol, which enter intermediary metabolism via the tricarboxylic acid (TCA) cycle. In addition to these two pathways, conjugation with sulphate, glucuronic acid or glycine has also been reported.

Glycol ether acetates are rapidly hydrolysed *in vivo* to the parent glycol ethers by plasma esterases; this is consistent with the view that the metabolism of the acetates is similar to that of the parent glycol ether.

According to their pathways of metabolism, the glycol ethers may be divided into three groups:

- Ethylene glycol mono- and di-alkyl ethers and their acetates;
- diethylene glycol mono- and di-alkyl ethers and their acetates;
- propylene glycol ethers.

Mono-ethylene glycol ethers

All mono-ethylene glycol ethers bearing a primary OH-group (alkoxyethanols) are primary alcohols that are oxidised via ADH and aldehyde dehydrogenase (ALDH) to their corresponding alkoxyacetic acids. Thus, for example, EGME and EGEE, and their corresponding acetates, are predominantly metabolised to MAA and EAA; EGBE is metabolised to BAA (Figure 1, starting at centre). It is noted that mono-propylene glycol mono-alkyl ethers with a primary OH function (*n*-alkoxypropanols) follow similar pathways yielding alkoxypropionic acid (Figure 3) (this section, below).




Figure 1: Metabolic pathways of mono-ethylen e glycol mono-alkyl ethers (alkoxyethanols) and mono-ethylene glycol di-alkyl ethers b

The toxicity profiles of these acids are very similar to their parent compounds. Investigations *in vivo* and *in vitro* have shown that nearly all effects of this group of glycol ethers are mediated by these metabolites. The only exception, so far, is PhAA that appears to be less haemolytic *in vitro* than the parent substance EGPhE. In the case of EGBE and EGPE (*i*- and *n*-) it was shown that the parent compounds are practically devoid of haemolytic activity. It is the bioavailability of MAA and EAA (in terms of peak concentration and area under the curve [AUC]) that determines the myelotoxic, spermatotoxic and developmentally toxic properties of EGME and EGEE. Likewise, the same appears to be true for 2-MPA as the active metabolite of 1PG2ME.

^a EGME (EGMEA), EGEE (EGEEA), EGIPE, (EGIPEA), EGnPE (EGnPEA), EGPhE and EGBE (EGBEA)

^b Glymes: EGDME and EGDEE (below)

The bioavailability of these metabolites depends largely on the dose but also the metabolic rate and species. There is evidence that MAA, and to a lesser extent also EAA, are fairly slowly excreted and that the excretion rates appear to be slower in larger organisms (such as rabbits or primates) than in rats and mice. This slow excretion rate is presumably the major reason why 1PG2ME and thus 2-MPA are more teratogenic in rabbits than in rats.

To some extent, MAA undergoes further metabolism. The identification of 2-methoxy-N-acetylglycine in the urine of EGME-exposed mice indicates that MAA may bind to coenzyme A (Mebus et al, 1992) and is incorporated into the intermediary metabolism. Sumner et al (1991, 1992) identified several metabolites after entry of the reactive thio-ester into common cellular pathways (TCA cycle; fatty acid biosynthesis). Though MAA is not overtly cytotoxic, the pattern of in vivo effects indicated that at least specific target cells may be affected, either by interference with the energy metabolism in the TCA-cycle as a "false substrate" and/or a reduced availability of small carbon units necessary for purine and pyrimidine nucleotide synthesis. Such mechanisms might be expected to disrupt cell proliferation and normal differentiation in critical stages, but the precise mechanism remains to be elucidated. Interestingly, simple physiological compounds (e.g. serine, formate and acetate) that may be introduced into the TCA cycle or tetrahydrofolate (THF) metabolism are able to protect against EGME/MAA-induced malformations and testicular lesions (Welsch et al, 1987; Mebus and Welsch, 1989; Mebus et al, 1992; Clarke *et al*, 1991a).


In addition to ADH-mediated oxidation of glycol ethers bearing a primary alcohol function, microsomal oxidation (catalysed by CYP MFO: O-demethylation or O-dealkylation) may also occur in male rats (Medinsky *et al*, 1990) or in pregnant mice (Clarke *et al*, 1991b) and lead to cleavage of the ether bond (Figure 1). This pathway has a rather low capacity and may be saturated but possibly also induced by repeated administrations. At a single dose of 5 mg/kgbw i.v., approximately 30% of EGME underwent oxidative cleavage to MEG; with a high single or repeated (and teratogenic) dose of EGME (100 mg/kgbw and above) only a few percent was metabolised by this route (Clarke *et al*, 1991b; Sabourin *et al*, 1992b). Though MEG itself exerts some developmental toxicity in rodents at high doses (\geq 500 mg/kgbw/d) (Price *et al*, 1985; Tyl *et al*, 1988), this pathway has no significance for the developmental and other typical effects of EGME.

Alkoxyacetic and alkoxypropionic acids are the most relevant biomonitoring parameters in exposed humans (Section 3.1.4.1). MAA was the major urinary metabolite in human volunteers exposed to 16 mg EGME/m³ (5 ppm) (Groeseneken *et al*, 1989a; Scott *et al*, 1989). Some investigations showed that MAA and EAA concentrations in exposed individuals have a tendency to increase over the course of a working week and decrease to some extent over the weekend. This is consistent with the respective half-lives of elimination of 77.1 (Groeseneken *et al*, 1989a) and 24 hours (Groeseneken *et al*, 1986a, 1987a).

Di-ethylene glycol ethers

Diethylene glycol ethers being etherified at only one OH function (alkoxy-ethoxy-ethanols) such as DEGME, may undergo a low level formation of ether cleavage and formation of alkoxyacetic acids such as MAA (Figure 2, centre). DEGME is a weak developmental and testicular toxicant that may act via such a mechanism. DEGEE has not shown these effects.

Figure 2: Metabolic pathways of diethylene glycol mono-alkyl ethers (alkoxy-ethoxy-ethanols) $^{\rm a}$ and diethylene glycol di-alkyl ethers $^{\rm b}$



^a DEGME, DEGEE (DEGEEA) and DEGBE (DEGBEA)

Glymes

Glycol ethers with both alcohol groups etherified (so-called glymes) may undergo oxidative ether cleavage to the mono-etherified compounds and alkoxy acids (upper right in Figure 1 for mono-ethylene glycol dialkyl ethers; Figure 2 for diethylene glycol dialkyl ethers). This process appears to be much dependent on metabolic status and has a higher capacity following enzyme induction; thus it is facilitated either by repeated administration or by co-administration of other enzyme


^b Glymes: DEGDME and DEGDEE

inducers. The propensity to produce MAA after oxidative cleavage is the reason why EGDME and DEGDME are developmental and testicular toxicants; MAA is the main metabolite. EGDEE and DEGDEE did not cause selective testicular or developmental toxicity in rats, mice or rabbits though one would expect the formation of EAA. This could be due to EAA having a 5-fold lower developmental and testicular toxicity as EGME /MAA. Dipropylene glycol dialkyl ethers are presumed to be metabolised by similar pathways.

Propylene glycol ethers

Mono-propylene glycol mono-alkyl ethers etherified at the primary carbon (*sec*-alkoxypropanols) are secondary alcohols that cannot be metabolised to alkoxypropionic acids (Figure 3). These compounds are either renally excreted after conjugation or, to some extent may form ketones that may enter the intermediary metabolism via the TCA cycle, eventually to CO₂. Propylene-based glymes may apparently bond to the formation of β-isomers (and 2-MPA and homologues). Also di- and tri-propylene glycol ethers such as DPGME and TPGME contain four or more isomers and are theoretically capable of forming 2-MPA, but metabolism studies have shown that this does not occur at a toxicologically hazardous level. The main metabolic route is therefore via dealkylation. The parent compound, DPGME, dipropylene glycol and the sulphates and glucuronides of DPGME have been identified as main urinary metabolites (Calhoun *et al*, 1986a,b; Miller, 1987).

Figure 3: Metabolic pathways of propylene glycol mono-alkyl ethers with primary ether bond ^a




^a 2PG1ME (2PG1MEA), 2PG1EE (2PG1EEA), 2PG1PhE and 2PG1BE

ECETOC TR No. 95

Freedom_0001156_0038

Mono-propylene glycol mono-alkyl ethers etherified at the secondary carbon (*n*-alkoxypropanols) are again primary alcohols, that can be oxidised via ADH to their corresponding alkoxypropionic acids (Figure 4), then following similar pathways as in Figure 1. Thus, for example, 1PG2ME (the primary or β-isomer) and its acetate are oxidised to 2-MPA.

Figure 4: Initial metabolic pathways of propylene glycol ethers with secondary ether bond a



a 1PG2ME (1PG2MEA)

2.7.3 Summary and conclusions

Glycol ethers and their acetates are readily absorbed following oral administration or inhalation. Dermal absorption is also an important exposure route. Once absorbed, glycol ethers are readily distributed throughout the body; no substantial accumulation of the parent compound has been observed.

The above considerations on metabolism and elimination allow the following generalisations to be made:

- 1. Compounds capable of giving rise to EGME, EGEE and/or their corresponding alkoxyacetic acids (MAA and EAA) exhibit bone marrow depression, and characteristic developmental, testicular and immunological toxicity. Realisation of this potential depends on the extent of formation and retention of the alkoxy acid metabolites.
- 2. EGDME and EGDEE are potent developmental toxicants which probably act via the formation of EGME (EGEE) and then MAA (EAA).
- 3. DEGME and DEGDME are also developmental toxicants in rats and mice, but only at high doses; this may be explained by the low level of EGME and MAA formed.
- 4. DEGEE and DEGDEE give rise to low levels of EGEE and EAA, but neither compound caused selective developmental toxicity in rats, mice or rabbits; DEGEE had no effect on fertility. This is plausible in view of the 5-fold lower developmental toxicity of EGEE/EAA compared to EGME/MAA.
- 5. Propylene glycol ethers with the ether bond on the primary carbon (2PG1ME, 2PG1EE, 2PG1BE, 2PG1PhE) are secondary alcohols that are primarily metabolised to CO₂; they do

- not form alkoxy propionic acids and have not been found to cause selective developmental toxicity.
- 6. Propylene glycol ethers with the ether bond on the secondary carbon (1PG2ME) are primary alcohols and are predominantly metabolised to 2-MPA. It is presumed that 2-MPA is the developmentally toxic metabolite derived from 1PG2ME.
- 7. DPGME and TPGME are potentially capable of forming 2-MPA, but metabolism studies have not identified this material in rat urine.
- 8. Following extensive physiological-based pharmacokinetic (PBPK) modelling of EGBE (Section 4.21.4.7), it was shown that humans do not produce BAA at a faster rate than rats nor do they excrete BAA at a slower rate. Thus, there are no indications of accumulation of BAA in humans. The resistance of human erythrocytes to BAA (in contrast to rodents), therefore, is not considered to be related to a kinetic difference, but to a difference in terms of toxicodynamics and species susceptibility at the cellular level.
- 9. Glycol ether acetates (esters) are rapidly hydrolysed to their corresponding parent glycol ethers.

2.8 Cardiac sensitisation

Cardiac sensitisation, linked to an increased responsiveness of the heart to the arrythmogenic effects of endogenous catecholamines, has been reported following inhalation of a number of organic solvents (Boon, 1987; Kristensen, 1989). In humans, the condition may be fatal and occurs following deliberate solvent abuse or accide ntal over-exposure to aliphatic, aromatic or chlorinated solvents (Kristensen, 1989). The underlying mechanism(s) of cardiac sensitisation has not been well elucidated (Baskin, 1995).

A literature search did not reveal any references to published data implicating glycol ethers in cardiac sensitisation (Copestake, 2002).

2.9 Neurotoxicity

EGME has been well recognised for effects on the central and peripheral nervous systems in humans. No such effects have been reported for EGEE or other glycol ethers. The only exception appears to be a single communication on EGPhE, suggesting peripheral nerve effects in humans after high dermal exposures (Morton, 1990) (Section 3.2.2), but this report has a number of confounding factors (Schmuck *et al*, 2000).

EGME (and EGDME) caused behavioural effects in an animal experiment in which inhalation exposure at fairly low levels inhibited active avoidance behaviour in trained rats (Goldberg *et al*, 1964).

No other glycol ether has shown neurological or behavioural effects as far as investigated in specifically designed studies or in the course of normal subchronic studies.

3. HUMAN EXPOSURE AND HEALTH EFFECTS

3.1 Human exposure

The main routes of human exposure to glycol ethers and their acetates are through inhalation and/or the skin. Dermal exposure may occur as a result of contact with both liquid and vapours forms. For some glycol ethers skin penetration is so efficient that dermal absorption is equal to or even exceeds inhalation exposure in contribution to the total systemic exposure (Section 3.1.1). This is accentuated as the vapour pressure of all glycol ethers is generally below 1 kPa at ambient temperature (20 - 25°C), and often considerably lower, reducing the potential for airborne concentrations unless an aerosol is generated or the compound is heated during use. As a consequence, no correlation exists between ambient air concentrations of glycol ethers and body burden in many instances. Hence, biological monitoring that determines systemic exposure, regardless of the route, plays an important role in the assessment of exposure to glycol ethers. For most glycol ethers biological monitoring methods have been developed. Unfortunately, with a few exceptions for the most commonly used glycol ethers, such as EGME(A), EGEE(A) and EGBE(A), most of the available biological monitoring methods have not been adequately validated (Section 3.1.4).

Further work is recommended with respect to validating biological monitoring methods, in particular in relation to (i) correlation with airborne values and (ii) the availability of good reference materials such as metabolite standards and appropriate biological limit values. In addition, only limited exposure data are currently available to characterise exposure of downstream users and consumers. It is advised to obtain data for these groups covering both qualitative (e.g. frequency, duration and control measures used) and quantitative exposure determinants which address personal air measurement and biological monitoring.

3.1.1 Human volunteer studies

In a number of human volunteer studies, healthy subjects were exposed to EGME, EGEE, EGBE or 2PG1ME to determine and compare inhalation and dermal exposure.

The respiratory uptake of EGME and the urinary excretion of its major metabolite MAA were measured in 7 resting male subjects exposed to 16 mg/m³ EGME (5 ppm) for 4 hours (cf. TLV a of 16 mg/m³, Section 3.3). The total dose was 0.25 mg EGME/kgbw; respiratory uptake was 76%. There was a rapid increase in the urinary excretion of MAA during exposure and elimination half-life averaged 77.1 hours (range 66 - 90 h), i.e. much longer than in the rat where the half-life was 9 to 13 hours [Aasmoe *et al*, 1999] [Section 4.8.4.7]). On cessation of exposure,

-

^a Threshold limit value

the urinary excretion rate was fairly constant for 4 to 6 hours and then showed a slow exponential decrease, with the excretion rate about one third of its maximal level after 120 hours. Approximately 85.5% of the absorbed EGME was excreted as MAA up to 120 hours after exposure, with half of this being excreted during the first 48 hours (Groeseneken *et al*, 1989a).

The dermal uptake of EGME and EGEE, both as liquid and as vapour, was measured in 5 resting volunteers (2 males, 3 females). The forearm and hand (skin surface area approximately 1,000 cm²) were exposed to EGME at 4,000 mg/m³ (1,260 ppm) or to EGEE at 3,700 mg/m³ (990 ppm) for 45 minutes. An area of 27 cm² on the forearm was exposed simultaneously to liquid EGME or EGEE for 15 minutes. For comparison to the dermal uptake, a reference inhalation exposure was performed in the same individuals. Each volunteer was exposed through a mouthpiece to vapours of EGME (48 mg/m³ [15.2 ppm]) and or EGEE (57 mg/m³ [15.2 ppm]) for 4 x 15 minutes, 10 minutes apart. Uptake was measured by determination of urinary MAA or EAA. Respiratory uptake was about 80%. Vaporised as well as liquid EGME and EGEE were both readily absorbed through the skin. EGME penetrates the skin more rapidly than EGEE, both as vapour (36 versus 19 mg/cm²/h) and as liquid (2.9 versus 0.7 mg/cm²/h). The elimination halflife for MAA and EAA averaged 72 and 42 hours, respectively. Forty-eight hours after exposure only 12% of the absorbed EGME was recovered as MAA, and 14% of the EGEE as EAA. A strong circadian rhythm was observed in the urinary excretion, which was judged due to protein binding of MAA and EAA in the blood and renal re-absorption. It was calculated by the authors (theoretical calculation based on pure EGME or EGEE), that exposure of both hands and forearms to liquid EGME or EGEE during 1 hour would exceed the respiratory uptake at the 8-hour TLV (5 ppm, 16 and 19 mg/m³ respectively; Section 3.3) by about 100-fold for EGME and by about 20-fold for EGEE. In the case of whole-body and inhalation exposure to vapour, the contribution of the skin to the total uptake would amount to 32 to 55% for EGME and to 40 to 42% for EGEE (Ke ić et al, 1997).

Five male subjects were exposed (whole-body, closed chamber) at rest to EGEE vapour concentrations of 10, 20 or 40 mg/m³ (2.7, 5.3 or 10.7 ppm) (TLV 5 ppm, 19 mg/m³); a further 5 male subjects were exposed to EGEE vapour (20 mg/m³) at rest and during physical exercise (30 or 60 Watt) for 4 hours. EAA was determined in urine samples collected over 42 hours. Maximal excretion of EAA was reached 3 to 4 hours after the end of the exposure period and the elimination half-life of EAA was 21 to 24 hours; around 23% of the absorbed EGEE was excreted as EAA within 42 hours. The excretion of urinary EAA was dose-related to EGEE uptake and also to pulmonary ventilation rate during physical exercise (Groeseneken *et al*, 1986a,b). In a separate study, similar results were reported for EGEEA (Groeseneken *et al*, 1987a,b).

The uptake of EGBE and the excretion of the urinary metabolite BAA were measured in 7 male volunteers exposed to 20 ppm EGBE (100 mg/m³) for 2 hours during light physical exercise

(50 Watt). The respiratory uptake rate averaged 10 μ mol/min, and blood levels of EGBE indicated that approximately 57% of inhaled EGBE was absorbed; the half-life of EGBE in the blood was approximately 40 minutes. EGBE blood concentrations flattened out after about 2 hours at around 7.4 μ mol/l (870 μ g/l). Maximal urinary excretion of BAA was recorded 5 to 12 hours after the start of exposure, with an elimination half-life of 5.77 hours. Less than 0.03% of the absorbed dose was excreted in the urine as EGBE (Johanson *et al*, 1986a).

The percutaneous absorption of EGBE was investigated in 12 experiments using 5 men who kept 2 or 4 fingers immersed in undiluted EGBE for 2 hours. Capillary blood samples collected from the unexposed hand were analysed for EGBE before, during and up to 4 hours after exposure. Urine was collected for 24 hours and analysed for BAA. The presence of EGBE in blood and of BAA in urine confirmed dermal uptake of EGBE. Percutaneous uptake rates ranged from 0.42 to 5.76 µmol/cm²/h (mean 1.56 µmol/cm²/h). The results indicated that exposure of large areas of skin to EGBE may result in significant absorption of the material by this route (Johanson *et al*, 1988).

In further dermal absorption studies, 4 male volunteers were exposed by inhalation only or whole-body (naked) without inhalation to 50 ppm EGBE vapour (245 mg/m³). Capillary blood samples were collected at regular intervals and analysed for EGBE. Two experiments separated by at least two weeks were carried out with each volunteer. Blood EGBE levels were 2 to 3 times higher following whole-body exposure compared to inhalation exposure at 23°C (29% humidity) and 4 to 5 times higher at 33°C (71% humidity). Dermal uptake of EGBE might, according to the authors, therefore account for about 75% (45 - 85% in individual experiments) of the total uptake during whole-body exposure (Johanson and Boman, 1991). This relatively high estimate of the dermal contribution to the total exposure would be expected for exposure to liquid EGBE but is quite unexpected for exposure to EGBE vapour. This is based on the anatomical structure and physiological properties of the lung and the skin with regard to vapour exchange (lungs receive 100% of the cardiac output and skin only 3% and the surface area of the lungs (30 - 100 m²), which is much larger than that of the skin, approximately 1.9 m²).

The most likely explanation is that the authors made a wrong assumption in considering blood collected from a fingertip prick to represent systemic arterial ("general") blood. It is more likely that such blood samples represent venous blood drained from the skin prior to dilution with pooled venous blood. Based on this assumption, a PBPK model predicted that dermal exposure to EGBE vapour would contribute no more than 20% to the systemic dose (Corley *et al*, 1994). Further modelling, based on blood and urine concentrations of EGBE, BAA, and BAA conjugates predicted that even under worst-case circumstances (no clothing, 100% of the body exposed) no more than 15 to 27% of the total uptake (depending on temperature and relative humidity) could be attributed to dermal uptake when exposed for 8 hours to 25 ppm EGBE (123 mg/m³). During moderate physical exercise (50 - 100 Watt), i.e. taking into account more

realistic exposure conditions, the percentage of dermal contribution to total uptake would drop to 5 to 9% (Corley *et al*, 1997).

Six volunteers (4 males and 2 females) were exposed to 100 ppm 2PG1ME vapour (375 mg/m³) for 8 hours including a 30-min break after 4 hours. Blood, breath and urine samples for the determination of 2PG1ME were collected from all volunteers before, during and up to 24 hours after the exposure. 2PG1ME was readily absorbed with rapid alveolar uptake and elimination. A steady state for 2PG1ME in alveolar air was reached within 1 hour. 2PG1ME was rapidly cleared from the lungs. Blood levels of 2PG1ME rose steadily throughout the exposure. Post-exposure blood levels of up to 103 μmol/l were attained. The mean elimination half-life was 93 minutes (range 81 - 111 min). Urinary levels of 2PG1ME ranged from 78 to 110 μmol/l (average 92 μmol/l) at the end of exposure. Results were more consistent when expressed in μmol/l than when corrected for urine volume or creatinine. The urinary half-life averaged 120 minutes (range 50 - 151 min) and elimination was virtually complete after 16 hours (Jones *et al*, 1997).

In another study, 4 volunteers were exposed to 2PG1ME vapour at a concentration of 100 ppm (375 mg/m³) for 4 hours, on two different occasions (at least a week apart), once without and once with respiratory protection (air-fed half-masks). Samples collected to determine the exposure included blood, before and immediately after the exposure (0 and 4 h), breath (0 and 4 h and then every 15 min for up to 7 h) and urine (0 and 4 hours and then at intervals up to 22 h). All samples were analysed for 2PG1ME. The percentage dermal uptake was calculated from the 4-hour blood sample, the combined breath samples from the first 0.5 hour after exposure, and the combined urine samples over the total collection period. There was considerable inter-individual and intra-individual variation, which was largest for breath and blood samples and smallest for urine samples. The relative contribution of dermal uptake was 4.2 ± 1.7% based on the urine samples, and approximately 10% based on blood or breath samples. The mean urinary half-life was 1.5 hour (range 1.1 - 2.0 h) after whole-body exposure compared to 2.7 hour (range 1.3 - 4.3 h) after skin-only exposure. This more prolonged elimination following dermal uptake is also found with other solvents (Brooke *et al*, 1998).

The above human volunteer studies indicate an inverse relationship between the urinary elimination half-life of alkoxyacetic acids and the length of the alkyl chain of the glycol ether (BAA 5.77 h, EAA 21 - 42 h, MAA 72 -77 h) and are suggestive of a similar relationship between the blood half-life of the glycol ethers and the length of their alkyl chain (EGBE 42 min, 2PG1ME 93 min).

A consistent urinary sampling pattern is important when using urinary alkoxyacetic acids as biomarkers for exposure to glycol ethers to reduce the variability in results. This is further commented on under Section 3.1.4.

3.1.2 Consumer exposure

Consumer products containing certain glycol ethers are widespread and many people in the general population may be exposed to a limited number of these materials, although actual exposure data are difficult to obtain. Sometimes, occupational exposure data may be read across to consumers, with appropriate adjustment factors to take account of the significantly lower exposure frequency and duration of consumers, resulting in lower overall exposures. Particular reference is made to the surveys of Vincent *et al* (1993) on window cleaning (EGBE), Vincent *et al* (1994) on paint stripping (EGEEA), Vincent *et al* (1996 cited by INSERM, 1999) on car washing (EGBE), cleaning (EGBE) and house painting (EGBE and EGBEA), and Norbäck *et al* (1996) on house painting (DEGBE, DEGEE, EGBE, DPGME, DEGME and DEGBEA) (Section 3.1.3). Other surveys specifically identifying consumer exposure are given below.

Procter and Gamble (1985) determined potential inhalation and dermal consumer exposure from the use of a hard surface cleaner containing DEGBE. The cleaner was diluted to 1.5% (0.06% DEGBE) and used to wash the floor, wall tiles, window and mirror of a typical bathroom with sealed room openings (area 146 square feet [15 m²], volume 10.4 m³) for 20 minutes. DEGBE vapour concentrations during the washing task were below the detection limit (0.01 ppm). Thereafter it rose steadily to around 0.06 ppm at 1.5 to 3 hours and then declined to below the detection limit at 24 hours. *In vitro* human skin penetration studies with cleaning product containing 4% DEGBE indicated a calculated maximum consumer exposure to DEGBE of 0.047 mg/kgbw for use of 3 minutes. Total daily consumer exposure to DEGBE from inhalation and topical exposure was estimated to be 0.059 mg/kgbw/d.

Using *in vitro* human skin penetration data, the maximum consumer exposure from hands-only use of an undiluted cleaning product containing 4% DEGBE for 3 minutes was estimated to be 0.047 mg/kgbw. Use of diluted cleaner (1.5% dilution) for 30 min/d would result in a dermal exposure of 0.0025 mg/kgbw. The maximum overall exposure by inhalation and topical contact was calculated to be 0.06 mg DEGBE/kgbw/d (Gingell *et al*, 1993). An estimate of consumer exposure to paint containing 0.6% of the acetate ester, DEGBEA, was 0.01 mg/kg/d for an 80-minute daily application (Gingell *et al*, 1993).

Gibson *et al* (1991) simulated domestic exposure of consumers by inhalation of DEGBE from the use of cleaning products containing up to 9% DEGBE. Several experiments with exposures exceeding those likely to be encountered by consumers found that peak airborne concentrations of DEGBE did not exceed 1.6 ppm (10.7 mg/m³), with average DEGBE concentrations in the breathing zone below 0.8 ppm (5.3 mg/m³).

A systemic dose for consumers (assuming 100% skin penetration) was estimated for EGPhE used as preservative in cosmetics at 180 mg/person/d, DEGEE as a cosmetic component at

30 mg/person/d, and DEGBE and EGBE, both as used in hair dyes, at 45 and 8 mg/person/application (1 x/4 - 8 wk) respectively. The data were based on these glycol ethers being present at the following maximum concentrations in the relevant products: EGPhE 1% and DEGEE 2% in leave-on and rinse-off cosmetics, DEGBE 9% and EGBE 2% in rinse-off hair dyes (Féderation des Industries de la Parfumerie (2002).

3.1.3 Occupational exposure

The following information comprises workplace exposures in terms of airborne (personal and area) concentrations and biological monitoring data, as far as they are available. The data are presented chronologically according to the date of publication of the source article. Exposure information contained in articles reviewed since the ECETOC (1995) report has been tabulated, where practicable, to assist in subsequent review. Where both airborne measurements and biological monitoring were performed at the same time, these have been included in tandem in the same table. Information on the exposure measurement methods used is summarised in Section 3.1.4.

NIOSH (1983) determined occupational exposures to EGME, EGEE, EGEEA and EGMEA at 8 survey sites in the USA; a total of 151 area and personal air samples were collected and analysed. Only 40% of the samples had detectable levels of glycol ethers, ranging from 0.04 - 2.77 ppm (0.13 - 8.76, 0.15 - 10.37, 0.22 - 15.22 and 0.20 - 13.6 mg/m³, respectively) for long-term (5 - 8 h) workshift samples and 0.21 to 11.9 ppm (0.66 - 37.7, 0.79 - 44.6, 1.15 - 65.4 and 1.03 - 58.4 mg/m³, respectively) for short-term (15 min) samples. Most personal concentrations results complied with the US Occupational Safety and Health Administration (OSHA) and American Conference of Governmental Industrial Hygienists (ACGIH) exposure limit values current at the time of the study.

Guest *et al* (1985) reported ambient air concentrations of DEGBEA arising from indoor application of paint containing approximately 0.58% DEGBEA. During painting for 6.33 hours, the maximum exposure concentration was 50 ppm (425 mg/m 3), leading to a maximum uptake of DEGBEA of 190 μ g/kgbw/d.

Earlier summarised data on workplace exposure levels in the manufacture of glycol ethers in European plants showed time-weighted average (TWA) personal exposure concentrations ranging from 0.12 to 6.4 ppm EGME (0.38 - 20.2 mg/m³), 0.01 to 6.5 ppm EGEE (0.04 - 24.3 mg/m³), 0.02 to 0.2 ppm EGiPE (0.09 - 0.9 mg/m³) and 0.01 to 2.7 ppm EGBE (0.05 - 13 mg/m³) (ECETOC, 1985).

The majority of 262 ambient air samples from 78 different Belgian plants and workshops revealed complex mixtures of ethylene glycol ethers with other solvents; the glycol ethers were often minor components. The most frequently identified compounds were EGEE, EGEEA, EGME, EGMEA and EGBE. Most personal exposure levels were far below the respective ACGIH (1984 as cited) occupational exposure limits, but approximately 25% were higher than the TLV. Most excursions were slight (< 1.5 x TLV) or moderate (2 - 2.5 x TLV), although some serious excursions above the TLV were observed (up to 819.5 mg/m³ [150 ppm] for EGEEA; up to 1,775 mg/m³ [360 ppm] for EGBE; up to 1,224 mg/m³ [327 ppm] for EGEE). These latter excursions were recorded in a mirror manufacturing plant but no information to explain the high results were noted (Veulemans *et al*, 1987) (Table 5).

Table 5: Workplace concentrations a (mg/m³) of ethylene glycol ethers in various Belgian industries, with TLVs (mg/m³) applicable at that time (1984) (Veulemans et al, 1987)

Glycol ether	EGME	EGMEA	EGEE	EGEEA	EGBE	EGBEA
Operation / TLV	16	24	19	27	120	-
Printing	-	4.3	9.8	16.4	4.1	12.7
		(3.9-4.7)	(0.7 - 182.0)	(0.3 - 186.8)	(1.5 - 17.7)	(4.6-26.5)
Painting	31.3	-	9.5	9.7	18.8	-
	(5.6 - 136.9)		(1.4 - 210.3)	(1.2 - 78.6)	(3.4-93.6)	
Car repair	7.9	2.3	-	8.9	5.9	-
•	(3.4 - 15.9)			(1.5 - 42.1)		
Various	-	11.6	17.1	9.9	8.5	10.6
		(0.4 - 143.3)	(3.1 - 1,224)	(0.6 - 819.5)	(0.2 - 1,775)	(8.9-11.7)

^a Geometric mean and range

Clapp *et al* (1987) found urinary EAA concentrations in the range of 16 to 163 mg/g creatinine in 7 workers exposed to EGEE who collected spot urine samples (not timed) on several working days. Separate personal airborne EGEE levels ranged from non-detectable to 23.8 ppm (89.1 mg/m³).

In 5 women with daily exposure to a mixture of EGEE and EGEEA the urinary excretion of EEA was measured during a 5-day period of normal production and 7 days following a 12-day production stop. Urinary EAA excretion flattened out after the third working day. Elimination of EAA was not complete after the weekends, and traces of EAA could still be detected in the urine even after a non-exposure period of 12 days. (This observation is consistent with the long apparent urinary half-life of EAA found by Ke ic *et al*, 1997). A good linear correlation was found between average combined EGEE and EGEEA air levels over 5 days (14.4 mg/m³) and EAA excretion at the end of the week (106 mg/g creatinine). It was estimated that repeated 5-day

^b Threshold limit values

full-shift exposure to either EGEE or EGEEA corresponded to a urinary concentration of 150 ± 35 and 32 mg EEA/g creatinine at the end of the shift or 16 hours after the end of exposure, respectively (Veulemans *et al*, 1987).

Johanson *et al* (1989) found good correlations between EGEEA and EGBE exposure and urinary EAA and BAA excretion, respectively, in 19 workers.

Paustenbach (1988) reported on personal and area air samples from 7 different companies in the semi-conductor industry. TWA concentrations of EGME were mainly around 0.1 ppm (0.3 mg/m³); concentrations of EGMEA were usually lower than 0.01 ppm (0.05 mg/m³); the average concentration of EGEE was 0.55 ppm (2.06 mg/m³) and of EGEEA generally less than 0.05 ppm (0.27 mg/m³).

Sparer *et al* (1988) evaluated exposures of 36 shipyard painters to EGME and EGEE. EGEE exposures ranged from 0 to 80.5 mg/m³ (TWA), with a mean of 9.9 mg/m³ and a median of 4.4 mg/m³. EGME exposures ranged from 0 to 17.7 mg/m³ (0 - 5.6 ppm) (TWA), with a mean of 2.6 mg/m³ (0.82 ppm) and a median of 1.6 mg/m³ (0.5 ppm).

Samples of 2PG1ME collected during manufacturing of paint, metals and plastics had average levels of 2 to 3 ppm (7 - 11 mg/m³) (Johanson, 1990). Peak levels of 0.5 to 7 ppm 2PG1ME (2 - 26 mg/m³) were reached in apartments painted with water based alkyd and acrylate paints (Kragh-Hansen, cited by Johanson, 1990). Parquet fitters in Finland were exposed to approximately 35 to 39 ppm 2PG1ME (131 - 146 mg/m³) during undercoat varnishing and 10 to 63 ppm (37 - 236 mg/m³) during varnishing (Johanson, 1990).

EGEE and EGEEA concentrations were measured in 17 workers of a varnish production plant by personal air sampling and urinary EAA determination, and EGBE levels by air sampling and urinary BAA determination. Urine samples were taken pre- and post-shift; post-shift EGBE blood levels were also measured. Measurements were only carried out on the second working day. The highest exposures were observed in 12 workers of the varnish production plant. Exposures to EGEE ranged from < 0.1 to 7.8 ppm (mean 2.8 ppm) (< 0.4 - 29.2, 10.5 mg/m³), EGEEA from < 0.1 to 11.1 ppm (mean 2.7 ppm) (< 0.5 - 61, 14.8 mg/m³) and EGBE from < 0.1 to 8.1 ppm (mean 1.1 ppm) (< 0.5 - 39.8, 5.4 mg/m³). Corresponding levels of EAA (combined EGEE and EGEEA exposure) in post-shift urine ranged from 50 to 497 mg/l (mean 168 mg/l) and of BAA from 0.6 to 30 mg/l (mean 10.5 mg/l). EGBE blood levels ranged from non-detectable to 570 μg/l (mean 121 μg/l). High urinary EAA levels (mean 129 mg/l) were measured in pre-shift urine samples, resulting from EGEE and EGEEA exposure the previous day and consistent with the slow elimination rate of EAA. Residual urine levels of BAA (3.3 mg/l) in pre-shift urine were lower than for EAA, consistent with the faster rate of elimination of BAA. There was no significant correlation between concentrations of these glycol ethers in air and levels of glycol

ethers or their metabolites in blood or urine (Angerer *et al*, 1990). In the documentation to the German Biologische Arbeitsstofftoleranzwerte (BAT) avalues, Angerer states that this is due to extensive dermal contact of the workers and that BAT (and other biological exposure limits) are best based on human volunteer studies where skin contact is carefully avoided (Angerer, 1993).

Personal exposure concentrations of several ethylene glycol ethers were reported across a number of industries in the USA. Monitoring results at several of the sites (particularly aerospace, electronics, automotive, and glycol ether formulation) indicated that airborne concentrations of the glycol ethers were generally non-detectable in all or most areas. This was generally attributed to infrequent usage and handling of only small quantities (often present in low percentages in preparations), the effectiveness of engineering controls (such as local exhaust ventilation, enclosures, dual mechanical seals on pumps and automation) and conscientious work practices (including frequent cleaning/maintenance and proper chemical storage). Job categories with the highest exposure potential were reported as including activities related to transfer and manual handling of glycol ether compounds, e.g. sampling, drum filling and spray application of paints and coatings. The highest reported short-term (15 min) task level of 11.9 ppm EGEEA (65.4 mg/m³) was noted for spray painting in airline maintenance, however, in this case the use of respiratory protection was observed (Piacitelli *et al*, 1990) (Table 6).

Table 6: Workplace concentrations of some glycol ethers in the USA (Piacitelli et al, 1990)

Job	Glycol Number of		8-h TWA c	oncentration	Short-term (15	Short-term (15 min) range	
		TWA (task) samples	(ppm)	(mg/m ³)	(ppm)	(mg/m ³)	
Aerospace	EGME	8 (3)	≤ 0.27	(≤ 0.85)	≤ 0.65 -1.04	(≤2.06 - 3.3)	
Aerospace	EGEE	5	≤ 0.22	(≤ 0.82)	-	-	
Aerospace	EGEEA	15 (3)	≤ 0.23	(≤ 1.26)	$\leq 0.33 - 0.86$	$(\leq 1.81 - 4.7)$	
Electronics	EGEEA	8 (2)	≤ 0.02	(≤ 0.11)	≤ 0.12	(≤ 0.66)	
Airline maintenance	EGEEA	13 (5)	0.29 - 2.69	(1.59 - 14.8)	1.73 - 11.9	(9.5 - 65.4)	
Coating manufacturing	EGEEA	6 (7)	0.07 - 0.35	(0.38 - 1.92)	0.41 - 1.85	(2.25 - 10.2)	
Automotive manufacturing	EGEEA	12 (2)	$\leq 0.02 - 0.05$	(≤ 0.11 - 0.27)	≤ 0.61	(≤3.35)	
Fuel distribution	EGME	10 (5)	$\leq 0.03 - 0.34$	(≤ 0.09 - 1.08)	0.21 - 6.86	(0.66 - 21.7)	
Paperboard manufacturing	EGME	9 (3)	≤ 0.04 - 1.06	(≤ 0.13 - 3.35)	≤ 0.22 - 5.25	(≤ 0.70 - 16.6)	
Glycol ether manufacturing	EGME	(2)	=	-	≤ 0.20 - 2.45	$(\leq 0.63 - 7.75)$	
Glycol ether manufacturing	EGEEA	31(2)	≤ 0.02 - 0.44	$(\leq 0.11 - 2.4)$	-	-	

2PG1ME was measured in ambient air, blood and urine of operators in a brake-hose production facility (Hubner *et al*, 1992) (Table 7).

_

^a Biological tolerance values for working materials

Table 7: 2PG1ME exposure of operators during brake-hose manufacturing (Hubner et al, 1992)

Job (number of samples) / Airborne cond 8-h TWA		Number	of samples	Number of samples / Blood concentration			
(mg 2PG	1ME/m ³)	(mg 2PG1	ME/l)	(mg 2PG1M	E/g creatinine)	(mg 2PC	G1ME/l)
Mean ± sd ^a	Range	Mean± sd	Median, range	Mean ± sd	Median, range	Mean ± sd	Median, range
Actual product	ion (5)	5		6		6	
82.2 ± 31.1	48.0 - 116.6	4.6 ± 3.4	3.2, 1.7 - 9.6	8.5 ± 12.7	3.1, 1.6 - 34.1	13.5 ± 4.4	14.6, 7.3 - 17.7
Leak testing (7)	8		8		8	
68.6 ± 54.0	18.0 - 184.0	4.2 ± 2.1	4.4, 1.3 - 7.2	6.5 ± 6.4	3.8, 0.6 - 14.7	11.0 ± 4.4	10.0, 7.3 - 20.1
Mounting (6)		8		8		8	
11.3 ± 4.4	5.5 - 17.0	ND ^b	ND	ND	ND	ND	ND

^a Standard deviation

The mean excretion half-life of 2PG1ME as determined in the three highest exposed individuals was 4.4 hours. A tentative biological exposure limit of 38 to 109 mg 2PG1ME/l blood or 10 to 31 mg/l urine was established, corresponding to an 8-h TWA air concentration of 375 ppm 2PG1ME (1,404 mg/m³) (Hubner *et al*, 1992).

Hallock *et al* (1993) reported on worker exposure to EGEEA and EGME in microelectronics manufacture. Full-shift personal air concentrations for EGEEA ranged from 0.001 to 0.64 ppm $(0.005 - 3.5 \text{ mg/m}^3)$ while short-term task-based exposures were between < 0.002 and 0.043 ppm (< 0.01 - 0.24 mg/m³). For EGME full-shift exposures were 0.003 to 0.53 ppm $(0.009 - 1.68 \text{ mg/m}^3)$ and task exposures < 0.002 and 2.3 ppm (< 0.006 - 7.3 mg/m³).

In a study of 30 silk-screen painters exposed to EGEEA, the 8-h TWA airborne concentration of EGEEA was 12 ppm (range 2.9 - 34 ppm) (66, 16 - 187 mg/m³) in 12 press operators; in other jobs the levels ranged from 0.7 to 7.6 ppm (3.8 - 42 mg/m³). The urinary excretion of EAA corresponded well with the air concentrations and ranged from 1.1 to 27 mg EAA/g creatinine in specimens collected at the end of the shift in the second half of the working week. The results indicated that dermal absorption of EGEEA was not a significant problem in that facility (Lowry et al, 1993).

Ethylene glycol exposure was studied in 19 workers in a varnish production plant (Table 8) and a group of 14 workers in the ceramic industry (Table 9). In 17 workers (all 14 workers in the ceramics industry and 3 of the varnish manufacturers), the kinetics of EAA were studied during an exposure-free weekend. The median half-life value for excretion was calculated as 57.4 or 63.4 hours, without or with creatinine correction, respectively (Söhnlein *et al*, 1993).

b Not detected, assuming 0.5 mg/l limit of detection

Table 8: Exposure of 19 workers in a varnish production plant (Söhnlein et al, 1993)

Workplace (number of operators /		Average (range) airbo	rne concentration		Average (range) urinary	metabolite concentration
Glycol ether						
	Monday		Tuesday		Monday	Tuesday
Varnish production (12)	(ppm)	(mg/m^3)	(ppm)	(mg/m^3)	(mg EAA/l)	(mg EAA/l)
EGEE	2.9 (< 0.6 - 15.2)	(11, < 2.2 - 57)	2.1 (< 0.1 - 6.2)	(8, < 0.4 - 23)	53.2 (2.3 - 180)	53.8 (11.1- 43.7)
EGEEA	0.5 (< 0.1 - 3.7)	(2.7, < 0.5 - 20.3)	0.1 (< 0.1 - 0.4)	$(0.5, \le 0.5 - 2.2)$		
Store (2)						
EGEE	< 0.1	(< 0.4)	< 0.1, 0.2	(< 0.4, 0.7)	3.1 (1.9 - 4.3)	3.4 (2.6 - 4.2)
EGEEA	< 0.1	(< 0.5)	< 0.1	(<0.5)		
Laboratory (4)						
EGEE	< 0.1	(< 0.4)	< 0.1	(< 0.4)	4.4 (1.9 - 6.0)	5.1 (3.9 - 7.6)
EGEEA	0.3 (< 0.1 - 0.4)	$(1.6, \le 0.5 - 2.2)$	0.3 (0.2 - 0.3)	(1.6, 1.1 - 1.6)		
Office (1)						
EGEE	< 0.1	(< 0.4)	< 0.1	(< 0.4)	7.7	9.8
EGEEA	< 0.1	(<0.5)	< 0.1	(< 0.5)		
Varnish production (12)					(mg BAA/l)	(mg BAA/l)
EGBE	0.5 (< 0.1 - 1.4)	(2.5, < 0.5 - 6.9)	0.6 (< 0.1 - 1.0)	(2.9, < 0.5 - 4.9)	0.2 (< 0.02 - 1.3)	16.4 (0.8 - 60.6)
Store (2)						
EGBE	< 0.1	(< 0.5)	0.1	(0.5)	0.09 (0.05 - 0.12)	0.9 (0.4 - 1.4)
Laboratory (4)		-	_			
EGBE	< 0.1	(<0.5)	< 0.1	(< 0.5)	0.04 (< 0.02 - 0.12)	1.6 (0.1 - 5.1)
Office (1)						
EGBE	< 0.1	(< 0.5)	< 0.1	(< 0.5)	< 0.02	0.9

Table 9: Urinary excretion of EEA in 17 workers (14 in ceramic industry and 3 in varnish production) (Söhnlein et al, 1993)

Average		(median)	Range		
Concentration	(mg/l)	(mg/g creatinine)	(mg/l)	(mg/g creatinine)	
Friday, post-shift urine	44.8 (29.8)	41.3 (27.6)	4.5 - 196.9	2.0 - 156.3	
Monday, pre-shift urine	19.3 (10.7)	17.1 (11.6)	3.1 - 85.1	1.3 - 79.2	
Calculated half-life	(h)	(h)	(h)		
	74.3 (57.4)	82.0 (63.4)	69.6 - 250.7	24.8 - 240.1	

A good correlation was observed between urinary BAA collected in 6 workers in a semi-conductor factory, engaged in polymerisation of resin dissolved in EGBE, at the end of the shift and airborne concentrations of EGBE during the shift. The airborne concentrations correlated better to the total BAA (r = 0.76, after acid hydrolysis of the conjugates) than to the either free BAA (r = 0.50) or conjugated BAA (r = 0.72). Creatinine correction slightly ameliorated the correlation (r = 0.78). The percentage of conjugated versus total BAA varied from 44% to 92% and decreased over the working week. Hydrolysis of the urine samples prior to analysis to determine free BAA seems essential for more reliable determination of the total body burden (Sakai *et al*, 1994), an observation also found by other investigators (Rettenmeier *et al*, 1993; Corley *et al*, 1997).

Occupational airborne exposures to EGBE and post-shift urine concentrations of BAA during use of window cleaning products were reported by Vincent *et al* (1993) (Table 10).

Table 0: Concentration of BEn personial and BAA in post-shift urine in window cleaners (Vincent et al, 1993)

Job	Airborne EG	BE concentratio	Urinary BA	Urinary BAA		
(No. of operators)	Mean ± sd ^a		Range		Mean ± sd	Range
	(No. of	samples)			(No. of samples)	
(ppm)		(mg/m ³)	(ppm)	(mg/m ³)	(mg/g creatin	ine)
Cleaning new car	2.33 ± 2.44	(11.4 ± 12)	< 0.10 - 7.33	(< 0.49 - 36)	111.3 ± 99.1	12.7 -
windows (7)	(15)				(12)	371
Cleaning used car	0.36 ± 0.41	(1.77 ± 2.0)	< 0.10 - 1.52	(< 0.49 - 7.47)	6.3 ± 6.7	< 2 -
windows (6)	(15)				(11)	24.4
Office cleaner of	$0.32 \pm < 0.1$	$(1.57 \pm < 0.5)$	< 0.30 - 0.73	(< 1.47 - 3.59)	$2.1 \pm < 1$	2 - 3.3
windows,	(32)				(32)	
half shifts (8)						

^a Standard deviation

A log-log correlation between EGBE exposure and BAA in urine was poor (r = 0.603), but statistically significant (p < 0.001). A better (r = 0.963, p < 0.001) log-log correlation was observed between BAA in urine and the quantity of cleaning product used, suggesting that dermal exposure was the most significant route of exposure as protective gloves were used only by 2 of 29 persons sampled (Vincent *et al*, 1993). These results may also be applicable as an indicator of consumer exposure albeit at lower levels (Section 3.1.2).

During paint stripping and painting operations a group of workers exposed to a variety of organic solvents, including EGEA, was monitored by personal air sampling and biological monitoring

of EAA (Vincent *et al*, 1994) (Table 10). These results may also be applicable as an indicator of consumer exposure albeit at lower levels (Section 3.1.2).

Table 11: Exposure to EGEEA in paint strippers and painters (Vincent et al., 1994)

Day	Number of operators	Airborne concen 8-h T		Uninary	concentration	(mg EAA/g cre	atinine)
			Pre-shift			Post-	shift
		Mean ± sd	Range	Mean ± sd	Median, range	Mean ± sd	Median, range
1	5	110 ± 29	81 - 150	125 ± 100	106, 55 - 297	117 ± 72	99, 25 - 197
2	9	63 ± 29	29 - 144	109 ± 52	81, 59 - 200	150 ± 59	139, 81 - 237
3	9	73 ± 27	38 - 127	98 ± 37	98, 38 - 160	141 ± 49	133, 82 - 215

Full-shift exposures to 2PG1EE solvent contaminated with 1-propylene glycol 2-ethyl ether (1PG2EE) (8%) during colour rotagravure printing were 6.5 to 34.1 mg 2PG1EE/m³ (median 15.3 mg/m³) and 0.9 to 3.9 mg 1PG2EE/m³ (median 1.9 mg/m³). Post-shift urine sampling showed levels of 2PG1EE of 0.2 to 2.8 mg/l (median 0.8 mg/l), without significant correlation with low airborne exposure to 2PG1EE; levels of 2-ethoxypropionic acid (2-EPA) of 2.8 to 37.2 mg/l (median 21.9 mg/l) showed a fair correlation (r = 0.657, p < 0.05) with airborne exposure to 1PG2EE (Bader *et al*, 1996).

Hammond *et al* (1996) reported full-shift and short-term task exposures to EGEEA and 2PG1MEA during micro-electronics manufacture (Table 12).

Table 12: Exposure to EGEEA and 2PG1MEA during micro-electronics manufacture (Hammond et al, 1996)

Glycol ether	Number of TWA (task) samples	Airborne	concentration,	Short-term concentration			
		Mean ± sd Geometric mean ± sd		Range			
		(ppb)	$(\mu g/m^3)$	(ppb)	$(\mu g/m^3)$	(ppb)	$(\mu g/m^3)$
EGEEA	23 (12)	64 ± 148	(352 ± 813)	22 ± 3.7	(121 ± 20.3)	< 2 - 110	(<11 - 605)
2PG1MEA	20 (46)	12 ± 14	(66 ± 77)	8 ± 2.5	(44 ± 14)	< 2 - 2,300	(< 11 - 12,640)

Vincent *et al* (1996 cited by INSERM, 1999) reported further surveys for a range of glycol ethers across a number of industries. The airborne glycol ether and urinary metabolite concentrations are shown in Table 13. The data on car washing (EGBE), cleaning (EGBE) and house painting (EGBE and EGBEA) may also be applicable as an indicator of consumer exposure albeit at lower levels (Section 3.1.2).

Table 13: Further surveys of industrial exposure to glycol ethers (Vincent et al, 1996 cited by INSERM, 1999)

Job (number of operators)	Glycol ether	Airborne concentration, 8-h TWA mean (range)		Biomarker	Urinary concentration, mean (range)	Remark
		(ppm)	(mg/m³)		(mg/g creatinine)	_
Aerospace (20)	EGEEA	14.8 (5.4 - 27.6)	(81.3, 29.7 - 151.7)	EAA	109 (2 - 237.4)	Respiratory protection equipment worn: exposure mostly dermal to liquid and vapour
Car washing (13)	EGBE	- (0.1 - 7.2)	(-, 0.5 - 35.4)	BAA	96.5 (7.4 - 371)	
Printed circuit manufacturing (13)	EGME	2.3 (0.1 - 18.1)	(7.3, 0.3 - 57.3)	MAA	39.2 (2 - 121.4)	
Cataphoresis (12)	EGBE	0.8 (0.1 - 6.2)	(3.9, 0.5 - 30.5)	BAA	17.9 (ND - 210)	Dermal route major contributor to exposure
Silk screen printing (110)	EGEEA	2.6 (0.1 - 20.6)	(14.3, 0.5 - 113)	EAA	- (0.1 - 20.6)	Dermal route major contributor to exposure
Cleaning (17)	EGBE	- (< 0.1 - 0.4)	(< 0.5 - 2.0)	BAA	- (< 0.1 - 0.4)	May duplicate some data from Vincent et al (1993)
Can coating (143)	EGEE(A)	-		EAA	10	
Metal frameworks (23)	EGEE(A)	-		EAA	9.6	
Paint manufacturing (248)	EGEE(A)	-		EAA,	10.1	
	EGBE(A)			BAA,		
	EGME			MAA		
Furniture manufacturing (50)	EGEE(A)	-		EAA,	9.1	
	EGBE(A)			BAA,		
	EGME			MAA		
Metallic packaging (79)	EGEE(A)	-		EAA,	7.5	
	EGBE(A)			BAA		
Auto paint(20)	EGEE(A)	-		EAA	7.1	
Plastics manufacturing (19)	EGEE(A)	-		EAA	6.9	
Pad printing (29)	EGEE(A)	-		EAA,	4.8	
	EGBE(A)			BAA		
Use of cutting fluids (13)	EGBE			BAA	3.2 (< 2 - 8.3)	

Table 13: Further surveys of industrial exposure to glycol ethers (cont'd) (Vincent et al, 1996 cited by INSERM, 1999)

Job (number of operators)	Glycol ether	Airborne concentration, 8-h TWA mean (range)		Biomark	er Urinary concentration, mean (range)	Remark
		(ppm)	(mg/m^3)		(mg/g creatinine)	
Offset printing (11)	EGBE(A)	-		BAA	2.2	
House painting (63)	EGBE(A)	-		BAA	< 2 (< 2 - 13.2)	

ND, not detected

Freedom_0001156_0058

Norbäck *et al* (1996) reported full-shift exposures for a range of glycol ethers during (industrial) house painting with water-based paints (Table 14). These results may also be applicable as an indicator of consumer exposure albeit at lower levels (Section 3.1.2).

Table 14: Personal full-shift air concentrations (mg/m³) of glycol ethers in house painters using water-based paints (Norbäck et al, 1996)

Number	of	Range	Mean	Geometric mean	
	samples				
DEGBE	20	< 0.01 - 8.1	0.8	0.02	
DEGEE	20	< 0.01 - 4	0.2	0.007	
EGBE	20	< 0.01 - 0.7	0.05	0.008	
DPGME	20	< 0.01 - 3.2	0.2	0.009	
DEGME	< 20	< 0.01 - 0.02	0.002	-	
DEGBEA	< 20	< 0.01 - 0.16	0.001	-	

Wesolowski and Gromiec (1997) reported exposures to various glycol ethers used by different paint and lacquer manufacturers (Table 15).

Table 15: Mean personal air concentrations (mg/m³) during paint and lacquer manufacturing (Wesolowski and Gromiec, 1997)

Glycol ether		Type of plant							
	Airtight mill	· ·	Non-airtight mill, primitive solvent handling	Small plant, ball mill, old resin plant	Modern plant, high volume production				
Number of samples:	23	28	27	26	75				
2PG1MEA	0.1	ND	ND	ND	ND				
EGBE	0.3	0.4	0.3	0.2	0.1				
EGEE	0.1	0.1	0.1	0.1	0.1				
EGEEA	0.3	0.1	0.1	0.1	0.1				
EGMEA	0.1	0 [sic]	0.1	0.1	0.1				

ND, not detected

The correlation between EGME exposure and urinary excretion of MAA was studied in operators of a circuit board manufacturing plant. Daily personal air samples and urine samples were collected on 6 consecutive days from 18 operators and 30 non-exposed controls. No MAA was found in the urine of the non-exposed workers. In exposed workers, highly significant correlations were observed between the urinary MAA at the end of the shift on the 5th working

day and the average exposure over the 5 preceding days (r = 0.702, p = 0.001) and between the weekly increase of urinary MAA and the average exposure over the 5 preceding days (r = 0.741, p = 0.0007). Biological exposure limits, corresponding to exposure (8 h/d) to 5 ppm EGME for 5 days, were 40 mg/g creatinine at the end of the shift or a weekly increase of MAA of 20 mg/g creatinine (Shih *et al*, 1999a).

Two groups of shipyard painters experienced low (n = 30) or high exposure (n = 27) to solvents, including EGEEA as determined by means of personal air and biological monitoring. The mean personal air concentration to EGEEA was 1.8 ppm (range ND - 8.1 ppm) (9.9 mg/m³, ND - 44.5 mg/m^3) and 3.0 ppm (ND - 18.3 ppm) (16.5 mg/m^3 , ND - 100.6 mg/m^3) in the low and high exposure group, respectively. The corresponding geometric mean/geometric standard deviation urinary levels of EAA were $9.2 \pm 5.6 \text{ mg/l}$ (range ND - 227 mg/l) or $0.6 \pm 11.3 \text{ (ND - }15.1) \text{ mg/g}$ creatinine in urine samples collected at the end of the shift. In unexposed controls urinary EAA was $0.1 \pm 2.6 \text{ (ND - }1.5) \text{ mg/g}$ creatinine (Kim *et al*, 1999).

Exposure of 3 male workers to 2PG1ME involved in cleaning of vats in an ink factory, was assessed by personal air monitoring and by determination of urinary 2PG1ME. Air concentrations were between 20 and 40 ppm (75 - 150 mg/m³) and correlated well with the urinary 2PG1ME after 5 hours of exposure. 2PG1ME was rapidly cleared from the body and 40 to 60% of the total urinary 2PG1ME was present as conjugates (Devanthéry *et al*, 2000).

Commercial, technical grade propylene glycol ethers may be contaminated with a small percentage of their β -isomer. Since β -isomers have a primary alcohol function, they can be metabolised to the corresponding 2-alkoxypropionic acids (Section 2.7.2.4), which can be determined in the urine of exposed individuals. Indeed, small amounts of 2-MPA and 2-EPA could be determined in the urine of 54 silkscreen printers with occupational exposure to various glycol ethers, including 2PG1MEA and 2PG1EEA. The urinary excretion of 2-MPA and 2-EPA immediately after the end of the shift was linearly dependent on the preceding personal airborne exposure to the technical grade 2PG1MEA and 2PG1EEA, respectively (Laitinen, 1997).

Exposure to 2PG1ME and DPGME and a variety of other solvents including DEGEE was measured in 38 workers involved in the removal of graffiti. Exposure was assessed by personal air monitoring as well as by biological monitoring through the determination of the glycol ethers or their metabolites in blood and urine. Exposure to glycol ethers was well below the Swedish permissible exposure levels and none of the glycol ethers could be detected in the urine of the workers. EAA and 2-MPA, however, were detected in almost every urine sample, including those of non-exposed controls. 2-Methoxy-ethoxyacetic acid (2-MEAA) was found in only a few workers. Urinary EAA, but not 2-MPA, was significantly lower in workers using gloves. There was no correlation between the concentration of the glycol ethers in air and the excretion of acid metabolites (Anundi *et al*, 2000).

3.1.4 Measurement methods

In air

It should be noted that ambient air and personal air monitoring data reported in the literature do not always reflect the actual exposures. There are normally wide variations in exposure conditions, not only between industrial plants but also within the same plant between different locations and times. Furthermore, sampling might have generally underestimated airborne concentrations as the glycol ethers could have become unstable on the collection medium (US-NIOSH, 1983). Measurement was further complicated in that many of the uses of glycol ethers also involved simultaneous exposure to other solvents, which may have interfered with the analysis. Finally, the use of air monitoring to determine body burden is insufficient to take account of dermal absorption, which can make a significant contribution to overall systemic body burden.

In view of their potentially greater sensitivity, the application of biological monitoring techniques may permit a more complete and accurate assessment of worker exposure to low concentrations of glycol ethers.

The majority of reported measurements were made using US-OSHA Method 53, or variations thereof, involving collection of the glycol ether vapour on a charcoal adsorbent, followed by solvent desorption and analysis by a gas chromatograph (GC) equipped with a flame-ionisation detector (FID) (US-OSHA, 1985). The techniques used are summarised in Table 16.

Table 16: Air measurement methods used

Sample collection	Extraction (desorbent)	Analysis	Reference
Drawing known volume of air through 100/50 mg charcoal tube and also using 3M and Dräger passive (diffusion) samplers	5% ethanol in CS ₂	GC-FID	Veulemans et al, 1987a
OSHA 53 Drawing known volume of air through charcoal tube	DCM ^a in ethanol	GC-FID	Piacitelli et al, 1990
OSHA 53 Drawing known volume of air through charcoal tube	5% DCM in methanol	GC-FID	Hallock et al, 1993
Drawing known volume of air through 100/50 mg charcoal tube	DCM	GC-FID	Vincent et al, 1993, 1994
OSHA 53 Drawing known volume of air through charcoal tube	5% methanol in DCM	GC-FID	Hammond et al, 1996
Dräger ORSA 5 diffusion tube	DCM in CS ₂	GC-FID	Bader et al, 1994
Drawing known volume of air through XAD7 resin tube	DCM	GC-FID	Norbäck et al, 1996

Table 16: Air measurement methods used (cont'd)

Sample collection	Extraction (desorbent)	Analysis	Reference
Drawing known volume of air through 100/50 mg	Methylene chloride	GC, detector NS	Vincent et al, 1996 cited
charcoal tubes			by INSERM 1999
Drawing known volume of air through 100/50 mg	CS_2	GC-FID	Wesolowski and Gromiec,
charcoal tube			1997

^a Dichloromethane

NS, not specified

Additional methods have been published, for example, US-OSHA (1990a) Method 79 on EGME, EGEE, EGMEA and EGEEA (this is a revision to OSHA 53 method to allow for the measurement of lower airborne vapour concentrations), US-OSHA (1990b) Method 83 on EGBE and EGBEA, and US-NIOSH (1994) Method 1403 on EGBE, that may be adapted for EGBEA. The UK Health and Safety Executive (HSE) has published a method for the determination of hazardous substances (MDHS 72) on glycol ether acetate vapours in air: volatile organic compounds in air, laboratory method using pumped solid sorbent tubes, thermal desorption and gas chromatography (HSE, 1993) and MDHS 96 on volatile organic compounds in air, laboratory method using pumped solid sorbent tubes, solvent desorption and gas chromatography (HSE, 2000).

Biological monitoring

Glycol ethers with a *primary* alcohol and their acetates, such as the ethylene glycol ethers (and certain propylene glycol ethers, e.g. 1PG2ME), are rapidly metabolised to the corresponding alkoxy acetic (or alkoxypropionic) acids and their conjugates, and excreted in the urine. Uptake is therefore usually measured by determination of urinary metabolites of these glycol ethers. Occasionally the concentration of the glycol ethers themselves are determined in blood, urine or exhaled air. Glycol ethers with a *secondary* alcohol, such as most propylene glycol ethers, are metabolised primarily by *O*-dealkylation, yielding propylene glycol and carbon dioxide (Section 2.7.2.1 and 2.7.2.4). As a consequence, uptake of these glycol ethers is normally assessed by determination of the glycol ethers themselves in urine, blood or exhaled air.

Numerous studies in occupational settings indicate that urinary analysis for alkoxycarboxylic acids is a useful method for the biological monitoring of occupational exposure to glycol ethers. Alkoxycarboxylic acids are not normally present in human urine and, in general, the extent of urinary excretion of these metabolites gives a much better indication of systemic exposure than airborne measurements of glycol ethers. An overview of the methods used in the literature is given in Table 17.

Table 17: Biological monitoring methods used

Biomarker	Specimen and sampling Extraction and solvent ^a or reference		Analysis	Reference	
BAA	Urine	Methylation, solid phase XAD-4 resin	GC-FID	Begerow et al, 1988	
MAA, EAA, BAA	Urine	Pentafluorobenzoyl ation, DCM/TBAS	GC-ECD	Johanson, 1989	
EAA	Urine	Acidification, DCM or pentafluorobenzoylation	GC-ECD	Begerow and Angerer, 1990	
EAA	Urine, post-shift, second half of working wk	Groeseneken et al, 1989b		Lowry et al, 1993	
EAA	Urine, pre-shift d 1 and post- shift d 2 of working wk	Begerow and Angerer, 1990		Söhnlein <i>et al</i> , 1993	
BAA	Urine, pre-shift d 1 and post- shift d 2 of working wk	Begerow et al, 1988		Söhnlein <i>et al</i> , 1993	
BAA and its glutamine conjugate	Urine, post-shift last d and pre-shift d 1 of working wk	Acidification, ethyl acetate extraction, derivatisation with 4-nitrobenzylbromide and 18-crown-6-ether	HPLC- UV	Rettenmeier <i>et al</i> , 1993	
BAA (free and conjugated)	Urine, spot samples and postshift	Acid hydrolysis, DCM/IPA (2:1), trimethyl-silylation	GC-FID	Sakai <i>et al</i> , 1994	
2PG1EE	Urine, post-shift	Acetone elution, solid phase+ DCM	GC-FID	Bader et al (1996)	
EPA	Urine, post-shift	As EAA according to Söhnlein <i>et al</i> , 1993	Bader	et al (1996)	
MAA, EEA, BAA	Urine, post-shift	Groeseneken et al, 1989b		Vincent <i>et al</i> (1993, 1994 and 1996)	
MAA, EAA	Urine	Groeseneken et al, 1989b		Ke ič et al, 1997	
MAA, EAA, BAA, MPA, EPA	Urine, post-shift	Acid hydrolysis, ethyl acetate, GC-FI methylation		Laitinen, 1997	
2PG1ME	Urine	Ethyl acetate, trimethyl-silylation	GC-MS	Jones et al, 1997	
2PG1ME	Urine, blood	Jones et al, 1997		Brooke et al, 1998	
MAA, EAA, BAA	Urine	Acid hydrolysis, DCM/IPA 2:1	GC-MS	Shih et al, 1999b	
EAA	Urine, post-shift	Sakai <i>et al</i> , 1994		Kim et al, 1999	
EAA, BAA, MPA, MEAA	Urine, post-shift	Johanson, 1989		Anundi et al, 2000	
PGME	Urine, during- and post-shift	Solid phase (LC-18) + ethyl acetate, trimethyl-silylation	GC-FID	Devanthéry <i>et al</i> , 2000	

^a DCM, dichloromethane; IPA, iso-pentyl alcohol; LC-18, type of silica gel; TBAS, tetra-*n*-butyl-ammonium hydrogen sulphate, XAD-4, type of Amberlite resin

A consistent urinary sampling pattern is important when using urinary alkoxyacetic acids as biomarkers for exposure to glycol ethers to reduce the variability in results. This sampling pattern should be related to the urinary half-life of the respective alkoxyacetic acid, e.g. for BAA, which has a relatively short urinary half-life of about 6 hours, sampling at the end of the shift would be

most appropriate. For MAA, which has a much longer urinary half-life of about 3 days lead to significant build up over the working week, sampling at the end of the working week would be more appropriate.

Sensitive techniques for the quantitative analysis of alkoxyacetic acids in urine have been developed in the late eighties (Johanson *et al*, 1988; Groeseneken *et al*, 1989b; Johanson, 1989) and have been adapted to recent developments in analytical chemistry (Laitinen 1997; Shih *et al*, 1999b; Johanson, 2000).

So far, only for EAA (Lowry, 1996) and for BAA (Angerer and Gündel, 1994) has the methodology been validated and have biological exposure limits been established (Table 18).

Table 18: Biological exposure limits

Biomarker	US-NIOSH (1990a,b)	Finnish Institute of Occupational Health (Laitinen, 1998)		DFG (2000)	ACGIH (2001)
(mg/g	creatinine)	(mmol/mol creatinine)	(mg/g creatinine)	(mg/l)	(mg/g creatinine)
MAA	-	3 ^b	(270)	-	Recommended, no value a
EAA	5 °	50 ^b	(5,200)	50 ^a	100 ^a
BAA	60	70 °	(8,300)	100 ^a	-

^a In post-shift urine collected at the end of the working week

An external quality control programme is available for MAA, EAA and BAA. The method for EEA is basically a validation of the methodology developed by Groeseneken *et al* (1989b), which therefore may be considered retrospectively validated.

3.2 Health effects

Widespread exposure to glycol ethers in consumer products such as paints, inks, lacquers, surface coatings and cleaning products has provided no conclusive data on adverse health effects in the general population.

^b In urine collected 14 - 16 h after exposure

c In post-shift urine

Limited information available on adverse health effects of glycol ethers in humans has come from case reports on accidental or intentional poisoning, workplace exposures, controlled short-term exposure studies and a few epidemiological studies.

3.2.1 Haematological effects

EGME and EGEE

Five workers believed to have been exposed to 61 to 3,960 ppm of EGME (193 - 12,530 mg/m³) suffered from anaemia and, in one case, hypocellular bone marrow (Zavon, 1963). In a seperate report, substitution of acetone for EGME as an industrial cleaning agent resulted in 2 cases of poisoning. Signs included neurobehavioural abnormalities and were reversible (Ohi and Wegman, 1978).

A cross-sectional, epidemiological study of employees engaged in the manufacture and packaging of EGME reported inconclusive evidence of toxic effects on haematological parameters among 53 workers exposed to EGME vapour (area monitoring 4 - 20 ppm [13 - 63 mg/m³]; personal monitoring 5.4 - 8.5 ppm TWA [17 - 27 mg/m³]) as compared with 44 non-exposed workers (Cook *et al*, 1982).

Low levels of RBC and WBC, platelets, haemoglobin (Hb) and haematocrit (Hct) were reported in an employee after 1 year of repeated respiratory and skin exposure to EGME. The average ambient air levels of EGME were approximately 35 ppm (range 18.2 - 57.8 ppm) (110, $58 - 183 \text{ mg/m}^3$). There was also a lower concurrent exposure to methyl-ethyl ketone and commercial PGME (mixture of α -isomer 2PG1ME with < 0.5% β -isomer 1PG2ME). All haematological parameters had returned to normal values one month after cessation of EGME exposure (Cohen, 1984).

Welch and Cullen (1988) described anaemia and granulocytopenia in shipyard painters exposed to EGME and EGEE. The airborne exposure to EGEE ranged from 0 to 21.5 ppm TWA (mean 2.6 ppm, median 1.2 ppm) (0 - 81, mean 9.7, median 4.5 mg/m³) and for EGME ranged from 0 to 5.6 ppm TWA (mean 0.8 ppm, median 0.4 ppm) (0 - 17.7, mean 2.5, median 1.3 mg/m³) (Sparer *et al*, 1988).

Questel (1992) evaluated a possible association between haemopathies reported as occupational disease and exposure to glycol ethers but did not demonstrate causality.

Mild macrocytic anaemia and leukopenia with an increased proportion of lymphocytes was described in 3 otherwise healthy young women dipping pieces of cellulose glass frames in a

mixture of acetone (70%) and EGME (30%) in a frame factory; exposure was probably predominantly by the dermal route. Examination 1 year after cessation of exposure showed normal haematological levels in 2 cases; the erythrocyte count in the third case did not normalise for 2 years (Larese *et al*, 1992).

Changes in lymphocyte sub-populations were reported in 9 parquet floor makers exposed to a variety of solvents including EGME, EGEE and EGBE. The exposure in this group was high and variable (Denkhaus *et al*, 1986).

Acute exposure of humans to EGEE caused depression of the CNS and metabolic acidosis. Chronic effects included CNS dysfunction (Section 3.2.2), bone marrow suppression, anaemia, and granulocytopenia (Browning and Curry, 1994).

FGBF

Erythrocyte osmotic fragility did not change in 2 men exposed to 114 ppm EGBE (560 mg/m³) for 4 hours, or in 2 men and 2 women, exposed to 114 ppm EGBE (560 mg/m³) for 8 hours. This was in contrast to effects on rats under the same exposure conditions, where haemolysis of erythrocytes was reported. Erythrocyte osmotic fragility did not change *in vivo* in 2 men and 1 woman exposed to 195 ppm EGBE (958 mg/m³) for 8 hours (Carpenter *et al*, 1956).

Johanson and Johnsson (1991) demonstrated that EGBE concentrations in the blood of 5 male volunteers who were exposed to 20 ppm EGBE (98 mg/m³) for 2 hours were approximately two orders of magnitude lower than those causing swelling and haemolysis of human erythrocytes *in vitro*.

DPGME

Aplastic anaemia was reported in a worker employed in offset printing and potentially exposed to a range of organic solvents (including EGEE and DPGME), insoluble pigments and acrylic and epoxy resins. In a study of other workers in the same plant, bone marrow abnormalities were diagnosed in 6 of 7 subjects examined; bone marrow hyperplasia was seen in 6 subjects and an increase in periodic acid Schiff (PAS)-stained positive stromal material was seen in 3 individuals. Although the myeloid/erythroid ratio in these subjects was lower than in the normal population, the other reported bone marrow changes (reduced cellularity, the presence of ringed sideroblasts and PAS-stained positive stromal material) were difficult to interpret in view of the absence of adequate controls and the fact that the cellular content of the peripheral blood was entirely normal (Cullen *et al.*, 1983). Since the workers were exposed to many different chemicals, with no

measure of individual skin or inhalation exposure to any one material, it is impossible to draw any conclusions from this study about a possible association between bone marrow changes and glycol ether exposure.

3.2.2 Behavioural and neurological effects

EGME

Early reports stated that repeated human exposure to solvents containing EGME could result in headache, lethargy, weakness, dizziness, ataxia, toxic encephalopathy and pathological reflexes (Donley, 1936; Parsons and Parsons, 1938; Greenburg *et al*, 1938; Groetschel and Schürmann, 1959; Browning, 1965; IPCS, 1990; Zavon, 1963; Nitter-Hauge, 1970; Ohi and Wegmann, 1978). Levels of exposure were poorly documented in most cases.

Cohen (1984) reported apathy, fatigue and tiredness in an employee after 1 year of repeated respiratory and dermal exposure to EGME. The average vapour exposure level was around 35 ppm (range 18.2 - 57.8 ppm) (68.2 - 216.5 mg/m³). There was also lower concurrent exposure to methyl ethyl ketone and (commercial) PGME.

EGPhE

Medical students dissecting human anatomical specimens preserved in a 1% solution of EGPhE in water complained of tiredness, dizziness and headache. Causality was not established (Froelich et al, 1984).

Retrospectively, 3 women were reportedly exposed (primarily by skin contact) to EGPhE, which was used as anaesthetic for handling fish at a salmon hatchery. During use of EGPhE the fish handlers reported headache, light-headedness, slurred speech, euphoria, grogginess and "feeling drunk". The workers also reported diminished sensation and strength of hands and fingers, especially in the preferred hand. After 1 year of exposure, additional symptoms developed without correlation with time and frequency of exposure, including excessive fatigue, irritability, impaired recent memory and of verbal or visual learning and comprehension, lowered intellectual and mental function, depression, somnolence and impaired concentration, some detected only 4 years after cessation of exposure. Persistent neuropathy did not develop, but neuropsychological testing verified that all 3 women had focal cognitive impairments that persisted up to at least 3 years after cessation of exposure. The author concluded that immediate and delayed effects of EGPhE on the CNS resemble those of other organic solvents (Morton, 1990). Information on exposures, status of other workers (who were not affected) or lifestyle confounders such as alcohol are lacking; comments on this article have been published (Schmuck *et al*, 2000).

3.2.3 Reproductive effects

An epidemiological survey was conducted in the semi-conductor industry in the USA. The study focussed on possible reproductive effects, such as infertility, complications during pregnancy, pregnancy outcomes, spontaneous abortions, preterm delivery and congenital malformations. Employees were interviewed about the occurrence of these possible effects. On the basis of the industrial process and the jobs held by the study subjects, sub-classifications were made according to exposure to chemicals or groups of chemicals. The researchers observed an association between chemical exposure to glycol ethers and the occurrence of spontaneous abortions (rate of 35% in manufacturing jobs compared to 18% in non-manufacturing workers). However, the researchers concluded, given the lack of quantifiable exposure data on glycol ethers and other chemicals the current association should be regarded as tentative until confirmed by studies which are able to discriminate the numerous chemical and physical exposures found in the semi-conductor industry (Pastides *et al*, 1988).

The study of Pastides *et al* (1988) was followed by a larger epidemiological study in the semi-conductor industry in the USA. This latter study consisted of a cross-sectional component, a retrospective component and a prospective component, with the retrospective and prospective components focussing mainly on reproductive effects. Most employees were exposed to a range of chemical and physical circumstances such as exposure to electromagnetic fields. In both the prospective and the retrospective components small increases in the occurrence of spontaneous abortions were seen, reaching a level of sta tistical significance, and showing a positive doseresponse relationship with the use of solvents, including glycol ethers. Adjustment for known factors that are related to spontaneous abortions, such as smoking, age, ethnicity, stress and socioeconomic status did not essentially alter the findings (Schenker *et al*, 1995) ^a. There was an association between spontaneous abortion rate and the exposures to various agents (15% in fabrication jobs compared to 10% in non-fabrication workers). However, it was not possible to accurately study the effect on the occurrence of spontaneous abortions by each individual agent.

In a review on the effects of glycol ethers on the reproductive health of occupationally exposed individuals, Figà-Talamanca *et al* (1997) concluded that the evidence accumulated at that time supports the hypothesis of an increased risk for spontaneous abortion among women in jobs involving exposure to glycol ethers, particularly among photo-lithography and diffusion workers in the semi-conductor industry.

In Europe, a large multi-centre case/control study was conducted to investigate possible occupational risk factors for congenital malformations. The study comprised 984 cases of congenital malformations that compared to 1,134 controls matched for place and date of birth. Information on jobs held during pregnancy was collected by interviewing the mothers of the

ECETOC TR No. 95

_

^a See also editorial and specific reports in American Journal of Industrial Medicine 28:635 (1995), special issue.

cases and controls. Data on other variables such as smoking, alcohol use and medical history were also collected. The case and control groups were matched for age, socio-economic status, employment during pregnancy, prior reproductive status (parity, previous spontaneous abortion and previous stillbirth), as well as tobacco and alcohol use. The job descriptions were then rated by a chemist with respect to the likelihood of exposure to glycol ethers. Within the total study group a small but statistically significant association was found between reported exposure to glycol ethers and congenital malformations, specifically for three subcategories of malformations (Cordier *et al*, 1997).

Windham *et al* (1991), in a case-control study of 1,926 respondents, reported an association between exposure to a number of solvents and spontaneous abortion with glycol ethers (not further specified) showing a slight association.

In a reproductive health study of male and female employees (and wives of male employees) of two semi-conductor manufacturing plants, a significant trend in spontaneous abortion rates was observed for female employees working in processes with the highest potential exposures to glycol ethers. Sub-fertility and conception delays were also reported. There was no positive trend in spontaneous abortion rates among wives of exposed male workers (Gray *et al*, 1993).

Swan *et al* (1995) analysed these epidemiology studies and concluded that there was an increase in spontaneous abortion rates associated with semi-conductor manufacture, which – on the basis of unspecified toxicological information – might be associated with glycol ethers.

Lamm *et al* (1996) have summarised the results of three epidemiology studies (Pastides *et al*, 1988; Schenker *et al*, 1992 [subsequently published by Schenker *et al*, 1995]; Gray *et al*, 1993; Corn and Cohen, 1993), conducted on workers in the semi-conductor industry, and concluded that increased risk of spontaneous abortion appears to be associated with exposure during the photolithography process, but cannot be attributed to any specific chemical.

Cordier *et al* (1997) interviewed 984 mothers whose children had major malformations and 1,134 matched controls from 4 European countries. On the basis of the interviews, potential exposure to glycol ethers was estimated; other workplace practices and exposure to other materials were not considered. An association between presumed glycol ether exposure and a number of specific malformations was reported.

The reports of the increased prevalence of spontaneous abortions in female workers in the semi-conductor industry led to a study by the UK Health and Safety Executive in the Scottish semi-conductor industry. No differences in prevalence of spontaneous abortions were noted as a result of occupational conditions, including exposure to glycol ethers (Elliot *et al*, 1998).

In another case-control study occupational exposure in the peri-conceptional period to glycol ethers and derivatives did not increase the risk for neural tube defects (Shaw *et al*, 1999).

The Occupational Exposure and Congenital Malformation Working Group investigated the possible association of maternal occupational exposure during pregnancy with the occurrence of oral clefts in a European case-referent study using 6 congenital malformation registers between 1989 and 1992. The occupational exposure of 851 women, including 100 mothers of babies with oral clefts and 751 mothers of healthy referent. The analysis suggested that exposures to several chemical classes were associated with orofacial clefts, whereby the glycol ethers had the lowest odds ratio (1.7, 95% confidence interval 0.9 - 3.3) (Lorente *et al*, 2000).

In a case-control study in Slovakia 196 mothers of live or stillborn babies with a major malformation or foetuses from therapeutic abortion were interviewed about various risk factors and compared with a control group. Potential exposure to various product families containing glycol ethers was identified in 15 women, 7 containing EGEE and 4 EGBE or its acetate. The overall risk of congenital anomalies was elevated (odds ratio 2.3, confidence interval 0.7 - 7.0) (Cordier *et al*, 2001).

EGME, EGMEA, EGEE, EGEEA and DEGDME

A cross-sectional, epidemiological study of employees manufacturing and packaging EGME reported no conclusive evidence of toxic effects on fertility indices among 53 workers exposed to EGME as compared with 44 non-exposed workers (area monitoring 4 - 20 ppm, personal monitoring 5.4 - 8.5 ppm TWA) (area 13 - 63, personal 17 - 27 mg/m³) (Cook *et al*, 1982).

The semen of 73 shipyard painters was examined following exposure to EGEE (0 - 21.5 ppm 8-h TWA; mean 2.6 ppm, median 1.2 ppm) (0 - 81, mean 9.7, median 4.5 mg/m³) for the previous 2 to 6 months. The painters also had been exposed to EGME (0 - 5.6 ppm 8-h TWA; mean 0.8 ppm, median 0.44 ppm) (0 - 17.7, mean 2.5, median 1.4 mg/m³) during the same period. The authors concluded that exposure to EGME and EGEE lowered sperm count in this group of painters, as compared with a control group of 55 non-exposed workers. This was consistent with an effect of these glycol ethers on spermatogenesis (Welch *et al*, 1988).

EGEE exposure had no effect on semen quality in metal casting workers exposed to EGEE (full-shift breathing zone measurement 0 - 24 ppm, geometric mean 6.6 ppm) (0 - 90 and 24.7 mg/m³, respectively) (Ratcliffe *et al*, 1989).

Bolt and Golka (1990) reported hypospadia (a developmental anomaly whereby the male urethra opens on the underside of the penis or perineum) in 2 young boys whose mother had experienced intensive (mainly dermal) occupational exposure to EGMEA during both pregnancies.

A study of spontaneous abortions in 200 employees of a book cover manufacturing plant showed an estimated relative risk among pregnant women working at the plant of 2.7 (95% confidence interval 1.35 - 5.42). An industrial hygiene survey reported that exposures to EGEEA were well below the TLV. In addition, it identified exposures to other toxicants reported to have adverse effect on reproduction and foetal development (Fidler *et al*, 1991).

In 1993, the results of a case-control study on patients from a reproductive disorders clinic were reported. The study consisted of 1,019 males with an abnormal spermiogram and 475 controls with a normal spermiogram; the case and control groups were matched for age, socio-economic status, smoking and alcohol consumption. Urine samples of the study subjects were collected and tested for the presence of MAA and EAA, as measures of exposure to EGME and EGEE respectively, and their acetates. EAA was detected in 39 cases and 6 controls, with a highly significant (p = 0.004) odds ratio of 3.11; MAA was detected in only 1 case and 2 controls. However, there was no correlation between urinary EAA concentration and sperm quality parameters, or between the case and control groups, although this might be related to the latency of the effects (Veulemans *et al*, 1993).

Low-level exposures to EGEEA had no effect on menstrual cycle period or duration in women employed in the liquid crystal display industry (Chia et al, 1997).

Saavedra *et al* (1997) described congenital malformations (with most of the manifestations in the craniofacial, musculoskeletal, and central nervous system) with varying degrees of mental retardation in 44 patients whose mothers have been occupationally exposed during pregnancy to EGME and MEG through cutaneous, oral, and respiratory routes in a Mexican factory. A subsequent "case-and-control" study revealed causality with the EGME and MEG exposure.

In exposed workers anaemic effects of EGME exposure were observed and correlated with the biological monitoring of urinary MAA. Spermatotoxic effects were not noted (Shih *et al*, 2000a).

El-Zein *et al* (2002) investigated 41 offspring children of 28 women occupationally exposed to EGME for an average duration of 4.6 years. Six children of 5 women exposed during pregnancy showed characteristic dysmorphic features that were not observed among 35 children of 23 women who had no exposure during pregnancy. No data on the height of exposure are presented.

EGBE, 1PG2ME and others

A number of congenital malformations including cleft lip reportedly correlated with maternal occupational exposures to glycol ethers. Women exposed were divided primarily into two groups: those exposed to EGBE and EGPE and their acetates; and those exposed to 1PG2ME and its acetate, as well as polyethylene and polypropylene compounds. These authors suggest this represents evidence of the human teratogenicity of EGBE and compounds of the propylene glycol series. It is also suggested that EGBE, rather than a causative agent, is acting as a marker for a wider range of occupational exposures (Cordier *et al*, 1997). This study suffers from several methodological problems and a lack of biological plausibility, since implicated agents have tested negative in animal studies. Selection and recall bias may have also contributed to these findings (Maldonado *et al*, 2003).

3.2.4 Other effects, including poisoning

EGME, EGEE and EGEEA

No cases of skin irritation, sensitisation or eye irritation have been reported in humans.

Young and Woolner (1946) reported a case of fatal poisoning when a man drank an estimated 200 ml of EGME (193 g) mixed with rum. The urine from this individual contained ethanol but no methanol, supporting the contention that EGME was not significantly metabolised through ether cleavage. The kidneys showed degenerative and toxic changes, there was liver fatty degeneration, the pancreas showed early necrosis and there was acute haemorrhagic gastritis.

Consumption of EGEE (40 ml [37 g]) by a woman led to dizziness, loss of consciousness, metabolic acidosis and renal and liver damage. She recovered after 6 weeks (Fucik, 1969 cited by Boatman, 2001).

Nitter-Hauge (1970) reported 2 cases of men who drank EGME (100 ml [97 g]). Symptoms included agitation, confusion, nausea, cyanosis, hyperventilation, tachycardia and metabolic acidosis. One case showed slight renal failure. Both cases recovered within 4 weeks.

No cytogenetic effects were noted in varnish production workers exposed to EGBE, EGEE, and EGEEA (Söhnlein *et al*, 1993).

Laitinen *et al* (1994) reported a relationship between decreased urinary levels of succinate dehyrogenase and excretion of urinary oxalic acid and alkoxyacetic acids in workers exposed to glycol ethers (including EGEE). Ammonia excretion by exposed workers was doubled compared with control values.

Saavedra *et al* (1997), in a study on women exposed during pregnancy to EGME and MEG through cutaneous, oral, and respiratory routes in a Mexican factory, reported that they sometimes suffered to varying degrees from symptoms of intoxication, from strong headaches or cutaneous rash to repeated vomiting with dehydration, temporal loss of consciousness and coma. In the severe cases, intra-hospital treatment was needed. No analytical data on the height of exposure are presented but the described exposure and intoxication scenarios suggest high exposure.

In the above study of El-Zein *et al* (2002) (Section 3.2.3), all 6 dysmorphic children, from mothers occupationally exposed to EGME, exclusively had increased levels of chromosome aberrations, including breaks, polyploid and endoreduplicated cells, but no translocations and inversions. The authors explain the pattern of their cytogenetic findings as a disposition for genetic instability characterised by a delay in cell division. No data on the height of exposure are presented.

EGBE

Exposure of two men to 114 ppm EGBE (560 mg/m³) for 4 hours resulted in nasal and eye irritation and a metallic taste in the mouth (Carpenter *et al*, 1956).

Exposure of two men and one woman to 195 ppm EGBE (958 mg/m³) for 8 hours resulted in discomfort, irritation of the nose, throat and eyes and disturbed taste; the woman also developed a headache. The woman excreted 300 mg of BAA, one man excreted 175 mg of BAA and the other man excreted only traces of BAA in urine collected for 24 hours after exposure (Carpenter *et al*, 1956).

Exposure of two male and female volunteers to either 100 or 195 ppm EGBE (491 or 958 mg/m³) for up to 8 hours resulted in varying degrees of discomfort ranging from headaches to emesis. All excreted BAA (75 to 250 mg) in their urine (Carpenter *et al*, 1956). There were no signs of haemolysis or any other systemic effects noted.

Browning (1965) reported 1 case of haematuria and 2 cases of eye/nose irritation and headache in workers exposed to EGBE.

A number of cases of human poisonings with EGBE have been summarised and reviewed by Udden (1996). Three of 4 cases of adult human poisonings with EGBE involved probable doses of EGBE of 25 to 60 g. Coma and metabolic acidosis were common features, with hypokalaemia and haemoglobinuria following ingestion of the higher doses. None died as a result of EGBE

ingestion, but all required hospitalisation and supportive treatment (Rambourg-Schepens *et al*, 1988; Gijsenbergh *et al*, 1989; Bauer *et al*, 1992; Litovitz *et al*, 1991).

A 50-year old woman ingested 250 to 500 ml of window cleaner containing 12% EGBE. Coma, metabolic acidosis, hypokalaemia, an increase in serum creatinine haemoglobinuria and progressive erythropenia were reported. She improved gradually with supportive treatment (Rambourg-Schepens *et al*, 1988).

Gijsenbergh *et al* (1989) reported a suicide attempt with 500 ml of a window cleaner containing EGBE and alcohol (percentages unknown). This resulted in coma, hypotension and metabolic acidosis.

A case of respiratory distress syndrome in a 53-year old man was reported following EGBE intoxication. Metabolic acidosis, shock, and non-cardiogenic pulmonary oedema resolved following supportive treatment. It is not clear whether the pulmonary effects reported were a consequence of EGBE or the unstable conditions of the patient. Such effects have not been reported in other poisonings (Bauer *et al*, 1992).

Massive ingestion of EGBE by a 19-year old, mentally retarded patient produced hypotension and hypoxia, believed to account for neurological injury that persisted following recovery (Burkhart and Donovan, 1998). An 18-year old male who ingested cleaner containing 22% EGBE on two separate occasions. Estimated doses received were 1.0 to 1.34 g/kgbw. Minimal hepatic abnormalities following the first episode were not seen following the second ingestion. Acid-base imbalance responded rapidly to haemodialysis and ethanol treatment. No haematological or renal abnormalities were present following either incident (Gualtieri *et al*, 1995).

Dean and Krenzelok (1992) reported that of 24 children ingesting EGBE-containing household cleaners, 2 required gastric emptying or lavage followed by hospitalisation, with recovery uneventful. All others were given fluids at home.

McKinney *et al* (2000) reported a 51-year old female who ingested up to 8 ounces (0.24 litre) of a cleaner (EGBE and isopropanol). She developed prolonged hyper-chloraemic metabolic acidosis and mental depression and received ethanol treatment but not haemodialysis. There was no renal dysfunction, oxaluria, or haemolysis present in this patient during the course of treatment and she was discharged without apparent sequelae.

Udden (1996) has suggested that haemo-dilution, as a result of i.v. fluid therapy, may have contributed to the haemolytic anaemia reported in some cases of human poisonings with EGBE.

EGBE did not cause skin sensitisation in human subjects exposed dermally to 10% aqueous solutions of EGBE, the highest level used in cosmetics (Greenspan *et al*, 1995).

Haufroid *et al* (1997) reported slight but significant decreases in Hct levels and increases in mean cell haemoglobin (MCHb) concentration in workers exposed to low levels of EGBE. Urinary BAA excretion was low in these latter studies. Low level exposure to EGBE in foundry workers has been correlated with increased D-glucaric acid excretion (Collinot *et al*, 1996). This latter effect may be an adaptive rather than toxic response.

EGPhE

Exposure of unknown degree to EGPhE coincided with a transient liver enlargement and tenderness in one worker. No laboratory or other clinical data were reported (Morton, 1990).

EGPhE tested negative in human clinical trials for skin irritation, sensitisation or phototoxicity (CIR, 1990). This glycol ether is considered safe as a cosmetic ingredient at concentrations less than 1%.

DEGME

20% DEGME in petrolatum caused no irritation or sensitisation in patch testing in 25 human subjects (cited by Opdyke, 1974).

DEGEE

A case report described an alcoholic male who drank a liquid containing approximately 300 ml DEGEE. CNS symptoms, dyspnoea, thirst, acidosis and albuminuria were reported and he recovered with symptomatic treatment (cited by Browning, 1965).

DEGEE was reported to be neither a primary irritant nor a skin sensitiser in humans (Cranch et al, 1942; Meininger, 1948; Opdyke, 1974).

DEGEE and DEGBEA

Repeated applications over several months of an insect repellent containing 50% DEGBEA, 15% DEGEE, 28% ethanol, 7% corn oil and a trace of lavender oil produced kidney failure in a 3-year old child (Hoehn, 1945; Draize *et al*, 1948).

A female office worker reported symptoms of irritation of the upper airways, erythema of the face, and swollen eyelids. Patch testing was positive for DEGBE and a paint additive containing DEGBE (Berlin *et al*, 1995). Lack of workplace monitoring information does not allow confirmation of DEGBE as the causative agent in this case.

1PG2ME, 1PG2MEA, 2PG1ME and 2PG1MEA

During controlled exposure of 6 human volunteers with commercial PGME (95 - 99% 2PG1ME, < 5% 1 PG2ME) at vapour concentrations from 50 to 2,000 ppm (190 - 7,500 mg/m³), the odour became noticeable at 10 ppm (37 mg/m³) and objectionable above 100 ppm (370 mg/m³) (Stewart *et al*, 1970).

Exposure to 250 ppm PGME (940 mg/m³) caused progressive irritation of nose, throat and eyes after 15 minutes; the volunteers were unable to smell PGME after 3 hours at that concentration. One person exposed to 2,000 ppm (7,500 mg/m³) did not show any neurological impairment. Blood cell count, erythrocyte sedimentation rate and serum chemistry did not differ in pre- and 16- hour post-exposure blood samples.

Emmen (1997, 2003) reported a level of 150 ppm PGME vapour (560 mg/m³) to be without irritant effect on the eyes of human subjects based on the lack of significant impact on a number of objective and subjective parameters measured before and following exposures.

DPGME

Patch tests with DPGME on 250 persons indicated no evidence of either skin irritation or sensitisation (Rowe *et al*, 1954).

DPGME levels in air of 300 to 400 ppm (1,850 - 2,465 mg/m³) have been described as very disagreeable. The odour threshold and irritation level for DPGME were reported to be 35 ppm and 74 ppm (216 and 456 mg/m³), respectively (Rowe *et al*, 1954).

A 20% solution of DPGME (0.04 ml) was applied to one eye of 10 human male volunteers; this caused a minor stinging sensation for 30 to 45 seconds, slight lachrymation for about a minute, mild conjunctival vascular injection and an increase in intra-ocular tension for 1 hour (Ballantyne, 1984a,b).

TEGME

Soldiers who drank brake fluid containing TEGME in place of alcoholic beverages required hospitalisation for gastric lavage and blood dialysis in the case of one individual. Otherwise, recovery from symptoms was rapid (Sprague, 1992 cited by Boatman and Knaak, 2001).

2PG1PhE

2PG1PhE has bactericidal properties and is used in medical disinfectants, and cleansing and in cosmetic formulations; it is mentioned as an antibacterial agent in pharmaceutical compositions of acne treatment (Roberts, 1986). No data are available on untoward effects in humans.

Other glycol ethers

No human data are available on the following glycol ethers: EGDME, TEGDME, EGDEE, DEGDEE, DEGEEA, TEGEE, EGiPE, EGnPE, EGnPEA, TEGBE, 2PG1EE, 2PG1EEA, DPGEE, TPGME and 2PG1BE.

3.3 Occupational exposure limit values

Several countries have adopted OEL values (Appendix C). The justification of some OELs takes account of critical effects on the reproductive system.

4. SUBSTANCE PROFILES (VOLUME II/CD)

4.1 Substance profile: EGME	14
4.2 Substance profile: EGMEA	71
4.3 Substance profile: EGDME	78
4.4 Substance profile: DEGME	84
4.5 Substance profile: DEGDME	93
4.6 Substance profile: TEGME	106
4.7 Substance profile: TEGDME	114
4.8 Substance profile: MAA	120
4.9 Substance profile: EGEE	137
4.10 Substance profile: EGEEA	160
4.11 Substance profile: EGDEE	171
4.12 Substance profile: DEGEE	177
4.13 Substance profile: DEGEEA	189
4.14 Substance profile: DEGDEE	192
4.15 Substance profile: TEGEE	196
4.16 Substance profile: EGiPE	201
4.17 Substance profile: EGiPEA	208
4.18 Substance profile: EGnPE	209
4.19 Substance profile: EGnPEA	216
4.20 Substance profile: EGPhE	221
4.21 Substance profile: EGBE	234
4.22 Substance profile: EGBEA	278
4.23 Substance profile: DEGBE	283
4.24 Substance profile: DEGBEA	297
4.25 Substance profile: TEGBE	302
4.26 Substance profile: EGHE	306
4.27 Substance profile: DEGHE	315
4.28 Substance profile: 2PG1ME	321
4.29 Substance profile: 2PG1MEA	342
4.30 Substance profile: 1PG2ME	351
4.31 Substance profile: 1PG2MEA	357
4.32 Substance profile: DPGME	362
4.33 Substance profile: TPGME	371
4.34 Substance profile: 2PG1EE	379
4.35 Substance profile: 2PG1EEA	386
4.36 Substance profile: DPGEE	391
4.37 Substance profile: PGPE	398
4.38 Substance profile: DPGPE	408
4.39 Substance profile: 2PG1PhE	413
4.40 Substance profile: 2PG1BE	419
4.41 Substance profile: DPGBE	429
4.42 Substance profile: TPGBE	441
4.43 Substance profile: PGTBE	448
4.44 Substance profile: DPGTBE	458

5. BIBLIOGRAPHY

5.1 Databases consulted

New references since the previous edition of this report (ECETOC, 1995) were found in the AGRICOLA, CABA, CANCERLIT, CSNB JICST-EPLUS, EMBAL, EMBASE, ESIOBASE, HEALSAFE, LIFESCI, TOXCENTER and TOXLIT databases on the European site hosted by Scientific and Technical Information Network (STN), using the CAS registry numbers for the glycol ethers of interest.

In addition, for PGPE, PTBE and DPGTBE the Toxicology Literature Online Databank (TOXLINE) of the US National Library of Medicine was searched on the internet (http://toxnet.nlm.nih.gov).

Similarly, the reference lists contained in the 5th edition of Patty's Toxicology chapters (Boatman, 2001; Boatman and Knaak, 2001) were updated by searching in the cluster on STN and in the Chemical Information Systems (CIS) in the USA, including MEDLINE, NIOSHTIC, TOXCENTER and BIOSIS, and in TOXLINE on the internet.

5.2 References quoted

Aasmoe L, Mathiesen M, Sager G. 1999. Elimination of methoxyacetic acid and ethoxyacetic acid in rat. *Xenobiotica* 29:417-424.

Aasmoe L, Winberg J-O, Aarbakke J. 1998. The role of liver alcohol dehydrogenase isoenzymes in the oxidation of glycolethers in male and female rats. *Toxicol Appl Pharmacol* 150:86-90.

Abbondandolo A, Bonatti S, Corsi C, Corti G, Fiorio R, Leporini C, Mazzaccaro A, Nieri R, Barale R, Loprieno N. 1980. The use of organic solvents in mutagenicity testing. *Mutat Res* 79:141-150.

ACGIH. 1991. Documentation of the threshold limit values and biological exposure indices - 6th ed. American Conference of Governmental Industrial Hygienists, Cincinnati, Ohio, USA.

ACGIH. 2001. TLVs and BEIs threshold limit values for chemical substances and physical agents. Biological exposure indices. American Conference of Governmental Industrial Hygienists, Cincinnati, Ohio, USA.

Ahmed AE, Jacob S, Au WW. 1994. Quantitative whole body autoradiographic disposition of glycol ether in mice: effect of route of administration. *Fundam Appl Toxicol* 22:266-276.

Aich S, Manna CK. 1996. Action ethylene glycol monomethyl ether on male reproductive organs of Indian wild rats. *Endocrine Regul* 30:153-162.

Allen DJ. 1993a. Ethyleneglycol monobutylether: acute dermal toxicity (limit test) in the rat. Unpublished report project 13/540. Safepharm Laboratories, Derby, UK. Mitsubishi Petrochemical, Tokyo, Japan.

Allen DJ. 1993b. Ethyleneglycol monobutylether: acute dermal toxicity (limit test) in the rat. Unpublished report project 1313/542. Safepharm Laboratories, Derby, UK. Mitsubishi Petrochemical, Tokyo, Japan.

Allen DJ. 1993c. Ethyleneglycol monobutylether: acute dermal toxicity test in the rabbit. Unpublished report project 1313/605. Safepharm Laboratories, Derby, UK. Mitsubishi Petrochemical, Tokyo, Japan.

Allen DJ. 1993d. Ethyleneglycol monobutylether: acute dermal toxicity test in the rabbit. Unpublished report project 1313/606. Safepharm Laboratories, Derby, UK. Mitsubishi Petrochemical, Tokyo, Japan.

Allen JA, Brooker PC, Birt DM, Howell A, Ridlon SA. 1987. Analysis of metaphase chromosomes obtained from CHO cell cultured *in vitro* and treated with 1-(1,1-dimethylethoxy)-2-propanol, CAS RN 57018-52-7 (commercially available from Arco Chemical Co. as Arcosolv PTB solvent). Unpublished report ARO 6/871093. Huntingdon Research Centre, Huntingdon, Cambridgeshire, UK. ARCO Chemical, Newtown Square, Pennsylvania, USA.

Almekinder JL, Lennard DE, Walmer DK, Davis BJ. 1997. Toxicity of methoxyacetic acid in cultured human luteal cells. *Fundam Appl Toxicol* 38:191-194.

Ambroso JL, Stedman DB, Elswick BA, Welsch F. 1998. Characterization of cell death induced by methoxyethanol in CD-1 mouse embryos on gestation day 8. *Teratology* 58:231-240.

American Chemistry Council. 2000. EGBE: A world of solutions. Ethylene Glycol Ethers Panel, American Chemistry Council, Arlington, Virginia, USA.

Andega S, Kanikkannan N, Singh M. 2001. Comparison of the effect of fatty alcohols on the permeation of melatonin between porcine and human skin. *J Controlled Release* 77:17-25.

Anderson D, Brinkworth MH, Jenkinson PC, Clode SA, Creasy DM, Gangolli SD. 1987. Effect of ethylene glycol monomethyl ether on spermatogenesis, dominant lethality, and F₁ abnormalities in the rat and the mouse after treatment of F males. *Teratogen Carcinogen Mutagen* 7:141-158.

Anderson D, Dhawan A, Yu T-W, Plewa MJ. 1996. An investigation of bone marrow and testicular cells *in vivo* using the comet assay. *Mutat Res* 370:159-174.

Andrew FD, Hardin BD. 1984. Developmental effects after inhalation exposure of gravid rabbits and rats to ethylene glycol monoethyl ether. *Environ Health Persp* 57:13-23.

Angerer J. 1993. Grenzwerte in biologischem Material: 2-Ethoxyethanol. In Henschler D, Lehnert G, eds, *Biologische Arbeitsstoff-Toleranz-We rte (BAT-Werte), Arbeitsmedizinischtoxikologische Begründungen* - Vol 1. VCH Verlag, Weinheim, Germany, p13.

Angerer J, Gündel J. 1994. Butoxyacetic acid. In Angerer J, Schaller KH, eds, *Analysis of hazardous substances in biological materials*, DFG, Volume 4, VCH Verlag, Weinheim, Germany, pp 131-145.

Angerer J, Lichterbeck E, Begerow J, Jekel S, Lehnert G. 1990. Occupational chronic exposure to organic solvents. *Int Arch Occup Environ Health* 62:123-126.

Anundi H, Langworth S, Johanson G, Lind ML, Akesson B, Friis L, Itkes N, Soderman E, Jonsson BA, Edling C. 2000. Air and biological monitoring of solvent exposure during graffiti removal. *Int Arch Occup Environ Health* 73:561-569.

Arashidani K, Yoshikawa M, Kikuchi M, Kawamoto T, Kodama Y. 1993. Cytogenetic study of ethylene glycol monomethyl ether using micronucleus test. *Sangyo Igaku (Jpn J Ind Health)* 35:286-287 [Japanese].

Arashidani K, Kawamoto T, Kodama Y. 1998. Induction of sister-chromatid exchange by ethylene glycol monomethylether and its metabolite. *Ind Health* 36:27-31.

Arco Chemical. 1991. Evaluation of the ability of Arcosolv PTB to induce chromosome aberrations in cultured peripheral human lymphocytes. Unpublished report, project 043291. RCC Notox, 's-Hertogenbosch, Netherlands. Arco Chemical Europe, Maidenhead, Berkshire, England, UK.

Arco Chemical. 1996a. Dipropylene glycol *t*-butyl ether: skin sensitisation in the guinea pig. Unpublished report ARO 24/960421/SS. Huntingdon Life Sciences, Huntingdon, Cambridgeshire, England, UK. ARCO Chemical Europe, Maidenhead, Berkshire, England, UK.

Arco Chemical. 1996b. DPTB: toxicity to rats by repeated oral administration for 14 days. Unpublished report ARO 25/960403. Huntingdon Life Sciences, Huntingdon, Cambridgeshire, England, UK. ARCO Chemical, Newtown Square, Pennsylvania, USA.

Arco Chemical. 1996c. Dipropylene glycol *t*-butyl ether (DPTB): toxicity to rats by repeated oral administration for 13 weeks incorporating a neur otoxicity screen and followed by a 4-week recovery period. Unpublished report ARO 26/962148. Huntingdon Life Sciences, Huntingdon, Cambridgeshire, England, UK. ARCO Chemical, Newtown Square, Pennsylvania, USA.

Arco Chemical. 1996d. Dipropylene glycol *t*-butyl ether (DPTB): bacterial mutation assay. Unpublished report ARO 27/960041. Huntingdon Life Sciences, Huntingdon, Cambridgeshire, England, UK. ARCO Chemical Europe, Maidenhead, Berkshire, England, UK.

Arco Chemical. 1996e. DPTB: mouse micronucleus test. Unpublished report ARO 28/960732. Huntingdon Life Sciences, Huntingdon, Cambridgeshire, England, UK. ARCO Chemical Europe, Maidenhead, Berkshire, England, UK.

Arco Chemical. 1996f. Dipropylene glycol *t*-butyl ether, physicochemical properties. Unpublished report ARO 21/961297. Huntingdon Life Sciences, Huntingdon, Cambridgeshire, England, UK. ARCO Chemical Europe, Maidenhead, Berkshire, England, UK.

Arco Chemical. 1997. DPTB: acute inhalation toxicity in rats (4-hour exposure). Unpublished report ARO 48/970681. Huntingdon Life Sciences, Huntingdon, Cambridgeshire, England, UK. ARCO Chemical, Newtown Square, Pennsylvania, USA.

Arco Chemical. n.d. Determination of the boiling point/boiling range of Arcosolv PTB (RCC Notox substance 11178). Unpublished report, project 043199. RCC Notox, 's-Hertogenbosch, Netherlands. ARCO Chemical Europe, Maidenhead, Berkshire, England, UK.

Arco Chemical. n.d. Determination of the freezing point/freezing range of Arcosolv PTB (RCC Notox substance 11178). Unpublished report, project 043188. RCC Notox, 's-Hertogenbosch, Netherlands. ARCO Chemical Europe, Maidenhead, Berkshire, England, UK.

Arco Chemical. n.d. Determination of the vapour pressure of Arcosolv PTB (RCC Notox substance 11178). Unpublished report, project 043223.. RCC Notox, 's-Hertogenbosch, Netherlands. ARCO Chemical Europe, Maidenhead, Berkshire, England, UK.

Ariel Research. 2002. Western European database, North American database on-line. Ariel Research Corporation, Bethesda, Maryland, USA [http://www.arielresearch.com/web/western europedb.asp, .../northamericadb.asp].

Arimoto S, Nakano N, Ohara Y, Tanaka K, Hayatsu HA. 1982. A solvent effect on the mutagenicity of tryptophan-pyrolysate mutagens in the *Salmonella*/ mammalian microsome assay. *Mutat Res* 102:105-112.

Arts JHE, Reuzel PGJ, Woutersen RA, Kuper CF, Falke HE, Klimisch HJ. 1992. Repeated-dose (28-day) inhalation toxicity of isopropylethylene glycol ether in rats. *Inhal Toxicol* 4:43-55.

Asaki AE, Houpt JT. 1990. Assessment of the developmental toxicity of propylene glycol monomethyl ether acetate (PM acetate) in rats. Report USA EHA-75-51-0753-90. United States Army Environmental Hygiene Agency, Aberdeen Proving Ground, MD, USA.

ATSDR. 1998. Toxicological profile for 2-butoxyethanol and 2-butoxyethanol acetate. Public Health Service, Agency for Toxic Substances and Disease Registry, U.S. Department of Health and Human Services, Atlanta, Georgia, USA.

Au WW, Morris DL, Legator MS. 1993. Evaluation of the clastogenic effects of 2-methoxyethanol in mice. *Mutat Res* 300:273-279.

Au WW, Ahmed AE, Chiewchanwit T, Hsie AW, Ma H, Moslen MT. 1996. Toxicity and genotoxicity of 2-methoxyethanol *in vitro* and *in vivo*. Occup Hyg 2:177-186.

Auletta CS, Schroeder RE, Krasavage WJ, Stack C. 1993. Toxicology of diethylene glycol butyl ether 4. Dermal subchronic/reproduction study in rats. *J Am Coll Toxicol* 12:161-168.

Bader M, Büttner J, Goen T, Angerer J. 1996. Occupational exposure to 1-ethoxy-2-propanol and 2-ethoxy-1-propanol ambient and biological monitoring. *Occup Hyg* 2:91-96.

Balasubramanian H, Kaphalia L, Campbell GA, Moslen MT. 1996. Induction of apoptosis in the rat thymus by 2-methoxyethanol is decreased by phenobarbital pretreatment. *Occup Hyg* 2:275-281.

Ballantyne B. 1984a. Eye irritancy potential of diethylene glycol monobutyl ether. *J Toxicol Cut Ocul Toxicol* 3:7-16.

Ballantyne B. 1984b. Local ophthalmic effects of dipropylene glycol monomethyl ether. *J Toxicol Cut Ocul Toxicol* 2:229-242.

Ballantyne B, Myers RC. 1987. The comparative acute toxicity and primary irritancy of the monohexyl ethers of ethylene and diethylene glycol. *Vet Human Toxicol* 29:361-366.

Ballantyne B, Vergnes J. 2001. *In vitro* and *in vivo* genetic toxicology studies with diethylene glycol monohexyl ether. *J Appl Toxicol* 21:449-460.

Ballantyne B, Jensen CB, Weaver EV. 2003. Percutaneous toxicokinetic and repeated cutaneous contact studies with ethylene glycol monohexyl ether. *J Appl Toxicol* 23:301-314.

Bantle JA, Finch RA, Fort DJ, Stover EL, Hull M, Kumsher-King M, Gaudet-Hull AM. 1999. Phase III interlaboratory study of FETAX part 3, FETAX validation using 12 compounds with and without an exogenous metabolic activation system. *J Appl Toxicol* 19:447-472.

Barale R, Presciuttini S, Rossi AM. 1979. *Schizosaccharomyces pombe*, mutazione genetica in avanti. In Magni GM, *Mutagenesi ambientale, metodiche di analisi*, vol 1 *in vitro* test. CNR, Roma, Italy, pp 105-121.

Barbee SJ, Terrill JB, DeSousa DJ, Conaway CC. 1984. Subchronic inhalation toxicology of ethylene glycol monoethyl ether in the rat and rabbit. *Environ Health Persp* 57:157-163.

Barber ED, Kolberg KF. 1987 The *in vitro* percutaneous absorption of 2-propoxyethanol (PE) through human stratum corneum and full thickness rat skin, HAEL 88-0017, Acc. No. 907124. Unpublished report 252940K, TX-89-030. Toxicological Sciences Laboratory, Health and Environment Laboratories, Eastman Kodak, Rochester, New York, USA. Eastman Chemicals Division, Kingsport, Tennessee, USA.

Barber ED, Teetsel NM, Kolberg KF, Guest D. 1992. A comparative study of the rates of *in vitro* percutaneous absorption of eight chemicals using rat and human skin. *Fundam Appl Toxicol* 19:493-497.

Barfknecht TR, Naismith RW, Matthew RH. 1986. Ames *Salmonella* / microsome plate test (EPA/OECD). Unpublished report, study PH 301-AR-002-86. Pharmakon Research International, Waverly, Pennsylviania, USA. ARCO Chemical, Newtown Square, Pennsylvania, USA.

Bartlett JMS, Kerr JB, Sharpe RM, 1988. The selective removal of pachytene spermatocytes using methoxy acetic acid as an approach to the study *in vivo* of paracrine interactions in the testis. *J And* 9:31-40.

Bartnik FG, Reddy AK, Klecak G, Zimmermann V, Hostynek JJ, Künstler K. 1987. Percutaneous absorption, metabolism and hemolytic activity of *n*-butoxyethanol. *Fundam Appl Toxicol* 8:59-70.

BASF. 1963. Arophor, Ergebnis der gewerbetoxikologischen Vorprüfung. Unpublished report XIII/386. Oettel and Zeller, 23.12.1963. BASF, Ludwigshafen, Germany.

BASF. 1966. Methoxyglykolacetat: gewerbetoxikologische Vorprüfung. Unpublished data (XV/334). Abt. Toxikologie (1.3.1966). BASF, Ludwigshafen, Germany.

BASF. 1979a. Bericht über die Bestimmung der gewerbetoxikologischen Grundprüfung von 2-Methoxypropanol-1 Unpublished report 78/185. Abt. Toxikologie, BASF, Ludwigshafen, Germany.

BASF. 1979b. Bericht über die Bestimmung der akuten Inhalationstoxizität (LC₅₀) von 2-Methoxypropanol bei 4-stündiger Exposition an Sprague-Dawley-Ratten. Unpublished report 78/185. Abt. Toxikologie. BASF, Ludwigshafen, Germany.

BASF. 1980. Methoxyessigsäure. Gewerbetoxikologische Grundprüfung. Unpublished report 80/171. Abt. Toxikologie. BASF, Ludwigshafen, Germany.

BASF. 1982a. Kurzbericht über einen Vorversuch mit 10-maliger Sondierung an Ratten mit Ethylglykol, 2-ethoxypropanol-1 und 2-Methoxypropyl-1-acetat. Unpublished report 82/289. Abt. Toxikologie. BASF, Ludwigshafen, Germany.

BASF. 1982b. Prüfung der akuten oralen Toxizität von Monophenylglykol tech. an der Ratte. Unpublished report 82/135. Hildebrand B and Kirsch P. BASF, Ludwigshafen, Germany.

BASF. 1983a. Monophenylglykol techn. Bericht über die akute Hautreiz-/Ätzwirkung an der intakten Rückenhaut des weissen Kaninchens in Anlehnung an OECD (Guideline 404). Unpublished report 83/143. Kirsch P and Grundler DJ. BASF, Ludwigshafen, Germany.

BASF. 1983b. Monophenylglykol techn. Bericht über die akute Reizwirkung am Auge des weissen Kaninchens in Anlehnung an OECD (Guideline 405). Unpublished report 83/143. Kirsch P and Grundler DJ. BASF, Ludwigshafen, Germany.

BASF. 1984a. Prüfung der subchronischen Inhalationstoxizität von 2-ethoxypropylacetat-1 an Wistar-Ratten (4-Wochen-Versuch). Unpublished report 37R0144 8315. Klimisch HJ, Deckardt K, Gembardt C, Hildebrand B. BASF Toxikologie, Ludwigshafen, Germany.

BASF. 1984b. Berichte über die Prüfung der akuten oralen und inhalativen Toxizität an Ratten von 2-Methoxypropylacetat-1 (78/185). Abt. Toxikologie. BASF, Ludwigshafen, Germany.

BASF. 1984c. Einmalige Inhalation von 2-Methoxypropylacetat-1 über 6 Stunden an Kaninchen und Hund (22.11.84). Abt. Toxikologie. BASF, Ludwigshafen, Germany.

BASF. 1984d. Prüfung der subchronischen Inhalationstoxizität von 2-Methoxypropylacetat-1 an Wistar-Ratten (4-Wochen-Versuch). Unpublished report. Klimisch HJ, Deckardt K, Gembardt C, Hildebrand B. BASF Toxikologie, Ludwigshafen, Germany.

BASF. 1988a. Ames Test: 2-Methoxypropanol-1. Unpublished results (report 91/233). Abt. Toxikologie. BASF, Ludwigshafen, Germany.

BASF. 1988b. Pränatale Toxizität von 2-Methoxypropanol-1 am Kaninchen nach inhalativer Aufnahme (85/510). BASF, Ludwigshafen, Germany.

BASF. 1989. Diethylene glycol monomethyl ether. Ames test (standard plate test and preincubation test with *Salmonella typhimurium*). Report/project 40M0745/884379 (22.2.89). Abt. Toxikologie. BASF, Ludwigshafen, Germany.

BASF. 1991a. Kurzbericht. Prüfung der Inhalationstoxizität von Butyldiglykol als Flüssigkeits-Aerosol bzw. Dampf an Ratten. 14-Tage Versuch (Range-finding). Unpublished report, project 30I0294/8521. Klimisch H-J, Deckardt K, Küttler K, Hildebrand B. Department of Toxicology, BASF, Ludwigshafen, Germany.

BASF. 1991b. Report. Study on the inhalation toxicity of butyldiglykol as a liquid aerosol in female rats, 14 days test including a 4-w eek post-exposure observation period. Unpublished report, project 39I0030/87055. Report Volume I. Klimisch H-J, Deckardt K, Gembardt C, Hildebrand B. Department of Toxicology, BASF, Ludwigshafen, Germany.

BASF. 1992. Report. Study on the inhalation toxicity of butyldiglykol as a vapour in rats 90-day test including an about 4-week post-exposure observation period. Unpublished report, project 50I0030/87002, Report Volume I. Klimisch H-J, Kirsch P, Deckardt K, Freisberg KO, Hildebrand B. Department of Toxicology, BASF, Ludwigshafen, Germany.

BASF. 2000. Report 2-butoxyethanol, acute eye irritation in rabbits. Unpublished report, project 11H0182/002053. Wiemann C, Hellwig J, Experimental Toxicology and Ecology, BASF, Ludwigshafen, Germany.

BASF. 2002. Report Protectol PE, maximization text in guinea pigs. Unpublished report, project 30H0498/12201. Gamer AO, Leibold E, Experimental Toxicology and Ecology, BASF, Ludwigshafen, Germany.

Baskin SI, Maduh EU. 1995. Fundamentals of cardiotoxicity. In Ballantyne B, Marrs T, Turner P, eds, *General and applied toxicology, abridged edition*. Macmillan, Basingstoke, Hants, UK, pp 531-554.

Basler A. 1986. An euploidy-inducing chemicals in yeast evaluated by the micro-nucleus test. *Mutat Res* 174:11-13.

Bauer P, Weber M, Muir JM, Protois JC, Bollaert PE, Condi A, Larcan A, Lambert H. 1992. Transient non-cardiogenic pulmonary edema following massive ingestion of ethylene glycol butyl ether. *Intensive Care Med* 18:250-251.

Beatti PJ, Brabec MJ. 1986. Methoxyacetic acid and ethoxyacetic acid inhibit mitochondrial function *in vitro*. *J Biochem Toxicol* 1:61-70.

Beatti PJ, Welsh MJ, Brabec MJ. 1984. The effect of 2-methyoxyethanol and methoxyacetic acid on Sertoli cell lactate production and protein synthesis *in vitro*. *Toxicol Appl Pharmacol* 76:56-61.

Begerow J, Angerer J. 1990. Improved method for the determination of urinary 2-ethoxyacetic acid by capillary gas chromatography with electron capture detection. *Fres J Anal Chem* 366:42-43.

Begerow J, Heinrich-Ramm R, Angerer J. 1988. Determination of butoxyacetic acid in urine by capillary gas chromatography. *Fres Z Anal Chem* 331:818-820.

Berger T, Miller MG, Horner CM. 2000. *In vitro* fertilization after *in vivo* treatment of rats with three reproductive toxicants. *Reprod Toxicol* 14:45-53.

Berlin K, Johanson G, Lindberg M. 1995. Hypersensitivity to 2-(2-butoxyethoxy)ethanol. *Contact Dermatitis* 32:54.

Bernard LG. 1989. A subchronic inhalation study of ethylene glycol monopropyl ether in rats using a functional observational battery and neuropathology to detect neurotoxicity. HAEL 88-0017. Acc. No 907124. Unpublished report 253001J, TX-89-91. Toxicological Sciences Laboratory, Health and Environment Laboratories, Eastman Kodak, Rochester, New York, USA. Eastman Chemicals Division, Eastman Kodak, Kingsport, Tennessee, USA.

Bernard AM, De Russis R, Normand JC, Lauwerys RR. 1989. Evaluation of the subacute nephrotoxicity of cyclohexane and other industrial solvents in the female Sprague Dawley rat. *Toxicol Lett* 45:271-280.

Berté F, Bianchi A, Gregotti C, Bianchi L, Tateo F. 1986. *In vivo* and *in vitro* toxicity of carbitol. *Boll Chim Farm* 125:401-403.

Beyrouty P, Broxup B, Losos G, Robinson K, Maurissen JPJ, Gill MW, Stack CR. 1993. Toxicology of diethylene glycol butyl ether 5. Dermal subchronic neurotoxicity study in rats. *J Am Coll Toxicol* 12:169-174.

BIBRA (British Industrial Biological Research Association). 1987. Toxicity profile of 2-butoxyethanol acetate. BIBRA Toxicology International, Carshalton, Surrey, UK.

BIBRA (British Industrial Biological Research Association). 1988. Toxicity profile of 2-phenoxyethanol. BIBRA Toxicology International, Carshalton, Surrey, UK.

Bier CB. 1985. Primary eye irritation study in albino rabbits administered test article PTB (20%). Unpublished report 51158. Bio-Research Laboratories. Montreal, Quebec, Canada. ARCO Chemical, Newtown Square, Pennsylvania, USA.

Biodynamics. 1983a. A 13-week inhalation toxicity study of ethylene glycol monoethyl ether in the rat. Project No. 82-7588, 1-16. Biodynamics Inc. USA.

Biodynamics. 1983b. A 13-week inhalation toxicity study of ethylene glycol monoethyl ether in the rabbit. Project No. 82-7589, 1-16. Biodynamics Inc. USA.

Blackburn DM, Foster PDM, Lloyd SC. 1985. Correlation between testicular effects produced *in vivo* and *in vitro* by ethylene glycol monomethyl ether (EGME) and 2-methoxyacetic acid (MAA) in rat. *J Pathol* 145:124 A.

Boatman RJ, Corley RA, Green T, Klaunig JE, Udden MM. 2004. Review of studies concerning the tumorigenicity of 2-butoxyethanol in B6C3F₁ mice and its relevance for human risk assessment. *J Toxicol Environ Health* B7:385–398.

Boatman RJ. 2001. Glycol ethers: ethers of propylene, butylene glycols, and other glycol derivatives. In Bingham E, Cohrssen B, Powell CH, eds. *Patty's Toxicology*, 5th Edition, vol. 7 part D, chapter 87. Wiley Interscience New York, NY, USA, pp 271-395.

Boatman RJ, Knaak JB. 2001. Ethers of ethylene glycol and derivatives. In Bingham E, Cohrssen B, Powell CH, eds. *Patty's Toxicology*, 5th Edition, vol. 7, part D, chapter 86. Wiley Interscience, New York, NY, USA, pp 73-270.

Boatman RJ, Schum DB, Guest D, Stack CR. 1993. Toxicology of diethylene glycol butyl ether 2. Disposition studies with ¹⁴C-diethylene glycol butyl ether and ¹⁴C-diethylene glycol butyl ether acetate after dermal application to rats. *J Am Coll Toxicol* 12:145-154.

Bolt HM, Golka K. 1990. Maternal exposure to ethylene glycol monoethylether acetate and hypospadia in offspring. A case report. *Br J Ind Med* 47:352-353.

Boon NA. 1987. Solvent abuse and the heart. British Medical Journal 294:722.

Bootman J. 1986. Mutagenicity test. Metaphase analysis. Human peripheral lymphocytes. Chromosome aberration. Unpublished report NIPA Laboratories. Life Science Res. Mid Clamorgan, GB-CF38-25N, UK.

Bootman J, May K. 1985. Mutagenicity studies, Ames test. Unpublished report December 1985. Life Science Research, UK.

BP. 1981a. Napsol PE1. Essai de toxicité aiguë par voie respiratoire chez le rat. Unpublished report 111217, 16 Nov 1981. Rondot G, Institut Français de Recherches et Essais Biologiques, Joinville-le-Pont, France. BP Chemicals, UK.

BP. 1981b. Napsol PE1. Test de tolérance locale chez le lapin. IFREB report 110336, 29 Oct. 1981. BP Chemicals, UK.

BP. 1983a. A study of the acute oral toxicology of ethoxypropanol in rats. B.P. GOHC Expt. No. 83T17. BP Chemicals, UK.

BP. 1983b. The four hour single exposure toxicity of ethoxypropanol in rats. B.P. GOHC Expt. No. 83T16. BP Chemicals, UK.

BP. 1983c. The acute respiratory sensory irritancy of ethoxypropanol in mice. B.P. GOHC Expt. No. 83T15. BP Chemicals, UK.

BP. 1983d. A study of the ten-day repeat dose oral toxicity of ethoxypropanol in rats. B.P. GOHC Expt. No. 83T18. BP Chemicals, UK.

BP. 1983e. The nine-day repeated exposure inhalation toxicity of ethoxypropanol in rats. B.P. GOHC Expt. No. 83T20. BP Chemicals, UK.

BP. 1984a. A study of the skin irritancy of ethoxypropanol in rabbits. B.P. GOHC Expt. No 84T042. BP Chemicals, UK.

BP. 1984b. A study of the eye irritancy of ethoxypropanol in rabbits. B.P. GOHC Expt. No 84T027. BP Chemicals, UK.

BP. 1985a. Acute oral toxicity to rats of et hoxypropyl acetate. Huntingdon Research Centre report 851078D/BPC 51/AC, 6th December 1985. BP Chemicals, UK.

BP. 1985b. Acute inhalation toxicity in rats, 4-hour exposure, ethoxypropyl acetate. Huntingdon Research Centre report BPC 55/851141, 26th Nov. 1985. BP Chemicals, UK.

- BP. 1985c. Ames metabolic activation test to assess the potential mutagenic effect of ethoxypropyl acetate. Huntingdon Research Centre report BPC 57/851010, 11th Nov. 1985. BP Chemicals, UK.
- BP. 1985d. Analysis of metaphase chromosomes obtained from CHO cells cultured *in vitro* and treated with ethoxypropyl acetate. Huntingdon Research Centre report BPC 851160. 13th Nov. 1985. BP Chemicals, UK.
- BP. 1985e. Dipropylene glycol monoethyl ether. Acute dermal irritation/corrosion test in the rabbit. Life Science Research Report No 85/BPO034/786. BP Chemicals, UK.
- BP. 1985f. Dipropylene glycol monoethyl ether: Acute eye irritation/corrosion test in the rabbit. Life Science Research Report No 85/BPO035/795. BP Chemicals, UK.
- BP. 1985g. Dipropylene glycol monoethyl ether: Delayed contact hypersensitivity study in guinea pigs. Life Science Research report 85/BPO032/788. BP Chemicals, UK.
- BP. 1985h. Dipropylene glycol monoethyl ether. Assessment of its mutagenic potential in histidine auxotrophs of *Salmonella Typhimurium*. Life Science Research report No 85/BP0036/698. BP Chemicals, UK.
- BP. 1986a. Dipropylene glycol monoethyl ether. Acute oral toxicity in the rat. Life Science Research report No 86/BPO033/06. BP Chemicals, UK.
- BP. 1986b. Ethoxypropanol 90 day inhalation study in rats. Huntingdon Research Centre report BPC 46/851294, 25th March 1986. BP Chemicals, UK.
- BP. 1986c. Effect of ethoxypropanol on pregnancy in the rat (inhalation exposure). Huntingdon Research Centre report BPC 47/86852, 1986. BP Chemicals, UK.
- BP. 1986d. Effect of ethoxypropanol on pregnancy of the rabbit (inhalation exposure). Huntingdon Research Centre report BPC 49/86965, 1986. BP Chemicals, UK.
- BP. 1986e. Irritant effects on rabbit skin of ethoxypropyl acetate. Huntingdon Research Centre report BPC 85937D/BPC 52/SE, 15th Jan. 1986. BP Chemicals, UK.
- BP. 1986f. Irritant effects on the rabbit eye of ethoxypropyl acetate. Huntingdon Research Centre report BPC 85938D/BPC 52/SE, 15th Jan. 1986. BP Chemicals, UK.

- BP. 1986g. Delayed contact hypersensitivity in the guinea pig with ethoxypropyl acetate. Huntingdon Research Centre report BPC 851091D/BPC54/SS, 15th Jan. 1986. BP Chemicals, UK.
- BP. 1986h. Ethoxypropyl acetate 28-day inhalation toxicity study in rats by administration on 5 days each week. Huntingdon Research Centre report BPC 56/8655, 9th April 1986. BP Chemicals, UK.
- BP. 1988a. Study to determine the ability of ethoxypropanol to induce mutation in five histidine-requiring strains of *Salmonella Typhimurium*. Report BOH 1/s' 1988. Microtest Research, UK.
- BP. 1988b. Study to evaluate the chromosome damaging potential of ethoxypropanol by its effects on cultured human lymphocytes using an *in vitro* cytogenetics assay. Report BOH 1/HLC, 1988. Microtest Res., UK.
- BP. 1990a. Dipropylene glycol monoethyl ether. Test to evaluate the acute toxicity following a single cutaneous application (limit test) in the rat. Report 007357, 1990. Hazleton, UK.
- BP. 1990b. Dipropylene glycol monoethyl ether. 4-week oral (gavage) toxicity study in the rat. Report 15590, 1990. Hazelton, UK.
- BP. 1990c. Dipropylene glycol monoethyl ether. Test to evaluate the ability to induce chromosome aberrations in human lymphocytes. Report 16490D, 1990. Hazelton, UK.
- BP. 1993. Dipropylene glycol monoethyl ether: OECD 476 mutation of L5178Y mouse lymphoma cells at the thymidine kinase TK +/- locus. Unpublished report. Safepharm Laboratories, Derby, UK, project number 222/70. BP Chemicals, London, UK.
- BP. 2001. (2-Ethoxy-methylethoxy)-propanol: Toxicity study by oral gavage administration to CD rats for 90 days followed by a 4-week recovery period. Unpublished report BPM 007/993352. Huntingdon Life Sciences, Huntingdon, Cambridges hire, England, UK. BP Chemicals, London, UK.
- Braun WH. 1997a. Primary eye irritation study with 2-methoxypropylacetate-1 in rabbits. Unpublished report, RCC project 639988, BASF 11H1044/839017. RCC Research and Consulting, Itingen, Switzerland. BASF, Ludwigshafen, Germany.

Braun WH. 1997b. Primary skin irritation study with 2-methoxypropylacetate-1 in rabbits (4-hour semi-occlusive application). Unpublished report, RCC project 639977, BASF 18H1044/839016. RCC Research and Consulting, Itingen, Switzerland. BASF, Ludwigshafen, Germany.

Breckenridge C, Rainey S, Procter BG. 1985a. A range-finding teratological study of inhaled Dowanol TPM in the albino rat. Unpublished report. Dow Chemical, Midland, Michigan, USA.

Breckenridge B, Collins C, Robinson K, Lulham G, Hamelin M, Osborne Band Procter BG. 1985b. A teratological study of inhaled Dowanol TPM in the albino rat. Unpublished report. Dow Chemical, Midland, Michigan, USA.

Breslin WJ, Zablotny CL, Cieszlak FS, Verschuuren HG, Yano BL. 1990a. Dipropylene glycol monomethyl ether (DPGME): inhalation teratology study in Fischer 344 rats. Unpublished report of Dow Chemical, Midland, Michigan, USA.

Breslin WJ, Zablotny CL, Cieszlak FS, Verschuuren HG, Yano BL. 1990b. Dipropylene glycol monomethyl ether (DPGME): inhalation teratology study in New Zealand white rabbits. Unpublished report of Dow Chemical, Midland, Michigan, USA.

Breslin WJ, Phillips JE, Lomax LG, Bartels MJ, Dittenber DA, Calhoun LL, Miller RR. 1991. Hemolytic activity of ethylene glycol phenyl ether (EGPE) in rabbits. *Fundam Appl Toxicol* 17:466-481.

Brinkworth MH, Weinbauer GF, Schlatt S, Nieschlag E. 1995. Identification of male germ cells undergoing apoptosis in adult rats. *J Reprod Fert* 105:25-33.

Brooke I, Cocker J, Delic JI, Payne M, Jones K, Gregg NC, Dyne D. 1998. Dermal uptake of solvents from the vapour phase: an experimental study in humans. *Ann Occup Hyg* 42:531-540.

Brown NA, Holt D, Webb M. 1984. The teratogenicity of methoxyacetic acid in the rat. *Toxicol Lett* 22:93-100.

Browning E. 1965. *Toxicity and metabolism of industrial solvents*. Elsevier, Amsterdam, Netherlands, pp 632-634.

Browning RG, Curry SC. 1994. Clinical toxicology of ethylene glycol monoalkyl ethers. *Human Exp Toxicol* 13:325-335.

Bruce RJ, Gollapudi BB, Verschuuren HG. 1987. Evaluation of propylene glycol *n*-butyl ether in the Ames *Salmonella*/ mammalian-microsome bacterial mutagenicity assay. Unpublished report. Dow Chemical, Midland, Michigan, USA.

Bruze M, Gruvberger B, Agrup G. 1988. Sensitization studies in the guinea pig with the active ingredients of Euxyl K400. *Contact Dermatitis* 18:37-39.

Budden R, Kühl UG, Buschmann G. 1978. Ausgewählte Untersuchungen zur pharmakodynamischen Eigenwirkung verschiedener Lösungsvermittler. 1. Mitteilung: Äthylendiäthylenglycol, N,N-Diäthylacetamid, Dimethylsulfoxid. *Arzneim-Forsch* 28:1571-1579.

Burkhart KK, Donovan JW. 1998. Hemodialysis following butoxyethanol ingestion. *Clin Toxicol* 36:723-725.

Budden R, Kühl UG, Buschmann G. 1978. Ausgewählte Untersuchungen zur pharmakodynamischen Eigenwirkung verschiedener Lösungsvermittler. 1. Mitteilung: Äthylendiäthylenglycol, N,N-Diäthylacetamid, Dimethylsulfoxid. *Arzneim-Forsch* 28:1571-1579.

Burkhart KK, Donovan JW. 1998. Hemodialysis following butoxyethanol ingestion. *Clin Toxicol* 36:723-725.

Butterworth KR, Gaunt IF, Grasso P. 1975. A nine-month toxicity study of diethylene glycol monoethyl ether in the ferret. Research report no. 15/1975. Br. Ind. Bio. Res. Assoc., UK.

Calhoun LL, Johnson KA, Miller RR. 1984. Propylene glycol monomethyl ether (PGME). 21-day dermal study in New Zealand White rabbits. Unpublished report of Dow Chemical, Midland, Michigan, USA.

Calhoun LL, Kastl PE, Hannah MA, Putzig CL, Miller RR. 1986a. Metabolism and disposition of tripropylene glycol monomethyl ether (TPGME) in male rats. Unpublished report. Dow Chemical, Midland, Michigan, USA.

Calhoun LL, Kastl, PE, Hannah MA, Miller RR. 1986b. Abstract presented at the American industrial hygiene conference, Dallas, Texas, USA, May 1986. [Abstract]

Calhoun LL, Zimmer MA, Schuetz DJ, Miller RR. 1986c. Propylene glycol phenyl ether. 28-day dermal toxicity study in rabbits. Unpublished report. Dow Chemical, Midland, Michigan, USA.

Carney EW, Johnson KA. 2000. Comparative developmental toxicity of the glycol ether metabolites, methoxyacetic acid and methoxypropionic acid. *Teratology* 61:53. [Abstract]

Carney EW, Tornesi B. 2001. Evaluation of methoxypropionic acid and β-propylene glycol monomethyl ether in the rabbit whole embryo culture assay. Unpublished report, study 011148. Toxicology & Environmental Research and Consulting, Dow Chemical, Midland Michigan USA. Oxygenated Solvents, Dow Chemical, Midland, Michigan, USA.

Carney EW, Crissman JW, Liberacki AB, Clements CM, Breslin WJ. 1999. Assessment of adult and neonatal reproductive parameters in Sprague-Dawley rats exposed to propylene glycol monomethyl ether vapor for two generations. *Toxicol Sci* 50:249-258.

Carpenter CP. 1947. Cellosolve. Queries and minor notes. J Am Med Ass 135:880.

Carpenter CP, Smyth HF. 1946. Chemical burns of the rabbit cornea. *Am J Ophthalmol* 29:1363-1372.

Carpenter CP, Pozzani UC, Weil CS, Nair JH, Keck GA, Smyth HF. 1956. The toxicity of butyl cellosolve solvent. *AMA Arch Ind Health* 14:114-131.

Carreon RE, Young JT, New MA, Olson KJ, Rao KS. 1980. Dowanol PM Acetate. Acute toxicological properties and industrial handling hazards. Unpublished report of Dow Chemical, Midland, Michigan, USA.

Carreon RE, Wall JM, Rao KS, Young JT. 1984. Propylene glycol monomethyl ether. Skin sensitization potential in the guinea pig. Unpublished report of Dow Chemical, Midland, Michigan, USA.

Cerven DR. 1992a. Dipropylene glycol *tertiary* butyl ether: single dose oral toxicity in rats / LD₅₀ in rats. Unpublished report MB 92-1741 A. Cerven DR, MB Research Laboratories, Spinnerstown PA, USA. ARCO Chemical, Newtown Square, PA, USA.

Cerven DR. 1992b. Dipropylene glycol *tertiary* butyl ether: acute dermal toxicity in rabbits / LD₅₀ in rabbits. Unpublished report MB 92-1741 B. Cerven DR, MB Research Laboratories, Spinnerstown, PA, USA. ARCO Chemical, Newtown Square, PA, USA.

Cerven DR. 1992c. Dipropylene glycol *tertiary* butyl ether: primary dermal irritation in albino rats. Unpublished report MB 92-1741 C. Cerven DR, MB Research Laboratories, Spinnerstown, PA, USA. ARCO Chemical, Newtown Square, PA, USA.

Cerven DR. 1992d. Dipropylene glycol *tertiary* butyl ether: primary eye irritation and/or corrosion in rabbits. Unpublished report MB 92-1741 C. Cerven DR, MB Research Laboratories, Spinnerstown, PA, USA. ARCO Chemical, Newtown Square, PA, USA.

Chang MJW, Vigon BW, Fadel LC, Placke ME. 1988. Determination of water and lipid solubility and octanol-water partition coefficient of propylene glycol mono-tertiary butyl ether (PTBE), final report. Unpublished report. Battelle, Columbus, Ohio, USA. Arco Chemical, Newtown Square, PA, USA.

Chapin RE, Lamb JC. 1984. Effects of ethylene glycol monomethyl ether on various parameters of testicular function in the F344 rat. *Environ Health Perspect* 57:219-224.

Chapin RE, Sloane RA. 1997. Reproductive assessment by continuous breeding: evolving study design and summaries of ninety studies. *Environ Health Perspect* 105 suppl 1:199-395.

Chapin RE, Dutton SL, Ross MD, Swaisgood RR, Lamb JC IV. 1985a. The recovery of the testis over 8 weeks after short-term dosing with ethylene glycol mono methyl ether. Histology, cell-specific enzymes, and rete testis fluid protein. *Fundam Appl Toxicol* 5:515-525.

Chapin RE, Dutton SL, Ross MD, LambJCIV. 1985b. Effects of ethylene glycol monomethyl ether (EGME) on mating performance and epididymal sperm parameters in F344 rats. *Fundam Appl Toxicol* 5:182-189.

Cheever KL, Plotnick HB, Richards DE, Weigel WW. 1984. Metabolism and excretion of 2-ethoxyethanol in the adult male rat. *Environ Health Perspect* 57:241-248.

Cheever KL, Richards DE, Weigel WW, Lal JB, Dinsmore AM, Daniel FB. 1988. Metabolism of bis(2-methoxyethyl)ether in the adult male rat. Evaluation of the principal metabolite as a testicular toxicant. *Toxicol Appl Pharmacol* 94:150-159.

Cheever KL, Weigel WW, Richards DE, Lal JB, Plotnick HB. 1989a. Testicular effects of bis(2-methoxyethyl) ether in the adult male rat. *Toxicol Ind Health* 5:1099-1109.

Cheever KL, Richards DE, Weigel WW, Begley KB. 1989b. The role of enzyme induction on metabolite formation of bis (2-methoxyethyl) ether in the rat. *Toxicol Ind Health* 5:601-607.

Cheever KL, Swearengin TF, Edwards RM, Nelson BK, Werren DW, Conover DL, DeBord DB. 2001. 2-Methoxyethanol metabolism, embryonic distribution, and macromolecular adduct formation in the rat: the effect of radiofrequency radiation-induced hyperthermia. *Toxicol Lett* 122:53-67.

Chester A, Hull J, Andrew F. 1986. Lack of teratogenic effect after ethylene glycol monoethyl ether (EGEE) in rats via drinking water. *Teratology* 33:57 [Abstract].

Chia SE, Foo SC, Khoo NY, Jeyaratnam J. 1997. Menstrual patterns of workers exposed to low levels of 2-ethoxyethylacetate (EGEEA). *Am J Ind Med* 31:148-152.

Chiewchanwit T, Au WW. 1994. Cytogenetic effects of 2-methoxyethanol and ist metabolite, methoxyacetaldehyde, in mammalian cells *in vitro*. *Mutat Res* 320:125-132.

Chiewchanwit T, Au WW. 1995. Mutagenicity and cytotoxicity of 2-butoxyethanol and its metabolite, 2-butoxyacetaldehyde, in Chinese hamster ovary (CHO-AS52) cells. *Mutat Res* 334:341-346.

Chinn H, Anderson E, Yoneyama M. 2000. Glycol ethers. CEH marketing research report 663.5000, September 2000. In SRI International, eds, *Chemical Economics Handbook*. SRI International, Menlo Park, CA, USA.

Chung W-G, Yu I-J, Park C-S, Lee K-H, Roh H-K, Cha Y-N. 1999. Decreased formation of ethoxyacetic acid from ethylene glycol monoethyl ether and reduced atrophy of testes in male rats upon combined administration with toluene and xylene. *Toxicol Lett* 104:143-150.

Cieszlak FS, Crissman JW. 1991. Dowanol PM glycol ether: an acute vapor inhalation study in Fischer 344 rats. Unpublished report, study K-005539-024. Toxicology Research Laboratory, Health and Environmental Sciences, Dow Chemical, Midland, Michigan, USA.

Cieszlak FS, Yano BL, Verschuuren HG. 1990. Dowanol DPnB: Acute aerosol LC50 study in Fischer 344 rats. Unpublished report, study K-005474-009. Toxicology Research Laboratory, Health and Environmental Sciences, Dow Chemical, Midland, Michigan, USA.

Cieszlak FS, Stebbins KE, Verschuuren HG. 1991. Dowanol DPnB: two-week aerosol toxicity study in Fischer 344 rats. Unpublished report, study K-005474-010. Toxicology Research Laboratory, Health and Environmental Sciences, Dow Chemical, Midland, Michigan, USA.

Cieszlak FS, Stott WT, Redmond JM, Crissman JW, Corley RA. 1996a. Propylene glycol monomethyl ether: a 13-week vapor inhalation study to evaluate hepatic and renal cellular proliferation, P450 enzyme induction and protein droplet nephropathy in Fischer 344 rats. Unpublished report, study K-005539-026B. Toxicology Research Laboratory, Health and Environmental Sciences, Dow Chemical, Midland, Michigan, USA. Chemicals and Performance Products, Dow Chemical, Midland, Michigan, USA.

Cieszlak FS, Stott WT, Redmond JM, Crissman JW, Corley RA. 1996b. Propylene glycol monomethyl ether: a 13-week vapor inhalation study to evaluate hepatic and renal cellular proliferation, P450 enzyme induction and protein droplet nephropathy in B6C3F₁ mice. Unpublished report, study K-005539-026A. Toxicology Research Laboratory, Health and Environmental Sciences, Dow Chemical, Midland, Michigan, USA. Chemicals and Performance Products, Dow Chemical, Midland, Michigan, USA.

CIR (Expert Panel Cosmetic Ingredient Review). 1990. Final report on the safety assessment of phenoxyethanol. *J Am Coll Toxicol* 9:259-278.

Clapp DE, Smallwood AW, Moseley C, DeBord KE. 1987. Workplace assessment of exposure to 2-ethoxyethanol. *Appl Ind Hyg* 2:183-187.

Clark AM, Maguire SM, Griswold MD. 1997. Accumulation of clusterin/sulfated glycoprotein-2 in degenerating pachytene spermatocytes of adult rats treated with methoxyacetic acid. *Biol Reprod* 57:37-46.

Clarke DO, Duignan JM, Welsch F. 1990. Embryo dosimetry and incidence of malformations in CD-1 mice following subcutaneous infusion of 2-methoxyethanol (2-ME). *Teratology* 41:544 [Abstract].

Clarke DO, Mebus CA, Miller FJ, Welsch F. 1991a. Protection against 2-methoxyethanol teratogenesis by serine enantiomers. Studies of potential alteration of 2-methoxyethanol pharmacokinetics. *Toxicol Appl Pharmacol* 110:514-526.

Clarke DO, Welsch F, Conolly RB. 1991b. Development of a physiologically-based description of 2-methoxy-ethanol pharmacokinetics in the pregnant mouse. *Teratology* 43:437 [Abstract].

Clarke DO, Duignan JM, Welsch F. 1992. 2-Methoxyacetic acid dosimetry teratogenicity relationships in 2-methoxyethanol-exposed pregnant CD-1 mice. *Toxicol Appl Pharmacol* 114:77-87.

CMA (Chemical Manufacturers Association). 1991. Glycol Ethers Panel research summary report, January 1991. Unpublished report CMA, Washington, DC, USA.

Coakley ME, Rawlings SJ, Brown NA. 1986. Short-chain carboxylic acids, a new class of teratogens. Studies of potential biochemical mechanisms. *Environ Health Perspect* 70:105-111.

Cohen R. 1984. Reversible subacute ethylene glycol monomethyl ether toxicity associated with microfilm production. A case report. *Am J Ind Med* 6:441-446.

Coles R, Brooks PN. 1993. Dipropylene glycol monoethyl ether: oral gavage one generation reproduction study in the rat. Unpublished report. Safepharm Laboratories, Derby, UK, project 222/71. BP Chemicals, London, UK.

Collinot JP, Collinot JC, Deschamps F, Decolin D, Siest G, Galteau MM. 1996. Evaluation of urinary D-glucaric acid excretion in workers exposed to butyl glycol. *J Toxicol Environ Health* 48:349-358.

Conquet Ph, Duran G, Laillier J, Chatrousse M. 1977. Evaluation of ocular irritation in the rabbit. Objective versus subjective assessment. *Toxicol Appl Pharmacol* 39:129-139.

Cook RR, Bodner KM, Kolesar RC, van Peenen PFD, Dickson GS, Flanagan K. 1982. A cross-sectional study of ethylene glycol monomethyl ether process employees. *Arch Environ Health* 37:346-351.

Copestake P. 2002. Re: review request [referring to a literature search on glycols ethers and cardiac sensitisation]. Personal communication (e-mail) to Wilson PB, Thomas M, Lyondell Chemical Europe, Maidenhead, Berkshire, England UK. TNO Bibra International, Carshalton, Surrey, England, UK.

Cordier S, Bergeret A, Goujard J, Ha M-C, Ayme S, Bianchi F, Calzolari E, DeWalle HEK, Knill-Jones R, Candela S, Dale I, Dananche B, de Vigan C, Fevotte J, Kel G, Mandereau L. 1997. Congenital malformations and maternal occupational exposure to glycol ethers. *Epidemiology* 8:355-363.

Cordier S, Szabova E, Fevotte J, Bergeret A, Plackova S, Mandereau L. 2001. Congenital malformations and maternal exposure to glycol ethers in the Slovak Republic. *Epidemiology* 12:592-593.

Corley RA, Johnson KA, Battjes JE, Verschuuren HG. 1989a. Propylene glycol *n*-butyl ether. An acute vapour inhalation study in Fischer 344 rats. Unpublished report. Dow Chemical, Midland, Michigan, USA.

Corley RA, Phillips JE, Johnson KA, Verschuuren HG. 1989b. Propylene glycol *n*-butyl ether. Two-week vapour inhalation study with Fischer 344 rats. Unpublished report. Dow Chemical, Midland, Michigan, USA.

Corley RA, Cieszlak FS, Breslin WJ, Lomax LG. 1990. Triethylene glycol monomethyl ether (TGME). 13-week dermal toxicity study in Sprague-Dawley rats. Report to the US Chemical Manufacturers Association, September 1990.

Corley RA, Bormett GA, Ghanayem BI. 1994. Physiologically based pharmacokinetics of 2-butoxyethanol and its major metabolite, 2-butoxyacetic acid, in rats and humans. *Toxicol Appl Pharmacol* 129:61-79.

Corley RA, Markham DA, Banks C, Delorme P, Masterman A, Houle JM. 1997. Physiologically based pharmacokinetics and the dermal absorption of 2-butoxyethanol vapor by humans. *Fundam Appl Toxicol* 39:120-130.

Corley RA, Weita KK, Mast TJ, Miller RA, Thrall BD. 1999. Short-term studies to evaluate the dosimetry and modes of action of 2-butoxyethanol in B6C3F1 mice, final report. Unpublished report, project 29753. Battelle Memorial Institute, Pacific Northwest Division, Columbus Operations, Richland Washington, USA. Ethylene Glycol Ethers Panel, Chemical Manufacturers Association, Arlington, Virginia, USA.

Corn M, Cohen R. 1993. Final report: Prospective exposure assessment, supplement to The Johns Hopkins University study of reproductive health among IBM employees in semiconductor manufacturing Unpublished report. Johns Hopkins University, Baltimore, Maryland, USA. International Business Machines (IBM) Corporation, Burlington, Vermont and East Fishkill, New York, USA.

Cosse PF, Atkin L. 1989. Triethylene glycol monomethyl ether: two-week dietary and drinking water palatability study in Sprague-Dawley rats. Unpublished report, study K-005610-003. Mammalian and Environmental Toxicology Research Laboratory, Health and Environmental Sciences, Dow Chemical, Midland, Michigan, USA.

Cranch AG, Smyth HF, Carpenter CP. 1942. External contact with monoethyl ether of diethylene glycol (Carbitol solvent). *Arch Dermatol Syph* 45:553-559.

Creasy DM, Foster PMD. 1984. The morphological development of glycol ether-induced testicular atrophy in the rat. *Exp Mol Pathol* 40:169-176.

Creasy DM, Flynn JC, Gray TJB, Butler WH. 1985. A quantitative study of stage-specific spermatocyte damage following administration to EGME in the rat. *Exp Molec Pathol* 43:321-336.

Creasy DM, Beech LM, Gray TJB, Butler WH. 1986. An ultrastructural study of ethylene glycol monomethyl ether-induced spermatocyte injury in the rat. *Exp Mol Pathol* 45:311-322.

Cullen MR, Rado T, Waldron JA, Sparer J, Welch LS. 1983. Bone marrow injury in lithographers exposed to glycol ethers and organic solvents used in multicolor offset and ultraviolet curing printing processes. *Arch Environ Health* 38:347-354.

Daamen PAM, Verschuuren HG. 1989. Skin sensitization potential of Dowanol TPnB in the guinea pig (Buehler test). Unpublished report, study 0666/1475. RCC Notox, 's-Hertogenbosch, Netherlands Dow Chemical Europe, Horgen, Switzerland.

Dahl AR, Miller SC, Petridou-Fischer J. 1987. Carboxylesterases in the respiratory tracts of rabbits, rats and Syrian hamsters. *Toxicol Lett* 36:129-136.

Daniel FB, Cheever KL, Begley KB, Richards DE, Weigel WW, Eisenmann CJ. 1991. Bis (2-methoxethyl) ether. Metabolism and embryonic disposition of a developmental toxicant in the pregnant CD-1 mouse. *Fundam Appl Toxicol* 16:567 -575.

Daniel FB, Eisenmann C, Cheever KL, Richards DE, Wiegel WW. 1986. Metabolism of a reproductive toxin, bis (2-methoxyethyl) ether, in the pregnant mouse. *Teratology* 33:75C.

Daston GP, Baines D, Elmore E, Fitzgerald MP, Sharma S. 1995. Evaluation of chick embryo neural retina cell culture as a screen for developmental toxicants. *Fundam Appl Toxicol* 26:203-210.

Daughtrey WC, Ward DP, Lewis SC, Peterson OR. 1984. Acute toxicity of dermally applied 2-ethoxyethanol. *Toxicologist* 4:180 [Abstract].

Davis BJ, Almekinder JL, Flagler N, Travlos G, Wilson R, Maronpot RR. 1997. Ovarian luteal cell toxicity of ethylene glycol monomethyl ether and methoxy acetic acid *in vivo* and *in vitro*. *Toxicol Appl Pharmacol* 142:328-337.

Dawson TAJ, Black RJ, Strang WC, Millership JS, Davies I. 1989. Delayed and immediate hypersensitivity to carbitols. *Contact Dermatitis* 21:52.

Day SJ. 2000. Evaluation of Dowanol PPh in the mouse bone marrow micronucleus test. Unpublished report, study 991204. Toxicology & Environmental Research and Consulting, Dow Chemical, Midland, Michigan, USA. Dow Chemical, Midland, Michigan, USA.

De Groot AC, Bos JD, Jagtman BA, Bruynzeel DP, van Joost T, Weyland JW. 1986. Contact allergy to preservatives II. *Contact Dermatitis* 15:218-222.

Dean BS, Krenzelok EP. 1992. Clinical evaluation of pediatric ethylene glycol monobutyl ether poisoning. *J Toxicol Clin Toxicol* 30:557-563.

Debets FMH. 1988. Evaluation of the acute oral toxicity of Dowanol TPnB in the rat. Unpublished report. RCC Notox, 's-Hertogenbosch, Netherlands. Dow Chemical Europe, Horgen, Switzerland.

Debets FMH, Verschuuren HG. 1987. Assessment of oral toxicity, including the haemolytic activity of Dowanol PnB in the rat. 14-day study. Toxicology Research Laboratory Report, Dow Europe, Horgen, Switzerland.

Deisinger PJ, Guest D. 1989. Metabolic studies with diethylene glycol monobutyl ether acetate (DGBA) in the rat. *Xenobiotica* 19:981-989.

Denkhaus W, Steldern D, Botzenhardt U, Konietzko H. 1986. Lymphocyte subpopulations in solvent-exposed workers. *Int Arch Occup Environ Health* 57:109-115.

Devanthéry A, Dentan A, Berode M, Droz PO. 2000. Propylene glycol monomethyl ether (PGME) occupational exposure. 1. Biomonitoring by analysis of PGME in urine. *Int Arch Occup Environ Health* 73:311-315.

Devanthéry A, Berode M, Droz PO, Pulkkinen J. 2003. Propylene glycol monomethyl ether (PGME) occupational exposure. 4. Analysis of 2-methoxypropionic acid in urine. *Int Arch Occup Environ Health* 76:151-155.

DFG. 2000. List of MAK and BAT values. Report No. 36, Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area. Wiley-VCH, Weinheim, Germany.

Dieter MP, Jameson CW, Maronpot RR, Langebach R, Braun AG. 1990. The chemotherapeutic potential of glycol alkyl ethers. Structure-activity studies of nine compounds in a Fischer-rat leukaemia transplant model. *Canc Chemother Pharmacol* 26:173-180.

Dill JA, Lee KM, Bates DJ, Anderson DJ, Johnson RE, Chou BJ, Burka LT, Roycroft JH. 1998. Toxicokinetics of inhaled 2-butoxyethanol and its major metabolite, 2-butoxyacetic acid in F344 rats and B6C3F₁ mice. *Toxicol Appl Pharmacol* 153:227-242.

Dodd DE, Snellings WM, Maronpot RR, Ballantyne B. 1983. Ethylene glycol monobutyl ether: Acute, 9-day and 90-day vapour inhalation studies in Fischer 344 rats. *Toxicol Appl Pharmacol* 68:405-414.

Dodd DE, Nachreiner DJ, Klonne DR, Kintigh WJ, Wise RC. 1990. Propasol Solvent P: fourteen-week vapor exposure inhalation study with Fischer 344 and Sprague Dawley rats. Unpublished report 53-44. Bushy Run Research Center, Export Pennsylvania, USA. Union Carbide Corporation, Danbury, Connecticut, USA.

Doe JE. 1984a. Ethylene glycol monoethyl ether and ethylene glycol monoethyl ether acetate teratology studies. *Environ Health Perspect* 57:33-41.

Doe JE. 1984b. Further studies on the toxicology of the glycol ethers with emphasis on rapid screening and hazard assessment. *Environ Health Perspect* 57:199-206.

Doe JE, Samuels DM, Tinston DJ, Wickramaratne GAD. 1983. Comparative aspects of the reproductive toxicology by inhalation in rats of ethylene glycol monomethyl ether and propylene glycol monomethyl ether. *Toxicol Appl Pharmacol* 69:43-47.

Doi AM, Roycroft JH, Herbert RA, Haseman JK, Hailey JR, Chou BJ, Dill JA, Grumbein SL, Miller RA, Renne RA, Bucher JR. 2004. Inhalation toxicology and carcinogenesis studies of propylene glycol mono-*t*-butyl ether in rats and mice. *Toxicol* 199:1-22.

Domoradzki JY, Thornton CM, Brzak KA. 2001. Propylene glycol monomethyl ether (PGME) and propylene glycol monomethyl ether acetate (PGMEA): A. *In vitro* hydrolysis of PGMEA in rat and human blood and liver homogenate. B. Kinetics of PGME and PGMEA following intravenous administration to Fischer 344 rats. Unpublished report, study 001023. Toxicology & Environmental Research and Consulting. Dow Chemical, Midland, Michigan, USA. American Chemistry Council, Arlington, Virginia, USA.

Domoradzki JY, Brzak KA, Thornton CM. 2003. Hydrolysis kinetics of propylene glycol monomethyl ether acetate in rats *in vivo* and in rat and human tissues *in vitro*. *Toxicol Sci* 75:31-39.

Donley DE. 1936. Toxic encephalopathy and volatile solvents in industry. Report of a case. *J Ind Hyg Tox* 18:571-577.

Dow. 1982. Unpublished data. Cited by Rowe VK and Wolf MA in Clayton GD and Clayton FE, eds, *Patty's Ind. Hyg. and Toxicol*. 3rd revised edition. Wiley, 3982.

Dow. 1984. Dowanol DB: A 5-week repeated vapor inhalation study in rats. Unpublished report. Gushow TS, Miller RR, Yano BL. Dow Chemical, Midland, Michigan, USA.

Dow. 1985. 2-Phenoxyethanol. Two week dermal probe study in female New Zealand white rabbits to assess haematological effects. Dow Chemical, Midland, Michigan, USA. Cited in IUCLID Data Set, European Commission, European Chemicals Bureau, 11 February, 2000.

Dow. 1986a. 2-Phenoxyethanol. Hemolytic investigations in rabbits and rats with cover letter. Unpublished report. Breslin WJ, Bartels MJ, Phillips JE, Dittenber DA, Lomax LG, Miller RR, Mammalian and Environmental Toxicology Research Laboratory. Dow Chemical, Midland, Michigan, USA.

Dow. 1986b. Ethylene glycol phenyl ether: 90-day dermal toxicity study in rabbits. Unpublished report by Phillips JE, Lomax LG, Calhoun LL, Miller RR. Mammalian and Environmental Toxicology Research Laboratory. Dow Chemical, Midland, Michigan, USA.

Dow. 1987. Evaluation of 2-phenoxyethanol in the Chinese hamster ovary cell/hypoxanthine-guanine-phosphoribosyl transferase (CHO/HGPRT) forward mutation assay. Linscombe Virginia, Gollapudi BB. Dow Chemical, Midland, Michigan, USA.

Dow. 1988. Evaluation of 2-phenoxyethanol in the rat bone marrow chromosomal aberration assay. Unpublished report. Gollapudi BB, Linscombe VA, Bruce RJ, Health and Environmental Sciences. Dow Chemical, Texas, USA.

Draize JH, Woodward G, Calvery HO. 1944. Methods for the study of irritation and toxicity of substances applied to the skin and mucous membranes. *J Pharmacol Exp Therap* 82:377-390.

Draize JH, Alvarez E, Whitesell MF, Woodard G, Hagen EC, Nelson AA. 1948. Toxicological investigations of compounds proposed for use as insect repellants. *J Pharmacol Exp Therap* 43:26.

Driscoll CD, Valentine R, Staples RE, Chromey NC, Kennedy GL. 1998. Developmental toxicity of diglyme by inhalation in the rat. *Drug Chem Toxicol* 21:119-136.

Du Pont. 1984. Acute inhalation toxicity of 2- (2-butoxyethoxy)ethyl acetate (Butyl Carbitol acetate). Submission to EPA with cover letter. E.I Du Pont de Nemours & Co, Newark, Delaware, USA, pp 4-6.

Du Pont. 1987. Unpublished data. Report HLR 523-87, Haskell Lab. Toxicol. Ind. Med., E.I Du Pont de Nemours & Co, Newark, Delaware, USA.

Du Pont. 1988a. Unpublished data. Report HLR 129-88. Haskell Lab. for Toxicol. and Ind. Med., E.I. Du Pont de Nemour & Co, Newark, Delaware, USA.

Du Pont. 1988b. Unpublished data. Report HLR 562-88. Haskell Lab. for Toxicol. and Ind. Med., E.I. Du Pont de Nemours & Co, Inc., Newark, Delaware, USA.

Duerksen-Hughes PJ, Yang J, Ozcan O. 1999. p53 Induction as a genotoxic test for twenty-five chemicals undergoing *in vivo* carcinogenicity testing. *Environ Health Perspect* 107:805-812.

Dugard PH, Walker M, Mawdsley SJ, Scott RC. 1984. Absorption of some glycol ethers through human skin *in vitro*. *Environ Health Perspect* 57:193-197.

Duprat P, Gradiski D. 1979. Percutaneous toxicity of butyl cellosolve (ethylene glycol monobutyl ether). *IRCS Med Sci* 7:26.

ECB (European Chemicals Bureau). 2000. IUCLID dataset, existing chemical substance ID 111-77-3, 2-(2-methoxyethoxy)ethanol, creation date 18-Feb-2000. ECB, Ispra, Italy.

ECETOC. 1994. Butoxyethanol criteria document, Special Report No. 7. European Centre for Ecotoxicology and Toxicology of Chemicals, Brussels, Belgium.

ECETOC. 1995. The toxicology of glycol ethers and its relevance to man. Technical Report No. 64. European Centre for Ecotoxicology and Toxicology of Chemicals, Brussels, Belgium.

Eisses KT. 1999. Concurrent teratogenic and mutagenic action of 2-methoxyethanol in *Drosophila melanogaster* larvae resulted in similar phenotypes: close resemblance to direct mutations. *Teratogen Carcinog Mutagen* 19:183-204.

Elias Z, Danière MC, Marande AM, Terzetti F. 1992. Augmentation par le butylglycol et l'éthylglycol de la fréquence des mutagènes dans les cellules V79 et les lymphocytes humains en culture. Poster presented at Forum Mutagenèse et Industrie, Paris, December 1992.

Elias Z, Danière MC, Marande AM, Poirot O, Terzetti F, Schneider O. 1996. Genotoxic and/or epigenetic effects of some glycol ethers: Results of different short-term tests. *Occup Hyg*:187-212.

Elliot BM, Ashby J. 1997. Review of the genotoxicity of 2-butoxyethanol. *Mutat Res* 387:89-96.

Elliot R, Jones J, McElvenny D, Pennington J, Northage C, Clegg T, Clarke S, Hodgson J, Osman J. 1998. Spontaneous abortions in the UK semiconductor industry, an HSE investigation. Health Safety Executive, Bottle, England, UK.

El-Zein RA, Abdel-Rahman SZ, Morris DL, Legator MS. 2002. Exposure to ethylene glycol monomethyl ether: clinical and cytogenetic findings. *Arch Environ Health* 57:371-376.

Ema M, Itami T, Kawasaki H. 1988. Teratology study of diethylene mono-*n*-butyl ether in rats. *Drug Chem Toxicol* 11:97-111.

Emmen HH. 1997. Human volunteer study with propylene glycol monomethyl ether, potential eye irritation during vapor exposure, final report. Unpublished report V97.116. TNO Nutrition and Food Research Laboratory, Zeist, Netherlands. Oxygenated Solvent Producers Association, CEFIC, Brussels, Belgium. Dutch Ministry of Social Affairs and Employment, Den Haag, Netherlands.

Emmen HH, Muijser H, Arts JH, Prinsen MK. 2003. Human volunteer study with PGME: eye irritation during vapour exposure. *Toxicol Lett* 140-141:249-259.

Enninga IC, Verschuuren HG. 1990. Evaluation of the clastogenic properties of dipropylene glycol *n*-butyl ether. Unpublished report, projects 0481/ECC138, 0676/ECC145, 1321/ECC174. RCC Notox, 's Hertogenbosch, Netherlands, Dow Chemical, Midland, Michigan, USA.

European Chemicals Bureau. 2000. European Union risk assessment report vol. 1, 1st priorty list. 2-(2-methoxyethoxy)ethanol, CAS No. 111-77-3, EINECS No. 203-906-6. Institute fot Health and Consumer Protection, European Commission Joint Research Centre, Ispra, Italy [ISBN 92-828-8399-X]. [http://ecb.jrc.it/existing-chemicals/degmereport005].

European Chemicals Bureau. 2001. European Union risk assessment report vol. 2, 1st priorty list. 2-(2-butoxyethoxy)ethanol, CAS No. 112-34-5, EINECS No. 203-961-6. Institute fot Health and Consumer Protection, European Commission Joint Research Centre, Ispra, Italy [ISBN 92-828-8398-1] [http://ecb.jrc.it/existing-chemicals/ degbereport004].

Exon JH, Mather GG, Bussiere JL, Olson DP, Talcott PA. 1991. Effects of subchronic exposure of rats to 2-methoxyethanol or 2-butoxyethanol. Thymic atrophy and immunotoxicity. *Fundam Appl Toxicol* 16:830-840.

Fairhurst S, Knight R, Marrs TC, Scawin JW, Spurlock MS, Swanston DW. 1989. Percutaneous toxicity of ethylene glycol mono methyl ether and of dipropylene glycol monomethyl ether in the rat. *Toxicol* 57:209-215.

Fédération des Industries de la Parfumerie. 2002. Evaluation de la sécurité dans un usage cosmétique: DEGBE, DEGEE, EGBE, EGPhE. Personal communication. Nohynek G, L'Oréal Recherche, Clichy, France. Presentation at the Ministère de l'Emploi et de la Solidarité, Direction Générale de la Santé, Paris, February 7, 2002. Fédération des Industries de la Parfumerie, Département Scientifique et Réglementaire, Paris, France.

Fellows JK, Luduene FP, Hanzlik PJ. 1947. Glucuronic acid excretion after diethylene glycol monoethyl ether (Carbitol) and some other glycols. *J Pharmacol Exptl Therap* 89:210-213.

Ferrala NF, Ghanayem BI, Nomeir AA. 1994. Determination of 1-methoxy-2-propanol and its metabolite 1,2-propanediol in rat and mouse plasma by gas chromatography. *J Chromatography B* 660:291-296.

Ferro. 2002. Industrial specialties, products and markets glycol diethers. Ferro Corporation, Cleveland, Ohio, USA [www.ferro.com].

Feuston MH, Bodnar KR, Kerstetter SL, Grink CP, Belcak MJ, Singer EJ. 1989. Reproductive toxicity of 2-methoxyethanol applied dermally to occluded and nonoccluded sites in male rats. *Toxicol Appl Pharmacol* 100:145-161.

Feuston MH, Kerstetter SL, Wilson PD. 1990. Teratogenicity of 2-methoxyethanol applied as a single dermal dose to rats. *Fundam Appl Toxicol* 15:448-456.

Fidler A, Crandall M, Kerndt P. 1991. Spontaneous abortions among employees of a book cover manufacturing plant. *Am J Epidemiol* 128:910-912.

Figà-Talamanca I, Cini C, Traina ME, Petrelli G. 1997. Effects of glycol ethers on the reproductive health of occupationally exposed individuals: Review of present day evidence. *J Clean Technol Environ Toxicol & Occup Med* 6:323-337.

Foster PMD, Creasy DM, Foster JR, Thomas LV, Cook MW, Gangolli SD. 1983. Testicular toxicity of ethylene glycol monomethyl and monoethyl ethers in the rat. *Toxicol Appl Pharmacol* 69:385-399.

Foster PMD, Creasy DM, Foster JR, Gray TJB. 1984. Testicular toxicity of ethylene glycol monomethyl and monoethyl ethers in the rat. *Environ Health Perspect* 57:207-217.

Foster PMD, Blackburn DM, Moore RB, Lloyd SC. 1986. Testicular toxicity of 2-methoxyacetaldehyde, a possible metabolite of ethylene glycol monomethyl ether, in the rat. *Toxicol Lett* 32:73-80.

Foster PMD, Lloyd SC, Blackburn DM. 1987. Comparison of the *in vivo* and *in vitro* testicular effects produced by methoxy-, ethoxy- and *n*-butoxyacetic acids in the rat. *Toxicol* 43:17-30.

France. 1985. Affections engendrées par les solvants organiques liquides à usage professionnel. Tableau 84 des maladies professionnelles prévues à l'article R.461-3 du Code de la sécurité sociale, Livre 4 Titre 6 Dispositions concernant les maladies professionnelles. Créé par Décret 85-1353 1985-12-17 art 1 Journal Officiel de la République Française 21 décembre 1985 [http://www.aimt67.org/dossier/Mp084.htm],

[http://www.ucanss.fr/services/textes documents/code ss/html/pag es/interface.html].

Froelich KW, Andersen LM, Knutsen A, Flood PR. 1984. Phenoxyethanol as a nontoxic substitute for formaldehyde in long-term preservation of human anatomical specimens for dissection and demonstration purposes. *Anat Rec* 208:271-278.

Gage JC. 1970. The subacute inhalation toxicity of 109 industrial chemicals. Br J Ind Med 27:1-18.

Galloway SM, Armstrong MJ, Reuben C, Colman S, Brown B, Cannon C. 1987. Chromosome aberrations and sister chromatid exchanges in Chinese hamster ovary cells. Evaluations of 108 chemicals. *Environ Mol Mutagen* 10 Suppl 10:1-175.

Gargas ML, Tyler TR, Sweeney LM, Corley RA, Weitz KK, Mast TJ, Paustenbach DJ, Hays SM. 2000a. A toxicokinetic study of inhaled ethylene gycol monomethyl ether (2-ME) and validation of a physiologically based pharmacokinetic model for the pregnant rat and human. *Toxicol Appl Pharmacol* 165:53-62.

Gargas ML, Tyler TR, Sweeney LM, Corely RA, Weitz KK, Mast TJ, Paustenbach DJ, Hays SM. 2000b. A toxicokinetic study of inhaled ethylene glycol ethyl ether acetate and validation of a physiologically based pharmacokinetic model for rat and human. *Toxicol Appl Pharmacol* 165:63-73.

Gaunt IF, Colley J, Grasso P, Lansdown ABG, Ganglli SD. 1968. Short-term toxicity of diethylene glycol monoethyl ether in the rat, mouse and pig. Fd Cosmet Toxicol 6:689-705.

Genschow E, Scholz G, Brown N, Piersma A, Brady M, Clemann N, Huuskonen H, Paillard F, Bremer S, Becker K, Spielmann H. 2000. Development of prediction models for three *in* vitro embryotoxicity tests in an ECVAM validation study. *In vitro MolecToxicol* 13:51-65.

George JD, Price CJ, Kimmel CA, Marr MC. 1987. The developmental toxicity of triethylene glycol dimethyl ether. *Fundam Appl Toxicol* 9:173-181.

George JD, Price CJ, Marr MC, Morrissey RE, Schwetz BA. 1990. Developmental toxicity of triethylene glycol dimethyl ether in New Zealand white rabbits. *Teratology* 41:50 [Abstract].

George JD, Price CJ, Marr MC, Kimmel CA, Schwetz BA, Morrissey RE. 1992. The developmental toxicity of ethylene glycol diethyl ether in mice and rabbits. *Fundam Appl Toxicol* 19:15-25.

Ghanayem BI. 1989. Metabolic and cellular basis of 2-butoxyethanol induced hemolytic anemia in rats and assessment of human risk *in vitro*. *Biochem Pharmacol* 38:1679-1684.

Ghanayem BI, Chapin RE. 1990. Calcium channel blockers protect against ethylene glycol monomethyl ether (2-methoxyethanol)-induced testicular toxicity. *Exper Molec Pathol* 52:279-290.

Ghanayem BI, Blair PC, Thompson MB, Maronpot RR, Matthews HB. 1987a. Effect of age on the toxicity and metabolism of ethylene glycol monobutyl ether (2-butoxyethanol) in rats. *Toxicol Appl Pharmacol* 91:222-234.

Ghanayem BI, Burka LT, Sanders JM, Matthews HB. 1987b. Metabolism and disposition of ethylene glycol monobutyl ether (2-butoxyethanol) in rats. *Drug Metab Disp* 15:478-484.

Ghanayem BI, Burka LT, Matthews HB. 1987c. Metabolic basis of ethylene glycol monobutyl ether (2-butoxyethanol) toxicity: Role of alcohol and aldehyde dehydrogenases. *J Pharmacol Exp Ther* 242:222-231.

Ghanayem BI, Burka LT, Matthews HB. 1989. Structure-activity relationships for the *in vitro* hematotoxicity of *n*-alkoxyacetic acids, the toxic metabolites of glycol ethers. *Chem Biol Interactions* 70:339-352.

Ghanayem BI, Sanders JM, Clark AM, Bailer J, Matthews HB. 1990a. Effects of dose, age, inhibition of metabolism and elimination on the toxicokinetics of 2-butoxyethanol and its metabolites. *J Pharmacol Exp Therap* 253:136-143.

Ghanayem BI, Ward SM, Blair PC, Matthews HB, 1990b. Comparison of the hematologic effects of 2-butoxyethanol using two types of hematology analyzers. *Toxicol Appl Pharmacol* 106:341-345.

Ghanayem BI, Sanchez IM, Matthews HB. 1992. Development of tolerance to 2-butoxyethanol-induced hemolytic anemia and studies to elucidate the underlying mechanisms. *Toxicol Appl Pharmacol* 112:198-206.

Ghanayem BI, Sullivan CA. 1993. Assessment of the haemolytic activity of 2-butoxyethanol and its major metabolite, butoxyacetic acid, in various mammals including humans. *Human Exp Toxicol* 12:305-311.

Ghanayem BI, Ward SM, Chanas B, Nyska A. 2000. Comparison of the acute hematotoxicity of 2-butoxyethanol in male and female F344 rats. *Hum Exp Toxicol* 19:185-192.

Ghanayem BI, Long PH, Ward SM, Chanas B, Nyska M, Nyska A. 2001. Hemolytic anemia, thrombosis, and infarction in male and female F344 rats following gavage exposure to 2-butoxyethanol. *Exp Toxicol Pathol* 53:97-105.

Gibson WB, Nolen GA, Christian MS. 1989. Determination of the developmental toxicity potential of butoxypropanol in rabbits after topical administration. *Fund Appl Toxicol* 13:359-365.

Gibson WB, Keller PR, Foltz DJ, Harvey GJ. 1991. Diethylene glycol mono butyl ether concentrations in room air from application of cleaner formulations to hard surfaces. *J Exp Env Epidem* 1:369-383.

Gijsenbergh FP, Jenco M, Veulemans H, Groeseneken D, Verberckmoes R, Delooz HH. 1989. Acute butylglycol intoxication: A case report. *Human Toxicol* 8:243-245.

Gilbert KS. 1995a. Dipropylene glycol *n*-propyl ether: acute dermal toxicity study in New Zealand White rabbits. Unpublished report, study DR-0005-2733-001D Toxicology Research Laboratory, Health and Environmental Sciences. Dow Chemical, Midland, Michigan, USA.

Gilbert KS. 1995b. Dipropylene glycol *n*-propyl ether: primary dermal irritation study in New Zealand White rabbits. Unpublished report, study DR-0005-2733-001B. Toxicology Research Laboratory, Health and Environmental Sciences. Dow Chemical, Midland, Michigan, USA.

Gilbert KS. 1995c. Dipropylene glycol *n*-propyl ether: primary eye irritation study in New Zealand White rabbits. Unpublished report, study DR-0005-2733-001C. Toxicology Research Laboratory, Health and Environmental Sciences. Dow Chemical, Midland, Michigan, USA.

Gilbert KS, Stebbins KE. 1995. Dipropylene glycol *n*-propyl ether: acute oral toxicity study in Fischer 344 rats. Unpublished report, study DR-0005-2733-001A. Toxicology Research Laboratory, Health and Environmental Sciences. Dow Chemical, Midland, Michigan, USA.

Gill MW, Hurley JM. 1990. Triethylene glycol monomethyl ether. Fourteen-day drinking water inclusion study in rats. Unpublished report 52-606, Bushy Run Research Center, Export Pennsylvania, USA. Report to the US Chemi cal manufacturers Association, Arlington, Virginia, USA.

Gill MW, Negley JE. 1990. Triethylene glycol monomethyl ether. Ninety day subchronic drinking water inclusion neurotoxicity study in rats. Report to the US Chemical Manufacturers Association. September 1990.

Gill MW, Fowler EH, Gingell R, Lomax LG, Corley RA. 1998. Subchronic dermal toxicity and oral neurotoxicity of triethylene glycol monomethyl ether in CD rats. *Internat J Toxicol* 17:1-22.

Gingell R, Krasavage WJ, Wise RC, Knaak JB, Bus J, Gibson WB, Stack CR. 1993. Toxicology of diethylene glycol butyl ether I. Exposure and risk assessment. *J Am Coll Toxicol* 12:139-144.

Gingell R, Boatman RJ, Bus JS, Cawley TJ, Knaak JB, Krasavage WJ, Skoulis NP, Stack CR, Tyler TR. 1994. In Clayton GD, Clayton FE, eds, *Patty's Ind. Hyg. and Toxicol*. 4th revised edition. Vol. Il, part D, 2761-2966. Wiley, New York, New York, USA.

Gingell R. Boatman RJ, Lewis S. 1998. Acute toxicity of ethylene glycol mono-*n*-butyl ether in the guinea pig. *Food Chem Toxicol* 36:825-829.

Goad PT, Cranmer JM. 1984. Gestation period sensitivity of ethylene glycol monoethyl ether in rats. *Toxicologist* 4:87 [Abstract].

Goldberg ME, Hann C, Smyth HF. 1962. Toxicologic implication of altered behavior induced by an industrial vapor. *Toxicol Appl Pharmacol* 4:148-164.

Goldberg ME, Johnson HE, Pozzani UC, Smyth HF. 1964. Effect of repeated inhalation of vapors of industrial solvents on animal behavior. 1. Evaluation of nine solvent vapors on pole-climb performance in rats. *Am Ind Hyg J* 25:369-375.

Goldberg ME, Johnson HE, Pozzani UC, Smyth HF. 1969. Effect of repeated inhalation of vapors of industrial solvents on animal behavior. *Ind Hyg J* 25:369-375.

Gollapudi BB, Linscombe VA, Verschuuren HG. 1988a. Evaluation of propylene glycol *n*-butyl ether in an *in vitro* chromosomal aberration assay utilizing Chinese hamster ovary (CHO) cells. Unpublished report. Dow Chemical, Midland, Michigan, USA.

Gollapudi BB, Linscombe VA, Verschuuren HG. 1988b. Evaluation of dipropylene glycol *n*-butyl ether in an *in-vitro* chromosomal aberration assay utilizing Chinese hamster ovary (CHO) cells. Unpublished report, study K-005474-007. Health and Environmental Sciences-Texas, Lake Jackson Research Center, Dow Chemical, Freeport, Texas, USA. Dow Chemical, Midland, Michigan, USA.

Gollapudi BB, Linscombe VA, McClintock ML, Sinha AK, Stack CR. 1993. Toxicology of diethylene glycol butyl ether 3. Genotoxicity evaluation in an *in vitro* gene mutation assay and an *in vivo* cytogenetic test. *J Am Coll Toxicol* 12:155-159.

Gollapudi BB, Barber ED, Lawlor TE, Lewis S. 1996. Re-examination of the mutagenicity of ethylene glycol monobutyl ether to *Salmonella* tester strain TA97a. *Mutat Res* 370:61-64.

Gottschling BC, Kamendulis LM, Klaunig JE. 2000. Modulation of focal and non-focal hepatocyte DNA synthesis in 2-butoxyethanol treated mice. *Toxicologist* 54:201 [Abstract].

Grandjean M, Szabo JR, Verschuuren HG. 1992. Propylene glycol *n*-butyl ether. 13-week drinking water study in Fischer 344 rats. Unpublished report. Dow Chemical, Midland, Michigan, USA.

Grandolfo M, Pipoli M, Foti C, Bonamonte D, Rigano L, Veña GA, Angelini G. 1996. Influence of vehicle on patch test response to nickel sulfate. *Contact Dermatitis* 35:173-174.

Grant D, Sulsh S, Jones HB, Gangolli SD, Butler WH. 1985. Acute toxicity and recovery in the hemopoietic system of rats after treatment with ethylene glycol monomethyl and monobutyl ethers. *Toxicol Appl Pharmacol* 77:187-200.

Gray TJB. 1986. Testicular toxicity *in vitro*: Sertoli-germ cell co-cultures as a model system. *Food Chem Toxicol* 24:601-605.

Gray TJB, Moss EJ, Creasy DM, Gangolli SD. 1985. Studies on the toxicity of some glycol ethers and alkoxyacetic acids in primary testicular cell cultures. *Toxicol Appl Pharmacol* 79:490-501.

Gray RH, Corn M, Cohen R, Correa A, Hakim R, Hou W, Shah F, Zauer H. 1993. Final report: The Johns Hopkins University retrospective and prospective studies of reproductive health among IBM employees in semiconductor manufacturing, Unpublished report. Johns Hopkins University, Baltimore, Maryland, USA. International Business Machines (IBM) Corporation, Burlington, Vermont and East Fishkill, New York, NY, USA.

Green T. 2000. The distribution of radioactivity in the female B6C3F₁ mouse following a single six-hour exposure to 2-butoxy[1-¹⁴C]ethanol by inhalation. Unpublished report CTL/R/1444. Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire UK. CEFIC, Brussels, Belgium.

Green T, Toghill A, Lee R, Moore R, Foster J. 2002. The development of forestomach tumours in the mouse following exposure to 2-butoxyethanol by inhalation: studies on the mode of action and relevance to humans. *Toxicol* 180:257-273.

Greenburg L, Mayers MR, Goldwater LJ, Burke WV, Moskowitz S. 1938. Health hazards in the manufacture of Fused Collars. I. Exposure to ethylen glycol monomethyl ether. *J Ind Hyg Tox* 20:134-147.

Greene JA, Sleet RB, Morgan KT, Welsch F. 1987. Cytotoxic effects of ethylene glycol monomethyl ether in the fore-limb bud of the mouse embryo. *Teratology* 36:23-34.

Greenspan AH, Reardon RC, Gingell R, Rosica KA. 1995. Human repeated insult patch test of 2-butoxyethanol. *Contact Dermatitis* 33:59-60.

Groeseneken D, Veulemans H, Masschelein R. 1986a. Respiratory uptake and elimination of ethylene glycol monoethyl ether after experimental human exposure. *Br J Ind Med* 43:544-549.

Groeseneken D, Veulemans H, Masschelein R. 1986b. Urinary excretion of ethoxyacetic acid after experimental human exposure to ethylene glycol monoethyl ether. *Br J Ind Med* 43:615-619.

Groeseneken D, Veulemans H, Masschelein R, Van Vlem E. 1987a. Ethoxyacetic acid: A metabolite of ethylene glycol monoethyl ether acetate in man. *Br J Ind Med* 44:488-493.

Groeseneken D, Veulemans H, Masschelein R, Van Vlem E. 1987b. Pulmonary absorption and elimination of ethylene glycol monoethyl ether acetate in man. *Br J Ind Med* 44:309-316.

Groeseneken D, Veulemans H, Masschelein R, Van Vlem E. 1988. Comparative urinary excretion of ethoxyacetic acid in man and rat after single low doses of ethylene glycol monoethyl. *Toxicol Lett* 41:57-68.

Groeseneken D, Veulemans H, Masschelein R, Van Vlem E. 1989a. Experimental human exposure to ethylene glycol monomethyl ether. *Int Arch Occup Environ Health* 61:243-247.

Groeseneken D, Veulemans H, Masschelein R, Van Vlem E. 1989b. An improved method for the determination in urine of alkoxyacetic acids. *Int Arch Occup Environ Health* 61:249-254.

Groetschel H, Schürmann D. 1959. Gruppenerkrankung bei der Anwendung von Äthylenglykolmonomethyl-äther als Lösungsmittel in einer Druckerei. *Arch Toxikol* 17:243-251.

Gross E. 1938. Toxikologie und Hygiene der technischen Lösungsmittel. Lehmann KB, Flury F, eds, Springer-Verlag Berlin; cited in MAK Documentation 2-Methoxyethylacetat (1984).

Grote IW, Woods M. 1955. Beta-phenylethyl alcohol as a preservative for ophthalmic solutions. *J Am Pharm Ass* 44:9-11.

Gualtieri J, Harris C, Roy R, Corley R, Manderfield C. 1995. Multiple 2-butoxyethanol intoxications in the same patient: Clinical findings, pharmacokinetics, and therapy. *J Toxicol Clinical Toxicol* 33:550-551.

Guest D, Hamilton ML, Deisinger PJ, DiVincenzo GD. 1984. Pulmonary and percutaneous absorption of 2-propoxyethyl acetate and 2-ethoxy ethyl acetate in beagle dogs. *Environ Health Perspect* 57:177-183.

Guest D, Deisinger PJ, Winter JE. 1985. Estimation of the atmospheric concentration of diethylene glycol monobutyl ether acetate resulting from the application of latex paint. Health and Environment Laboratories, Eastman Kodak, Rochester, New York, USA.

Gulati DK, Hommel L, Russel S, Poonacha KB. 1985a. Environmental Health Research and Testing, Inc. Ethylene glycol monomethyl ether. Reproduction and fertility assessment in CD-1

when administered in drinking water.1-40, 54, 58. NTIS/PB 86-120128, US Department of Commerce, Springfield, Virginia, USA.

Gulati DK, Mounce RC, Shaver S, Russel S, Poonacha KB. 1985b. Ethylene glycol monomethyl ether. Reproduction and fertility assessment in CD-1 when administered in drinking water (revised September 1985), 1-49, 81-82, 85, 88. NTIS/PB 86-163136. Environ. Health Res. and Testing, Inc. US Department of Commerce, Springfield, Virginia, USA.

Gulati DK, Barnes LH, Russell S, Poonacha KB. 1985c. Ethylene glycol monoethyl ether acetate. Reproduction and fertility assessment in CD-1 mice when administered in drinking water. NTP, 1-51,75-76, 80,84, 89-101,317-320,327. National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park NC, USA

Gulati DK, Hommel-Barnes L, Welch M, Russell S, Lamb JC. 1986. Propylene glycol monomethyl ether: reproduction and fertility assessment in CD-1 mice when administered in drinking water. Final report. Environmental Health Research and Testing, Cincinnati, Ohio, USA. NTP-report 86-062. National Toxicology Programme, National Institute of Environmental Health Sciences, Research Triangle Park NC, USA.

Gulati DK, Hope E, Barnes LH, Russels S, Poonacha KB. 1988a. Ethylene glycolmethylether reproduction and fertility assessment when administered in drinking water. NTP report 88-106; NTIS/PB 88-211446. Environ. Health Res. and Testing Inc., USA.

Gulati DK, Hope E, Russels S, Poonacha KB, Mounce RC. 1988b. Ethylene glycolmonomethylether reproduction and fertility assessment in C57BL/6 mice when administered in drinking water. NTP 38-069; NTIS 88-192240. Environ. Health Res. and Testing Inc., USA.

Gulati DK, Hope E, Barnes LH, Russel S, Poonacha KB. 1989. Environ. Health Res. and Testing, Inc. Ethylene glycol monomethyl ether reproduction and fertility assessment in C3H mice when administered in drinking water (revised), 1-483. NTIS/PB 89-152565, US Department of Commerce, Springfield, Virginia, USA.

Gulati DK, Hope E, Barnes LH, Russell S, Poonacha KB. 1990a. Environ. Health Res. and Testing, Inc. Reproductive toxicity of ethylene glycol monomethyl ether (CAS No.109-86-4) in Sprague-Dawley rats, litter two, 1-76. NTIS-PB 90-252313, US Department of Commerce, Springfield, Virginia, USA.

Gulati DK, Hope E, Christman KL, Barnes LH, Russell S. 1990b. Environ. Health Res. and Testing, Inc. Reproductive toxicity of ethylene glycol monomethyl ether (CAS No.109-86-4) in

Sprague-Dawley rats, litter two, 1-72. NTIS-PB 90-252321, US Department of Commerce, Springfield, Virginia, USA.

Gushow TS, Miller RR, Yano BL. 1981. Downool DB, a 5-week repeated vapour inhalation study in rats. Unpublished report. Toxicology Research Laboratory, Health and Environmental Sciences, Dow Chemical, Midland, Michigan, USA.

Gushow TS, Phillips JE, Lomax LG, Verschuuren HG. 1987. Dipropylene glycol *n*-butyl ether: an acute vapour inhalation study in Fischer 344 rats. Unpublished report. Toxicology Research Laboratory, Health and Environmental Sciences, Dow Chemical, Midland, Michigan, USA.

Guzzie PJ, Slesinski RS, Hengler WC, Tyler TR. 1986. Assessment of 2-ethoxyethanol for genotoxicity using a battery of *in vitro* and *in vivo* test systems. *Environ Mutagen* 8, Suppl 6:33.

Hagensen JH, Combs MA, Cholakis JM, Carter JL, Steele DH, Ridlon SA. 1982. Acute inhalation toxicity test in Sprague-Dawley rats using A209429. Unpublished report, project 7450-B. Midwest Research Institute, Kansas City, Missouri, USA. ARCO Chemical, Newtown Square, Pennsylvania, USA.

Hall DE, Lee FS, Austin P, Fairweather FA. 1966. Short-term feeding study with diethylene glycol monethyl ether in rats. *Food Cosmet Toxicol* 4:263-268.

Hallock MF, Hammond SK, Kenyon E, Smith TJ, Smith ER. 1993. Assessment of task and peak exposures to solvents in the micro-electronics industry. *Appl Occup Environ Hyg* 8:945-954.

Hammond SK, Hines CJ, Hallock MF, Woskie SR, Kenyon EM, Schenker MB. 1996. Exposures to glycol ethers in the semi-conductor industry. *Occup Hyg* 2:355-366.

Hanley TR, Yano BL, Nitschke KD, John JA, 1984a. Comparison of the teratogenic potential of inhaled ethylene glycol monomethyl ether in rats, mice, and rabbits. *Toxicol Appl Pharmacol* 75:409-422.

Hanley TR, Young JT, Sohn JA, Rao KS. 1984b. Ethylene glycol monomethyl ether (EGME) and propylene glycol monomethylether (PGME). Inhalation fertility and teratogenicity studies in rats, mice and rabbits. *Environ Health Perspect* 57:7-12.

Hanley TR, Calhoun LL, Yano BL, Rao KS. 1984c. Teratologic evaluation of inhaled propylene glycol monomethyl ether in rats and rabbits. *Fundam Appl Toxicol* 4:784-794.

Hanzlik PJ, Luduene FP, Lawrence WS, Hanzlik H. 1947a. Acute toxicity and general systemic actions of diethylene glycol monoethyl ether (carbitol). *J Ind Hyg Toxicol* 29:190-195.

Hanzlik PJ, Lawrence WS, Fellows JK, Luduena FP, Laqueur GL. 1947b. Epidermal applications of diethylene glycol monoethyl ether (carbitol) and some other glycols. *J Ind Hyg Toxicol* 20:325-341.

Hanzlik PJ, Lawrence WS, Laqueur GL. 1947c. Comparative chronic toxicity of diethylene glycol monoethyl ether (Carbitol) and some related glycols. Results of continued drinking and feeding. *J Ind Hyg Toxicol* 29:233-241.

Hardin BD, Eisenmann CJ. 1987. Relative potency of four ethylene glycol ethers for induction of paw malformations in the CD-1 mouse. *Teratology* 35:321-328.

Hardin BD, Niemeier RW, Smith RJ, Kuczuk MH, Mathinos PR, Weaver TF. 1982. Teratogenicity of 2-ethoxyethanol by dermal application. *Drug Chem Toxicol* 5:277-294.

Hardin BD, Goad PT, Burg JR. 1984. Developmental toxicity of four glycol ethers applied cutaneously to rats. *Environ Health Perspect* 57:69-74.

Hardin BD, Goad PT, Burg JR. 1986. Developmental toxicity of diethylene glycol monomethyl ether (diEGME). *Fundam Appl Toxicol* 6:430-439.

Hardin BD, Schuler RL, Burg JR, Booth GM, Hazelden KP, MacKenzie KM, Piccirillo VJ, Smith KN. 1987. Evaluation of 60 chemicals in a preliminary developmental toxicity test. *Teratogen Carcinogen Mutagen* 7:29-48.

Hardy CJ, Coombs DW, Lewis DJ, Klimisch HJ. 1997. Twenty-eight-day repeated-dose inhalation exposure of rats to diethylene glycol monoethyl ether. *Fundam Appl Toxicol* 38:143-147. Haufroid V, Thirion F, Mertens P, Buchet J-P, Lison D. 1997. Biological monitoring of workers exposed to low levels of 2-butoxyethanol. *Int Arch Occup Environ Health* 70:232-236.

Hausen BM. 1993. The sensitizing potency of Euxyl K 400 and its components 1,2-dibromo-2,4-dicyanobutane and 2-phenoxyethanol. *Contact Dermatitis* 28:149-153.

Hays SM, Elswick BA, Blumenthal GM, Welsch F, Conolly RB, Gargas ML. 2000. Development of a physiologically based pharmacokinetic model of 2-methoxyethanol and 2-methoxyacetic acid disposition in pregnant rats. *Toxicol Appl Pharmacol* 163:47-74.

Heindel JJ, Gulati DK, Russell VS, Reel JR, Lawton AD, Lamb JC. 1990. Assessment of ethylene glycol monobutyl and monophenyl ether reproductive toxicity using a continuous breeding protocol in Swiss CD-1 mice. *Fundam Appl Toxicol* 15:683-696.

Hellwig J. 1993. Study of the prenatal toxicity of 2-methoxyethanol in rats after dermal application. Unpublished report No 00R53/89002. Abt. Toxikologie. BASF, Ludwigshafen, Germany.

Hellwig J, Klimisch HJ, Jäckh R. 1994. Prenatal toxicology of inhalation exposure to 2-methoxypropanol in rabbits. *Fundam Appl Toxicol* 23:608-613.

Henck JW, Yakel HO, Olson KJ, Rao KS. 1980. Propylene glycol methyl ether acetate. Acute toxicological properties and industrial handling hazards. Unpublished report of Dow Chemical, Midland, Michigan, USA.

Hext P. 1984. Ethylene glycol butyl ether and butoxyacetic acid: Their effects on erythrocyte fragility in four species. Unpublished report CTL Y00704/003. Imperial Chemical Industries, Central Toxicology Laboratory, Macclesfield, Cheshire UK [EPA/OTS 89-890000727].

Hoberman AM. 1990a. Triethylene glycol monoethyl ether (TGME): Oral developmental toxicity study in Crl:CD(SD)BR pregnant rats. Report to the US Chemical Manufacturers Association, March 1990.

Hoberman AM. 1990b. Triethylene Glycol Monomethyl Ether (TGME): Oral developmental toxicity study in New Zealand White rabbits. Report to the US Chemical Manufacturers Association, March 1990.

Hoberman AM, Krasavage WJ, Christian MS, Stack CR. 1996. Developmental toxicity studies of triethylene glycol monomethyl ether administered orally to rats and rabbits. *J Am Coll Toxicol* 15:349-370.

Hobson DW, D'Addario AP, Bruner RH, Uddin DE. 1986a. A subchronic dermal exposure study of diethylene glycol monomethyl ether and ethylene glycol monomethyl ether in the male guinea pig. *Fundam Appl Toxicol* 6:339-348.

Hobson DW, Wyman JF, Lee LH, Bruner RH, Uddin DE. 1986b. Evaluation of the subchronic toxicity of diethylene glycol monobutyl ether administered orally to rats. Report of US Navy, cited in 'petition to delete five unique glycol ethers from the Clean Air Act list of Hazardous Air Pollutants', CMA, October 11 1991. National Technical Information Service P89-1554.

Hoehn D. 1945. Nephrosis probably due to excessive use of Sta-Way insect repellent. JAm Med Assoc 128:153.

Hoffmann HD, Gelbke HP. 1984. Bericht über die Prüfung der Stabilität von 2-Methylpropylglykoletheracetat in Rattenplasma. Unpublished report 84/73. BASF, Ludwigshafen, Germany.

Hoffmann HD, Jäckh R. 1985. Cleavage of glycol ether acetates by rat plasma *in vitro*. Unpublished manuscript. Dept. Toxicol. BASF, Ludwigshafen, Germany.

Hoflack JC, Lambolez L, Elias Z, Vasseur P. 1994. Mutagenicity of ethylene glycol ethers and their metabolites in *Salmonella typhimurium*. Abstracts of international symposium on health hazards of glycol ethers, page IV 22. Abbaye de Pont-à-Mousson, Nancy, France.

Hoflack JC, Lambolez L, Elias Z, Vasseur P. 1995. Mutagenicity of ethylene glycol ethers and of their metabolites in *Salmonella typhimurium* his-. *Mutat Res* 341:281-287.

Hoflack JC, Durand MJ, Poirier GG, Maul A, Vasseur P. 1997. Alteration in methylmethanesulfonate-induced poly(ADP-ribosyl)ation by 2-butoxyethanol in Syrian hamster embryo cells. *Carcinogenesis* 18:2333-2338.

Hofmann T, Engelbart K, Jung R, Mayer D, Langer KH. 1992. Triethylene glycol dimethylether, rein; Subakute orale Toxizität (28 Applikationen in 29 Tagen) an männlichen und weiblichen Wistar-Ratten. Bericht Nr. 92.0371. Pharm. Entwicklung. Zentrale Toxikologie. Hoechst, Frankfurt, Germany.

Holladay SD, Comment CE, Kwon J, Luster MI. 1994. Fetal hematopoietic alterations after maternal exposure to ethylene glycol monomethyl ether: prolymphoid cell targeting. *Toxicol Appl Pharmacol* 129:53-60.

Holloway AJ, Moore HDM, Foster PMD. 1990. The use of rat *in vitro* fertilization to detect reductions in the fertility of spermatozoa from males exposed to ethylene glycol monomethyl ether. *Reprod Toxicol* 4:21-27.

Hong HL, Canipe J, Jameson CW, Boorman GA. 1988a. Comparative effects of ethylene glycol and ethylene glycol momomethyl ether exposure on hematopoiesis and histopathology in B₆C₃F₁ mice. *J Environ Pathol Toxicol Oncol* 8:27-38.

Hong HL, Silver M, Boorman GA. 1988b. Demonstration of residual bone marrow effect in mice exposed to ethylene glycol monomethyl ether. *Toxicol* 50:107-115.

Horimoto M, Isobe Y, Isogai Y, Tachibana M. 2000. Rat epididymal sperm motion changes induced by ethylene glycol monoethyl ether, sulfasalazine, and 2,5-hexandione. *Reprod Toxicol* 14:55-63.

Horton VL, Sleet RB, John-Greene JA, Welsch F. 1985. Developmental phase-specific and dose-related teratogenic effects of ethylene glycol monomethyl ether in CD-1 mice. *Toxicol Appl Pharmacol* 80:108-118.

Houchens DP, Ovejera AA, Niemeier RW. 1984. Effects of ethylene glycol monomethyl (EGME) and monoethyl (EGEE) ethers on the immunocompetence of allogeneic and syngeneic mice bearing L 1210 mouse leukaemia. *Environ Health Perspect* 57:113-118.

House RV, Lauer LD, Murray MJ, Ward EC, Dehan JH. 1985. Immunological studies in B6C3F1 mice following exposure to ethylene glycol monomethyl ether and its principal metabolite methoxyacetic acid. *Toxicol Appl Pharmacol* 77:358-362.

Howes D. 1988. Absorption and metabolism of 2-phenoxyethanol in rat and man. Cosmetic Science '88, 15th IFSCC International Congress.

HSE (Health and Safety Executive). 1988. Glycol ether and glycol acetate vapours in air. Laboratory method using Tenax adsorbent tubes, thermal desorption and gas chromatography. HSE Occupational and Medical Hygiene Laboratory, Merseyside, England, , UK.

HSE (Health and Safety Executive). 1993. MDHS 72 (February 1992), volatile organic compounds in air, laboratory method using pumped solid sorbent tubes, thermal desorptoin and gas chromatography. In *Handbook of Occupational Hygiene*, instalment 67. Wolters Kluwer (UK), Croner CCH, London, United Kingdom, pp 13.3:763-776.

HSE (Health and Safety Executive). 2000. MDHS 96 (March 2000), volatile organic compounds in air (4), laboratory method using pumped solid sorbent tubes, thermal desorptoin and gas chromatography. In *Handbook of occupational hygiene*, instalment 68. Wolters Kluwer (UK), Croner CCH, London, United Kingdom, pp 13.3:801-825.

Hubner B, Lehnert G, Schaller KH, Welte D, Angerer J. 1992. Chronic occupational exposure to organic solvents. XV. Glycol ether exposure during manufacture of brakehoses. *Int Arch Occup Environ Health* 64:261-264.

Hüls. 1989. Bestimmung der Mutagenität von Ethylglykolacetat in *Salmonella*/Säuger-Mikrosomen-Mutagenitätstest nach Ames, gemäß EG-Richtlinie 84/449/EWG B 14. Unpublished report AM-89/22. Schöberl, Ps-Biologie/Toxikologie. Hüls, Marl, Germany.

Hüls. 1990a. Prüfung der akuten Hautreizwirkung von Ethyldiglykolacetat. Unpublished report 1750. Mürmann P, Ps-Biologie/Toxikologie. Hüls, Marl, Germany.

Hüls. 1990b. Prüfung der akuten Augen- und Schleimhautreizwirkung von Ethyldigglykolacetat. Unpublished report 1751. Mürmann P, Ps-Biologie/Toxikologie. Hüls, Marl, Germany.

Hüls. 1990c. Prüfung auf hautsensibilisierende Wirkung am Meerschweinchen von Ethyldiglykolacetat. Unpublished report 1752. Mürmann P, Ps-Biologie/Toxikologie. Hüls, Marl, Germany.

Hüls. 1990d. Bestimmung der Mutagenität von Ethyldiglykolacetat in *Salmonella*/Säuger-Mikrosomen-Mutagenitätstest nach Ames, Mutagenitätstest nach der Richtlinie 84/449/EWG B 14. Unpublished report 90/23. Schöberl, Ps-Biologie/Toxikologie. Hüls, Marl, Germany.

Hürtt ME, Zenick H. 1986. Decreasing epididymal sperm reserves enhances the detection of ethoxyethanol-induced spermatotoxicity. *Fundam Appl Toxicol* 7:348-353.

Hutson DH, Pickering BA. 1971. The metabolism of isopropyl oxitol in rat and dog. *Xenobiotica* 1:105-119.

IARC (International Agency for Research on Cancer). 2005. Formaldehyde, 2-Butoxyethanol and 1-*tert*-Butoxy-2-propanol. In Monographs on the evaluation of carcinogenic risks to humans, Vol. 88. IARC Press, Lyon, France [ISBN 92 8321].

Indo M. 2000. DPM: Chromosomal aberration test in cultured mammalian cells. Unpublished report FBM 00-8027. Fuji Biomedix, Kobuchizawa Laboratories, Kitakoma-gun, Yamanashi-ken, Japan. Dow Chemical, Midland, Michigan, USA.

Innis JD, Nixon GA, Verschuuren HG. 1990. Sub-chronic (13-week) dermal toxicity study with propylene glycol *n*- butyl ether in albino rabbits. Unpublished report. Dow Europe, Horgen, Switzerland.

INSERM. 1999. Ethers de glycol, quels risques pour la santé? Synthèse et recommendations. Dépôt légal No 272794M. Institut National de la Santé et de la Recherche Médicale, Montpellier, France [ISBN 2-85598-762-8; English translation].

IPCS (International Programme on Chemical Safety). 1990. 2-Methoxyethanol, 2-ethoxyethanol and their acetates. Environmental Health Criteria 115. World Health Organization, Geneva, Switzerland.

IPCS (International Programme on Chemical Safety). 1998. 2-Butoxyethanol, Concise International Chemical Assessment Document 10. World Health Organization, Geneva, Switzerland.

IUCLID (International Uniform Chemical Database). 2000. Dataset, existing chemical substance ID: 122-99-6, CAS 122-99-6, EINECS name 2-phenoxyethanol. In IUCLID, CD-Rom ed 2-2000, list of the 2 604 EU high production volume chemicals. European Commission, Joint Research Centre, Institute for Health and Consumer Protection, European Chemicals Bureau, Ispra, Italy.

Jacobs G. 1992. Eye irritation tests on two glycol ethers. J Am Coll Toxicol 11:378.

Jacobs GA, Martens MA. 1989. An objective method for the evaluation of eye irritation *in vivo*. *Food Chem Toxicol* 27:255-258.

Jacobs G, Martens M, Mosselmans G. 1987. Proposal of limit concentrations for skin irritation within the context of a new EEC directive on the classification and labelling of preparations. *Regul Toxicol Pharmacol* 7:370-378.

Jacobs GA, Castellazzi A, Dierickx PJ. 1989. Evaluation of a non-invasive human and an *in vitro* cytotoxicity method as alternatives to the skin irritation test on rabbits. *Contact Dermatitis* 21:239-244.

Jakasa I, Mohammadi N, Kruse J, Ke ic S. 2004. Percutaneous absorption of neat and aqueous solutions of 2-butoxyethanol in volunteers. *Int Arch Occup Environ Health* 77:79-84.

Jenkins-Sumner S, Stedman D, Cheng S, Welsch F, Fennell T. 1996. Characterization of urinary metabolites produced following administration of [1,2,methoxy- ¹³C]-2-methoxyethanol to male F-344 rats and pregnant CD-1 mice. *Occup Hyg* 2:25-31.

Johanson G. 1986. Physiologically based pharmacokinetic modeling of inhaled 2-butoxyethanol in man. *Toxicol Lett* 34:23-31.

Johanson G. 1989. Analysis of ethylene glycol ether metabolites in urine by extractive alkylation and electron-capture gas chromatography. *Arch Toxicol* 63:107-111.

Johanson G. 1990. NEG and NIOSH basis for an occupational health standard: propylene glycol ethers and their acetates. Arbete och Halsa nr 32.

Johanson G. 1994. Inhalation toxicokinetics of butoxyethanol and its metabolite butoxyacetic acid in the male Sprague-Dawley rat. *Arch Toxicol* 68:588-594.

Johanson G. 2000. Toxicity review of ethylene glycol monomethyl ether and its acetate ester. *Crit Rev Toxicol* 30:307-345.

Johanson G, Boman A. 1991. Percutanous absorption of 2-butoxyethanol vapour in human subjects. *Br J Med* 48:788-792.

Johanson G, Fernstrom P. 1986. Percutaneous uptake rate of 2-butoxyethanol in the guinea pig. *Scand J Work Environ Health* 12:499-503.

Johanson G, Fernstrom P. 1988. Influence of water on the percutaneous absorption of 2-butoxyethanol in guinea pigs. *Scand J Work Environ Health* 14:95-100.

Johanson G, Johnsson S. 1991. Gas chromatographic determination of butoxyacetic acid in human blood after exposure to 2-butoxyethanol. *Arch Toxicol* 65:433-435.

Johanson G, Kronborg H, Näslund PH, Nordqvist MB. 1986a. Toxicokinetics of inhaled 2-butoxyethanol (ethylene glycol monobutyl ether) in man. *Scand J Work Environ Health* 12:594-602.

Johanson G, Wallen M, Nordqvist MB. 1986b. Elimination kinetics of 2-butoxyethanol in the perfused rat liver -dose dependence and effects of ethanol. *Toxicol Appl Pharmacol* 83:315-320.

Johanson G, Boman A, Dynésius B. 1988. Percutaneous absorption of 2-butoxyethanol in man. *Scand J Work Environ Health* 14:101-109.

Johanson G, Michel I, Norbäck D, Nise G, Tillberg A. 1989. Biological monitoring of exposure to ethylene glycol ethers. *Arch Toxicol Suppl* 13:108-111.

Johnson EM, Newman CH, Gabel BE, Boerner TF, Dausky LA. 1988. An analysis of the hydra assay's applicability and reliability as a developmental toxicity prescreen. *J Am CoIl Toxicol* 7:2.

Johnson KA, Baker PC, Marty MS, Kan HL, Maurissen JP. 2002. Diethylene glycol mono-butyl ether: 13-week drinking water study in Fischer 344 rats. Unpublished report, study 001204, Toxicology & Environmental Research and Consulting, Dow Chemical, Midland, Michigan, USA. Glycol Ethers Panel, American Chemistry Council, Arlington, Virginia, USA.

Jones K, Cocker J. 2003. A human exposure study to investigate biological monitoring methods for 2-butoxyethanol. *Biomarkers* 8:360-370.

Jones E, Fenner LA, Ridlon SA. 1987. Ames metabolic activation test to assess the potential mutagenic effect of ARCOSolv PTB. Unpublished report ARO 9/871215. Huntingdon Research

Centre, Huntingdon, Cambridgeshire, England UK. ARCO Chemical, Newtown Square, Pennsylvania, USA [Summary].

Jones K, Dyne D, Cocker J, Wilson HK. 1997. A biological monitoring study of 1-methoxy-2-propanol: analytical method development and a human volunteer study. *Sci Total Environ* 199:23-30.

Jones K, Cocker J, Dodd LJ, Fraser I. 2003. Factors affecting the extent of dermal absorption of solvent vapours: a human volunteer study. *Ann Occup Hyg* 47:145-150.

Jonker D, Lina BAR, Verschuuren HG. 1988. Subchronic (13-week) dermal toxicity study with propylene glycol *n*-butyl ether in rats. Unpublished report. Dow Europe, Horgen, Switzerland.

Jönsson AK, Steen G. 1978. *n*-Butoxyacetic acid, a urinary metabolite from inhaled *n*-butoxyethanol (butylcellosolve). *Acta Pharmacol Toxicol* 42:354-356.

Ju SA, Pyo CO, Kim SK, Lee GI, Choe SY, Kim BS. 1998. 2-Methoxyethanol-induced suppression of *in vitro* immune responses of human peripheral blood mononuclear cells. *J Toxicol Publ Health* 14:55-61.

Kamendulis LM, Park JJ, Klaunig JE. 1999. Potential mechanisms of rodent liver toxicity by 2-butoxyethanol: Oxidative stress studies, final report. Unpublished report, project 98-102. Indiana University School of Medicine, Division of Toxicology, Indianapolis Indiana, USA. Ethylene Glycol Ethers Panel, American Chemistry Council, Arlington Virginia, USA.

Kamerling JP, Duran M, Bruinvis L, Ketting D, Wadman SK, de Groot CJ, Hommes FA. 1977. (2-Ethoxyethoxy)acetic acid. An unusual compound found in the gas chromatographic analysis of urinary organic acids. *Clin Chim Acta* 77:397-405.

Kaphalia BS, Ghanayem BI, Ansari GAS. 1996. Nonoxidative metabolism of 2-butoxyethanol via fatty acid conjugation in Fischer 344 rats. *J Toxicol Environ Health* 49:463-479.

Karel L, Landing H, Harvey TS. 1947. The intraperitoneal toxicity of some glycols, glycol ethers, glycol esters, and phthalates in mice. *Fed Proc* 6:342.

Katz GV. 1987. Subchronic inhalation toxicity study of ethylene glycol monopropyl ether in the rat. HAEL 85-0105. Acc. No. 907124. Unpublished report 230857C, TX-86-216. Toxicological Sciences Section, Health and Environment Laboratories, Eastman Kodak, Rochester, New York, USA. Tennessee Eastman, Kingsport, Tennessee, USA.

Katz GV, Krasavage WJ, Terhaar CJ. 1984. Comparative acute and subchronic toxicity of ethylene glycol monopropylether and ethylene glycol monopropyl ether acetate in the rat. *Environ Health Perspect* 57:165-175.

Kawamoto T, Matsuno K, Kayama F, Hirai M, Arashidani K, Yoshikawa M, Kodama Y. 1990a. Acute oral toxicity of ethylene glycol monomethyl ether and diethylene glycol monomethyl ether. *Bull Environ Contam Toxicol* 44:602-608.

Kawamoto T, Matsuno K, Kayama F, Hirai M, Arashidani K, Yoshikawa, Kodama Y. 1990b. Effect of ethylene glycol monomethyl ether and diethylene glycol monomethyl ether on hepatic metabolizing enzymes. *Toxicol* 62:265-274.

Kawamoto T, Matsuno K, Kayama F, Hirai M, Arashidani K, Yoshikawa M, Kodanna Y. 1991. Induction of GTP by ethylene glycol monomethyl ether. *Toxicol Ind Health* 7:473-474.

Kayama F, Yamashita U, Kawamoto T, Kodama Y. 1991. Selective depletion of immature thymocytes by oral administration of ethylene glycol monomethyl ether. *Int J Immunopharmacol* 13:531-540.

Keith G, Coulais C, Edorh A, Bottin C, Ri hn B. 1996. Ethylene glycol monobutyl ether has neither epigenetic nor genotoxic effects in acute treated rats and in sub-chronic treated v-HA-ras transgenic mice. *Occup Hyg* 2:237-249.

Kennah HE, Hignet S, Laux PE, Dorko JD, Barrow CS. 1989. An objective procedure for quantitating eye irritation based upon changes of corneal thickness. *Fundam Appl Toxicol* 12:258-268.

Kennedy CH, Bechtold WE, Chang IY, Henderson RF. 1993. Effect of dose on the disposition of 2-ethoxyethanol after inhalation by F344/N rats. *Fundam Appl Toxicol* 21:486-491.

Kerckaert GA, Brauninger R, LeBoeuf RA, Isfort RJ. 1996. Use of the Syrian hamster embryo cell transformation assay for carcinogenicity prediction of chemicals currently being tested by the National Toxicology Program in rodent bioassays. *Environ Health Perspect* 104:1075-1084.

Ke ić S, Mahieu K, Monster AC, de Wolff FA. 1997. Dermal absorption of vaporous and liquid 2-methoxyethanol and 2-ethoxyethanol in volunteers. *Occup Environ Med* 54:38-43.

Kim B-S, Smialowicz RJ. 1997. The role of metabolism in 2-methoxyethanol-induced suppression of in vitro polyclonal antibody responses by rat and mouse lymphocytes. *Toxicol* 123:227-239.

Kim Y, Lee N, Sakai T, Kim KS, Yang JS, Park S, Lee CR, Cheong HK, Moon Y. 1999. Evaluation of exposure to ethylene glycol monoethyl ether acetates and their possible haematological effects on shipyard painters. *Occup Environ Med* 56:378-382.

Kimmel CA. 1996. Reproductive and developmental effects of diethylene and triethylene glycol (methyl-, ethyl-) ethers. *Occup Hyg* 2:131-151.

Kirk HD, Yano BL, Haut KT, Verschuuren HG, Breslin WJ. 1992. Tripropylene glycol *n*-butyl ether: 13-week drinking water toxicity study in Fischer 344 rats. Unpublished report, study K-005-632-006. Toxicology Research Laboratory, Health and Environmental Sciences. Dow Chemical, Midland, Michigan, USA.

Kirkland DJ. 1983. Metaphase analysis of Chinese hamster ovary cells treated with Dowanol DPM. Unpublished report of Dow Chemical, Midland, Michigan, USA.

Kirkland DJ, Varley R. 1983. Bacterial mutagenicity test on Dowanol DPM. Unpublished report of Dow Chemical, Midland, Michigan, USA.

Kirkland DJ, Verschuuren HG. 1983. Metaphase analysis of Chinese Hamster Ovary (CHO) cells treated with Dowanol PM. Unpublished report. Dow Europe, Horgen, Switzerland.

Kirkland DJ, Varley R, Verschuuren HG. 1983. Bacterial mutagenicity test on Dowanol PM. Unpublished report of Dow Chemical, Midland, Michigan, USA.

Klimisch HJ, Krisch P, Deckardt K, Freisberg KO, Hildebrand B. 1992. Study on the inhalation toxicity of butyldiglykol as a vapor in rats 90-day test including an about 4-week post-exposure observation period. Unpublished report, project 5010030/87002, Volume 1. Department of Toxicology, BASF, Ludwigshafen, Germany.

Klonne DR, Dodd DE, Pritts IM, Troup CM, Nachreiner DJ, Ballantyne B. 1987. Acute, 9-day and 13-week inhalation studies of ethylene glycol monohexyl ether. *Fundam Appl Toxicol* 8:198-206.

Klonne DR, Kintigh WJ, Gorham WF. 1989a. Propasol Solvent P: nine-day vapor inhalation study on rats. Unpublished report 51-5. Bushy Run Research Center, Export Pennsylvania, USA. Union Carbide Corporation, Danbury, Connecticut, USA.

Klonne DR, Kintigh WJ, Nachreiner DJ, Gorham WF. 1989b. Propasol Solvent P: additional two-week vapor exposure study with male Fischer 344 and Sprague Dawley rats. Unpublished report 52-28. Bushy Run Research Center, Export Pennsylvania, USA. Union Carbide Corporation, Danbury, Connecticut, USA.

Klonne DR, Kintigh WJ, Gorham WF, Dodd DE, Frank FR. 1989c. Propasol Solvent B, nine-day vapor inhalation study on rats. Unpublished report 51-5. Bushy Run Research Center, Export Pennsylvania, USA. Union Carbide Corporation, Danbury, Connecticut, USA.

Kobayashi Y. 2000. Oral repeated dose 4-week toxicity study of DPM in rats and 2-week recovery study. Unpublished report FBM 99-2691. Fuji Biomedix, Kobuchizawa Laboratories, Kitakoma-gun, Yamanashi-ken, Japan. Dow Chemical, Midland, Michigan, USA [Summary].

Koeter HBWM, Snijders GBM, Falke HE. 1987. Inhalation Embryotoxicity/teratogenicity study isopropylethylene glycolether in rats. TNO report V85.416/241371. Inhalation Toxicology; sponsored by BG Chemie, Germany.

Koeter H, van Marwijk MW, Zwart A, Reuzel P. 1988. Embryotoxicity/teratogenicity study with isopropylethyleneglycolether in New Zealand White rabbits. CIVO/TNO report V 88222; sponsored by BG Chemie, Germany.

Krasavage WJ. 1986. Subchronic oral toxicity of ethylene glycol monobutyl ether in male rats. *Fundam Appl Toxicol* 6:349-355.

Krasavage WJ, Katz GV. 1984a. Developmental toxicity of ethylene glycol monopropyl ether acetate (EGPEA) in the rat. *Environ Health Perspect* 57:25-32.

Krasavage WJ, Katz GV. 1984b. Developmental toxicity of ethylene glycol monopropyl ether (EGPE) in the rat. Unpublished report 180278X, TX-84-02. Toxicological Sciences Section, Health and Environment Laboratories, Eastman Kodak, Rochester, New York, USA. Tennessee Eastman, Kingsport, Tennessee, USA.

Krasavage WJ, Katz GV. 1985. Developmental toxicity of ethylene glycol monopropyl ether in the rat. *Teratology* 32:93-102.

Krasavage WJ, Terhaar CJ. 1981a. Comparative toxicity of nine glycol ethers: I. Acute oral LD₅₀. Unpublished data, Corporate Health and Environment Laboratories, report No TX-81-16, February 17, 1981. Eastman Kodak.

Krasavage WJ, Terhaar CJ. 1981b. Comparative toxicity of nine glycol ethers II. Acute dermal LD50. Unpublished data, Eastman Kodak, Corporate Health and Environment Laboratories, Report No. TX-81-38, July 1.

Krasavage WJ, Vlaovic MS. 1982. Comparative toxicity of nine glycol ethers: III. Six weeks repeated dose study. Unpublished data, Corporate Health and Environment Laboratories, report No TX-82-06, March 15, 1982.

Krasavage WJ, Hosenfeld RS, Katz GV. 1990. Ethylene glycol monopropyl ether. A developmental toxicity study in rabbits. *Fundam Appl Toxicol* 15:517-527.

Krishnamurthy H, Weinbauer GF, Aslam H, Yeung C-H, Nieschlag E. 1998. Quantification of apoptotic testicular germ cells in normal and methoxyacetic acid-treated mice as determined by flow cytometry. *J Andro* 19:710-717.

Kristensen TS. 1989. Cardiovascular diseases and the work environment. A critical review of the epidemiologic literature on chemical factors. *Scand J Work Environ Health* 15:245-264.

Kroes R, Wester PW. 1986. Forestomach carcinogens, possible mechanisms of action. *Food ChemToxicol* 24:1083-1089.

Krotov YA, Lykova AS, Skachkov MA, Mitrofanova AI. 1981. Sanitary-toxicological characteristics of diethylene glycol ethers (carbitols) used in air pollution control. *Gig Sanit* 2:14-17.

Ku WW, Ghanayem BI, Chapin RE, Wine RN. 1994. Comparison of the testicular effects of 2-methoxyethanol (ME) in rats and guinea pigs. *Exp Molec Pathol* 61:119-133.

Ku WW, Wine RN, Chae BY, Ghanayem BI, Chapin RE. 1995. Spermatocyte toxicity of 2-methoxyethanol (ME) in rats and guinea pigs: evidence for the induction of apoptosis. *Toxicol Appl Pharmacol* 134:100-110.

Kumagai S, Oda H, Matsunaga I, Kosaka H, Akasaka S. 1999. Uptake of 10 polar organic solvents during short-term respiration. *Toxicol Sci* 48:255-263.

Kurantsin-Mills J, Hodge KL, Entsuah R, Le ssin LS. 1992. Ethylene glycol monobutyl ether alters the flow properties of red blood cells in the rat. *FASEB J* 6: A1912.

Kvelland I. 1988. The mutagenic effect of five oil dispersants and of ethylene glycol monobutyl ether in bacteriophage T4D. *Hereditas* 109:149-150.

Kynoch SR, Parcell BI, Ridlon SA. 1988. Delayed contact hypersensitivity in the guinea pig with ARCOSolv PTB. Unpublished report 87718D/ARO 5/SS(G). Huntingdon Research Centre, Huntingdon, Cambridgeshire, UK. ARCO Chemical, Newtown Square, Pennsylvania, USA.

Laborit H, Jouany JM, Gerard J, Drouet J. 1961. Sur un syndrome expérimental d'Excitation-Hypotonie. *Arch Int Pharmacodyn* 131:151-163.

Laitinen J. 1997. Biomonitoring of technical grade 1-alkoxy-2-propanol acetates by analysing urinary 2-alkoxypropionic acids. *Sci Total Environ* 199:31-39.

Laitinen J. 1998. Correspondence between occupational exposure limit and biological action level values for alkoxyethanols and their acetates. *Int Arch Occup Environ Health* 71:117-124.

Laitinen J, Liesivuori J, Turunen T, Savolainen H. 1994. Urinary biochemistry in occupational exposure to glycol ethers. *Chemosphere* 29:781-787.

Laitinen J, Liesivuori J, Savolainen H. 1997. Biological monitoring of occupational exposure to 1-methoxy-2-propanol. *J Chromatogr B Biomed Sci Appl* 694:93-98.

Lamm SH, Kutcher JS, Morris CB. 1996. Spontaneous abortions and glycol ethers used in the semiconductor industry: An epidemiologic review. *Occup Hyg* 2:339-354.

Landry TD, Yano BL. 1984. Dipropylene glycol monomethyl ether. A 13-week inhalation study in rats and rabbits. *Fundam Appl Toxicol* 4:612-617.

Landry TD, Yano BL, Battjes JE. 1981. Dowanol DPM. A two-week inhalation toxicity study in rats and mice. Unpublished report of Dow Chemical, Midland, Michigan, USA.

Landry TD, Gushow TS, Yano Bl. 1983. Propylene glycol monomethyl ether. A 13-week vapor inhalation toxicity study in rats and rabbits. *Fundam Appl Toxicol* 3:627-630.

Larese F, Fiorito A, De Zotti R. 1992. The possible haematological effects of glycol monomethyl ether in a frame factory. *Br J Ind Med* 49:131-133.

Larese Filon F, Fiorito A, Adami G, Barbieri P, Coceani N, Bussani R, Reisenhofer E. 1999. Skin absorption *in vitro* of glycol ethers. *Int Arch Occup Environ Health* 72:480-484.

Laug EP, Calvery HO, Morris HJ, Woodard G. 1939. The toxicology of some glycols and derivatives. *J Ind Hyg Toxicol* 21:173-201.

Lawlor TE. 1996. Mutagenicity test with propylene glycol *n*- propyl ether in the *Salmonella-Escherichia coli* / mammalian microsome reverse mutation assay preincubation method with confirmatory assay. Unpublished report 8 May 1996. Corning Hazleton, Vienna, Virginia, USA. Dow Chemical, Midland, Michigan, USA.

Lawlor TE, Linscombe VA. 1997. Mutagenicity test with dipropylene glycol *n*- propyl ether (Dowanol DPnP) in the *Salmonella-Escherichia coli*/mammalian-microsome reverse mutation assay. Unpublished report, study 18883-0-422R. Covance Laboratories, Vienna, Virginia, USA. Dow Chemical, Midland, Michigan, USA.

Lawrence JN, Dickson FM, Benford DJ. 1997. Skin irritant-induced cytotoxicity and prostaglandin E12 release in human skin keratinocyte cultures. *Toxicol In Vitro* 11:627-631.

Leber AP, Scott RC, Hodge MCE, Johnson D, Krasavage WJ. 1990. Triethylene glycol ethers. Evaluations of *in vitro* absorption through human epidermis, 21-day dermal toxicity in rabbits and a developmental toxicity screen in rats. *J Am CoII Toxicol* 9:507-515.

Lee KP, Kinney 1A. 1989. The ultrastructure and reversibility of testicular atrophy induced by ethylene glycol monomethyl ether (EGME) in the rat. *Toxicol Pathol* 17:759-773.

Lee KP, Kinney 1A, Valentine R. 1989. Comparative testicular toxicity of bis(2-methoxyethyl) ether and 2-methoxyethanol in rats. *Toxicol* 59:239-258.

Lee KM, Dill JA, Chou BJ, Roycroft JH. 1998. Physiologically based pharmacokinetic model for chronic inhalation of 2-butoxyethanol. *Toxicol Appl Pharmacol* 153:211-226.

Lee Y, NR Lee, T Sakai, K-S Kim, JS Yang, S Park, CR Lee, H-K Cheong, Y Moon. 1999. Evaluation of exposure to ethylene glycol monoethyl ether acetates and their possible haematological effects on shipyard painters. *Occup Environ Med* 56:378-382.

Lehmann KB, Flury F. 1943. Toxicology and hygiene of industrial solvents. Williams and Wilkins, Baltimore, Maryland, USA.

Lehmann, KB, Flury F *et al* . 1938. Toxikologie und hygiene der Technischen Lösungsmittel. J Springer, Berlin, Germany.

Leonhardt DE, Coleman LW, Bradshaw WS. 1991. Perinatal toxicity of ethylene glycol dimethyl ether in the rat. *Repro Toxicol* 5:157-162.

Li L-H, Wine RN, Chapin RE. 1996. 2-Methoxyacetic acid (MAA)-induced spermatocyte apoptosis in human and rat testes: an *in vitro* comparison. *J Androl* 17:538-549.

Li L-H, Wine RN, Miller DS, Reece JM, Smith M, Chapin RE. 1997. Protection against methoxyacetic-acid-induced spermatocyte apoptosis with calcium channel blockers in cultured rat seminiferous tubules: possible mechanisms. *Toxicol Appl Pharmacol* 144:105-119.

Liesivuori J, Laitinen J, Savolainen H. 1999. Rat model for renal effects of 2-alkoxyalcohols and their acetates. *Arch Toxicol* 73:229-232.

Lina BAR, Jonker D, Beems RB. 1988. Subchronic (13-week) dermal toxicity study with dipropylene glycol *n*-butyl ether in rats, final report. Unpublished report V87.421/270513. TNO Division for Nutrition and Food Research, Zeist, Netherlands. Dow Chemical Europe, Horgen, Switzerland.

Linscombe VA, Gollapudi BB. 1990. Evaluation of Triethylene Glycol Monomethyl Ether in the Chinese hamster ovarycell/Hypoxanthine-Guani ne-Phosphoribosyl-Transferase (CHO/HGPRT) forward mutation assay. Report to the US Chemical Manufacturers Association, March 1990.

Linscombe VA, Verschuuren HG. 1991. Evaluation of dipropylene glycol *n*-butyl ether in an *invitro* chromosomal assay utilizing Chinese hamster ovary (CHO-K₁,S₁B) cell line. Unpublished report, study TXT:K-005474-008. Health and Environmental Sciences-Texas, Lake Jackson Research Center, Dow Chemical, Freeport, Texas, USA. Dow Chemical, Midland, Michigan, USA.

Linscombe VA, Okowit DW, Kropscott BE. 1995. Evaluation of Dowanol DPnB in the Chinese hamster ovary cell/ hypoxanthine-guanine-phosp horibosyl transferase (CHO/HGPRT) forward mutation assay. Unpublished report, study K-005474-011. Toxicology Research Laboratory, Health and Environmental Sciences. Dow Chemical, Midland, Michigan, USA.

Linscombe VA, Shabrang SN, Verschuuren HG. 1996. Evaluation of Dowanol PnP in an *in vitro* chromosomal aberration assay utilising rat lymphocytes. Unpublished report 9 July 1996. Corning Hazleton. Health and Environmental Sciences, Toxicology Research Laboratory, Midland, Michigan, USA. Dow Europe, Horgen, Switzerland.

Linscombe VA, Jackson KM, Beuthin AS. 2002. Evaluation of dipropylene glycol *n*-propyl ether (DPnP) in an *in vitro* chromosomal aberration assay utilizing rat lymphocytes. Unpublished report, study 011155. Toxicology & Environmenta l Research and Consulting. Dow Chemical, Midland, Michigan, USA.

Litovitz TL, Bailey KM, Schmitz BF, Holm KC. 1991. 1990 annual report of the American Association of Poison Control Centers National Data Collection System. *Amer J Emer Med* 9:461-509.

Lockley DJ, Howes D, Williams FM. 2002. Percutaneous penetration and metabolism of 2-ethoxyethanol. *Toxicol Appl Pharmacol* 180:74-82.

Lomax LG, Gushow TS, Hopkins PJ. 1987. Dipropylene glycol normal butyl ether: 2-week nose-only vapour inhalation study with Fischer 344 rats. Unpublished report, study DR0287-5038-003. Mammalian and Environmental Toxicology Research Laboratory, Health and Environmental Sciences. Dow Chemical, Midland, Michigan, USA.

Long PH, Maronpot RR, Ghanayem BI, Roycroft JH, Nyska A. 2000. Dental pulp infarction in female rats following inhalation exposure to 2-butoxyethanol. *Toxicol Pathol* 28:246-252.

Lorente C, Cordier S, Bergeret A, De Walle HE, Goujard J, Ayme S, Knill-Jones R, Calzolari E, Bianchi F. 2000. Maternal occupational risk factors for oral clefts. Occupational Exposure and Congenital Malformations Working Group. *Scand J Work Environ Health* 26:137-145.

Loveday KS, Anderson BE, Resnik MA, Zeiger E. 1990. Chromosome aberration and sister chromatid exchange tests in Chinese hamster ovary cells *in vitro*. V. Results with 46 chemicals. *Environ Mol Mutagen* 16:272-303.

Lovell CR, White IR, Boyle J. 1984. Contact dermatitis from phenoxyethanol in aqueous cream BP. *Contact Dermatitis* 11:187.

Lowry LK. 1996. 2-Ethoxyethanol (EGEE) and 2-ethoxyethyl acetate (EGEEA). In *Biological monitoring of chemical exposure in the workplace*, Vol. 1, WHO, Geneva, pp. 175-185.

Lowry LK, Stumpp DA, Orbaugh C, Rieders F. 1993. Applications of biological monitoring in occupational health practice: practical application of urinary 2-ethoxyacetic acid to assess exposure to 2-ethoxyethyl acetate in large format silk-screening operations. *Int Arch Occup Environ Health* 65:47-51.

Lulham G, Procter B. 1985. A 4- and 13-week inhalation toxicity study (with 3-week regression) of Arcosolv PTB in the albino rat, research report vol 1. Unpublished report, project 81910. Bio-Research Laboratories. Montreal, Quebec Canada. ARCO Chemical, Newtown Square, PA, USA.

Lykova AS, Shachkov MA, Mitrofanova AB, Davydova MP, Saparmamedov ES. 1976. Materials toward getting health standards for monoisopropyl and monobutylethers of ethylene glycol in atmospheric air. *Gig Sanit* 11:7-11.

Lynch D, Toraason M. 1996. 2-Ethoxyethanol and 2-methoxyethanol-developmental toxicity in *Drosophila . Occup Hyg* 2:171-174.

Lyondell Chemical. 2000. PTB: preliminary study of reproductive performance in CD rats by oral gavage administration. Unpublished report ACR034/000040. Huntingdon Life Sciences, Eye, Suffolk, England, UK. Lyondell Chemical Worldwide, Newtown Square, PA, USA.

Lyondell Chemical. 2001a. Evaluation of the mutagenic activity of Arcosolv PTB in an *in vitro* mammalian cell gene mutation test with L5178Y mouse lymphoma cells (with independent repeat). Unpublished report, project 301523. Notox, 's-Hertogenbosch, Netherlands. Lyondell Chemical Europe, Maidenhead, Berkshire, UK.

Lyondell Chemical. 2001b. PTB: study of reproductive function and fertility in the CD rat by oral gavage administration. Unpublished report ACR035/003252. Huntingdon Life Sciences, Eye, Suffolk, England, UK. Lyondell Chemical Worldwide, Newtown Square, PA, USA.

Ma H, An J, Hsie AW, Au WW. 1993. Mutagenicity and cytotoxicity of 2-methoxyethanol and ist metabolites in Chinese hamster cells (the CHO/HPRT and AS52/GPT assays). *Mutat Res* 298:219-225.

Maclennon A, Hedgecock. J. 1988. Human repeat insult patch test with dipropylene glycol *n*-butyl ether. Unpublished report DET 1169. CTC International, Chelmsford, UK. Dow Europe, Horgen, Switzerland.

Maldonado G, Delzell E, Tyl RW, Sever LE. 2003. Occupational exposure to glycol ethers and human congenital malformations. *Int Arch Occup Environ Health* 76:405-423.

Matsui H, Takahashi M. 1999. A novel quantitative morphometry of germ cells for the histopathological evaluation of rat testicular toxicity. *J Toxicol Sci* 24:17-25.

Mayhew DA, Sigier WF, Pepple SC. 1983. 90-day Subchronic dermal toxicity study in rabbits with ethylene glycol monobutyl ether. WIL Research Laboratories, Inc., Report to the Chemical Manufacturers Association, Washington, USA.

McClintock ML, Gollapudi BB. 1990. Evaluation of triethylene glycol monomethyl ether (TGME) in the mouse bone marrow micronucleus test. Unpublished report report, Dow Chemical, Midland, Michigan, USA.

McClintock ML, Gollapudi BB, Verschuuren HG. 1988. Evaluation of dipropylene glycol *n*-butyl ether in the mouse bone marrow micronucleus test. Unpublished report, study TXT:K-005632-004. Health and Environmental Sciences-Texas, Lake Jackson Research Center, Dow Chemical, Freeport, Texas, USA. Dow Chemical, Midland, Michigan, USA.

McClintock ML, Gollapudi BB, Verschuuren HG. 1989. Evaluation of tripropylene glycol *n*-butyl ether in the mouse bone marrow micronucleus test. Unpublished report, study TXT:K-005474-006. Health and Environmental Sciences-Texas, Lake Jackson Research Center, Dow Chemical, Freeport, Texas, USA. Dow Chemical Europe, Horgen, Switzerland.

McGregor DB. 1984. Genotoxicity of glycol ethers. Environ Health Perspect 57:97-103.

McGregor DB, Willins MJ, McDonald P, Holmstrom M, McDonald D, Niemei er RW. 1983. Genetic effects of 2-methoxyethanol and bis (2-methoxy) ether. *Toxicol Appl Pharmacol* 70:303-316.

McKinney PE, Palmer RB, Blackwell W, Benson BE. 2000. Butoxyethanol ingestion with prolonged hyperchloremic metabolic acidosis treated with ethanol therapy. *Clin Toxicol* 38:787-793.

Ma-Hock L, Klimisch H-J, Gembardt C, Deck ardt K, Jäckh R. 2005. Investigations on the subchronic toxicity of 2-methoxypropanol-1(acetate) in rats. *Human & Experimental Toxicology* 24:1-5.

Mebus CA, Welsch F. 1989. The possible role of one-carbon moieties in 2-methoxyethanol and 2-methoxyacetic acid-induced developmental toxicity. *Toxicol Appl Pharmacol* 99:98-109.

Mebus CA, Clarke DO, Stedman DB, Welch F. 1992. 2-Methoxyethanol metabolism in the pregnant CD-1 mouse and embryos. *Toxicol Appl Pharmacol* 112:87-94.

Medinsky MA, Singh G, Bechtold WE, Bond JA, Sabourin PJ, Birnbaum IS, Henderson RF. 1990. Disposition of three glycol ethers administered in drinking water to male F344/N rats. *Toxicol Appl Pharmacol* 102:443-455.

Meininger WE. 1948. External use of 'Carbitol Solvent', Carbitol and other reagents. *Arch Dermatol Syph* 58:19-25.

Melnick R1. 1984. Toxicities of ethylene glycol and ethylene glycol monoethyl ether in Fischer 344/N rats and B6C3F1 mice. *Environ Health Perspect* 57:147-155.

Mendrala AL. 1983. Evaluation of Dowanol DPM in the rat hepatocyte unscheduled DNA synthesis assay. Unpublished report. Dow Chemical, Midland, Michigan, USA.

Mendrala AL, Schumann AM. 1982a. Evaluation of Dowanol TPM in the Ames' *Salmonella*/mammalian microsomal mutagenicity assay. Unpublished report. Dow Chemical, Midland, Michigan, USA.

Mendrala AL, Schumann AM. 1982b. Evaluation of Dowanol TPM in the rat hepatocyte unscheduled DNA synthesis assay. Unpublished report. Dow Chemical, Midland, Michigan, USA.

Mendrala AL, Schumann AM. 1983a. Evaluation of Dowanol PM in the rat hepatocyte unscheduled DNA synthesis assay. Unpublished report. Dow Chemical, Midland, Michigan, USA.

Mendrala AL, Schumann AM. 1983b. Evaluation of Dowanol PM acetate in the Ames' *Salmonella*/mammalian microsomal mutagenicity assay. Unpublished report. Dow Chemical, Midland, Michigan, USA.

Mendrala AL, Schumann AM. 1983c. Evaluation of Dowanol PM acetate in the rat hepatocyte unscheduled DNA synthesis assay. Unpublished report. Dow Chemical, Midland, Michigan, USA.

Merkle J, Klimisch HJ, Jäckh R. 1987. Prenatal toxicity of 2-methoxypropylacetate-1 in rats and rabbits. *Fundam Appl Toxicol* 8:71-79.

Miller RR. 1987. Metabolism and disposition of glycol ethers. Drug Metab Rev 18:1-22.

Miller RR, Ayers JA, Calhoun LL, Young JT, McKenna MJ. 1981. Comparative short-term inhalation toxicity of ethylene glycol monomethyl ether and propylene glycol monomethyl ether in rats and mice. *Toxicol Appl Pharmacol* 61:368-377.

Miller RR, Calhoun LL, Yano BL. 1982a. Ethylene glycol monomethyl ether. 13-week vapor inhalation study with male rabbits. Unpublished report. Dow Chemical, Midland, Michigan, USA.

Miller RR, Carreon RE, Young JT, McKenna MJ. 1982b. Toxicity of methoxyacetic acid in rats. *Fundam Appl Toxicol* 2:158-160.

Miller RR, Ayres JA, Young JT, McKenna MJ. 1983a. Ethylene glycol monomethyl ether. l. Subchronic vapor inhalation study with rats and rabbits. *Fundam Appl Toxicol* 3:49-54.

Miller RR, Hermann EA, Langvardt PW, McKenna MJ, Schwetz BA. 1983b. Comparative metabolism and disposition of ethylene glycol monomethyl ether and proplylene glycol monomethyl ether in male rats. *Toxicol Appl Pharmacol* 67:229-237.

Miller RR, Hermann EA, Young JT, Calhoun LL, Kastl PE. 1984. Propylene glycol monomethyl ether acetate (PGMEA) metabolism, disposition, and short-term vapor inhalation toxicity studies. *Toxicol Appl Pharmacol* 75:521-530.

Miller RR, Eisenbrandt DL, Gushow TS, Weiss SK. 1985a. Diethylene glycol monomethyl ether 13-week vapor inhalation toxicity study in rats. *Fundam Appl Toxicol* 5:1174-1179.

Miller RR, Hermann EA, Calhoun LL, Kastl PE, Zakett D. 1985b. Metabolism and disposition of dipropylene glycol monomethyl ether (DPGME) in male rats. *Fundam Appl Toxicol* 5:721-726.

Miller RR, Lomax LG, Calhoun LL. 1985c. Tripropylene glycol monomethyl ether (TPGME). 2-week aerosol inhalation toxicity study in rats and mice. Unpublished report. Dow Chemical, Midland, Michigan, USA.

Miller RR, Langvart PW, Calhoun LL, Yahrmarkt MA. 1986. Metabolism and disposition of propylene glycol monomethyl ether (PGME) beta isomer in male rats. *Toxicol Appl Pharmacol* 83:170-177.

Ministry of Health and Welfare Japan. 1998. Toxicity testing reports of environmental chemicals 6. Propylene glycol momonethyl ether acetate. Chemicals Investigation Promoting Council, Office of Environmental Chemicals Safety, Environmental Health Bureau, Ministry of Health and Welfare, Japan, pp 205-223.

Mizell MJ, Atkin L, Yano BL. 1990. Tripropylene glycol *n*-butyl ether: 28-day gavage toxicity study in Fischer 344 rats. Unpublished report, study K-005-632-005. Toxicology Research Laboratory, Health and Environmental Sciences. Dow Chemical, Midland, Michigan, USA.

Moffet BS, Linnet S, Blair D. 1976. Toxicology of isopropyl oxitol. Inhalation exposure of dogs, rabbits, guinea pigs and rats. Unpublished report TLGR 0039.76. Tunstall Laboratory, Sittinbourne Research Centre. Shell Research, London, UK.

Morel G, Lambert AM, Rieger B, Subra I. 1996. Interactive effect of combined exposure to glycol ethers and alcohols on toxicodynamic and toxicokinetic parameters. *Arch Toxicol* 70:519-525.

Morgott DA, Nolan RJ. 1987. Nonlinear kinetics of inhaled propylene glycol monomethyl ether in Fischer 344 rats following single and repeated exposures. *Toxicol Appl Pharmacol* 89:19-28.

Morris HJ, Nelson AA, Calvery HO. 1942. Observations on the chronic toxicities of propylene glycol, ethylene glycol, diethylene glycol mono-ethyl-ether, and diethylene glycol mono-ethyl-ether. *J Pharmacol Exp Therap* 74:266-273.

Morrissey RE, Lamb JC, Schwetz BA, Teague JL, Morris RW. 1988. Association of sperm, vaginal cytology, and reproductive organ weight data with results of continuous breeding reproduction studies in Swiss (CD-1) mice. *Fundam Appl Toxicol* 11:359-371.

Morrissey RE, Lamb JC, Morris RW, Capin RE, Gulati DK, Heindel JJ. 1989. Results and evaluations of 48 continuous breeding reproduction studies conducted in mice. *Fundam Appl Toxicol* 23:747-777.

Morton WE. 1990. Occupational phenoxyethanol neurotoxicity: A report of three cases. *J Occup Med* 32:42-45.

Moslen MT, Kaphalia L, Balasubramanian H, Yin Y-M, Au WW. 1995. Species differences in testicular and hepatic biotransformation of 2-methoxyethanol. *Toxicol* 96:217-224.

Moss EJ, Thomas LV, Cook MW, Waiters DG, Foster PMD, Creasy DM, Bray TJB. 1985. The role of metabolism in 2-methoxyethanol-induced testicular toxicity. *Toxicol Appl Pharmacol* 79:480-489.

Mottu F, Stelling M-J, Rüfenacht DA, Doelker E. 2001. Comparative hemolytic activity of undiluted organic water-miscible solvents for intravenous and intra-arterial injection. *J Pharm Sci Technol* 55:16-23.

Myers RC, Tyler TR. 1992. Acute toxicologic evaluation of dipropylene glycol monobutyl ether. *J Am Coll Toxicol* B 1:172 [Summary].

Myers RC, Carpenter CP, Cox EF. 1977. Miscellaneous toxicity studies. Unpublished report 40-6. Carnegie-Mellon Institute of Research, Pittsburgh PA, USA. Union Carbide Corporation, Danbury, Connecticut, USA.

Myhr BC, Bowers LR, Caspary WJ. 1986. Results from the testing of coded chemicals in the L5178Y TK+/- mouse lymphoma mutagenesis assay. *Environ Mutagen* 8, Suppl 6:58.

Nagano K, Nakayama E, Koyano M, Oobayashi H, Adachi H, Yamada T. 1979. Testicular atrophy of mice induced by ethylene glycol mono alkyl ethers. *Sanyo Igaku (Jap. J. Ind. Health)* 21:29-35 [Japanese; English translation]

Nagano K, Nakayama E, Oobayashi H, Yamada T, Adachi H, Nishizawa T, Ozawa H, Nakaichi M, Okuda H, Minami K, Yamazaki K. 1981. Embryotoxic effects of ethylene glycol monomethyl ether in mice. *Toxicol* 20:335-343.

Nagano K, Nakayama E, Oobayashi H, Nishizawa T, Okuda H, Yamazaki K. 1984. Experimental studies on toxicity of ethylene glycol alkyl ethers in Japan. *Environ Health Perspect* 57:75-84.

Neeper-Bradley TL. 1992a. Developmental toxicity of Propasol Solvent P vapor in CD (Sprague Dawley) rats. Unpublished report 54-28. Bushy Run Research Center, Export Pennsylvania, USA. Union Carbide Corporation, Danbury, Connecticut, USA.

Neeper-Bradley TL. 1992b. Developmental toxicity of Propasol Solvent P vapor in New Zealand White rabbits. Unpublished report 54-29. Bushy Run Research Center, Export, PA, USA. Union Carbide Corporation, Danbury, Connecticut, USA.

Nelson BK, Brightwell WS, Setzer JV, Taylor BJ, Hornung RW. 1981. Ethoxyethanol behavioral teratology in rats. *Neurotoxicology* 2:231-249.

Nelson BK, Brightwell WS, Burg JR, Massari VJ. 1984a. Behavioral and neurochemical alterations in the offspring of rats after maternal or paternal inhalation exposure to the industrial solvent 2-methoxyethanol. *Pharmacol Biochem Behav* 20:261-279.

Nelson BK, Setzer JV, Brightwell WS, Mathinos PR, Kuczuk MH, Weaver TE, Goad PT. 1984b. Comparative inhalation teratogenicity of four glycol ether solvents and an amino derivative in rats. *Environ Health Perspect* 57:261-271.

Nelson BK, Vorhees CV, Scott WJ, Hastings L. 1989. Effects of 2-methoxyethanol on foetal development, postnatal behavior, and embryonic intracellular pH of rats. *Neurotoxicol Teratol* 11:273-284.

Nelson BK, Snyder DL, Shaw PB. 1999. Developmental toxicity interactions of salicylic acid and radiofrequency radiation or 2-methoxyethanol in rats. *Reprod Toxicol* 13:137-145.

Nipa. 1977. Phenoxetol. Toxicity in oral administration to rats for thirteen weeks. Life Science Research report reference 77/NLL5/375. Nipa Laboratories, Portypridd, UK.

Nipa. 1982a. Ames metabolic activation test to assess the potential mutagenic effect of phenoxetol. Huntingdon Research Centre report reference NPA 18/82692. Nipa Laboratories, Portypridd, UK.

Nipa. 1982b. Micronucleus test on phenoxyethanol. Huntingdon Research Centre test report reference NPA 19/82966. Nipa Laboratories, Portypridd, UK.

Nipa. 1985. Phenoxetol erythrocyte osmotic resistance. Toxicol Laboratories report reference *CU7/8504*. Nipa Laboratories, Portypridd, UK.

Nitter-Hauge S. 1970. Poisoning with ethylene glycol monomethyl ether. *Acta med scand* 188:277- 280.

Nolen GA, Gibson WB, Benedict JH, Briggs DW, Schardein JL. 1985. Fertility and teratogenic studies of diethylene glycol monobuthyl ether in rats and rabbits. *Fundam Appl Toxicol* 5:1137-1143.

Norbäck D, Wieslander G, Edling C, Johanson G. 1996. House painters exposure to glycol and glycol ethers from water-based paints. *Occup Hyg* 2:111-117.

Norris JM, Olson KJ. 1968. Toxicological properties and industrial handling hazards of Dowanol PPh (1-Phenoxy-2-propanol). Unpublished report. Dow Chemical, Midland, Michigan, USA.

NTIS. 1984. Report PB86-197605, prepared for NIOSH; 9. Jan. 1984. National Toxicology Inform. Service, USA.

NTP. 1984. Reproduction and fertility assessment of ethylene glycol monophenyl ether (CAS #122-99-6) in CD-1 mice when administered in the feed. NTP report #RACB83101. National Toxicology Program, National Institutes of Health, National Institute of Environmental Health Sciences (NIEHS), Research Triangle Park, NC, USA [http://ntp-server.niehs.nih.gov/htdocs/RT-studies/RACB83101.html].

NTP. 1986. Methoxy Acetic Acid and PGME. Reproduction and fertility assessment in CD-1 mice when administered in the drinking water. NTP reports 86-040 and 86-062, Res. Triangle Inst., RTP, N.C. National Toxicology Program, USA.

NTP. 1987a. Teratologic evaluation of diethylene glycol diethyl ether (Cas no. 112-36-7) administered to CD-1 mice on gestational days 6 through 15. NTP report 88-017; November 6. National Toxicology Programm, USA.

NTP. 1987b. Teratologic evaluation of diethylene glycol diethyl ether (CAS no.112-36-7) administered to New Zealand White rabbits on gestational days 6 through 19. NTP report 88-018; December 7. National Toxicology Programm, USA.

NTP. 1993. NTP Technical Report on Toxicity Studies of Ethylene Glycol Ethers: 2-Methoxyethanol, 2-Ethoxyethanol, 2-Butoxyethanol Administered in Drinking Water to F344/N

Rats and B6C3F1 Mice, Toxicity Report Series No. 26, National Toxicology Program, Research Triangle Park NC, USA.

NTP. 2000. Toxicology and carcinogenesis studies of 2-butoxyethanol (Cas No. 111-76-2) in F344/N rats and B6C3F₁ mice (inhalation studies). National Toxicology Program Technical Report Series No. 484. National Toxicology Program, Research Triangle Park NC, USA.

NTP. 2004. Toxicology and carcinogenesis studies of propylene glycol mono-t-butyl ether (CAS No. 57018-52-7) in F344/N rats and B6C3F₁ mice and a toxicology study of propylene glycol mono-t-butyl ether in male NBR rats (inhalation studies). Technical Report 515. National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park NC, USA.

Nyska A, Maronpot RR, Ghanayem BI. 1999a. Ocular thrombosis and retinal degeneration induced in female F344 rats by 2-butoxyethanol. *Hum Exper Toxicol* 18:577-582.

Nyska A, Maronpot RR, Long PH, Roycroft JH, Hailey JR, Travlos GS, Ghanayem BI. 1999b. Disseminated thrombosis and bone infarction in female rats following inhalation exposure to 2-butoxyethanol. *Toxicol Pathol* 27:287-294.

O'Flaherty EJ, Nau H, McCandless D, Beliles RP, Schreiner CM, Scott WJ. 1995. Physiologically based pharmacokinetics of methoxyacetic acid: dose-effect considerations in C57BL/6. *Teratology* 52:78-89.

Ohi G, Wegman DH. 1978. Transcutaneous ethylene glycol monomethyl ether poisoning in the work setting. *J Occup Med* 20:675-676.

Ong T. 1980. Internal NIOSH Communication. In NIOSH, 1983. Current Intelligence Bulletin N°39, NMS/PB 80155742, 1-22. National Institute of Occupation Safety and Health. Cincinnati, Ohio, USA.

Opdyke DL. 1974. Monographs on fragrance raw materials. Diethylene glycol monomethyl ether. *Food Cosmet Toxicol* 12:517-519.

Osgood C, Zimmering S, Mason JM. 1991. Aneuploidy in *Drosophila* II, further validation of the FIX and ZESTE genetic test systems employing female *Drosophila melanogaster*. *Mutat Res* 259:147-163.

Oudiz D, Zenick H. 1986. *In vivo* and *in vitro* evaluations of spermatotoxicity induced by 2-ethoxyethanol treatment. *Toxicol Appl Pharmacol* 84:576-583.

Oudiz DJ, Zenick H, Niewenhuis RJ, McGinnis PM. 1984. Male reproductive toxicity and recovery associated with acute ethoxyethanol exposure in rats. J Toxicol Environ Health 13:763-775.

Park J, Kamendulis LM, Klaunig JE. 2002a. Effects of 2-butoxyethanol on hepatic oxidative damage. *Toxicol Lett* 126:19-29.

Park J, Kamendulis LM, Klaunig JE. 2002b. Mechanisms of 2-butoxyethanol carcinogenicity: studies on Syrian hamster embryo (SHE) cell transformation. *Toxicol Sci* 68:43-50.

Parsons CE, Parsons MEM. 1938. Toxic encephalopathy and Granulopenic Anemia due to solvents in industry. Report of two cases. *J Ind Hyg Tox* 20:124-133.

Pastides H, Calabrese EJ, Hosmer DW, Harris DR. 1988. Spontaneous abortion and general illness symptoms among semiconductor manufacturers. *J Occup Med* 30:543-551.

Paustenbach DJ. 1988. Assessment of the developmental risks resulting from occupational exposure to select glycol ethers within the semiconductor industry. *J Toxicol Environ Health* 23:29-75.

Peiris LDC, Moore HDM. 2001. Effects of acute and chronic doses of methoxy acetic acid on hamster sperm fertilising ability. *Asian J Androl* 3:209-216.

Pels Rijken WR. 1995. Assessment of the acute oral toxicity with dipropylene glycol *n*-propyl ether (Dowanol DPnP) in the rat. Unpublished report, project 152674. Notox Toxicological Research & Consultancy, 's-Hertogenbosch, Netherlands. Dow Chemical, Midland, Michigan, USA.

Phillips JE, Quast JF, Miller RR, Calhoun LL, Dittember DA. 1985. Ethylene glycol phenyl ether and propylene glycol phenyl ethers. comparative 2-week dermal toxicity study in female rabbits. Unpublished report. Dow Chemical, Midland, Michigan, USA.

Piacitelli GM, Votaw DM, Radha Krishnan E. 1990. An exposure assessment of industries using ethylene glycol ethers. *Appl Occup Env Hyg* 5:107-114.

Pis'ko GT, Werbilow AA. 1988. Gig Tr Prof Zabol 32:48-54 [Cited by ECETOC, 1995].

Pitt JA, Carney EW. 1999. Evaluation of various toxicants in rabbit whole-embryo culture using a new morphologically-based evaluation system. *Teratology* 59:102-109.

Plasterer MR, Bradshaw WS, Booth GM, Carter MW, Schuler RL, Hardin BD. 1985. Developmental toxicity of nine selected compounds following prenatal exposure in the mouse. Naphthalene, p-nitrophenol, sodium selenite, dimethyl phthalate, ethylenethiourea, and four glycol ether derivatives. *J Toxicol Environ Health* 15:25-38.

Poet TS, Soelberg JJ, Curry TL, Studniski KG, Corley RA. 2002. *In vivo* kinetic studies with 2-butoxyethanol, part 1, target tissue dosimetry, final report (draft). Unpublished report, project 40974. Battelle Memorial Institute, Pacific Northwest National Laboratory, Richland Washington, USA. Ethylene Glycol Ethers Panel, American Chemistry Council, Arlington, Virginia, USA.

Poet TS, Soelberg JJ, Weitz KK, Mast TJ, Miller RA, Thrall BD, Corley RA. 2003. Mode of action and pharmacokinetic studies of 2-butoxyethanol in the mouse with an emphasis on forestomach dosimetry. *Toxicol Sci* 71:176-89.

Pottenger LH, Dryzga MD, Hansen SC. 1999. 2-Methoxypropionic acid (2-MPA): blood time course of 2-MPA following oral gavage administration of 2-MPA and β-PGME to female New Zealand white rabbits. Unpublished report HET DR0035-3855-003. Toxicology & Environmental Research and Consulting, Dow Chemical, Midland, Michigan, USA. Glycol Ethers TS&D/H&ES, Dow Chemical, Midland, Michigan, USA.

Pozzani UC, Carpenter CP. 1965. Repeated inhalation of *n*-butoxypropanol (mixed isomers) by rats. Union Carbide Corporation, solvents and coatings materials division, Mellon Institute special report 28-11, Danbury, Connecticut, USA.

Pozzani UC, Weil CS, Carpenter CP. 1959. The toxicological basis of threshold limit values. 5. The experimental inhalation of vapor mixtures by rats, with notes upon the relationship between single dose inhalation and single dose oral data. *Am Ind Hyg Ass J* 20:364-369.

Price CJ, Kimmel CA, Tyl RW, Marr MC. 1985. The developmental toxicity of ethylene glycol in rats and mice. *Toxicol Appl Pharmacol* 81:113-127.

Price CJ, Kimmel CA, George JD, Marr MC. 1987. The developmental toxicity of diethylene glycol dimethyl ether in mice. *Fundam Appl Toxicol* 8:115-126.

Procter and Gamble. 1982. Twenty-eight-day dermal toxicity study in rabbits with E-2019.01, butylcarbitol [DGBE]. Unpublished report, project ECM-BTS 753 [authors sanitised], Huntingdon Research Centre, Huntingdon, Cambridgeshire, England, UK. Procter and Gamble, European Technical Centre, Strombeek-Bever, Belgium [NIS 2057].

Procter and Gamble. 1985. Consumer exposure to DGBE from the use of hard surface cleaners with cover letter to EPA dated 28 January 1985. EPA document FYI-OTS-0286-0471, Procter and Gamble, HES, Cincinnati, Ohio, USA [TSCA doc 40-8578148].

Questel F. 1992. Toxicité hématologique des éthers de glycols. Dissertation Université Paris, Faculté de Médecine Lariboisière Saint-Louis. France.

Rambourg-Schepens MO, Buffet M, Bertault R, Jaussaud M, Journe B, Fay R, Lamiable D. 1988. Severe ethylene glycol butyl ether poisoning. Kinetics and metabolic pattern. *Human Toxicol* 7:187-189.

Rampy LW, Keeler PT, Gehring PJ. 1973. DOT test for corrosiveness conducted on Dowanol PPh (1-phenoxypropanol). Unpublished report. Dow Chemical, Midland, Michigan, USA.

Rao KS, Cobel-Geard SR, Young JT, Hanley jr. TR, Hayes WC, John JA, Miller RR. 1983. Ethylene glycol monomethyl ether. II. Reproductive and dominant lethal studies in rats. *Fundam Appl Toxicol* 3:80-85.

Ratcliffe JM, Schrader SM, Clapp DE, Halperin WE, Turner TW, Hornung RW. 1989. Semen quality in workers exposed to 2-ethoxyethanol. *Br J Ind Med* 46:399-406.

Rawcliffe I, Creasy D, Timbrell JA. 1989. Urinary creatine as a possible marker for testicular damage: studies with the testicular toxic compound 2-methoxyethanol. *Reprod Toxicol* 3:269-274.

Rawlings SJ, Shuker DEG, Webb M, Brown NA. 1985. The teratogenic potential of alkoxy acids in post-implantation rat embryo culture: structure-activity relationships. *Toxicol Lett* 28:49-58.

Raymond LW, Williford LS, Burke WA. 1998. Eruptive cherry angiomas and irritant symptoms after one acute exposure to the glycol ether solvent 2-butoxyethanol. *J Occup Environ Med* 40:1059-1064.

Reijnders JBJ, Van Garderen HG. 1987. Evaluation of the acute dermal toxicity of Dowanol TPnB in the rat. Unpublished report. RCC Notox, 's-Hertogenbosch, Netherlands. Dow Chemical Europe, Horgen, Switzerland.

Reijnders JBJ, Verschuuren HG. 1987. Evaluation of the acute dermal toxicity of Dowanol PnB in the rat. Unpublished report 066/873. RCC Notox, 's-Hertogenbosch, Netherlands. Dow Europe, Horgen, Switzerland.

Reijnders JBJ, Zucker-Keiser AMM, Verschuuren HG. 1987. Evaluation of the acute oral toxicity of Dowanol PnB in the rat. Toxicol. Res. lab. Report, Dow Europe, Horgen, Switzerland.

Rettenmeier AW, Hennigs R, Wodarz R. 1993. Determination of butoxyacetic acid and *n*-butylacetyl-glutamine in urine of lacquerers exposed to 2-butoxyethanol. *Int Arch Occup Environ Health* 65:151-153.

Reuzel PGJ, Kuper CF, Falke HE. 1987. A sub-acute (28 day) inhalation toxicity study of isopropylethyleneglycolether in rats. TNO report No. V85.434/241372. Inhalation Toxicology; sponsored by BG Chemie, Germany.

Riddle M, Williams W, Andrews D, Copeland C, Luebke R, Smialowicz R. 1992. Species and strain comparisons of immunosuppression by 2-methoxy-ethanol (ME) and 2-methoxyacetic acid (MAA). *Toxicologist* 12:177 [Abstract].

Riddle MM, Williams WC, Smialowicz RJ. 1996. Repeated high dose oral exposure or continuous subcutaneous infusion of 2-methoxy acetic acid does not suppress humoral immunity in the mouse. *Toxicol* 109:67-74.

Ritter ER, Scott WJ, Randall JL, Ritter JM. 1985. Teratogenicity of dimethoxyethyl phthalate and its metabolites methoxyethanol and methoxyacetic acid in the rat. *Teratology* 32:25-31.

Roberts CD. 1986. Pharmaceutical compositions for acne treatment. UK Patent Appl. No. 2165151, 04/09/86, Smith and Nephew Associates Co. PLC.

Robinson K, Beyrouty P, Osborne B. 1989. A 3-month study of potential effects of diethylene glycol butyl ether on behaviour and neuromorphology in rats. Report to CMA dated September 5, 1989, cited in 'petition to delete five unique glycol ethers from the clean air act list of hazardous air pollutants', CMA, October 11 1991.

Rohm and Haas. 1989. Acute skin and eye irritation toxicity reports (final report) with cover sheets and letter dated 081089. EPA/OTS Doc 86-890001526S.

Römer KG, Balge F, Freundt KJ. 1985. Ethanol-induced accumulation of ethylene glycol monoalkyl ethers in rats. *Drug Chem Toxicol* 8:255-264.

Roper CS, Howes D, Blain PG, Williams FM. 1997. Percutaneous penetration of phenoxyethanol through rat and human skin. *Food Chem Toxicol* 35:1009-1016.

Roper CS, Howes D, Blain PG, Williams FM. 1998. A comparison of the absorption of a series of ethoxylates through rat skin. *Toxicol In Vitro* 12:57-65.

Roudabush RI, Terhaar CJ, Fassett DW, Dziuba SP. 1965. Comparative acute effects of some chemicals on the skin of rabbits and guinea pigs. *Toxicol Appl Pharmacol* 7:559-565.

Rowe VK, Wolf MA. 1982. Patty's Industrial Hygiene and Toxicology, 3rd ed, vol 2c. Wiley, New York, New York, USA, pp 3920-3928, 4047-4052.

Rowe VK, McCollister DD, Spencer HC, Oyen F, Hollingsworth RL, Drill VA. 1954. Toxicology of mono-, di- and tripropylene glycol methyl ethers. *AMA Arch Ind Hyg Occup Med* 9:509-525.

RTECS. 1991. Registry of Toxic Effects of Chemical Substances. National Institute for Occupational Safety and Health, Government Research Center, NTIS, Springfield, Virginia, USA.

Saavedra D, Arteaga M, Tena M. 1997. Industrial contamination with glycol ethers resulting in teratogenic damage. *Ann NY Acad Sci* 837:126-137.

Saavedra-Ontiveros D, Arteaga Martínez M, Serrano-Medina B, Reynoso-Arizmendi F, Prada-Garay N, Cornejo-Roldán. 1996. Contaminación industrial con solventes orgánicos como causa de teratogénesis. *Salud Publica de Mexico* 38:3-12.

Sabourin PJ, Medinsky MA, Birnbaum IS, Griffith WC, Henderson RF. 1992a. Effect of exposure concentration on the disposition of inhaled butoxyethanol by F344 rats. *Toxicol Appl Pharmacol* 114:232-238.

Sabourin PJ, Medinsky MA, Thurmond F, Birnbaum LS, Henderson RF. 1992b. Effect of dose on the disposition of methoxyethanol, ethoxyethanol and butoxyethanol administered dermally to male F344/N rats. *Fundam Appl Toxicol* 19:124-132.

Saghir SA, Brzak KA, Bartels MJ. 2003. Oral absorption, metabolism and excretion of 1-phenoxy-2-propanol in rats. *Xenobiotica* 33:1059-1071.

Sakai T, Araki T, Morita Y, Masuyama Y. 1994. Gaschromatographic determination of butoxyacetic acid after hydrolysis of conjugated metabolites in urine from workers exposed to 2-butoxyethanol. *Int Arch Occup Environ Health* 66:249-254.

Sakata T. 2000. DPM: Bacterial reverse mutation assay. Unpublished report FBM 00-8026. Fuji Biomedix, Kobuchizawa Laboratories, Kitakoma-gun, Yamanashi-ken, Japan. Dow Chemical, Midland, Michigan, USA.

Samson YE, Gollapudi BB. 1990. Evaluation of triethylene glycol monomethyl ether (TGME) in the Ames *Salmonella/mammalian-microsome* bacterial mutagenicity assay. Report to the US Chemical Manufacturers Association, March 1990.

Samson YE, Gollapudi BB, Verschuuren HG. 1989. Evaluation of tripropylene glycol *n*-butyl ether in the Ames *Salmonella*/mammalian-microsome bacterial mutagenicity assay. Unpublished report, study TXT:K-005632-003. Health and Environmental Sciences-Texas, Lake Jackson Research Center, Dow Chemical, Freeport, Texas, USA. Dow Europe, Horgen, Switzerland.

Samuels DM, Doe JE, Tinston DJ. 1984. The effects of the rat testis of single inhalation exposures to ethylene glycol monoalkyl ethers in particular ethylene glycol monomethylether. *Arch Toxicol* Suppl. 7:167-170.

Sanderson DM. 1959. A note on glycerol formal as a solvent in toxicity testing. *Pharmacol* 11:150-156.

Savolainen H. 1980. Glial cell toxicity of ethyleneglykol monomethylether vapor. *Environ Res* 22:423-430.

Sawant SD, Doucet PG, Slob W, Blaylock BL, Mehendale HM. 1999. Experimental mathematical validation of a novel concept of extended 2-butoxyethanol autoprotection. *Int J Toxicol* 18:307-316.

Schardein JL. 1988a. Inhalation developmental toxicity study in rats. Unpublished report 419-029. International Research and Development Corporation, Mattawan, Michigan, USA. ARCO Chemical, Newtown Square PA, USA.

Schardein JL. 1988b. Inhalation developmental toxicity study in rabbits. International Research and Development Corporation Unpublished report 419-031. International Research and Development Corporation, Mattawan, Michigan, USA. ARCO Chemical, Newtown Square PA, USA.

Schenker MB. 1996. Reproductive health effects of glycol ether exposure in the semiconductor industry. *Occup Hyg* 2:367-372.

Schenker MB, Gold EB, Beaumont JJ, Eskenazi B, Hammond SK, Lasley BL, McCurdy SA, Samuels JJ, Saiki CL, Swan SH. 1995. The association of spontaneous abortion and other reproductive effects with work in the semiconductor industry. *Am J Ind Med* 28:639-659.

Schmuck G, Steffens W, Bomhard E. 2000. 2-Phenoxyethanol: a neurotoxicant? Letter to the editor. *Arch Toxicol* 74:281-283.

Schrader SM, Turner TW, Ratcliffe JM, Welch LS, Simon SD. 1996. Combining reproductive studies of men exposed to 2-ethoxyethanol to increase statistical power. *Occup Hyg* 2:411-415.

Schuler RL, Hardin BD, Niemeier RW, Booth G, Hazelden K, Piccirillo V, Smith K. 1984. Results of testing fifteen glycol ethers in a short-term *in vivo* reproductive toxicity assay. *Environ Health Perspect* 57:141-146.

Schwetz BA, Price CJ, George JD, Kimmel CA, Morrissey RE, Marr MC. 1992. The developmental toxicity of diethylene and triethylene glycol dimethyl ethers in rabbits. *Fundam Appl Toxicol* 19:238-245.

Scortichini BH, John-Greene JA, Quast JF, Rao KS. 1986. Teratologic evaluation of dermally applied diethylene glycol monomethyl ether in rabbits. *Fundam Appl Toxicol* 7:68-75.

Scortichini BH, Quast JF, Rao KS. 1987. Teratologic evaluation of 2-phenoxyethanol in New Zealand white rabbits following dermal exposure. *Fundam Appl Toxicol* 8:272-279.

Scott WJ, Nau H, Wittfoht W, Merker HJ. 1987. Ventral duplication of the autopod. Chemical induction by methoxyacetic acid in rat embryos. *Development* 99:127-136.

Scott WJ, Fradkin R, Wittfoht W, Nau H. 1989. Teratologic potential of 2-methoxyethanol and transplacental distribution of its metabolite, 2-methoxyacetic acid, in non-human primates. *Teratology* 39:363-373.

Sehgal A, Osgood C. 1990. Rapid and efficient detection of chemically-induced aneuploidy using *Drosophila* females. *Env Mol Mut* 15:53-54 [Abstract 198A].

Sharpe AM. 1989. Possible role of elongated spermatids in control of stage-dependent changes in the diameter of the lumen of the rat seminiferous tubule. *J Androl* 10:304-310.

Shaw GM, Velie EM, Katz EA, Morland KB, Schafer DM, Nelson V. 1999. Maternal occupational and hobby chemical exposures as risk factors in neural tube defects. *Epidemiology* 10:124-129.

Shell. 1991. Di-ethoxypropane Chernoff-Kavlock assay in rats. Unpublished report 7721, Inveresk Research International. Shell Internationale Petroleum Mij, 's-Gravehage, Netherlands.

Shepard KP. 1988a. Skin sensitization study (Buehler method) of 2-propoxyethanol. HAEL 88-0017. Acc No. 907124. Unpublished report 244864T, TX-88-62. Toxicological Sciences Laboratory, Health and Environment Laboratories, Eastman Kodak, Rochester, New York, USA. Eastman Chemicals Division, Eastman Kodak, Kingsport, Tennessee, USA.

Shepard KP. 1988b. Skin sensitization study (footpad method) of 2-propoxyethanol. HAEL 88-0017. Acc. No. 907124. Unpublished report 244863S, TX-88-61. Toxicological Sciences Laboratory, Health and Environment Laboratories, Eastman Kodak, Rochester, New York, USA. Eastman Chemicals Division, Eastman Kodak, Kingsport, Tennessee, USA.

Shepard KP. 1993a. Diethylene glycol monopropyl ether. Skin sensitization study (Buehler method) in the guinea pig. HAEL number: 93-0080. KAN: 379122, final report. Unpublished report 290976G, TX-93-197. Toxicological Sciences Laboratory, Eastman Kodak, Rochester, New York, USA. Eastman Chemical, Kingsport, Tennessee, USA.

Shepard KP. 1993b. Diethylene glycol monopropyl ether. Skin sensitization study (footpad method) in the guinea pig. HAEL number: 93-0080, KAN: 379122, final report. Unpublished report 282568N, TX-93-122. Toxicological Sciences Laboratory, Eastman Kodak, Rochester, New York, USA. Eastman Chemical, Kingsport, Tennessee, USA.

Shepard KP. 1994. Ethylene glycol butylether; acute dermal toxicity study in the guinea pig. Toxicol. Sciences Laboratory. Eastman Kodak, Rochester, New York, USA.

Shideman FE, Procita L. 1951. The pharmacology of the mono methyl ethers of mono-, di-, and tripropylene glycol in the dog with observations on the auricular fibrillation produced by these compounds. *J Pharmacol Exp Therap* 102:79-87.

Shih TS, Liou SH, Chen CY, Chou JS. 1999a. Correlation between urinary 2-methoxy acetic acid and exposure of 2-methoxy ethanol. *Occup Environ Med* 56:674-678.

Shih TS, Chou JS, Chen CY, Smith TJ. 1999b. Improved method to measure urinary alkoxyacetic acids. *Occup Environ Med* 56:460-467.

Shih T-S, Hsieh A-T, Liao G-D, Chen Y-H, Liou S-H. 2000a. Haematological and spermatotoxic effects of ethylene glycol monomethyl ether in copper clad laminate factories. *Occup Environ Med* 57:348-352.

Shih TS, Wang PY, Chen CY, Smith TJ, Hu YP. 2000b. Measurement of percutaneous uptake of 2-methoxy ethanol vapor in humans. *J Occup Environ Med*. 42:475-82.

Shih T-S, Liou S-H, Chen C-Y, Smith TJ. 2000c. Urinary 2-methoxy acetic acid accumulation in response to 2-methoxy ethanol exposure. *Arch Environ Health* 56:20-25.

Shih T-S, Pan R-N, Chou J-S, Chen C-Y, Hu Y-P. 2001. Gas chromatographic-mass spectrometric assay for 2-methoxyethanol and 2-methoxyacetic acid in human plasma and its application to pharmacokinetic studies. *Chromatographia* 54:389-393.

Shimizu H, Suzuki Y, Takemura N, Goto S, Matsushita H. 1985. The results of microbial mutation test for forty-three industrial chemicals. *Jpn J Ind Health* 27:400-419.

Shyr LJ, Sabourin PJ, Medinsky MA, Birnbaum LS, Henderson RF. 1993. Physiologically based modeling of 2-butoxyethanol disposition in rats following different routes of exposure. *Environ Res* 63:202-218.

Siesky AM, Gottschling BC, Park JJ, Kamendulis LM, Klaunig JE. 2001. Modulation of hepatic cell proliferation and oxidative stress in 2-butoxyethanol treated mice. *Toxicologist* 60:287 [Abstract].

Singh P, Zhao S, Blaylock BL. 2001. Topical exposure to 2-butoxyethanol alters immune responses in female BALB/c mice. *Int J Toxicol* 20:383-390.

Sipes IG, Carter DE. 1994. Chemical disposition in mammals: the metabolism and disposition of propylene glycol *t*-butyl ether in the male Fischer 344 rat, final report. NIEHS contract NO1-ES-85320. Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona. National Toxicology Program, US Department of Health and Human Services, Research Triangle Park, North Carolina, USA.

Sivarao DV, Mehendale HM. 1995. 2-Butoxyethanol autoprotection is due to resilience of newly formed erythrocytes to hemolysis. *Arch Toxicol* 69:526-532.

Sleet RB, Ross P. 1997. Serine-enhanced restoration of 2-methoxyethanol-induced dysmorphogenesis in the rat embryo and near-term fetus. *Toxicol Appl Pharmacol* 145:415-424.

Sleet RB, John-Greene JA, Welsch. 1986. Localization of radioactivity from 2-methoxy(1, 2-¹⁴C)ethanol in maternal and conceptus compartments of CD-1 mice. *Toxicol Appl Pharmacol* 84:25-35.

Sleet RB, Greene JA, Welsch F. 1988. The relationship of embryotoxicity to disposition of 2-methoxy-ethanol in mice. *Toxicol Appl Pharmacol* 93:195-207.

Sleet RB, Price CJ, Marr MC. 1989. Ethylene glycol monobutyl ether (CAS No. 111-76-2) administered to Fischer-344 rats on either gestational days 9-11 or days 11-13. NTP Study TER88076. National Toxicology Program, Report NTP-89-058 [NTIS PB89-165849].

Slesinski RS, Guzzie PJ, Tyler TR. 1988. Cytotoxicity and genotoxic potential of ethylene glycol monoethyl ether acetate (EGEE.Ac) in a battery of short term test systems. *Environ Molec Mutagen* 11, Suppl 11:97 [Abstract].

Smialowicz RJ. 1996. The immunotoxicity of 2-methoxyethanol and its metabolites. *Occup Hyg* 2:269-274.

Smialowicz RJ, Riddle MM, Rogers RR, Copeland CB, Luebke RW, Andrews DL. 1991a. Evaluation of the immunotoxicity of orally administered 2-methoxy-acetic acid in Fischer-344 rats. *Fundam Appl Pharmacol* 17:771-781.

Smialowicz RJ, Riddle MM, Luebke RW, Copeland CB, Andrews D, Rogers RR, Gray LE, Laskey JW. 1991b. Immunotoxicity of 2-methoxyetha nol following oral administration in Fischer 344 Rats. *Toxicol Appl Pharmacol* 109:494-506.

Smialowicz RJ, Riddle MM, Williams WC, Copeland CB, Luebke RW, Andrews DL. 1992a. Differences between rats and mice in the immunosuppressive activity of 2-methoxyethanol and 2-methoxyacetic acid. *Toxicol* 74:57-67.

Smialowicz RJ, Williams WC, Riddle MM, Andrews DL, Luebke RW, Copeland CB. 1992b. Comparative immunosuppression of various glycol ethers orally administered to Fischer 344 rats. *Fundam Appl Toxicol* 18:621-627.

Smialowicz RJ, Riddle MM, Williams WC. 1993. Methoxyacetaldehyde, an intermediate metabolite of 2-methoxyethanol, is immunosuppressive in the rat. Fund Appl Toxicol 21:1-7.

Smialowicz RJ, Riddle MM, Williams WC. 1994. Species and strain comparisons of immunosuppression by 2-methoxyethanol and 2-methoxyacetic acid. *Int J Immunopharmacol* 16:695-702.

Smyth HF, Carpenter CP. 1948. Further experience with the range-finding test in the industrial toxicology laboratory. *J Ind Hyg* 30:63-68.

Smyth HF, Seaton J, Fischer L. 1941. The single dose toxicity of some glycols and derivatives. *J Ind Hyg Toxicol* 23:259-268.

Smyth HF, Carpenter CP, Weil CS. 1951. Range-finding toxicity data. List IV. *Arch Ind Hyg Occ Med* 4:119-122.

Smyth HF, Carpenter CP, Weil CS, Pozzani UC. 1954. Range-finding toxicity data: list V. AMA Arch Ind Hyg Occup Med 10:61-68.

Smyth HF, Carpenter CP, Weil CS, Pozzani UC, Striegel JA. 1962. Range finding toxicity data. List VI. Am Ind Hyg Assoc J 23:95-107.

Smyth HF, Carpenter CP, Boyd SC. 1964. Summary of toxicological data - A 2 year study of diethylene glycol monoethyl ether in rats. *Food Cosmet Toxicol* 2:641-642.

Smyth HF, Carpenter CP, Weil CS, Pozzani UC, Striegel SA, Nycum JS. 1969. Range-finding toxicity data. List VII. *Am Ind Hyg Assoc J* 30:470-476.

Söhnlein B, Letzel S, Weltle D, Rüdiger HW, Angerer J. 1993. Occupational chronic exposure to organic solvents. XIV. Examinations concerning the evaluation of a limit value for 2-ethoxyethanol and 2-ethoxyethyl acetate and the genotoxic effects of these glycol ethers. *Int Arch Occup Environ Health* 64:479-484.

Sparer J, Welch LS, McManus K, Cullen MR. 1988. Effects of exposure to ethylene glycol ethers on shipyard painters. I. Evaluation of exposure. *Am Ind Med* 14:497-507.

Spencer PJ, Crissman JW, Stott WT, Corley RA, Cieszlak FS, Schumann AM, Hardisty JF. 2002. Propylene glycol monomethyl ether (PGME): inhalation toxicity and carcinogenicity in Fischer 344 rats and B6C3F1 mice. *Toxicol Pathol* 30:570-579.

Spielmann H. 1986. Bewertung des embryotoxischen Risikos von Industriechemikalien in der Schwangerschaft. *Geburtsh Frauenheilk* 46.

Stebbins KE, Baker PC. 1999. Dipropylene glycol *n*-propyl ether: 2-week drinking water study in Fischer 344 rats. Unpublished report. Health & Environmental Research Laboratories, Dow Chemical, Midland, Michigan, USA. Oxygenated Solvents Speciality Chemicals, Dow Chemical, Midland, Michigan, USA.

Stedmann DB, Welsch F. 1989. Inhibition of DNA synthesis in mouse whole embryo culture by 2-methoxacetic acid and attenuation of the effects by simple physiological compounds. *Toxicol Lett* 45:111-117.

Stenger EG, Aeppli L, Müller D, Peheim E, Thomann P. 1971. Zur Toxikologie des Äthylenglykol-Monoäthyläthers. *Arzneim-Forsch* 21:880-885.

Stenger EG, Aeppli L, Machemer L, Müller D, Trokan J. 1972. Zur Toxizität des Propylenglykolmonomethylaethers. *Arzneim-Forsch* 22:569-574.

Stewart RD, Baretta ED, Dodd HC, Torkelson TR. 1970. Experimental human exposure to vapor of propylene glycol monomethyl ether. *Arch Environ Health* 20:218-223.

Stott WT, Kan HL. 2000. Dowanol PnB and DPnB mechanism of liver weight increase in Fischer 344 rats. Unpublished report. Toxicology & Environmental Research and Consulting, Dow Chemical, Midland, Michigan, USA. Oxygenated Solvents Speciality Chemicals, Dow Chemical, Midland, Michigan, USA.

Stott WT, McKenna MJ. 1984. The comparative absorption and excretion of chemical vapors by the upper, lower, and intact respiratory tract of rats. *Fundam Appl Toxicol* 4:594-602.

Stott AE, McKenna MJ. 1985. Hydrolysis of several glycol ether acetates and acrylate esters by nasal mucosal carboxylesterase *in vitro*. *Fundam Appl Toxicol* 5:399-404.

Sumner SCJ, Clarke DO, Welsch F, Fennell TR. 1991. Urinary metabolites of 2-methoxyethanol determined by NMR spectroscopy. *Toxicologist* 22:50 [Abstract].

Sumner SC, Stedman DB, Clarke DO, Welsch F, Fennell TR. 1992. Characterization of urinary metabolites from [1,2 methoxy-¹³C]-2-methoxyethanol in mice using ¹³C nuclear magnetic resonance spectroscopy. *Chem Toxicol* 5:553-560.

Suter L, Meier G, Bechter R, Bobadilla M. 1998. Flow cytometry as a sensitive tool to assess testicular damage in rat. *Arch Toxicol* 72:791-797.

Swan SH, Forest W. 1996. Reproductive risks of glycol ethers and other agents used in semiconductor manufacturing. *Occup Hyg* 2:373-385.

Swan SH, Beaumont JJ, Hammond SK, VonBehren J, Green RS, Hallock MF, Woskie SR, Hines CJ, Schenker MB. 1995. Historical cohort study of spontaneous abortion among fabrication workers in the Semiconductor Health Study: agent-level analysis. *Am J Ind Med* 28:751-769.

Sweeney LM, Tyler TR, Kirman CR, Corley RA, Reitz RH, Paustenbach DJ, Holson JF, Whorton MD, Thompson KM, Gargas ML. 2001. Proposed occupational exposure limits for select ethylene glycol ethers using PBPK models and Monte Carlo simulations. *Toxicol Sci* 62:124-139.

Tennant RW, Ashby J. 1991. Classification according to chemical structure, mutagenicity to *Salmonella* and level of carcinogenicity of a further 39 chemicals tested for carcinogenicity by the U.S. National Toxicology Program. *Mutat Res* 257:209-227.

Terry KK, Elswick BA, Welsch F, Conolly RB. 1995. Development of a physiologically model describing 2-methoxyacetic acid disposition in the pregnant mouse. *Toxicol Appl Pharmacol* 132:103-114.

Terry KK, Stedman DB, Bolon B, Welsch F. 1996. Effects of 2-methoxyethanol on mouse neurulation. *Teratology* 54:219-229.

Thévenaz Ph, Luetkemeier H, Mladenovic P, Verschuuren HG. 1988a. Two-week dietary toxicity study in rats with dipropylene glycol *n*-butyl ether. Unpublished report DET 1167, RCC Laboratories, Itingen, Switzerland. Dow Chemical, Midland, Michigan, USA.

Thévenaz Ph, Luetkemeier H, Vogel W, Schlotke B, Terrier Ch, Verschuuren HG. 1988b. 13-week dietary toxicity study in rats with dipropylene glycol *n*-butyl ether. Unpublished report, project 092158. RCC Research and Consulting, Itingen, Switzerland. Dow Chemical, Midland, Michigan, USA.

Thompson ED, Coppinger WJ, Valencia R, Iavicoli J. 1984. Mutagenicity testing of diethylene glycol monobutyl ether. *Environ Health Perspect* 57:105-112.

Tinston DJ. 1983. Ethylene glycol monoethyl ether acetate (EEAc). probe inhalation teratogenicity study in rabbits. Unpublished report CTL/T/2043. ICI Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire UK.

Tinston DJ, Doe JE, Godley MJ, Head LK, Killick M, Litchfield KH, Wickramaratne GA. 1983a. Ethylene glycol monoethyl ether (EE). Teratogenicity study in rats. Unpublished report. ICI Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire UK.

Tinston DJ, Doe JE, Thomas M, Wickramaratne GA. 1983b. Ethylene glycol monoethyl ether (EE). Inhalation teratogenicity study in rabbits. Unpublished report. ICI Central ToxicologyLaboratory, Alderley Park, Macclesfield, Cheshire, UK.

Toraason M, Stringer B, Stober P, Hardin BD. 1985. Electrocardiographic study of rat foetuses exposed to ethylene glycol monomethyl ether (EGME). *Teratology* 32:33-39.

Toraason M, Breitenstein MJ, Smith RJ. 1986a. Ethylene glycol monomethyl ether (EGME) inhibits rat embryo ornithine decarboxylase (ODC) activity. *Drug Chem Toxicol* 9:191-203.

Toraason M, Niemeier RW, Hardin BD. 1986b. Calcium homeostasis in pregnant rats treated with ethylene glycol monomethyl ether (EGME). *Toxicol Appl Pharmacol* 86:197-203.

Tornesi B, Carney EW. 2001. Comparative toxicity of methoxypropionic acid enantiomers in the rat whole embryo culture assay. Unpublished report, study 010065. Toxicology & Environmental Research and Consulting, Dow Chemical, Midland Michigan USA. Oxygenated Solvents, Dow Chemical, Midland, Michigan, USA.

Traina ME, Fazzi P, Urbani E, Mantovani A. 1997. Testicular creatine and urinary creatine-creatinine profiles in mice after the administration of the reproductive toxicant methoxyacetic acid. *Biomarkers* 2:103-110.

Truhaut R, Duterte-Catella H, Nguyen Phu-Lich, Vu Ngoc Huyen. 1979. Comparative toxicological study of ethyl glycol acetate and butyl glycol acetate. *Toxicol Appl Pharmacol* 51:117-127.

Tyl RW, Millicovsky G, Dodd DE, Pritts IM, France KA, Fisher LC. 1984. Teratologic evaluation of ethylene glycol monobutyl ether in Fischer 344 rats and New Zealand white rabbits following inhalation exposure. *Environ Health Perspect* 57:47-68.

Tyl RW, Prittis IM, France KA, Fisher LC, Tyler TR. 1988. Developmental toxicity evaluation of inhaled 2-ethoxyethanol acetate in Fischer 344 rats and New Zealand white rabbits. *Fundam Appl Toxicol* 10:20-39.

Tyl RW, Ballantyne B, France KA, Fisher LC, Klonne DR, Pritts IM. 1989. Evaluation of the developmental toxicity of ethylene glycol monohexylether vapor in Fischer 344 rats and New Zealand white rabbits. *Fundam Appl Toxicol* 12:269-280.

Tyl RW, Welsch F, Marr MC, Myers CB. 1999. Developmental toxicity evaluation of inhaled isopropyl cellosolve (ethylene glycol monoisopropyl ether, EGIE) vapor in CD (Sprague-Dawley) rats. Unpublished report 97006/572. Chemical Industry Institute of Toxicology, Research Triangle Park. North Carolina, USA. UCC study 96U1661. Union Carbide, Danbury, Connecticut, USA.

Tyler TR. 1984. Acute and subchronic toxicity of ethylene glycol monobutyl ether. *Environ Health Perspect* 57:185-191.

Udden MM. 1992. The effects of butoxyacetic acid on the deformability of red blood cells from rat and humans. Baylor College of Medicine, Houston, Texas, USA.

Udden MM. 1994. Hemolysis and decreased deformability of erythrocytes exposed to butoxyacetic acid, a metabolite of 2-butoxyethanol: II. Resistance in red blood cells from humans with potential susceptibility. *J Appl Toxicol* 14:97-102.

Udden MM. 1996. Effects of butoxyacetic acid on human red blood cells. Occup Hyg 2:283-290.

Udden MM. 2000. Rat erythrocyte morphological changes after gavage dosing with 2-butoxyethanol: A comparison with *in vitro* effects of butoxyacetic acid on rat or human erythrocytes. *J Appl Toxicol* 20:381-387.

Udden MM. 2002. *In vitro* sub-hemolytic effects of butoxyacetic acid on human and rat erythrocytes. *Toxicol Sci* 69:258-264.

Udden MM, Patton CS. 1994. Hemolysis and decreased deformability of erythrocytes exposed to butoxyacetic acid, a metabolite of 2-butoxyethanol. I. Sensitivity in rats and resistance in normal humans. *J Appl Toxicol* 14:91-96.

Uemura K. 1980. The teratogenic effects of ethylene glycol dimethyl ether on mouse. *Acta Obst Jpn* 32:113-121 (In Japanese).

Unilever. 1976. Ethylene glycol monobutyl ether. effects of subcutaneous injection upon pregnancy in the rat. Life Science Research Report 76/URL6/089. Unilever Research, UK.

Unilever. 1981a. Acute oral toxicity of phenoxyethanol in rats. Research Report RAT 81280. Unilever Research, UK.

Unilever. 1981b. Sensitisation potential of 2-phenoxyethanol in the Magnusson and Kligman guinea pig maximisation test. Research report SSM 81267. Unilever Research, UK.

Unilever. 1984a. Magnusson and Kligman guinea pig maximisation test with butyl dioxitol. Research Report SSM 84 369. Unilever Research, UK.

Unilever. 1984b. Absorption and excretion of [1-14C] butyl carbitol in female Wistar rats. Research Report PES 84 1057. Unilever Research, UK.

Unilever. 1984c. Bacterial reverse gene mutation assay with butyl carbitol. Research Report ULR/105D. Unilever Research, UK.

Unilever. 1984d. Bacterial reverse gene mutation assay with butyl carbitol. Research Report ULR/105C. Unilever Research, UK.

Unilever. 1984e. Investigation of the haemolytic potential of butyl carbitol, carbitol, and butyl cellosolve in the female guinea pig. Research Report PES 84 1020. Unilever Research, UK.

Unilever. 1984f. Teratogenicity of phenoxyethanol by subcutaneous injection in Colworth Wistar rats. Research report PES 841023. Unilever Research, UK.

Unilever. 1985. Study to evaluate the chromosome damaging potential of phenoxetol (2-phenoxyethanol) by its effects on cultured Chinese hamster ovary (CHO) cells using an *in vitro* cytogenetics assay. Microtest research report reference ULR 3/CHO/KF17/CH3. Unilever Research, UK.

Unilever. 1987a. The effect of subcutaneously administered carbitol and butyl carbitol on the pregnancy and offspring of the Colworth Wistar rat. Research Report PES 87 1031. Unilever Research, UK.

Unilever. 1987b. Further investigation of the haemolytic potential of butyl carbitol in the Colworth Wistar rat. Research Report PES 87 1008. Unilever Research, UK.

Unilever. 1989. Sensitisation potential of 2-butoxyethanol in the Magnusson and Kligman guinea pig maximisation test. Research report SM 890835. Unilever Research, UK.

Unilever. 1990. The effect of 2-butoxyethanol and 2-butoxyacetic acid on the proliferation of guinea pig lymphocytes *in vitro*. Research report IM890541. Unilever Research, UK.

Unilever. 1991a. [EGPhE] 28 day subacute oral toxicity study in rats. Research report 1430. Unilever Research, UK.

Unilever. 1991b. [EGPhE] 13 week subacute oral toxicity study in rats with 5 week recovery phase. Research report FT870647. Unilever Research, UK.

Union Carbide. 1950. Range-finding test on *n*-hexyl carbitol. Unpublished report R 5-9-1950. Bushy Run Research Center, Export, Pennsylvania, USA. Union Carbide Corporation, Danbury, Connecticut, USA.

Union Carbide. 1964. Range finding tests on *n*-propyl monoether of propylene glycol (1-propoxypropan-2-ol and 2-propoxypropan-1-ol). Unpublished report, special report 27-45. Mellon Institute of Industrial Research, Pittsburgh PA, USA. Union Carbide Corporation, Danbury, Connecticut, USA.

Union Carbide. 1984. Summary of acute toxicity on copies of index cards (1939-1949 studies). Union Carbide report to EPA 19 March, 1984. Union Carbide Corporation, Danbury, Connecticut, USA.

Union Carbide. 1985a. Hexyl cellosolve, *Salmonella*/microsome (Ames) bacterial mutagenicity assay. Unpublished report 48-82. Bushy Run Research Center, Export, Pensylvania, USA. Union Carbide Corporation, Danbury, Connecticut, USA.

Union Carbide. 1985b. Hexyl cellosolve, *in vitro* cytogenetic studies. Unpublished report 48-108. Bushy Run Research Center, Export, Pensylvania, USA. Union Carbide Corporation, Danbury, Connecticut, USA.

Union Carbide. 1985c. Hexyl cellosolve *in vitro* genotoxicity studies: CHO/HGPRT gene mutation test, sister chromatid exchange assay. Unpublished report report 48-124. Bushy Run Research Center, Export Pennsylvania, USA. Union Carbide Corporation, Danbury, Connecticut, USA.

Union Carbide. 1986. Propasol Solvent P: acute toxicity and primary irritancy studies. Unpublished report 49-179. Bushy Run Research Center, Export Pennsylvania, USA. Union Carbide Corporation, Danbury, Connecticut, USA.

Union Carbide. 1987a. Propasol Solvent P: nine-day vapor exposure study on rats. Unpublished report, Project Report 49-120. Bushy Run Research Center, Export Pennsylvania, USA. Union Carbide Corporation, Danbury, Connecticut, USA.

Union Carbide. 1987b. Propasol Solvent P: nine-day vapor exposure study on male rats, rabbits and guinea pigs with particular reference to ocular effects. Unpublished report 50-8. Bushy Run Research Center, Export Pennsylvania, USA. Union Carbide, Danbury, Connecticut, USA.

Union Carbide. 1989a. Butyl cellosolve *in vitro* mutagenesis studies, 3-test battery with attachments, cover sheets and letter dated 060689. EPA/OTS doc 86-890000946. Union Carbide, Danbury, Connecticut, USA.

Union Carbide. 1989b. Hexyl cellosolve (ethylene glycol monohexyl ether). Nine-day repeated cutaneous dose toxicity study in albino rabbits. Unpublished report 52-5. Bushy Run Research Center, Export, Pensylvania, USA. Union Carbide Corporation, Danbury, Connecticut, USA.

US-EPA (Environmental Protection Agency). 1982a. Report on oral LD₅₀ in rats, Olin Corp. Studies of MB Res. Lab.; EPA/OTS Document File 0206799.

US-EPA (Environmental Protection Agency). 1982b. Acute dermal toxicity in rabbits, Olin Corp. Studies of MB Res. Lab.; EPA/OTS Document File 0206799.

US-EPA (Environmental Protection Agency). 1982c. Inhalation toxicity in rats, Olin Corp. Studies of MB Res. Lab.; EPA/OTS Document File 0206799.

US-EPA (Environmental Protection Agency). 1982d. Primary dermal irritation in rabbits, Olin Corp. Studies of MB Res. Lab.; EPA/OTS Document File 0206799.

US-EPA (Environmental Protection Agency). 1982e. Report on rabbit eye irritation, Olin Corp. Studies of MB Res. Lab.; EPA/OTS Document File 0206801.

US-EPA (Environmental Protection Agency). 1982f. Comparative human skin irritation study on five test materials, Olin Corp. Studies of MB Res. Lab.; EPA/OTS Document File 0206799.

US-EPA (Environmental Protection Agency). 1982h. Report on oral LD₅₀ in rats, Olin Corp. Studies of MB Res. Lab.; EPA/OTS Document File 0206801.

US-EPA (Environmental Protection Agency). 1982i. Report on acute dermal toxicity in rabbits, Olin Corp. Studies of MB Res. Lab.; EPA/OTS Document File 0206801.

US-EPA (Environmental Protection Agency). 1982j. Report on primary dermal irritation in rabbits, Olin Corp. Studies of MB Research Lab.; EPA/OTS Document File 0206801.

US-EPA (Environmental Protection Agency). 1982k. Report on rabbit eye irritation, Olin Corp. Studies of MB Research Lab.; EPA/OTS Document File 0206799.

US-EPA (Environmental Protection Agency). 1985. Single dose and thirty-day dose toxicity of ethoxy tryglycol. Union Carbide Corp. Studies of Mellon Inst. Indus. Res. EPA/OTS. Document File 0206831.

US-EPA (Environmental Protection Agency). 1991. Alpha-2μ-globulin: Association with chemically induced renal toxicity and neoplasia in the male rat. EPA/625/3-91/019F. Risk Assessment Forum, EPA, Washington DC, USA.

US-EPA (Environmental Protection Agency). 1999. Ethylene glycol monobutyl ether (EGBE) (2-butoxyethanol), CASRN 111-76-2. Integrated Risk Information System (IRIS). EPA, Washington, DC, USA.

US-EPA (Environmental Protection Agency). 2002. US Environmental Protection Agency, 2-Phenoxyethanol (2PE). EPA Office of Pollution Prevention and Toxics, Washington DC, USA [http://www.epa.gov:oppt:chemtest/ phenoxet.htm].

US-NIOSH (Occupational Safety and Health Administration). 1983. Current Intelligence Bulletin No.39; Glycol Ethers; 2-methoxyethanol and 2-ethoxyethanol. #/PB 84155142, 1-22. National Institute of Occupation Safety and Health. Department of Health and Human Services, Cincinnati, Ohio, USA.

US-NIOSH (Occupational Safety and Health Administration). 1990a. Criteria for a recommended standard. Occupational exposure to ethylene glycol monobutyl ether and ethylene glycol monobutyl ether acetate. US Dept. of Health and Human Services, Public Health Service, Centers for Disease Control, Washington, DC, USA [http://www.cdc.gov/niosh/90-118.html].

US-NIOSH (Occupational Safety and Health Administration). 1990b. Criteria for a recommended standard. Occupational exposure to ethylene glycol monomethyl ether, ethylene glycol monoethyl ether and their acetates. US Dept. of Health and Human Services, Public Health Service, Centers for Disease Control, Washington, DC, USA [http://www.cdc.gov/niosh/91-119.html]

US-NIOSH (Occupational Safety and Health Administration). 1991. Criteria for a recommended standard occupational experience to EGME, EGEE and their acetates. DHHS, Publication 91-119. National Institute for Occupation Safety and Health, Cincinnati, Ohio, USA.

US-NIOSH (Occupational Safety and Health Administration). 1994. Alcohols IV, method 1403, issue 2. In NIOSH manual of analytical methods (NMAM), 4th ed. National Institute for Occupation Safety and Health, Cincinnati, Ohio, USA [http://www.cdc.gov/niosh/nmam/pdfs/1403.pdf].

US-OSHA (Occupational Safety and Health Administration). 1985. 2-Methoxyethanol (methyl cellosolve, 2ME), 2-methoxyethyl acetate (methyl cellosolve acetate, 2MEA), 2-ethoxyethanol (cellosolve, 2EE), 2-ethoxyethyl acetate (cellosolve acetate, 2EEA). Method No. 53. OSHA, Washington DC, USA.

US-OSHA (Occupational Safety and Health Administration). 1990a. 2-Methoxyethanol (methyl cellosolve, 2ME), 2-methoxyethyl acetate (methyl cellosolve acetate, 2MEA), 2-ethoxyethanol (cellosolve, 2EE), 2-ethoxyethyl acetate (cellosolve acetate, 2EEA). Method No. 79. OSHA, Washington DC, USA.

US-OSHA (Occupational Safety and Health Administration). 1990b. 2-Butoxyethanol (butyl cellosolve), 2-butoxyethyl acetate (butyl cellosolve acetate), Method No. 83. OSHA, Washington DC, USA.

Valencia R, Mason JM, Woodruff RC, Zimmering S. 1985. Chemical mutagenesis testing in *Drosophila*. III. Results of 48 coded compounds tested for the National Toxicology Program. *Environ Mutagen* 7:325-348.

Valentine R, O'Neill AJ, Lee KP, Kennedy GL. 1998. Subchronic inhalation toxicity of diglyme. *Food Chem Toxicol* 37:75-86.

Van de Waart EJ, Enninga IC. 1987. Evaluation of the mutagenic activity of Dowanol-DPnB in the Ames *Salmonella*/microsome test. Unpublished report, Notox Toxicological Research & Consultancy, 's-Hertogenbosch, Netherlands. Dow Chemical Europe, Horgen, Switzerland.

Vankerkom J. 1987. Guinea-pig sensitization study, modified Buehler method, test substance dipropylene glycol *n*-butyl ether. Unpublished report, SCK-CEN, Biology Department, Mol, Belgium. Dow Chemical Europe, Horgen, Switzerland.

Vankerkom J, Verschuuren HG. 1987. Propylene glycol *n*-butyl ether. Guinea pig sensitization study with modified Buehler method. Unpublished report. Dow Europe, Horgen, Switzerland.

Veulemans H, Groeseneken D, Masschelein R, Van Vlem E. 1987a. Survey of ethylene glycol ether exposures in Belgian industries and workshops. *Am Ind Hyg Assoc J* 48:671-676.

Veulemans H, Groeseneken D, Masschelein R, Van Vlem E. 1987b. Field study of the urinary excretion of ethoxyacetic acid during repeated daily exposure to the ethyl ether of ethylene glycol and the ethyl ether of ethylene glycol acetate. *Scand J Work Environ Health* 13:239-242.

Veulemans H, Steeno 0, Masschelein R, Groese neken D. 1993. Exposure to ethylene glycol ethers and spermatogenic disorders in man: a case control study. *Br J Ind Med* 50:71-78.

Villalobos-Pietrini R, Gomez-Arroyo S, Altamirano-Lozano M, Orozco P, Rios P. 1989. Cytogenetic effects of some cellosolves. *Rev Int Contam Ambient* 5:41-48.

Vincent R, Cicolella A, Subra I, Rieger B, Poirot P, Pierre F. 1993. Occupational exposure to 2-butoxyethanol for workers using window cleaning agents. *Appl Occup Env Hyg* 8:580-586.

Vincent R, Poirot P, Subra I, Rieger B, Cicolella A. 1994. Occupational exposure to organic solvents during paint stripping and painting operations in the aeronautical industry. *Int Arch Occup Environ Health* 65:377-380.

Von Oettingen WF, Jirouch EA. 1931. The pharmacology of ethylene glycol and some of its derivatives in relation to their chemical constitution and physical properties. *J Pharmacol Exp Ther* 42:355-372.

Waalkens-Berendsen DH, Koeter HBWM, van Marwijk MW, Verschuuren HG. 1989. Dermal embryotoxicity/ teratogenicity study with propylene glycol *n*-butyl ether (PnB) in rats. Toxicology Research Laboratory report, Dow Europe, Horgen, Switzerland.

Wagner VO. 1996. Bacterial reverse gene mutation assay with an independent repeat assay, test article isopropyl cellosolve. Unpublished report, study G96BH00.502001. Microbiological Associates, Rockville Maryland, USA. UCC project 96U1633. Union Carbide, Danbury, Connecticut, USA.

Wahlberg JE, Boman A. 1979. Comparative percutaneous toxicity of ten industrial solvents in the guinea pig. *Scand J Work Environ Health* 5:343-351.

Wall JM. 1988. Tripropylene glycol *n*- butyl ether: acute toxicologic properties. Unpublished report, study ID K-0005632-002. Mammalian and Environmental Toxicology Laboratory, Health and Environmental Sciences. Dow Chemical, Midland, Michigan, USA.

Walther R. 1942. The toxicology of glycols. Arch Gewerbepath Gewerbehyg 11:327-344.

Wang W, Chapin RE. 2000. Differential gene expression detected by suppression subtractive hybridization in the ethylene glycol monomethyl ether-induced testicular lesion. *Toxicol Sci* 56:165-174.

Wang W, Wine RN, Chapin RE. 2000. Rat testicular Src: normal distribution and involvement in ethylene glycol monomethyl ether-induced apoptosis. *Toxicol Appl Pharmacol* 163:125-134.

Weil CS. 1972. Statistics vs safety factors and scientific judgement in the evaluation of safety for man. *Toxicol Appl Pharmacol* 21:454-463.

Weil CS, Wright GJ. 1967. Intra- and interlaboratory comparative evaluation of single oral test. *Toxicol Appl Pharmacol* 11:378-388.

Welch LS, Cullen MR. 1988. Effect of exposure to ethylene glycol ethers on shipyard painters 1, hematologic effects. *Am J Ind Med* 14:527-536.

Welch LS, Schrader SM, Turner TW, Cullen MR. 1988. Effects of exposure to ethylene glycol ethers on shipyard painters 2. Male reproduction. *Am J Ind Med* 14:509-526.

Welsch F, Sleet RB, Greene JA. 1987. Attenuation of 2-methoxyethanol and methoxyacetic acidinduced digit malformations in mice by simple physiological compounds. Implications for the role of further metabolism of methoxyacetic acid in developmental toxicity. *J Biochem Toxicol* 2:225-240.

Welsch F, Blumenthal GM, Conolly RB. 1995. Physiologically based pharmacokinetic models applicable to organogenesis: extrapolation between species and potential use in prenatal toxicity risk assessments. *Toxicol Lett* 82/83:539-547.

Werner HW, Mitchell JL, Miller JW, von Oettingen WF. 1943a. The acute toxicity of vapours of several monoalkyl ethers of ethylene glycol. *J Ind Hyg Toxicol* 25:157-163.

Werner HW, Mitchell JL, Miller JW, von Oettingen WF. 1943b. Effects of repeated exposure of dogs to monoalkyl ethylene glycol ether vapors. *J Ind Hyg Toxicol* 25:409 -414.

Werner HW, Nawrocki CZ, Mitchell JL, Miller JW, von Oettingen WF. 1943c. Effects of repeated exposures of rats to vapors of monoalkyl ethylene glycol ethers. *J Ind Hyg Toxicol* 25:374-379.

Wesolowski W, Gromiec JP. 1997. Occupational exposure in polish paint and lacquer industry. *Int J Occup Med Environ Health* 10:79-88.

Weterings PJJM, Daamen PAM, Verschuuren HG. 1987a. Assessment of primary skin irritation/corrosion by Dowanol PnB in the rabbit. Unpublished report. Dow Europe, Horgen, Switzerland.

Weterings PJJM, Daamen PAM, Verschuuren HG. 1987b. Assessment of primary skin irritation/corrosion by Dowanol PnB diluted to 75%, 50%, and 25% (w/w) in the rabbit. Unpublished report. Dow Europe, Horgen, Switzerland.

Weterings PJJM, Daamen PAM, Verschuuren HG. 1987c. Assessment of acute eye irritation/corrosion by Dowanol PnB in the rabbit. Unpublished report. Dow Europe, Horgen, Switzerland.

Weterings PJJM, Daamen PAM, Verschuuren HG. 1988a. Assessment of primary skin irritation/corrosion by Dowanol TPnB in the rabbit. Unpublished report 0666/874. NoTox, 's-Hertogenbosch, Netherlands. Dow Chemical, Midland, Michigan, USA.

Weterings PJJM, Daamen PAM, Verschuuren HG. 1988b. Assessment of acute eye irritation/corrosion by Dowanol TPnB in the rabbit. Unpublished report 0666/875. NoTox, 's-Hertogenbosch, Netherlands. Dow Chemical, Midland, Michigan, USA.

Whittacker SG, Zimmermann FK, Dicus B, Piegorsch WW, Fogel Sand Resnick MA. 1989. Detection of induced mitotic chromosome loss in *Saccharomyces cerevisiae*, an interlaboratory study. *Mutat Res* 224:31-78.

Wickramaratne GA. 1986. The teratogenic potential and dose-response of dermally administered ethylene glycol monomethyl ether (EGME) estimated in rats with the Chernoff-Kavlock assay. J Appl Toxicol 6:165-166.

Wier PJ, Lewis SC, Traul KA. 1987. A comparison of developmental toxicity evident at term to postnatal growth and survival using ethylene glycol monoethyl ether, ethylene glycol monobutyl ether and ethanol. *Terat Carc Mutagen* 7:55-64.

Wiley FH, Hueper WC, Bergen DS, Blood FR. 1938. The formation of oxalic acid from ethylene glycol and related solvents. *J Ind Hyg Toxicol* 20:269-277.

Wilkinson SC, Williams FM. 2002. Effects of experimental conditions on absorption of glycol ethers through human skin *in vitro*. *Int Arch Occup Environ Health* 75:519-527.

Williams TM, Borghoff SJ. 2001. Characterization of *tert*-butyl alcohol binding to $\alpha_{2\mu}$ -globulin in F344 rats. *Toxicol Sci* 62:228-235.

Williams J, Foster PMD. 1988. The production of lactate and pyruvate as sensitive indices of altered rat sertoli cell function *in vitro* following the addition of various testicular toxicants. *Toxicol Appl Pharmacol* 94:160-170.

Williams J, Reel JR, George JD, Lamb JC. 1990. Reproductive effects of diethylene glycol and diethylene glycol monoethyl ether in Swiss CD-1 mice assessed by a continuous breeding protocol. *Fundam Appl Toxicol* 14:622-635.

Williams WC, Riddle MM, Copeland CB, Andrews DL, Smialowicz RJ. 1995. Immunological effects of 2-methoxyethanol administered dermally or orally to Fischer 344 rats. *Toxicol* 98:215-223.

Wilmer JWGM, van Marwijk MW. 1988. Dermal embryotoxicity/teratogenicity study with dipropylene glycol *n*-butyl ether (DPnB) in rats (final report). Unpublished report V88.057/270509. TNO CIVO Institutes, Zeist, Netherlands. Dow Chemical, Midland, Michigan, USA.

Windham GC, Shusterman D, Swan SH, Fenster Land Eskenazi B. 1991. Exposure to organic solvents and adverse pregnancy outcome. *Am J Ind Med* 20:241-259.

Wine RN, Ku WW, Li L-H, Chapin RE. 1997. Cyclophilin A is present in rat germ cells and is associated with spermatocyte apoptosis. *Biolog Reprod* 56:439-446.

Wingard B. 1982a. Acute oral LD₅₀ study in rats of A209429. Unpublished report, study 410-0935. Toxigenics, Decatur, IL, USA. ARCO Chemical, Newtown Square, PA, USA.

Wingard B. 1982b. Acute dermal toxicity study in rabbits of A209429 at a dose level of 2 grams per kilogram of body weight. Unpublished report, study 410-0936. Toxigenics, Decatur, IL, USA. ARCO Chemical, Newtown Square, PA, USA.

Wingard B. 1982c. Primary dermal irritation study in rabbits of A209429. Unpublished report, study 410-0938. Toxigenics, Decatur, IL, USA. ARCO Chemical, Newtown Square, PA, USA.

Wingard B. 1982d. Primary eye irritation study in rabbits of A209429. Unpublished report, study 410-0937. Toxigenics, Decatur, IL, USA. ARCO Chemical, Newtown Square, PA, USA.

Wolfe MA. 1954. Results of range finding toxicological tests on diethylene glycol mono methyl ether. Report from Biochemical Research Dept. (File T5.13-36-1), Dow Chemical, Midland, Michigan, USA.

Wright NP. 1997. EDP: chromosome aberration test in CHO cells *in vitro*. Unpublished report. Safepharm Laboratories, Derby, UK. SPL project no. 572/103. BP Chemicals, London, UK.

Xue H, Kamendulis LM, Klaunig JE. 1999. A potential mechanism for 2-butoxyethanol (2-BE) induced mouse liver neoplasia. *Toxicologist* 48:231 [Abstract].

Yamano T, Noda T, Shimizu M, Moriata S, Naguhama M. 1993. Effects of diethylene glycol monomethyl ether on pregnancy and postnatal development in rats. *Arch Environ Contam Toxicol* 24:228-235.

Yano BL, Baker PC. 2000. Dipropylene glycol *n*-propyl ether: 13-week drinking water toxicity study in Fischer 344 rats. Unpublished report, study ID 001007, Toxicology & Environmental Research and Consulting. Dow Chemical, Midland, Michigan, USA.

Yonemoto J, Brown NA, Webb M. 1984. Effects of dimethoxyethyl phthalate, monomethoxyethyl phthalate, 2-methoxyethanol and methoxyacetic acid on post-implantation rat embryos in culture. *Toxicol Lett* 21:97-102.

Young EG, Woolner LB. 1946. A case of fatal poisoning from 2-methoxyethanol. *J Ind Hyg Toxicol* 28:267-268.

Zavon MR. 1963. Methyl cellosolve intoxication. Am Ind Hyg Assoc J 24:36-41.

Zeiger E, Haworth S, Mortelmans K, Speck W. 1985. Mutagenicity testing of di(2-ethylhexyl)phthalate and related chemicals in *Salmonella*. *Environ Mutagen* 7:213-232.

Zeiger E, Anderson B, Haworth S, Lawlor T, Mortelmans K. 1992. *Salmonella* mutagenicity tests. V. Results from the testing of 311 chemicals. *Environ Molec Mutagen* 19:2-141.

Zempel JA, Campbell RA, Verschuuren HG. 1991. Metabolism and disposition of dipropylene glycol *n*-butyl ether in male Fischer 344 rats. Unpublished report, study K-005474-005. Health and Environmental Sciences - Texas, Dow Chemical, Freeport, Texas, USA. Dow Chemical Europe, Horgen, Switzerland.

Zimmermann FK, Mayer VW, Scheel I, Resnick MA. 1985. Acetone, methylethylketone, ethyl acetate, acetonitrile and other polar aprotic solvents are strong inducers of aneuploidy in *Saccharomyces cerevisiae*. *Mutat Res* 149:339-351.

Zissu D. 1995. Experimental study of cutaneous tolerance to glycol ethers. *Contact Dermatitis* 32:74-77.

5.3 References not quoted

- **The following references subsequent to the previous edition (ECETOC, 1995) were consulted by the Task Force, but not cited for the specific reasons indicated.
- *Andrew FD, Buschborn RL, Cannon WC, Miller RA, Montgomery LF, Phelps DW, Sikov MR. 1981. Teratologic assessment of ethylbenzene and 2-ethoxyethanol. Report prepared for the National Institute for Occupational Safety and Health under Contract 23111 03805 (NIOSH contract #210-79-0037). Battelle Pacific Northwest Laboratories, Richland, Washington, USA [Covered by Andrew and Hardin, 1984].
- *Arco Chemical. n.d. Summary of notification dossier of a new chemical substance in accordance with Directive 92/32/EEC (Articles 7/8/9/12), OJ L154, Vol 35, 5 June 1992 Unpublished report 98-06-9264-00. RCC Notox, 's-Hertogenbosch, Netherlands. ARCO Chemical Europe, Maidenhead, Berkshire, England, UK [Final SNIF as sent to HSE, excerpts].
- *ARCO Chemie Nederland. 1985. Material safety datasheet, Arcosolv PTB. ARCO, Rotterdam, Netherlands [PGTBE, covered by Arco Chemical, n.d.].
- *Arts JHE, Falke HE, Woutersen RA. 1988. TNO report No. V87.299/260985. Inhalation toxicology; sponsored by BG Chemie, Germany [Covered by Arts *et al*, 1992].
- *BASF. 1984. Bericht über die Prüfung der Stabilität von Glykoletheracetat in Rattenplasma. Unpublished report. Hoffmann HD, Gelbke HP. BASF Toxikologie, Ludwigshafen, Germany [Covered by Hoffmann and Gelbke, 1984; Hoffmann and Jäckh, 1985].
- *BASF. 1984. Prüfung von 2-Methoxypropylacetat-1 auf praenatale Toxizität an Wistar-Ratten nach inhalativer Exposition. Unpublished report project 37R0144/8315, vol 1 and 2. Merkle J, Klimisch HJ, Merkle J, Hildebrand B. BASF Toxikologie, Ludwigshafen, Germany [Covered by Merkle *et al*, 1987].
- *BASF. 1985. Pränatale Toxizität: Untersuchungen mit 2-Methoxypro pylacetat-1, 1-Methoxypropanol-2 und 2-Methoxypropanol-1. Personal communication. Gelbke P. BASF, Ludwigshafen, Germany [Covered by Merkle *et al*, 1987].
- *Bennett D. 2000. The distribution of radioactivity in the female B6C3F₁ mouse following a single intravenous injection of 2-butoxy[1-¹⁴C]ethanol. Unpublished report CTL/R/1446. Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire, UK. CEFIC, Brussels, Belgium [Covered by Green *et al*, 2002].

- *BP. 1981. Napsol PE1 (ethoxypropanol). Test for the determination of the index of ocular irritation in the rabbit (following the recommendations of the Journal Officiel de la République française of 21/4/71 and 5/6/73). Institut Français de Recherches et Essais Biologiques, Joinville-le-Pont, France. BP Chemicals, UK.
- *Breslin WJ, Clerzlak FS, Zablotny CL, Corley RA, Yano BL, Verschuuren HG. 1990. Developmental toxicity of inhaled dipropylene glycol monomethyl ether (DPGME) in rabbits and rats. *Toxicologist* 10:39 [Abstract; full reports by Breslin *et al*, 1990a,b].
- Bus JS, Crissman JW, Fox TR, Redmond J, Cieszlak FS, Corley RA, Stott WT. 1992. Rat and mouse liver and kidney response to inhaled propylene glycol monomethyl ether (PGME). *Toxicologist* 12:234.
- *Cheever KL, Weigel WW, Richards DE, Lal JB, Plotnick HB. 1985. Testicular effects of bis(2-methoxyethyl)ether in the adult male rat. Equimolar dose comparison with 2-methoxyethanol and 2-ethoxyethanol. *Toxicologist* 5:140 [Abstract; covered by Cheever *et al*, 1989a].
- *Cicolella A. 1992. Les éthers de glycol, état actuel des connaissances, perspectives de recherche. *Cahiers de notes documentaires* 148:359 [Review].
- *Delbarre F, Kahan A, de Gery A, Konrad K. 1980. Action immunomodulatrice du méthoxy-2-éthanol et de dérivés homologues chez le rat. *C R Acad Sci Paris* 291:215-218 [Possible therapeutic effects of EGME on adjuvant arthritis].
- *DFG (Deutsche Forschungsgemeinschaft). 1982. Zur Frage einer frucht- und hodenschädigenden Wirkung von Glykolethern. Mitteilung Senatskommission der DFG zur Prüfung gesundheitsschädlicher Arbeitsstoffe. VCH, Weinheim, Germany. *ASP* 6/82:154 [Review].
- *DFG (Deutsche Forschungsgemeinschaft). 1996. Diethylene glycol monobutyl ether (completed 1992). In Greim H, ed, *Occupational toxicants, critical data evaluation for MAK values and classification of carcinogens* Vol 7. Commission for the investigation of health hazards of chemical compounds in the work area. VCH, Weinheim, Germany [Review].
- *Dow. 1947. Unpublished data. Report on preliminary toxicity tests on propylene glycol monoethyl ether. Cited in Patty's. Dow Chemical, Midland, Michigan, USA [Cited by Gingell *et al*, 1994).
- *Drill VA. 1950. Unpublished data. 90-day skin absorption of dipropylene glycol ethyl ether (D-17) in rabbits. Dow Chemical, Midland, Michigan, USA [Cited by Gingell *et al*, 1994].

- *Eastman. 1982. Material safety data sheet, NTIS/OTS 0505466, 1-8. Eastman Chemical Products, Inc., USA.
- *ECETOC (European Centre for Ecotoxicology and Toxicology of Chemicals). 1982. The toxicology of ethylene glycol monoalklylethers and its relevance to man. Technical report No 4. ECETOC, Brussels, Belgium [Superseded by ECETOC, 1985, 1995].
- *ECETOC (European Centre for Ecotoxicology and Toxicology of Chemicals). 1985. The toxicology of glycol ethers and its relevance to man: An up-dating of ECETOC Technical Report No 4. Technical report No 17. ECETOC, Brussels, Belgium [Superseded by ECETOC, 1995].
- *Environmental Defense. 2002. Envirofacts warehouse chemical references, chemical profiles, scorecard for 1-hydroxy-2-phenoxyethane. Environmental Defense, New York, NY, USA [http://www.scorecard.org/chemical-profiles/] [Review].
- *Ferrala NF, Jouzaitis J, Hetu G, Ghanayem B, Nomeir AA. 1992. Comparative metabolism and disposition of 1-methoxy-2-propanol (PGME) in male Fischer 344 rats and male B6C3F₁ mice following p.o and i.v. administration. *Toxicologist* 12:234 [Abstract]; covered by Ferrala *et al*, 1994].
- *Fucik H. 1969. Prac Lek 21:116 [Cited by Boatman, 2001].
- *Green CE, Gordon GR, Cohen PM, Nolen HW, Peters JH, Tyson CA. 1996. *In vitro* metabolism of glycol ethers by human and rat hepatocytes. *Occup Hyg* 2:67-75.
- *Green T. 2001. 2-Butoxyethanol induced forestomach tumours in the mouse: Studies on the modes of action. Unpublished report CTL/R024439. Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire, UK. CEFIC, Brussels, Belgium [Covered by Green *et al*, 2002].
- *Hall AL. 1984. Cosmetically acceptable phenoxyethanol. *Cosmet Sci Technol* 1 Special issue: Cosmet Drug Preserv 79-108 [Review].
- *Hamlin JW, Hudson B, Sheen AD, Saunders KJ. 1982. The measurement of glycol ether levels in the workplace. European supplement to Poly mers Paint Colour Journal, October 13, 1982 [Early BP method].
- *Hanley TR, Yano BL, Nitschke KD, John JA, 1982. Ethylene glycol monomethyl ether: Inhalation teratology study rats and rabbits. Unpublished report, Dow Chemical, Midland, Michigan, USA [Covered by Hanley *et al*, 1984a,b].

- *Hardin BD. 1983. Reproductive toxicity of the glycol ethers. *Toxicol* 27:91-102. [Review]
- *Hardin BD, Bond GP, Andrew FD, Beliles RP, Niemeier RW. 1981. Testing of selected workplace chemicals for teratogenic potential. Unpublished report, NIOSH Division of Biomedical and Behavioral Science, Cincinnati, Ohio, USA; Batelle Pacific Northwest Laboratories, Richland, Washington, USA; Litton Bionetics, Rockville, Maryland, USA [Preliminary studies, including EGEE by inhalation].
- *Hoechst. 1996. Unpublished report 96.1043. Hoechst, Frankfurt/Main, Germany [No available; cited by ECB, 2000].
- *INRS. 1983. Toxicité pour l'homme des éthers monoalkylés de l'éthylèneglycol. Note établie à partir du rapport technique N°4 de l' « European Chemical Industry Ecology and Toxicology Centre » Bruxelles, juillet 1982. Report No. ND 1422-111-83. *Cahiers de notes documentaires* 111:215 [Review].
- *INRS. 1992. Les éthers de glycol. Etat actuel des connaissances. Perspectives de recherche. *Cahiers de notes documentaires* 148:359 [Review].
- *IPCS (International Programme on Chemical Safety). 2003. Concise international chemical assessment document, 2-butoxyethanol: Human health aspects, update. Unpublished report, first draft prepared by Copestake P, Toxicology Advice & Consulting, Carshalton, Surrey, UK. IPCS, Geneva, Switzerland [Review].
- *Ito Y, Noda A, Akagi H, Ka wamura M, Soshi S, Sakogawa T. 1997. Research Institute for Animal Science in Biochemistry and Toxciology, Sagaihara-shi, Kanagawa, Japan [Japanese; English summary by Health and Welfare Japan, 1998, pp 209-215].
- *Johanson G. 1988. Aspects of biological monitoring of exposure to glycol ethers. *Toxicol Letters* 43:5-21 [Review].
- *Johanson G. 1988. Toxicokinetics of 2-butoxyeth anol, update, distribution, metabolism, and excretion in man and laboratory animals. *Arbete och Hälsa* 3 [Review]
- *John JA, Scortichini BH, Jefries TK, Berdasco NM, Quast JF, Rao KS. 1984. Diethylene glycol monomethyl ether (DEGME): Dermal teratology study in rabbits. Unpublished report, Dow Chemical, Chemical Manufacturers Association, Midland, Michigan, USA [Covered by Scortichini et al, 1986].

- *Johnston JD, Jamieson GG, Wright S. 1992. Reproductive and developmental hazards and employment policies. *Br J Ind Med* 49:85-94 [Review; refers to proposed hypothesis for mechanism of foetotoxicity of EGME (Working, 1985 as quoted)].
- *Katz GV. 1978. Basic toxicity of 2-propoxyethanol. Unpublished report 104723Q. Toxicological Section, Health and Environment Laboratories, Eastman Kodak, Rochester, New York, USA. Eastman Chemicals Division, Eastman Kodak, Kingsport, Tennessee, USA [Covered by Katz *et al*, 1984].
- *Katz GV. 1983. Two week inhalation toxicity of 2-propoxyethanol. Unpublished report 152988S, TX-83-15. Toxicological Section, Health and Environment Laboratories, Eastman Kodak, Rochester, New York, USA. Eastman Chemicals Division, Eastman Kodak, Kingsport, Tennessee, USA [Covered by Katz *et al*, 1984].
- *Kirk-Othmer. 1980. Encyclopedia of chemical technology Vol 11, Glycols (Ethylene and Propylene), 3rd ed. John Wiley & Sons [Cited in IPCS, 1990].
- *Kodak. 1982. Vol. MSDS-10, p 170A [Cited by RTECS, Registry of Toxic Effects of Chemical Substances (1991).
- *Kodak. 1984a. Toxicity studies with diethylene glycol monobutyl ether. I. Acute oral LD₅₀. Eastman Kodak, cited in petition to delete five unique glycol ethers from the Clean Air Act list of Hazardous Air Pollutants, October 11 1991. Chemical Manufacturers Association, Arlington, Virginia, USA [Covered by Krasavage and Terhaar, 1981a].
- *Kodak. 1984b. Toxicity studies with diethylene glycol monobutyl ether. II. Acute dermal LD₅₀. Eastman Kodak, cited in petition to delete five unique glycol ethers from the clean air act list of hazardous air pollutants, October 11 1991. Chemical Manufacturers Association, Arlington, Virginia, USA [Covered by Krasavage and Terhaar, 1981b].
- *Krasavage WJ. 1989. A developmental toxicity probe study of ethylene glycol monopropyl ether in the rabbit. HAEL 88-0017. Acc. No. 907124. Unpublished report 252946R, TX-89-36. Toxicological Sciences Laboratory, Health and Environment Laboratories, Eastman Kodak, Rochester, New York, USA. Eastman Chemicals Division, Eastman Kodak, Kingsport, Tennessee, USA [Covered by Krasavage *et al*, 1990].
- *Krasavage WJ, Hosenfeld RS. 1989. A developmental toxicity study with ethylene glycol monopropyl ether in the rabbit. Unpublished report 252947S, TX-89-37. Toxicological Sciences Laboratory, Health and Environment Laboratories, Eastman Kodak, Rochester, New York, USA.

Eastman Chemicals Division, Eastman Kodak, Kingsport, Tennessee, USA [Covered by Krasavage et al, 1990].

*Krasavage WJ, Katz GV. 1983. 2-Propoxyethanol: inhalation teratology probe in rats. Unpublished report 152987R, TX-83-14. Toxicological Sciences Section, Health and Environment Laboratories, Eastman Kodak, Rochester, New York, USA. Eastman Chemicals Division, Eastman Kodak, Kingsport, Tennessee, USA [Covered by Krasavage *et al*, 1990].

*Laitinen J, Liesivuori J, Savolainen H. 1996. Urinary alkoxyacetic acids and renal effects of exposure to ethylene glycol ethers. *Occup Environ Med* 53:595-600 [Suggests low BEL; covered by Laitinen, 1998].

*Laitinen J, Liesivuori J, Savolainen H. 1998. Urinary NAG and GAG as biomarkers of renal effects in exposure to 2-alkoxyalcohols and their acetates. *J Occup Environ Med* 40:595-600 [Dermal vapour absorption methodology].

*Liberacki AB, Crissman JW, Carney EW, Breslin WJ, Clements CM. 1997. Propylene glycol monomethyl ether; two-generation inhalation reproduction study in Sprague-Dawley rats. Unpublished report. Toxicology Research Laboratory, Health and Environmental Research Laboratories, Dow Chemical, Midland, Michigan, USA [Covered by Carney *et al*, 1999].

*Linscombe VA, Gollapudi BB. 1987. Evaluation of diethylene glycol monobutyl ether in the Chinese hamster ovary cell/hypoxanthine-guani ne-phosphoribosyl transferase (CHO/HGPRT) forward mutation assay. Unpublished report, study K001699-13. Health and Environmental Sciences-Texas, Lake Jackson Research Center, Dow Chemical, Freeport, Texas, USA. Glycol Ethers Panel, Chemical Manufacturers Association, Arlington, Virginia, USA [Covered by Gollapudi *et al*, 1993].

*McClintock ML, Gollapudi BB. 1987. Evaluation of diethylene glycol monobutyl ether in the mouse bone marrow micronucleus test. Unpublished report, study K001699-12. Health and Environmental Sciences-Texas, Lake Jackson Research Center, Dow Chemical, Freeport, Texas, USA. Glycol Ethers Panel Chemical Manufacturers Association, Arlington, Virginia, USA [Covered by Gollapudi *et al*, 1993].

*McGregor DB. 1980. Tier II mutagenic screening of 13 NIOSH priority compounds, individual compound report 2-methoxyethanol. Unpublished report 22. Inveresk Research International, Musselburgh, Scotland, UK. Contract No. 210-78-0026. National Institute for Occupational Safety and Health. Division of Biomedical and Behavioural Science. Experimental Toxicology Branch. Cincinnati, Ohio, USA [Covered by McGregor, 1983].

- *Miller RR, Eisenbrandt DL, Gushow TS, Weiss SK. 1984. Diethylene glycol monomethyl ether (DEGME): 13-week vapor inhalation study in rats. Unpublished report, Dow Chemical, Midland, Michigan, USA [Covered by Miller *et al*, 1985a].
- *Musshoff U, Madeja M, Binding N, Witting U, Speckmann E-J. 1999. Effects of 2-phenoxyethanol on *n*-methyl-D-aspartate (NMDA) receptor-mediated ion currents. *Arch Toxicol*. 73:55-59 [Almost all of 17 glycol ethers tested, except EGPhE, failed to reduce NMDA-induced ion currents in *Xenopus* oocytes, suggesting a lack of neurotoxic potential; see also letters to the editor by Schmuck *et al*, 2000 and Musshoff *et al*, 2000].
- *Musshoff U, Madeja M, Binding N, Witting U, Speckmann E-J. 2000. 2-Phenoxyethanol: a neurotoxicant? Reply. Letter to the editor. *Arch Toxicol* 74:284-287 [See Musshoff *et al*, 1999].
- *NTP (National Toxicology Program). 1987. Teratologic evaluation of diethylene glycol dimethyl ether (CAS No.111-96-6) administered to New Zealand white rabbits on gestational days 6 through 15. NTP report 87-108. Available through NTIS/PB87-209532/AS. NTP, National Institute of Environmental Health Sciences, Research Triangle Park NC, USA [Covered by Schwetz *et al*, 1992].
- *NTP (National Toxicology Program). 1987. Teratologic evaluation of ethylene glycol diethyl ether (CAS No. 629-14-1) administered to CD-1 mice on gestational days 6 through 15. NTP report 87-244. NTP, National Institute of Environmental Health Sciences, Research Triangle Park NC, USA [Covered by George *et al*, 1992].
- *NTP (National Toxicology Program). 1987. Teratologic evaluation of ethylene glycol diethyl ether (CAS No. 629-14-1) administered to New Zealand white rabbits on gestational days 6 through 19. NTP report 87-342. NTP, National Institute of Environmental Health Sciences, Research Triangle Park NC, USA [Covered by George *et al*, 1992].
- *Park JJ, Kamendulis LM, Klaunig JE. 2000. Effects of 2-butoxyethanol, 2-butoxyacetic acid, and ferrous sulfate on the morphological transformation of Syrian hamster embryo (SHE) cells. *Toxicologist* 54:201 [Abstract].
- *Piacitelli G, Votaw D, Krishnan R. 1989. An extent of exposure assessment in industries using ethylene glycol ethers. Summary report No. 134.20.18. National Institute for Occupational Safety and Health. Cincinnati, Ohio, USA [Covered by Piacitelli *et al*, 1990].
- *Procter and Gamble. 1983. Dermal teratology study in rabbits, test article B0547-01 [DGBE]. Unpublished report project ECM-BTS 753. [Authors sanitised]. International Research and

Development Corporation, Mattawan, Michigan, USA. Procter and Gamble, Cincinnati, Ohio, USA [Covered by Nolen *et al*, 1985].

*Procter and Gamble. 1984. Study of fertility and general reproductive performance in rats, test article B0547-01 [DGBE]. Unpublished report project ECM-BTS 753. [Authors sanitised]. International Research and Development Corporation, Mattawan, Michigan, USA. Procter and Gamble, Cincinnati, Ohio, USA [NIS 2057] [Covered by Nolen *et al*, 1985].

*Reel JR, Lawton D. 1984. Diethylene glycol monoethyl ether. Reproduction and fertility assessment in CD-1 mice when administered in the drinking water. Unpublished report. Research Triangle Institute, Research Triangle Park, NC, USA. National Toxicology Programme, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA [Covered by Williams *et al*, 1990].

*Rowe VK. 1952. Toxicological information on Dowanol 62-B (methyl ether of tripropylene glycol). Confidential Report of Dow Chemical, Midland, Michigan, USA [Covered by Rowe et al, 1954].

*Ruth JH. 1986. Odor thresholds and irritation levels of several chemical substances: a review. *Am Ind Hyg Assoc J* 47:142 [Review].

*Saparmamedov E. 1974. Zdravookhr Turkm 18:26-31 [Cited by Boatman, 2001].

*Schenker M. 1992. Epidemiologic study of reproductive and other health effects among workers employed in the manufacture of semiconductors. University of California. Report to the Semiconductor Industry Association, San Jose, CA, USA [Superseded by Schenker, 1996].

*Schenker M, Beaumont J, Eskenazi B, Gold E, Hammond K, Lasley B, McCurdy S, Samuels S, Swan S. 1992. Epidemiologic study of reproductive and other health effects among workers employed in the manufacture of semiconductors. Final Report to the Semiconductor Industry Association, San Jose, CA, USA [Superseded by Schenker *et al*, 1995].

*Shell. 1988. Unpublished report [Cited by Tyl et al, 1988].

*Shibuya T, Hara T, Kawakami K, Horiya N. 1997. Reverse mutation test of propylene glycol monomethyl ether acetate on bacteria. Hatano Research Institute, Food and Drug Safety Center, Hadano-shi, Kanagawa, Japan [Japanese; English summary by Ministry of Health and Welfare Japan, 1998, pp 220-223].

- *Shideman FE, Procita L. 1951. The pharmacology of the mono methyl ethers of mono-, di-, and tripropylene glycol in the dog with observations on the auricular fibrillation produced by these compounds. *J Pharmacol Exp Therap* 102:79-87 [Not relevant for acute toxicity of TPGME].
- *Shih T-S, Wang P-Y, Chen C-Y, Lu C-J, Smith TJ. 2000. A new technology to measure skin absorption of vapors. *Arch Environ Health* 55:250-258 [Methodology development; covered by Shih *et al*, 2000b].
- *Sivak JG, Herbert KL, Baczmanski AL. 1995. The use of the cultured bovine lens to measure the *in vitro* ocular irritancy of ketones and acetates. *ATLA* 23:689-698 [Alternative test validation].
- *Sleet RB, Greene JA, Welsch F. 1986. Localization of radioactivity from 2-methoxy[1,2-¹⁴C]ethanol in maternal and conceptus compartments of CD-1 mice. *Toxicol Appl Pharmacol* 84:25-35 [Distribution of radioactivity].
- *Smallwood AW, DeBord KE, Lowry LK. 1984. Analyses of ethylene glycol monoalkyl ethers and their proposed metabolites in blood and urine. *Environ Health Perspect* 57:249-253 [Early biomonitoring, see Table 17].
- *Spencer PJ. 2005. New toxicity data for the propylene glycol ethers a commitment to public health and safety. *Toxicol Lett* 156:181-188 [Review].
- *Sprague A. 1992. Illness Report Involving the Ingestion of Dot 3 Brake Fluid, Eisenhower Army Hospital, Atlanta, GA, USA, unpublished [Cited in Boatman and Knaak, 2001].
- *Tanaka N, Kasakabe H, Sasaki K, Wakuri S, Nakagawa Y, Watanabe M, Ohshima S, Hahimoto K. 1997. *In vitro* chromosomal aberration test of propylene glycol ether acetate on cultured Chinese hamster cells. Hatano Research Institute, Food and Drug Safety Center, Hadano, Kanagawa, Japan [Japanese; English summary cited by Ministry of Health and Welfare Japan, 1998, pp 224-226].
- *Topping DC. 1983. Pulmonary function in animals exposed to 2-propoxyethanol by inhalation. Acc. No. 907124. HS&HFL 82-0234. Unpublished report 152989T, TX-83-16. Toxicological Section, Health and Environment Laboratories, Eastman Kodak, Rochester, New York, USA. Eastman Chemicals Division, Eastman Kodak, Kingsport, Tennessee, USA [Lung function test, no toxicity information].
- *Tyl RW. 1984. A teratologic evaluation of ethylene glycol monobutyl ether in Fischer 344 rats and New Zealand white rabbits following inhalation exposure. Unpublished report, Union

Carbide Bushy Run Research Centre, Export, Pensylvania, USA. Chemical Manufacturers Association, Washington Delaware, USA [Covered by Tyl et al, 1984].

*Tyler TR. 1987. Review of repeated exposures to glycol ethers. Unpublished report 5845B. Union Carbide, Danbury, Connecticut, USA [Review].

*Tyler TR. 1990. Testimony on proposed standard No. 8 toxic air pollutants. South Carolina Department of Health and Environmental Control Bureau of Air Quality Control. Chemical Manufacturers Association Glycol Ethers Panel. Columbia, SC, USA [Review].

*UK-HSC (Health and Safety Commission). 1984. Glycol ethers, proposals for control limits. Unpublished report ACTS 31/84. Advisory Committee on Toxic Substances (ACTS). HSC, London, UK [Review].

*Unilever. 1984 [Cited and reviewed by CIR, 1990].

*Union Carbide. 1953. Range-finding test on 2-ethylhexyl cellosolve. Unpublished report R5-16-53. Bushy Run Research Center, Export, Pennsylvania, USA. Union Carbide Corporation, Danbury, Connecticut, USA [Covered by Smyth *et al*, 1954].

*Union Carbide. 1987. [DEGHE]. Bushy Run Research Center, Project Report 50-119 [Covered by Ballantyne and Vergnes, 2001].

*Union Carbide. 1987. [DEGHE]. Bushy Run Research Center, Project Report 50-55 [Covered by Ballantyne and Vergnes, 2001].

*Union Carbide. 1987. [DEGHE]. Bushy Run Research Center, Project Report 50-139 [Covered by Ballantyne and Vergnes, 2001].

*Union Carbide. 1988. Hexyl carbitol, *in vivo* mouse micronucleus study. Unpublished report, January 12, 1988. Bushy Run Research Center, Export, Pensylvania, USA. Union Carbide Corporation, Danbury, Connecticut, USA [Covered by Ballantyne and Vergnes, 2001].

*US-OSHA (Occupational Safety and Health Administration). 1987. Toxicology update, glycol ethers and acetates. Advance notice of proposed rulemaking 87-4. OSHA, Washington, DC, USA [Review].

*Veulemans H, Steeno 0, Masschelein R, Groeseneken D. 1991. Spermatogenic disorders in man and exposure to ethylene glycol ethers: a case control study. Unpublished report. Katholieke Universiteit, Leuven, Belgium [Covered by Veulemans *et al*, 1993].

*Vincent R, Rieger B, Subra I, Poirot P. 1996. Exposure assessment to glycol ethers by atmosphere and biological monitoring. *Occup Hyg* 2:79-99 [Cited by INSERM, 1999].

*Wilkinson SC, Williams FM. 1997. Factors affecting dermal absorption of 2-ethoxyethanol from aqueous solution *in vitro*. *Toxicol* 148:37-38 [Abstract].

*Wyman JF, Hobson DW. 1985. Subchronic evaluation of diethylene glycol monobutyl ether by gavage in Fischer 344 rats. Naval Medical Research and Development Command, Task MF58524001-0006. Notice of Research project Tox-Tips. National Library of Medicine, Toxicology Information Program, Bethesda, Maryland, USA [Abstract cited by Hobson *et al*, 1986b, 1987].

APPENDIX A: SPECIAL ABBREVIATIONS

ADH Aldehyde dehydrogenase

ADME Absorption distribution metabolism elimination

ALP or AP
Alkaline phosphatase
ALT
Alanine aminotransferase
ATP
Adenosine triphosphate
AUC
Area under the curve
BAA
2-Butoxy acetic acid
BAL
2-Butoxy acetaldehyde

BAT Biologischer Arbeitsstoff-Toleranz-Wert ^a

BEAA 2-(2-butoxyethoxy)acetic acid

bw Body weight

CHL Chinese hamster lung
CHO Chinese hamster ovary
CNS Central nervous system

Con A Concanavalin A CYP Cytochrome P450

d Day

D4²⁰ Relative density
 DCM Dichloromethane
 DNA Deoxyribonucleic acid
 EAA Ethoxy acetic acid
 EG Ethylene glycol

EMH Extramedullary haemopoiesis

EPA Ethoxypropionic acid

F Female F344 Fischer 344

FSH Follicle stimulating hormone FOB Functional observation battery

GC Gas chromatography

g.d. Gestation day

GI-tract Gastrointestinal tract
GLP Good laboratory practice

GSH Glutathione

h Hour

Hb Haemoglobin Hct Haematocrit

HGPRT Hypoxanthine-guanine-phosphoribosyl transferase

ECETOC TR No. 95 170

Freedom_0001156_0175

^a Biological tolerance value at the workplace

APPENDIX A: SPECIAL ABBREVIATIONS (CONT'D)

i.p. Intraperitoneal i.v. Intravenous

LC₅₀ Lethal concentration for 50% of the exposed animals

LD₅₀ Lethal dose for 50% of the exposed animals

LDH Lactate dehydrogenase LH Luteinising hormone

LO(A)EL Lowest observed (adverse) effect level

LP Lymphoproliferative

M Male

MAALD 2-Methoxyacetaldehyde

MAK Maximale Arbeitsplatzkonzentration ^a

MCHb Mean cell haemoglobin MCV Mean corpuscular volume

MEAA (2-Methoxy-ethoxy) acetic acid

MEG Monoethylene glycol
MEL Maximum exposure limit
MFO Mixed function oxidase

mg Milligramme mmol Millimole ml Millilitre

MAA Methoxy acetic acid MPA Methoxy propionic acid

NA Not available

NCE Normochromatic erthyrocytes

ND Not detected

n Number of samples or subjects

NK Natural killer

NKA Natural killer (cell) activity

NO(A)EL No-observed (adverse) effect level

NS Not specified, not stated NZW New Zealand white

OEL Occupational exposure limit (value)

PAS Periodic acid Schiff

PBPK Physiologically-based pharmacokinetic

ECETOC TR No. 95 171

Freedom_0001156_0176

^a Maximum workplace concentration

APPENDIX A: SPECIAL ABBREVIATIONS (CONT'D)

PCE Polychromatic erthyrocytes
PCT Proximal convoluted tubule

PD Protective dose
PFC Plaque-forming cell
PHA Phytohaemagglutinine
PHAA Phenoxy acetic acid

PNPH p-Nitrophenol ppm Parts per million

PROD Pentoxyresorufin O-dealkylase

PWN Poak wead nitrogen RBC Red blood cell(s)

Supernatant of centrifuged 9,000 x g liver homogenate

s.c. Subcutaneoussd Standard deviationSD Sprague-Dawley

SCE Sister chromatid exchange

SGPT Serum glutamic pyruvic transaminase

SHE Syrian hamster embryo
SRBC Sheep red blood cell(s)
ST Sulfphotransferase

STEL Short-term exposure limit

TCA Tricarboxylic acid
TK Thymidine kinase
TLV Threshold limit value

TNP-LPS Trinitrophenyl-lipopolysaccharide

TPG Tripropylene glycol
TWA Time-weighted average

UGT UDP- glucuronosyl transferase

WBC White blood cell(s)

wk Week

+/- With or without, in the presence or absence of

-ve Negative: no effects

+ve Positive: effects (on organ or system)

±ve Equivocal

↓ Decrease

↑ Increase

µmol Micromole

µg Microgramme

APPENDIX B: CONVERSION FACTORS FOR VAPOUR CONCENTRATIONS IN AIR

Conversion factors for vapour concentrations in air can be calculated from the molar volume of an ideal gas at 0°C: 22.4136 litre.

1
$$mg/m^3 = 22.4136/Mw \times 1,013.25/P \times (273+T)/273 \text{ ppm} \dots (Eq. B.1)$$

1 $ppm = Mw/22.4136 \times P/1.013.25 \times 273/(273+T) mg/m^3 \dots (Eq. B.2)$

where Mw = molecular weight, $T = \text{temperature } (^{\circ}\text{C})$ and P = pressure (hPa).

For European standard conditions, 20°C and 1,013.25 hPa (=1 atm = 760 mm Hg), the formulae become

1
$$mg/m^3 = 24.0556/Mw ppm$$
 (Eq. B.3)
1 $ppm = Mw/24.0556 mg/m^3$ (Eq. B.4)

In the USA and other countries 25°C is used, and the formulae are:

1
$$mg/m^3 = 24.4661/Mw ppm$$
(Eq. B.5)
1 $ppm = Mw/24.4661 mg/m^3$ (Eq. B.6)

APPENDIX C: OCCUPATIONAL EXPOSURE LIMIT VALUES

Several countries have adopted OEL values (Table C.1). The justification of some OELs (also) takes account of critical effects on the reproductive system.

Table C.1: OEL values a,b

Country ^c (ppm)	Concentration, 8-h ^d TWA		STEL, 15-min		Skin notation	Pregnancy group
		$(mg/m^3)^e$	(ppm)	$(mg/m^3)^{e}$		
1. Ethylene glycol me	ethyl ether (EGME),	CAS No. 109-86-4, s	tructural formula	ı: CH ₃ -O-CH ₂ -CH ₂	-ОН	
Austria	5	15	10	30	Yes	
Belgium	5	16	-	-	Yes	
Denmark	5	16	-	-	Yes	
EU	-	-	-	-	-	May impair fertility (R60), May cause harm to the unborn child (R61), Toxic for reproduction (Category 2)
Finland	0.5	1.6	-	-	Yes	
France	5	16	-	-	Yes f	
Germany	5	16	20	64	Yes	Toxic for reproductive purposes
Ireland	5	16	-	-	Yes	Category 2 reproductive toxins: toxic for reproduction for humans
Italy	5	16	-	-	Yes	
Netherlands	0.3	1	-	-	Yes	Toxic to reproduction
Norway	5	16	-	-	Yes	Reproduction damaging substance
Portugal	-	-	-	-	-	
Spain	5	16	-	-	Yes	Substance that can and should be considered harmful for the fertility of human beings or should be considered toxic for their development.
Sweden	0.1	-	-	-	Yes	Reproduction-dist urbing substances. Observation list: properties impairing reproduction.

Freedom_0001156_0181

Table C.1: OEL values a,b (cont'd)

Country c	Concentrat	tion, 8-h ^d TWA	STEL	, 15-min	Skin notation	Pregnancy group
(ppm)		$(mg/m^3)^{e}$	(ppm)	$(mg/m^3)^{e}$		
Switzerland	5	15	10	30	Yes	Harm to the foetus is possible even when the MAK value is complied with.
UK	5	16	-	-	Yes	
US-ACGIH	5	-	-	-	Yes	Critical effect: reproductive
US-NIOSH	0.1	0.3	-	-	-	Reproductive and developmental effects
US-OSHA	25	80	-	-	Yes	
Japan	5	16	-	-	Yes	
2. Ethylene glycol me	ethyl ether acetate (E	GMEA), CAS No. 11	0-49-6, structura	l formula CH ₃ -O-C	CH ₂ CH ₂ OCOC	Н ₃
Austria	5	25	10	50	Yes	
Belgium	5	24	-	-	Yes	
Denmark	5	24	-	-	Yes	
EU	-	-	-	-	-	May impair fertility (R60), May cause harm to the unborn child (R61), Toxic for reproduction (Category 2)
Finland	0.5	2.5	-	-	Yes	
France	5	24	-	-	Yes ^f	
Germany	5	25	20	100	Yes	Toxic for reproductive purposes
Ireland	5	24	-	-	Yes	Category 2 reproductive toxins: toxic for reproduction for humans
Italy	5	24	-	-	Yes	

Freedom_0001156_0182

Table C.1: OEL values a,b (cont'd)

Country ^c	Concentrati	on, 8-h ^d TWA	STEL	., 15-min	Skin notation	Pregnancy group
(ppm)		$(mg/m^3)^e$	(ppm)	$(mg/m^3)^{e}$		
Netherlands	0.3	1.5	-	-	Yes	Toxic to reproduction
Norway	5	22	-	-	Yes	Reproduction damaging substance
Spain	5	24	-	-	Yes	Teratogen Category TR2: Substance that can and should be considered harmful for the fertility of human beings or should be considered toxic for their development.
Sweden	0.1	-	-	-	Yes	Group B: reproduction-disturbing substances. Observation list: properties impairing reproduction.
Switzerland	5	25	10	50	Yes	Harm to the foetus is possible even when the MAK value is complied with.
UK	5	25	-	-	Yes	
US-ACGIH	5	-	-	-	Yes	Critical effect: reproductive
US-NIOSH	0.1	0.5	-	-	Yes	Reproductive and developmental effects
US-OSHA	25	120	-	-	Yes	
Japan	5	24	-	-	Yes	
3. Ethylene glycol dim	nethyl ether (EGDME), CAS No. 110-71-4	4, structural form	nula: CH ₃ -O-CH ₂ -	CH ₂ -O-CH ₃	
-		-	-	-	-	
4. Diethylene glycol m	nethyl ether (DEGME)), CAS No. 111-77-3	3, structural form	nula: CH ₃ -(O-CH ₂ -	CH ₂) ₂ –OH	
Denmark	25	-	-	-	-	
EU	-	-	-	-	-	Possible risk of harm to the unborn child (R63), Toxic for reproduction (Category 3)

Table C.1: OEL values a,b (cont'd)

Country ^c	Concentrat	Concentration, 8-hd TWA		., 15-min	Skin notation	Pregnancy group
(ppm)		$(mg/m^3)^{e}$	(ppm)	$(mg/m^3)^{e}$		
Netherlands	9	45	-	-		Toxic to reproduction
5. Diethylene glycol di	imethyl ether (DEGD	OME), CAS No. 111-	-96-6, structural f	ormula: CH ₃ -(O-C	H ₂ -CH ₂) ₂ -O-CH ₃	
Austria	5	27	20	108	-	
Germany	5	28	20	112	Skin	
Netherlands	5	27	-	-		
Norway	-	-	-	-	-	Reproduction damaging substance
Switzerland	5	27	10	54	-	
6. Triethylene glycol r	nethyl ether (TEGM)	E), CAS No. 112-35	-6, structural forr	nula: CH ₃ -(O-CH ₂	-СН ₂) ₃ -ОН	
-		-	-	-	-	
7. Triethylene glycol d	limethyl ether (TEGI	DME), CAS No. 112	2-49-2, structural	formula: CH ₃ -(O-0	CH ₂ -CH ₂) ₃ -O-CH ₃	
-		-	-	-	-	
3. Methoxy-acetic acid	d (MAA), CAS No. 62	25-45-6, structural 1	ormula: CH ₃ –O–	СН2-СООН		
Netherlands	5	19	-	-	-	
EU	-	-	-	-	-	May impair fertility (R60), May cause harm to the unborn child (R61), Toxic for reproduction (Category 2)
Switzerland	5	19	10	38	-	Harm to the foetus is possible even when the MAK value is complied with.

Freedom_0001156_0184

Table C.1: OEL values a,b (cont'd)

Country ^c	Concentrati	on, 8-h ^d TWA	STEL	., 15-min	Skin notation	Pregnancy group	
(ppm)	$(mg/m^3)^e$		(ppm) $(mg/m^3)^e$				
9. Ethylene glycol ethy	yl ether (EGEE), CAS	No. 110-80-5, struc	ctural formula: C	C ₂ H ₅ -O-CH ₂ -CH ₂ -C	ЭН		
Austria	5	19	20	76	Yes		
Belgium	5	18	-	-	Yes		
Denmark	5	18.5	-	-	Yes		
EU	-	-	-	-	-	May impair fertility (R60), May cause harm to the unborn child (R61), Toxic for reproduction (Category 2)	
France	5	19	-	-	Yes f		
Finland	2	7.5	-	-	Yes		
Germany	5	19	20	76	Yes	Substances which are Carcinogenic, Mutagenic or Toxic for Reproductive Purposes	
Ireland	5	18	-	-	Yes	Substance should be regarded as if it is toxic for reproduction for humans (Category 2 reproductive toxins).	
Italy	5	18	-	-	Yes		
Netherlands	5	19	-	-	Yes	Substances toxic to reproduction	
Norway	5	18	-	-	Yes	Reproduction Damaging Substance	
Spain	5	18	-	-	Yes	Substance that can and should be considered harmful for the fertility of human beings or should be considered toxic for their development)	
Sweden	5	19	10	40	Yes	Substance has reproduction-disturbing effects. Properties impairing reproduction.	

Table C.1: OEL values a,b (cont'd)

Country ^c	Concentrat	ion, 8-h ^d TWA	STEL	, 15-min	Skin notation	Pregnancy group
(ppm)		$(mg/m^3)^{e}$	(ppm)	$(mg/m^3)^{e}$		
Switzerland	5	19	10	38	Yes	Harm to the foetus is possible even when the MAK value is complied with.
UK	10	37	-	-	Yes	
US-ACGIH	5	-	-	-	Yes	Critical Effect(s): Reproductive
US-NIOSH	0.5	1.8	-	-	Yes	Reproductive and developmental effects
US-OSHA	200	740	-	-	Yes	
Japan	5	18	-	-	Yes	
10. Ethylene glycol et	hyl ether acetate (EG	EEA), CAS No. 111	-15-9, structural	formula: C ₂ H ₅ -O-C	CH ₂ -CH ₂ -O-CO-C	Н ₃
Austria	5	27	20	108	Yes	
Belgium	5	27	-	-	Yes	
Denmark	5	27.0	-	-	Yes	
EU	-	-	-	-	-	May impair fertility (R60), May cause harm to the unborn child (R61), Toxic for reproduction (Category 2)
France	5	27	-	-	Yes ^f	
Finland	2	11	-	-	Yes	
Germany	5	27	20	108	Yes	Substances which are carcinogenic, mutagenic or toxic for reproductive purposes
Ireland	10	54	-	-	Yes	Substance should be regarded as if it is toxic for reproduction for humans (Category 2 reproductive toxins).
Italy	5	27	_	_	Yes	

Freedom_0001156_0186

Table C.1: OEL values a,b (cont'd)

Country ^c	Concentrati	on, 8-h ^d TWA	STEL	, 15-min	Skin notation	Pregnancy group
(ppm)		$(mg/m^3)^{e}$	(ppm)	$(mg/m^3)^{e}$		
Norway	5	27	-	-	Yes	Reproduction damaging substance
Spain	5	27	-	-	Yes	Substance that can and should be considered harmful for the fertility of human beings or should be considered toxic for their development
Sweden	5	30	10	50	Yes	Substance has reproduction-disturbing effects. Properties impairing reproduction
Switzerland	5	27	10	54	Yes	Harm to the foetus is possible even when the MAK value is complied with
Netherlands	5	27	-	-	Yes	Substances toxic to reproduction
UK	10	55	-	-	Yes	
US-ACGIH	5	-	-	-	Yes	Critical Effect(s): Reproductive
US-NIOSH	0.5	2.7	-	-	Yes	Reproductive and developmental effects
US-OSHA	100	540	-	-	Yes	
Japan	5	27	-	-	Yes	
1. Ethylene glycol di	ethyl ether (EGDEE),	CAS No. 629-14-1,	structural formu	ıla: C ₂ H ₅ -O-CH ₂ -C	CH ₂ -O-C ₂ H ₅	
-		-	-	-	-	
12. Diethylene glycol	ethyl ether (DEGEE),	CAS No. 111-90-0,	structural formu	la: C ₂ H ₅ (O-CH ₂	CH ₂) ₂ -OH	
Netherlands	32	180	-	-	Yes	
Sweden	15	80	30	170	Yes	
US-AIHA	25	140	-	-	-	

Table C.1: OEL values a,b (cont'd)

Country ^c	Concentrat	ion, 8-h ^d TWA	STEL	, 15-min	Skin notation	Pregnancy group
(ppm)		$(mg/m^3)^{e}$	(ppm)	$(mg/m^3)^e$		
13. Diethylene glycol	ethyl ether acetate (D	EGEEA), CAS No.	112-15-2, structu	ral formula: C ₂ H ₅ -((O-CH ₂ -CH ₂) ₂ -O-(СО-СН3
Sweden	15	110	30	220	Yes	
14. Diethylene glycol	diethyl ether (DEGD)	EE), CAS No. 112-30	5-7, structural for	rmula: C ₂ H ₅ (O-CI	H ₂ -CH ₂) ₂ -O-C ₂ H ₅	
-		-	-	-	-	
15. Triethylene glycol	(mono) ethyl ether (T	EGEE), CAS No. 11	12-50-5, structura	nl formula: C ₂ H ₅ -(C)СН ₂ СН ₂) ₃ ОН	
-		-	-	-	-	
16. Ethylene glycol is	opropy l ether (EgiPE)	, CAS No. 109-59-1	, structural form	ula: (CH ₃) ₂ CH-O-(CH ₂ –CH ₂ –OH	
Austria	5	22	10	44	Yes	
Belgium	25	108	-	-	Yes	
Denmark	5	22	-	-	Yes	
France	25	105	-	-	Yes ^f	
Germany	5	22	20	88	Yes	If the MAK and BAT values are complied with, there should be no risk for the foetus
Ireland	25	106	-	-	Yes	
Italy	25	106	-	-	Yes	
Netherlands	10	44	-	-	Yes	
Norway	20	80	-	-	-	
Sweden	10	45	20	90	Yes	

Freedom_0001156_0188

Table C.1: OEL values a,b (cont'd)

Country ^c	Concentrati	on, 8-h ^d TWA	STEL, 15-min		Skin notation	Pregnancy group
(ppm)		$(mg/m^3)^{e}$	(ppm)	$(mg/m^3)^{e}$		
Switzerland	5	22	10	44	Yes	The foetus will not be harmed if the MAK value is complied with.
US-ACGIH	25	-	-	-	Yes	
17. Ethylene glycol iso	propyl ether acetate	(EGiPEA), CAS No	. 91598-97-9, stru	uctural formula: (Cl	H ₃) ₂ CH–O–CH ₂ –CH	H ₂ –О–СО–СН 3
-		-	-	-	-	
18. Ethylene glycol n-	propyl ether (EgnPE)	, CAS No. 2807-30-	9, structural form	nula: C ₃ H ₇ -O-CH ₂ -	-CH ₂ -OH	
Denmark	25	110	-	-	-	
Germany	20	86	20	86	Yes	If the MAK and BAT values are complied with, there should be no risk for the foetus
Netherlands	10	44	-	-	Yes	
Sweden	10	45	20	90	Yes	
Switzerland	20	85	40	170	Yes	The foetus will not be harmed if the MAK value is complied with.
19. Ethylene glycol n-	propyl ether acetate (EGnPEA), CAS No	. 20706-25-6, stru	uctural formula: C ₃	H ₇ -O-CH ₂ -CH ₂ -O-	-СО-СН 3
Germany	20	120	20	120	Yes	If the MAK and BAT values are complied with, there should be no risk for the foetus
Netherlands	10	60	-	-	Yes	
Switzerland	20	120	40	240	Yes	The foetus will not be harmed if the MAK value is complied with.

Table C.1: OEL values a,b (cont'd)

Country ^c	Concentrati	on, 8-h ^d TWA	STEL	, 15-min	Skin notation	Pregnancy group
(ppm)		$(mg/m^3)^{e}$	(ppm)	$(mg/m^3)^{e}$		
20. Ethylene glycol pl	henyl ether (EGPhE),	CAS No. 122-99-6,	structural formu	la: C ₆ H ₅ -O-CH ₂ -C	Н₂−ОН	
Germany	20	110	20	110	-	If the MAK and BAT values are complied with, there should be no risk for the foetus
Netherlands	20	110	-	-	-	
Switzerland	20	110	40	220	Yes	The foetus will not be harmed if the MAK value is complied with.
21. Ethylene glycol n-	-butyl ether (EGBE), (CAS No. 111-76-2, s	tructural formula	a: C ₄ H ₉ –O–CH ₂ –Cl	H ₂ –OH	
Austria	20	100	40	200	Yes	
Belgium	25	123	-	-	Yes	
Denmark	20	98	-	-	Yes	
EU	20	98	50	246	Yes	
Finland	20	98	50	250	Yes	
France	25	120	-	-	Yes f	
Germany	20	98	80	392	Yes	If the MAK and BAT values are complied with, there should be no risk for the foetus
Ireland	25	120	-	-	Yes	
Italy	20	97	-	-	Yes	
Netherlands	20	100	50	246	Yes	
Norway	10	50	-	-	Yes	
Spain	20	98	-	-	Yes	

Freedom_0001156_0190

Table C.1: OEL values a,b (cont'd)

Country ^c	Concentrati	on, 8-h ^d TWA	STEL	, 15-min	Skin notation	Pregnancy group
(ppm)		$(mg/m^3)^{e}$	(ppm)	$(mg/m^3)^{e}$		
Sweden	10	50	20	100	Yes	
Switzerland	20	100	40	200	Yes	
UK	25	123	~	-	Yes	
US-ACGIH	20	-	-	-	Yes	
US-NIOSH	5	24	-	-	Yes	
US-OSHA	25	120	-	-	Yes	
22. Ethylene glycol n-	butyl ether acetate (E	GBEA), CAS No. 1	12-07-2, structura	al formula: C ₄ H ₉ –O	CH ₂ CH ₂ OCO-	-CH ₃
Austria	20	135	40	270	Yes	
Denmark	20	130	-	-	Yes	
EU	20	133	50	333	Yes	
Finland	20	130	50	330	Yes	
Germany	20	130	80	520	Yes	If the MAK and BAT values are complied with, there should be no risk for the foetus
Netherlands	20	135	50	333	Yes	
Norway	10	65	-	-	Yes	
Spain	20	133	50	333	Yes	
Sweden	10	70	20	140	Yes	
Switzerland	20	135	40	270	Yes	
US-ACGIH	20	-	-	-	-	
US-NIOSH	5 ^g	33	-	-	-	

Freedom_0001156_0191

Table C.1: OEL values a,b (cont'd)

Country ^c	Concentrat	ion, 8-h ^d TWA	STEL	, 15-min	Skin notation	Pregnancy group
(ppm)		$(mg/m^3)^{e}$	(ppm)	$(mg/m^3)^e$		
23. Diethylene glycol	butyl ether (DEGBE)	, CAS No. 112-34-5,	structural formu	ıla: C ₄ H ₉ –(O–CH ₂ –	CH ₂) ₂ –OH	
Austria	15	100	15	100	-	
Denmark	-	100	-	-	-	
Germany	-	100	-	100	-	If the MAK and BAT values are complied with, there should be no risk for the foetus
Netherlands	9	50	~	-	Yes	
Sweden	15	100	30	200	-	
Switzerland	-	100	-	100	-	The foetus will not be harmed if the MAK value is complied with.
24. Diethylene glycol	butyl ether acetate (E	DEGBEA), CAS No.	124-17-4, structu	ral formula: C ₄ H ₉ –	(O-CH ₂ -CH ₂) ₂ -O-	CO–CH ₃
Netherlands	15	130	30	250	-	
Sweden	15	130	30	250	-	
25. Triethylene glycol	n-butyl ether (TEGE	BE), CAS No. 143-22	2-6, structural for	rmula: C ₄ H ₉ –(O–Cl	H ₂ -CH ₂) ₃ -OH	
-		-	-	-	-	
26. Ethylene glycol (n	nono) <i>n-</i> hexyl ether (l	EGHE), CAS No. 112	2-25-4, structural	formula: C ₆ H ₁₃ –O	-CH₂-CH₂-OH	
-		-	-	-	-	
27. Diethylene glycol	(mono) hexyl ether (I	DEGHE), CAS No. 1	12-59-4, structur	al formula: C ₆ H ₁₃ –(O-CH ₂ -CH ₂) ₂ -OH	
	<u> </u>		•	_		

Freedom_0001156_0192

Table C.1: OEL values a,b (cont'd)

Country ^c	Concentration	n, 8-h ^d TWA	STEL, 1	5-min	Skin notation	Pregnancy group
(ppm)		$(mg/m^3)^{e}$	(ppm)	(mg/m^3)	e	
28. 2-Propylene glyco	l 1-methyl ether (2PG1	ME), CAS No. 10	07-98-2, structural fo	rmula:	CH ₃ -CH-CH ₂ -O-CH ₃	
					ОН	
Austria	50	187	50	187	Yes	•
Belgium	100	374	150	561	-	
Denmark	50	185	-	-	-	
EU	100	375	150	568	Yes	
France	100	360	-	-	_ f	
Finland	100	370	150	560	-	
Germany	100	370	100	370	-	If the MAK and BAT values are complied with, there should be no risk for the foetus
Ireland	100	360	300	1,080	Yes	
Italy	100	369	150	553	-	
Netherlands	100	375				
Norway	50	180	-	-	Yes	
Spain	100	374	200	748	Yes	
Sweden	50	190	75	300	Yes	
Switzerland	100	360	200	720	-	The foetus will not be harmed if the MAK value is complied with.
UK	100	375	300	1,120	Yes	
US-ACGIH	100	-	150	-	-	
US-NIOSH	100	360	150	540	-	

Table C.1: OEL values a,b (cont'd)

Country ^c	Concentrati	ion, 8-h ^d TWA	STEL	, 15-min	Skin notation	Pregnancy group
(ppm)		$(mg/m^3)^{e}$	(ppm)	$(mg/m^3)^e$		
29. 2-Propylene glyco	l 1-methyl ether 2-ace	tate (2PG1MEA), (CAS No. 108-65-6,	, structural formula:	СН₃–СН–СН	I ₂ -O-CH ₃
					О-СО-СН	3
Austria	50	275	100	550	-	
Belgium	50	275	100	550	Yes	
Denmark	50	270	-	-	-	
EU	50	275	100	550	Yes	
Finland	50	270	100	550	Yes	
Germany	50	270	50	270	-	If the MAK and BAT values are complied with, there should be no risk for the foetus
Ireland	50	275	100	550	Yes	
Italy	50	275	100	550	-	
Netherlands	100	550	-	-	-	
Norway	50	270	-	-	Yes	
Spain	50	275	100	550	Yes	
Sweden	50	250	75	400	Yes	
Switzerland	50	275	50	275	-	The foetus will not be harmed if the MAK value is complied with.
UK	50	274	150	822	-	
Canada	50	75	-	-	Yes	

Table C.1: OEL values a,b (cont'd)

Country ^c	Concentra	tion, 8-h ^d TWA	STE	L, 15-min	Skin notation	Pregnancy group
(ppm)		$(mg/m^3)^{e}$	(ppm)	(mg/m^3)	e	
US-AIHA	100	541	-	-	-	
US-California	100	541	150	811	-	
30. 1-Propylene glyco	ol 2-methyl ether (1Pe	G2ME), CAS No. 1	589-47-5, structu	ral formula:	H ₃ C−CH−CH ₂ −OH	
					O-CH 3	<u>.</u>
Austria	20	75	40	150	-	
Denmark	20	75	-	-	-	
EU						May cause harm to the unborn child (R60), Toxic for reproduction (Category 2)
Germany	20	75	80	300	-	
Netherlands	-	-	-	-	-	Substances toxic to reproduction
Norway	20	75	-	-	Yes	Reproduction damaging substance
Spain	20	75	-	-	-	
Sweden	50	190	75	300	Yes	
Switzerland	20	75	40	150	Yes	Harm to the foetus is possible even when the MAK value i complied with
Canada	20	-	40	-	-	Possible reproductive toxin
31. 1-Propylene glyco	ol 2-methyl ether 1-ac	eetate (1PG2MEA),	CAS No. 70657-7	70-4, structural 1	Cormula: CH ₃ -C	H-CH ₂ -O-CO-CH ₃
						-CH₃
Austria	20	110	40	220	-	

Table C.1: OEL values a,b (cont'd)

Country ^c	Concentrati	on, 8-h ^d TWA	STEL	, 15-min	Skin notation	Pregnancy group	
(ppm)		$(mg/m^3)^{e}$	(ppm)	$(mg/m^3)^{e}$			
Denmark	20	110	-	-	-		
EU	-	-	-	-	-	May cause harm to the unborn child (R61), Toxic for reproduction (Category 2)	
Germany	20	110	80	440	-		
Netherlands	-	-	-	-	-	Substances toxic to reproduction	
Norway	20	110	-	-	Yes	Reproduction damaging substance	
Switzerland	20	110	40	220	Yes	Harm to the foetus is possible even when the MAK value is complied with	
Canada	20	-	40	-	-	Possible reproductive toxin	
32. Dipropylene glyco	ol methyl ether (DPGM	1E), CAS No. 34590	1-94-8, structurai	iormuia: CH ₃ -	-(O−CH ₂ −CH) ₂ −OH □ CH ₃		
Austria							
	50	307	100	614	-		
	50 50	307 308	100	614		•	
Belgium					-		
Belgium Denmark	50	308	-	-	- Yes		
Belgium Denmark EU	50 50	308 300	-	-	- Yes Yes		
Belgium Denmark EU Finland	50 50 50	308 300 308	-	- - -	- Yes Yes Yes		
Belgium Denmark EU Finland France Germany	50 50 50 50	308 300 308 310	-	- - -	- Yes Yes Yes Yes		
Belgium Denmark EU Finland France	50 50 50 50 100	308 300 308 310 600	- - - -	- - - -	Yes Yes Yes Yes Yes		

Table C.1: OEL values a,b (cont'd)

Country ^c	Concentration, 8-hd TWA		STEL	₂ , 15-min	Skin notation	Pregnancy group
(ppm)		$(mg/m^3)^{e}$	(ppm)	$(mg/m^3)^{e}$		
Netherlands	50	300				
orway	50	300	-	-	Yes	
pain	50	308	-	-	Yes	
weden	50	300	75	450	Yes	
witzerland	50	300	50	300	Yes	
K	50	308	-	-	Yes	
anada-Alberta	100	606	150	909	Yes	
anada, British Columbia	100	-	150	-	Yes	
anada, Ontario	100	605	150	910	Yes	
exico	100	600	150	900	Yes	
S-ACGIH	100	-	150	-	Yes	
S-NIOSH	100	600	~	-	Yes	
S-OSHA	100	600	-	-	Yes	
S-California	100	600	150	900	Yes	
JS-North Carolina	100	600	150	900	Yes	
3. Tripropylene glycol met	hyl ether (TPG	ME), CAS No. 2549	8-49-1, structura	l formula: CI	H ₃ -(O-CH ₂ -CH) ₃ -C	. ЭН
	•				CH ₃	

Table C.1: OEL values a,b (cont'd)

Country ^c	Concentration, 8-hd TWA	STEL, 1	5-min	Skin notation	Pregnancy group
(ppm)	$(mg/m^3)^{e}$	(ppm)	$(mg/m^3)^{e}$		
34. 2-Propylene glycol	1-ethyl ether (2PG1EE), CAS No. 1569-0	2-4, structural forr	nula: CH ₃ -	$CH-CH_2-O-C_2H_5$	
			ОН		
Denmark	100 -	-	-	-	
35. 2-Propylene glycol	1-ethyl ether 2-acetate (2PG1EEA), CAS	No. 54839-24-6, st	ructural formula:	CH ₃ CHCH	2-O-C2H5
				□ O-CO-	CH ₃
-	-	-	-	**	•
36. Dipropylene glycol	ethyl ether (DPGEE), CAS No. 30025-38	-8, structural form	ula: C ₂ H ₅ (C	D-CH-CH)₂-OH □ CH₃	
-	-	-	-	-	
37. Propylene glycol <i>n</i> -	-propyl ether (PGPE), CAS No. 1569-01-3	3, structural formu	la: C ₃ H ₇ -O-C	CH ₂ −CH−CH ₃ □ OH	
Denmark	100 -	-	-	-	
38. Dipropylene glycol	n-propyl ether (DPGPE), CAS No. 2991	1-27-1, structural fe	ormula: C ₃]	H ₇ (OCH ₂ CH) ₂	-ОН
				CH ₃	
-	-	-	-	-	
39. 2-Propylene glycol	1-phenyl ether (2PG1PhE), CAS No. 770	-35-4, structural fo	3	CH-CH ₂ -O-C ₆ H ₅	
-	-	-	-	-	

Freedom_0001156_0198

Table C.1: OEL values a,b (cont'd)

Country ^c	Concentration, 8-hd TWA	STEL, 15-min	Skin notation	Pregnancy group
(ppm)	$(mg/m^3)^{e}$	(ppm) (mg	/m ³) ^e	
40. 2-Propylene glycol 1-	n-butyl ether (2PG1BE), CAS No. 513	1-66-8, structural formula:	C_4H_9 –O–CH $_2$ –CH–OH	
Denmark	100 -	-	- CH ₃	
41. Dipropylene glycol 1-	butyl ether (DPGBE), CAS No. 29911	-28-2, structural formula:	C ₄ H ₉ −(O−CH ₂ −CH) ₂ −OH □ CH ₃	
- 42. Tripropylene glycol 1	-butyl ether (TPGBE), CAS No. 55934	- 1-93-5, structural formula:	- 	
-		-	CH 3	
43. Propylene glycol tert-	butyl ether (PGTBE), CAS No. 57018-	52-7, structural formula:	CH ₃ -CH(OH)-CH ₂ -O-C	(CH ₃) ₃
-	-	-		
44 D' 1 1 1 4	rt-butyl ether (DPGTBE), CAS No. 13	2739-31-2, structural form	ula: C ₆ H ₁₃ -O-CH ₂ -CH ₂ -	-OH

The value may be advisory or official (tentative or legally binding)

b Ariel Research, 2002

For additional EU national information, see: http://europe.osha.eu.int/good_practice/risks/ds/oel/For EU OEL activities, see: http://europe.eu.int/comm/employment_so cial/hands/areas/oels_en.htm For Japan, see: http://joh.med.uoeh-u.ac.jp/oel/index.html.

d NIOSH 10-h TWA

Some agencies use (slightly) different conversion factors based on variations in temperature, pressure and/or normal gas volume, cf. Appendix C.

Affections engendrées par les solvants organiques liquides à usage professionnel: ..., glycols et leurs éthers ... (France, 1985)

g Recommended value (EGBEA)

MEMBERS OF THE TASK FORCE

D. Owen (Chairman) Shell Chemicals

UK - London

H. Verschuuren (Chairman) ^a Dow Europe

H - Horgen

R. Boatman b Eastman Kodak Company

USA - Rochester, New York

R. Ebert ^a Hüls

D - Marl

K. Huckle ^a Dow Corning

B - La Hulpe

B. Huisman ^a Shell

NL - Den Haag

R. Jäckh BASF

Ludwigshafen

N. Moore ^c BP Chemicals

UK - Sunbury-on-Thames

G. Nohynek L'Oréal Research

F - Clichy

D. Pope b Unilever Research

UK - Bedford

P. Spencer ^a Dow Chemical

USA - Midland, Michigan

M. Thomas Lyondell Chemical Europe

UK - Maidenhead

a Part-time

^b Corresponding member on behalf of the American Chemical Council, USA - Arlington, Virginia

^c Presently at Dow Europe, CH - Horgen

S. Williams ^a BP Chemicals

UK - London

J. Wilmer Dow Europe

CH - Horgen

W. Haebler (Secretary) ^a ECETOC

B - Brussels

H. Vrijhof (Secretary) ECETOC

B - Brussels

Acknowledgement

The contribution of A. Margary (Shell Chemicals, UK - London) to Section 3.1 of this report and the editorial input from J. Kelsey (BP Chemicals, UK - Sunbury-on-Thames) are gratefully acknowledged.

MEMBERS OF THE SCIENTIFIC COMMITTEE

(Peer Review Committee)

B. Hildebrand (Chairman) ^a Consultant - Weinheim

G. Randall b AstraZeneca

Director, Environmental Laboratory UK - Brixham

E. Bomhard a,c Bayer D - Wuppertal Industrial Toxicologist

C. Braun Akzo Nobel Occupational Toxicologist NL - Arnhem

P. Calow d University of Sheffield Professor of Zoology UK - Sheffield

N. Carmichael e Aventis CropScience Head, Toxicology F - Sophia Antipolis

C. d'Hondt Syngenta Head, Environmental Safety Department CH - Basel

P. Douben Unilever

Head, SEAC Environmental Protection Department UK - Sharnbrook

T. Feijtel Procter and Gamble B - Brussels Manager, Professional and Regulatory Services

Technical University Munich Director, Institute of Toxicology and Environmental Hygiene D - Munich

J. Jackson ^a Monsanto Senior Associate, Medical Adviser B - Brussels

C. Money ExxonMobil Industrial Hygiene Adviser - Europe B - Brussels

A. Sarrif a,f DuPont Director, Toxicology Affairs, Europe B - Mechelen

G. Swaen g Maastricht University NL - Maastricht Head, Occupational Epidemiology Unit

B. van Ravenzwaay f Director, Experimental Toxicology and Ecology D - Ludwigshafen

H-J. Wiegand Degussa Head, Product Safety Department D - Düsseldorf

^a Retired

b Presently consultant, UK - Stoke Gabriel, Devon, and Chairman of Scientific Committee since 1-04-2003 Presently consultant, D - Wuppertal; acted as Technical Editor

^d Presently director of the Environmental Assessment Institute, DK - Copenhagen

e Resigned

f Steward responsible for primary peer review

g Employed by Dow Chemical, USA - Midland, Michigan since 1-10-2004

ECETOC PUBLISHED REPORTS

Monographs

No.	Title
No. 1	Good Laboratory Practice (Published October 1979)
No. 2	A Contribution to Strategy for Identification and Control of Occupational Carcinogens (Published September 1980)
No. 3	Risk Assessment of Occupational Chemical Carcinogens (Published May 1985)
No. 4	Hepatocarcinogenesis in Laboratory Rodents: Relevance for Man (Published October 1982)
No. 5	Identification and Assessment of the Effects of Chemicals on Reproduction and Development (Reproductive Toxicology) (Published December 1983)
No. 6	Acute Toxicity Tests, LD ₅₀ (LC ₅₀) Determinations and Alternatives (Published May 1985)
No. 7	Recommendations for the Harmonisation of International Guidelines for Toxicity Studies (Published December 1985)
No. 8	Structure-Activity Relationships in Toxicology and Ecotoxicology: An Assessment (Summary) (Published June 1986)
No. 9	Assessment of Mutagenicity of Industrial and Plant Protection Chemicals (Published June 1987)
No. 10	Identification of Immunotoxic Effects of Chemicals and Assessment of their Relevance to Man (Published August 1987)
No. 11	Eye Irritation Testing (Published June 1988)
No. 12	Alternative Approaches for the Assessment of Reproductive Toxicity (with emphasis on embryotoxicity/teratogenicity) (Published November 1989)
No. 13	DNA and Protein Adducts: Evaluation of their Use in Exposure Monitoring and Risk Assessment (Published October 1989)
No. 14	Skin Sensitisation Testing (Published March 1990)
No. 15	Skin Irritation (Published July 1990)
No. 16	Early Indicators of Non-Genotoxi c Carcinogenesis (Published June 1991)
No. 17	Hepatic Peroxisome Proliferation (Published May 1992)
No. 18	Evaluation of the Neurotoxic Potential of Chemicals (Published September 1992)
No. 19	Respiratory Allergy (Published August 1993)
No. 20	Percutaneous Absorption (Published August 1993)
No. 21	Immunotoxicity: Hazard Identification and Risk Characterisation (Published September 1994)
No. 22	Evaluation of Chemicals for Oculotoxicity (Published November 1994)
No. 23	Receptor Mediated Mechanisms in Chemical Carcinogenesis (Published December 1995)
No. 24	Risk Assessment for Carcinogens (Published July 1996)
No. 25	Practical Concepts for Dose Selection in Chronic Toxicity and Carcinogenicity Studies in Rodents (Published February 1996)
No. 26	Aquatic Toxicity Testing of Sparingly Soluble Volatile and Unstable Substances (Published September 1996)
No. 27	Aneuploidy (Published August 1997)
No. 28	Threshold-Mediated Mutagens - Mutation Research Special Issue (Published January 2000)
No. 29	Skin Sensitisation Testing for the Purpose of Hazard Identification and Risk Assessment (Published September 2000)
No. 30	Genetic Susceptibility to Environmental Toxicants (Published October 2001)
No. 31	Guidance on Evaluation of Reproductive Toxicity Data (Published February 2002)
No. 32	Use of Human Data in Hazard Classification for Irritation and Sensitisation (Published July 2002)
No. 33	Application of Physiological - Toxicokinetic Modelling to Health Hazard Assessment of Chemcial Substances (Published February 2003)

Technical Reports

No. Title

- No. 1 Assessment of Data on the Effects of Formaldehyde on Humans (updated by TR No. 6) (Published January 1979)
- No. 2 The Mutagenic and Carcinogenic Potential of Formaldehyde (Published May 1981)
- No. 3 Assessment of Test Methods for Photodegradation of Chemicals in the Environment (Published August 1981)
- No. 4 The Toxicology of Ethylene Glycol Monoalkyl Ethers and its Relevance to Man (updated by TR No. 17) (Published June 1982)
- No. 5 Toxicity of Ethylene Oxide and its Relevance to Man (Published September 1982)
- No. 6 Formaldehyde Toxicology: An Up-Dating of ECETOC Technical Reports 1 and 2 (Published September 1982)
- No. 7 Experimental Assessment of the Phototransformation of Chemicals in the Atmosphere (Published September 1983)
- No. 8 Biodegradation Testing: An Assessment of the Present Status (Published November 1983)
- No. 9 Assessment of Reverse-Phase Chromatographic Methods for Determining Partition Coefficients (Published December 1983)
- No. 10 Considerations Regarding the Extrapolation of Biological Data in Deriving Occupational Exposure Limits (Published February 1984)
- No. 11 Ethylene Oxide Toxicology and its Relevance to Man: An Up-Dating of ECETOC Technical Report No. 5 (Published March 1984))
- No. 12 The Phototransformation of Chemicals in Water: Results of a Ring-Test (Published June 1984)
- No. 13 The EEC 6th Amendment: A Guide to Risk Evaluation for Effects on the Environment (Published March 1984)
- No. 14 The EEC 6th Amendment: A Guide to Risk Evaluation for Effects on Human Health (Published March 1984)
- No. 15 The Use of Physical-Chemical Properties in the 6th Amendment and their Required Precision, Accuracy and Limiting Values (Published June 1984)
- No. 16 A Review of Recent Literature on the Toxicology of Benzene (Published December 1984)
- No. 17 The Toxicology of Glycol Ethers and its Relevance to Man: An Up-Dating of ECETOC Technical Report No. 4 (updated by TR No. 64) (Published April 1985)
- No. 18 Harmonisation of Ready Biodegradability Tests (Published April 1985)
- No. 19 An Assessment of Occurrence and Effects of Dialkyl-o-Phthalates in the Environment (Published May 1985)
- No. 20 Biodegradation Tests for Poorly-Soluble Compounds (Published February 1986)
- No. 21 Guide to the Classification of Carcinogens, Mutagens, and Teratogens under the 6th Amendment (Published February 1986)
- No. 22 Classification of Dangerous Substances and Pesticides in the EEC Directives. A Proposed Revision of Criteria for Inhalational Toxicity (Published January 1987)
- No. 23 Evaluation of the Toxicity of Substances to be Assessed for Biodegradability (Published November 1986)
- No. 24 The EEC 6th Amendment: Prolonged Fish Toxicity Tests (Published October 1986)
- No. 25 Evaluation of Fish Tainting (Published January 1987)
- No. 26 The Assessment of Carcinogenic Hazard for Human Beings exposed to Methylene Chloride (Published January 1987)
- No. 27 Nitrate and Drinking Water (Published January 1988)
- No. 28 Evaluation of Anaerobic Biodegradation (Published June 1988)
- No. 29 Concentrations of Industrial Organic Chemicals Measured in the Environment: The Influence of Physico-Chemical Properties, Tonnage and Use Patterns (Published June 1988)
- No. 30 Existing Chemicals: Literature Reviews and Evaluations (Fifth Edition) (No longer available) (Published May 1994)
- No. 31 The Mutagenicity and Carcinogenicity of Vinyl Chloride: A Historical Review and Assessment (Published July 1988)
- No. 32 Methylene Chloride (Dichloromethane): Human Risk Assessment Using Experimental Animal Data (Published May 1988)
- No. 33 Nickel and Nickel Compounds: Review of Toxicology and Epidemiology with Special Reference to Carcinogenesis (Published February 1989)
- No. 34 Methylene Chloride (Dichloromethane): An Overview of Experimental Work Investigating Species Differences in Carcinogenicity and their Relevance to Man (Published March 1989)

- No. 35 Fate, Behaviour and Toxicity of Organic Chemicals Associated with Sediments (Published January 1990)
- No. 36 Biomonitoring of Industrial Effluents (Published April 1990)
- No. 37 Tetrachlorethylene: Assessment of Human Carcinogenic Hazard (Published May 1990)
- No. 38 A Guide to the Classification of Preparations Containing Carcinogens, Mutagens and Teratogens (Published July 1990)
- No. 39 Hazard Assessment of Floating Chemicals After an Accidental Spill at Sea (Published July 1990)
- No. 40 Hazard Assessment of Chemical Contaminants in Soil (Published April 1992)
- No. 41 Human Exposure to N-Nitrosamines, their Effects and a Risk Assessment for N-Nitrosodiethanolamine in Personal Care Products (Published August 1990)
- No. 42 Critical Evaluation of Methods for the Determination of N-Nitrosamines in Personal Care and Household Products (Published February 1991)
- No. 43 Emergency Exposure Indices for Industrial Chemicals (Published March 1991)
- No. 44 Biodegradation Kinetics (Published September 1991)
- No. 45 Nickel, Cobalt and Chromium in Consumer Products: Allergic Contact Dermatitis (Published March 1992)
- No. 46 EC 7th Amendment: Role of Mammalian Toxicokinetic and Metabolic Studies in the Toxicological Assessment of Industrial Chemicals (Published May 1992)
- No. 47 EC 7th Amendment "Toxic to Reproduction": Guidance on Classification (Published August 1992)
- No. 48 Eye Irritation: Reference Chemicals Data Bank (Second Edition) (Published June 1998)
- No. 49 Exposure of Man to Dioxins: A Perspective on Industrial Waste Incineration (Published December 1992)
- No. 50 Estimating Environmental Concentrations of Chemicals using Fate and Exposure Models (Published November 1992)
- No. 51 Environmental Hazard Assessment of Substances (Published January 1993)
- No. 52 Styrene Toxicology Investigation on the Potential for Carcinogenicity (Published August 1992)
- No. 53 DHTDMAC: Aquatic and Terrestrial Hazard Assessment (CAS No. 61789-80-8) (Published February 1993)
- No. 54 Assessment of the Biodegradation of Chemicals in the Marine Environment (Published August 1993)
- No. 55 Pulmonary Toxicity of Polyalkylene Glycols (Published December 1997)
- No. 56 Aquatic Toxicity Data Evaluation (Published December 1993)
- No. 57 Polypropylene Production and Colorectal Cancer (Published February 1994)
- No. 58 Assessment of Non-Occupational Exposure to Chemicals (Published May 1994)
- No. 59 Testing for Worker Protection (Published April 1994)
- No. 60 Trichloroethylene: Assessment of Human Carcinogenic Hazard (Published May 1994)
- No. 61 Environmental Exposure Assessment (Published September 1994)
- No. 62 Ammonia Emissions to Air in Western Europe (Published July 1994)
- No. 63 Reproductive and General Toxicology of some Inorganic Borates and Risk Assessment for Human Beings (Published February 1995)
- No. 64 The Toxicology of Glycol Ethers and its Relevance to Man (Published August 1995)
- No. 65 Formaldehyde and Human Cancer Risks (Published May 1995)
- No. 66 Skin Irritation and Corrosion: Reference Chemicals Data Bank (Published March 1995)
- No. 67 The Role of Bioaccumulation in Environmental Risk Assessment: The Aquatic Environment and Related Food Webs (Published October 1995)
- No. 68 Assessment Factors in Human Health Risk Assessment (updated by TR No. 86) (Published August 1995)
- No. 69 Toxicology of Man-Made Organic Fibres (Published April 1996)
- No. 70 Chronic Neurotoxicity of Solvents (Published February 1996)
- No. 71 Inventory of Critical Reviews on Chemicals (Only available to ECETOC members) (Published August 1996)
- No. 72 Methyl tert-Butyl Ether (MTBE) Health Risk Characterisation (Published June 1997)
- No. 73 The Value of Aquatic Model Ecosystem Studies in Ecotoxicology (Published December 1997)
- No. 74 QSARs in the Assessment of the Environmental Fate and Effects of Chemicals (Published June 1998)
- No. 75 Organophosphorus Pesticides and Long-term Effects on the Nervous System (Published December 1998)
- No. 76 Monitoring and Modelling of Industrial Organic Chemicals, with Particular Reference to Aquatic Risk Assessment (Published January 1999)
- No. 77 Skin and Respiratory Sensitisers: Reference Chemicals Data Bank (Published August 1999)

- No. 78 Skin Sensitisation Testing: Methodological Considerations (Published December 1999)
- No. 79 Exposure Factors Sourcebook for European Populations (with Focus on UK Data) (Published June 2001)
- No. 80 Aquatic Toxicity of Mixtures (Published July 2001)
- No. 81 Human Acute Intoxication from Monochloroacetic Acid: Proposals for Therapy (Published November 2001)
- No. 82 Risk Assessment in Marine Environments (Published December 2001)
- No. 83 The Use of T25 Estimates and Alternative Methods in the Regulatory Risk Assessment of Non-threshold Carcinogens in the European Union (Published December 2002)
- No. 84 Scientific Principles for Soil Hazard Assessment of Substances (Published July 2002)
- No. 85 Recognition of, and Differentiation between, Adverse and Non-adverse Effects in Toxicology Studies (Published December 2002)
- No. 86 Derivation of Assessment Factors for Human Health Risk Assessment (Published February 2003)
- No. 87 Contact Sensitisation: Classification According to Potency (Published April 2003)
- No. 88 Environmental Risk Assessment of Difficult Substances (Published June 2003)
- No. 89 (Q)SARS: Evaluation of the Commercially Available Software for Human Health and Environmental Endpoints with Respect to Chemical Management Applications (Published September 2003)
- No. 90 Persistence of Chemicals in the Environment (Published October 2003)
- No. 91 Aquatic Hazard Assessment II (Published November 2003)
- No. 92 Soil and Sediment Risk Assessment (Published December 2004)
- No. 93 Targeted Risk Assessment (Published December 2004)
- No. 94 Whole Effluent Assessment (Published December 2004)

Joint Assessment of Commodity Chemicals (JACC) Reports

No. Title

- No. 1 Melamine (Published February 1983)
- No. 2 1,4-Dioxane (Published February 1983)
- No. 3 Methyl Ethyl Ketone (Published February 1983)
- No. 4 Methylene Chloride (Published January 1984)
- No. 5 Vinylidene Chloride (Published August 1985)
- No. 6 Xylenes (Published June 1986)
- No. 7 Ethylbenzene (Published August 1986)
- No. 8 Methyl Isobutyl Ketone (Published May 1987)
- No. 9 Chlorodifluoromethane (Published October 1989)
- No. 10 Isophorone (Published September 1989)
- No. 11 1,2-Dichloro-1,1-difluoroethane (HFA-132b) (Published May 1990)
- No. 12 1-Chloro-1,2,2,2-tetrafluoroethane (HFA-124) (updated by JACC No. 25) (Published May 1990)
- No. 13 1,1-Dichloro-2,2,2-trifluor oethane (HFA-123) (updated by JACC No. 33) (Published May 1990)
- No. 14 1-Chloro-2,2,2-trifluorometha ne (HFA-133a) (Published August 1990)
- No. 15 1-Fluoro 1,1-dichloroethane (HFA-141B) (updated by JACC No. 29) (Published August 1990)
- No. 16 Dichlorofluoromethane (HCFC-21) (Published August 1990)
- No. 17 1-Chloro-1,1-difluoroethane (HFA-142b) (Published August 1990)
- No. 18 Vinyl Acetate (Published February 1991)
- No. 19 Dicyclopentadiene (CAS: 77-73-6) (Published July 1991)
- No. 20 Tris-/Bis-/Mono-(2-ethylhe xyl) phosphate (Published May 1992)
- No. 21 Tris-(2-butoxyethyl)-phosphate (CAS:78-51-3) (Published March 1992)
- No. 22 Hydrogen Peroxide (CAS: 7722-84-1) (Published January 1993)
- No. 23 Polycarboxylate Polymers as Used in Detergents (Published November 1993)
- No. 24 Pentafluoroethane (HFC-125) (CAS: 354-33-6) (Published May 1994)

ECETOC TR No. 95 200

- No. 25 1-Chloro-1,2,2,2-tetrafluoroethane (HCFC-124) (CAS No. 2837-89-0) (updated by JACC No. 46) (Published July 1994)
- No. 26 Linear Polydimethylsiloxanes (CAS No. 63148-62-9) (Published September 1994)
- No. 27 *n*-Butyl Acrylate (CAS No. 141-32-2) (Published August 1994)
- No. 28 Ethyl Acrylate (CAS No. 140-88-5) (Published September 1994)
- No. 29 1,1-Dichloro-1-fluoroethane (HCFC-141b) (CAS No. 1717-00-6) (Published December 1994)
- No. 30 Methyl Methacrylate (CAS No. 80-62-6) (Published February 1995)
- No. 31 1,1,1,2-Tetrafluoroethane (HFC-134a) (CAS No. 811-97-2) (Published February 1995)
- No. 32 Difluoromethane (HFC-32) (CAS No. 75-10-5) (Published May 1995)
- No. 33 1,1-Dichloro-2,2,2-trifluoroethane (HCFC-123) (CAS No. 306-83-2) (Published February 1996)
- No. 34 Acrylic Acid (CAS No. 79-10-7) (Published September 1995)
- No. 35 Methacrylic Acid (CAS No. 79-41-4) (Published May 1996)
- No. 36 n-Butyl Methacrylate; Isobutyl Methacrylate (CAS No. 97-88-1) (CAS No. 97-86-9) (Published December 1996)
- No. 37 Methyl Acrylate (CAS No. 96-33-3) (Published September 1998)
- No. 38 Monochloroacetic Acid (CAS No. 79-11-8) and its Sodium Salt (CAS No. 3926-62-3) (Published June 1999)
- No. 39 Tetrachloroethylene (CAS No. 127-18-4) (Published December 1999)
- No. 40 Peracetic Acid (CAS No. 79-21-0) and its Equilibrium Solutions (Published January 2001)
- No. 41 n-Butanol (CAS No. 71-36-3) (Published March 2004)
- No. 42 Tetrafluoroethylene (CAS No. 116-14-3) (Published December 2003)
- No. 43 sec-Butanol (CAS No. 78-92-2) (Published March 2004)
- No. 44 1, 1, 3, 3-Pentafluoropropa ne (HFC-245fa) (Published June 2004)
- No. 45 1, 1-Difluoroethane (HFC-152a) (CAS No. 75-37-6) (Published September 2004)
- No. 46 1-Chloro-1,2,2,2-tetrafluoroethane (HCFC-124) CAS No. 2837-89-0 (Second Edition) (Published November 2004)

Special Reports

No. Title

- No. 8 HAZCHEM; A Mathematical Model for Use in Risk Assessment of Substances (Published October 1994)
- No. 9 Styrene Criteria Document (Published June 1995)
- No. 10 Hydrogen Peroxide OEL Criteria Document (CAS No. 7722-84-1) (Published July 1996)
- No. 11 Ecotoxicology of some Inorganic Borates (Published March 1997)
- No. 12 1,3-Butadiene OEL Criteria Document (Second Edition) (CAS No. 106-99-0) (Published January 1997)
- No. 13 Occupational Exposure Limits for Hydrocarbon Solvents (Published August 1997)
- No. 14 n-Butyl Methacrylate and Isobutyl Methacrylate OEL Criteria Document (Published May 1998)
- No. 15 Examination of a Proposed Skin Notation Strategy (Published September 1998)
- No. 16 GREAT-ER User Manual (Published March 1999)
- No. 17 Risk Assessment Report for Existing Substances Methyl tertiary-Butyl Ether (Published December 2003)

Documents

No. Title

- No. 32 Environmental Oestrogens: Male Reproduction and Reproductive Development (Published January 1996)
- No. 33 Environmental Oestrogens: A Compendium of Test Methods (Published July 1996)
- No. 34 The Challenge Posed by Endocrine-disrupting Chemicals (Published February 1996)
- No. 35 Exposure Assessment in the Context of the EU Technical Guidance Documents on Risk Assessment of Substances (Published May 1997)
- No. 36 Comments on OECD Draft Detailed Review Paper: Appraisal of Test Methods for Sex-Hormone Disrupting Chemicals (Published August 1997)

ECETOC TR No. 95 201

- No. 37 EC Classification of Eye Irritancy (Published December 1997)
- No. 38 Wildlife and Endocrine Disrupters: Requirements for Hazard Identification (Published January 1998)
- No. 39 Screening and Testing Methods for Ecotoxicological Effects of Potential Endocrine Disrupters: Response to the EDSTAC Recommendations and a Proposed Alternative Approach (Published January 1999)
- No. 40 Comments on Recommendation from Scientific Committee on Occupational Exposure Limits for 1,3-Butadiene (Published October 2000)
- No. 41 Persistent Organic Pollutants (POPs) Response to UNEP/INC/CEG-I Annex 1 (Published January 2000)
- No. 42 Genomics, Transcript Profiling, Proteomics and Metabonomics (GTPM). An Introduction (Published April 2001)
- No. 43 Contact Sensitisation: Classification According to Potency. A Commentary (Published July 2003)

Workshop Reports

No. Title

- No. 1 Workshop on Availability, Interpretation and Use of Environmental Monitoring Data 20-21 March 2003, Brussels (Published December 2003)
- No. 2 Strategy Report on Challenges, Opportunities and Research needs arising from the Definition, Assessment and Management of Ecological Quality Status as required by the EU Water Framework Directive based on the workshop EQS and WFD versus PNEC and REACH are they doing the job? 27-28 November 2003, Budapest (Published March 2004)
- No. 3 Workshop on the Use of Human Data in Risk Assessment 23-24 February 2004, Cardiff (Published November 2004)
- No. 4 Influence of Maternal Toxicity in Studies on Developmental Toxicity 2 March 2004, Berlin (Published October 2004)
- No. 5 Workshop on Alternative Testing Approaches in Environmental Risk Assessment 7-9 July 2004, Paris (Published December 2004)

ECETOC TR No. 95 202